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Abstract 
Primary focal hyperhidrosis (PFHH) is a medical condition characterised by over-
activity of the eccrine sweat glands, primarily occurring on palmar, plantar and 
axillary regions. PFHH can have a significant adverse impact on a patient’s quality 
of life. Multiple intradermal injections of a commercial formulation of botulinum 
toxin A (BTX A) (Botox
®
) is the most effective non-surgical treatment currently 
licensed in the UK for cases of severe PFHH. Although effective, intradermal BTX 
A injections are associated with considerable pain and discomfort for the patient and 
are time-consuming for the administering clinician. This study aims to evaluate the 
potential of using pocketed microneedle devices for minimally invasive intradermal 
delivery of BTX A, as a liquid formulation, into human skin. 
Pocketed microneedles, metallic 700 µm-long needles containing a cavity within the 
needle shaft, were selected as an appropriate and relatively untested intradermal 
delivery device. Pocketed microneedle devices (PMDs) were liquid loaded by 
immersion into a ‘Botox® like’ formulation that mimicked the composition of the 
commercial Botox
®
 formulation, with the exception of BTX A, which was replaced 
by the model macromolecular protein β-galactosidase (~465 kDa). A water-soluble 
dye was also included to enable visualisation. Microneedles were assessed for 
loading uniformity by light microscopy and the formulation residency time was 
evaluated by monitoring evaporation using a digital camera. The microneedle 
loading capacity was determined using an established quantitative assay for β-
galactosidase. Studies using excised human breast skin, maintained in organ culture, 
examined delivery of the model β-galactosidase from liquid loaded PMDs and the 
time-dependent diffusion of the protein within the dermal tissue. A more clinically 
representative model of BTX A, formaldehyde inactivated BTX A, i.e., botulinum 
toxoid, was used to determine the deposition pattern of the therapeutic within the 
skin. Following skin delivery the toxoid was detected by immnohistochemical 
staining and fluorescence imaging, following its conjugation to an appropriate 
fluorophore. 
Immersion of the PMD into a ‘Botox® like’ formulation resulted in successful uptake 
and retention of the model protein solution. Quantitative studies indicated that 
nanogram quantities (~100 ng/microneedle array) of the β-galactosidase model can 
be loaded and retained on individual microneedles, in a liquid state. These results 
suggest that the loading capacity of the microneedle device is appropriate for 
therapeutic botulinum toxin formulations, although loading uniformity will need to 
be addressed. Histological analysis revealed effective delivery of the model β-
galactosidase from a PMD to the epidermal and the dermal layers of the skin. Rapid 
and extensive diffusion of the protein within the deeper dermis was also 
demonstrated. Further, immunohistochemical and fluorescence studies indicated 
effective PMD loading and successful delivery of botulinum toxoid to the dermis of 
human skin. These data suggest that it should be possible for BTX A to access its 
therapeutic target (the eccrine sweat glands) following delivery via PMDs.  
This study has demonstrated for the first time that pocketed microneedles represent a 
viable, minimally invasive alternative, for the intradermal delivery of botulinum 
toxin A (Botox
®
). Future pre-clinical and clinical studies are now required to test and 
optimize a microneedle-based delivery system that is most suited to clinical practice.  
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1.1 Overview 
Botulinum toxin A (BTX A) is an extremely potent neurotoxin that has increasing 
applications in both the cosmetic and the medical industry. As a therapeutic, BTX A 
is directly administered to its site of action to treat hypersecretory or muscular 
defects. Multiple injections of BTX A (Botox
®
-5ng per vial) is the most effective 
licensed treatment for primary focal hyperhidrosis (PFHH) in the UK (Glaser et al. 
2007c). Local intradermal administration targets the site of action, the eccrine sweat 
glands in the dermis, and reduces the risk of systemic uptake (Moreau 2003; 
Naumann et al. 1998b). However, the treatment relies upon numerous painful 
injections by skilled clinicians. This Thesis investigates the use of microneedle array 
devices (MDs) as an alternative minimally invasive approach to deliver BTX A to 
human skin for the treatment of PFHH.  
In order to evaluate the cutaneous delivery capability of a MD, it is crucial to 
understand the structural features of human skin. This introductory Chapter provides 
some background information of the anatomy of the skin with particular focus upon 
the structure of the dermis and the eccrine sweat glands here located. This is 
followed by more detailed information regarding the use of BTX A in the treatment 
of this PFHH, the therapeutic options currently available for this condition and their 
limitations. Alternative methods employed to date for minimally invasive BTX A 
administration are also outlined. In addition, general information regarding the 
different BTX A drugs currently available in the market, as well as their therapeutic 
and cosmetic applications, are provided. Subsequently, an overview of the 
microneedle concept and the principal microneedle applications is given. The 
Chapter terminates with a brief summary of the key points previously illustrated and 
an explanation of how they combine to provide a rationale for using microneedles as 
an alternative delivery method for BTX A administration. 
 
1.2 Physiology of the skin 
The skin is the largest organ of the body constituting approximately 15% of the 
entire body weight in humans (Kanitakis 2002). It can be defined as a barrier which 
separates and protects the internal body structures from external insults such as 
chemicals, pathogen microorganisms, radiation, physical injuries and varying 
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temperatures (Elias 2005). Skin plays also a key role in preventing water loss from 
the organism, stimulating immune responses, maintaining homeostasis of body 
temperature and perceiving various sensations such as pain, heat or pressure (Baroni 
et al. 2012). 
The skin is essentially constituted of two distinct but mutually interacting layers 
(Figure 1.1); i) the epidermis, a stratified epithelium, which communicates with the 
external environment and ii) the dermis, a connective tissue, underlying the 
epidermis, which constitutes the major part of the skin. The junction between dermis 
and epidermis, termed dermo-epidermal junction, provides mechanical support to the 
skin and controls migration of cells and molecules between the two layers. The 
adipose tissue, residing at the bottom of the dermis, provides mechanical protection 
of the underlying organs (Barry 1983b). 
 
 
Figure 1.1 An illustration of the structural features of human skin. Figure adapted from 
http://www.dkimages.com/discover/home/Health-and-Beauty/Human-Body/Skin-
Hair-and-Nails/Skin-Hair-and-Nails-43.html (undated). 
 
1.2.1 Epidermis  
The epidermis is a multilayered epithelium whose thickness varies according to 
anatomic sites, from 0.8-1 mm on the palms and the soles to 60 µm on the eyelids 
(Barry 1983b). It is constituted for the major part by cells called keratinocytes, so 
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termed due to the presence of the protein keratin, the main structural protein of the 
skin. Other cell populations are Langerhans cells, known to stimulate immune 
responses, Merkel cells, receptor cells associated with the sense of touch and shape 
discrimination and melanocytes, cells producing the cutaneous pigment melanin 
(Haake 2001). The epidermis can be divided in two main layers: the stratum corneum 
and the viable epidermis. The first one represents the outermost layer of the 
epidermis and consists of a 15 µm-thick, flattened, non-nucleated (dead) cell layer 
(Barry 1983b). This layer acts as a lipophilic barrier limiting access to the underlying 
epidermis to low molecular weight (< 500 Da) and relatively lipophilic compounds 
(Benson 2008). The lipophilic nature of this layer prevents loss of epidermal water 
and thus maintains hydration of the skin. Due to the extremely high molecular weight 
and hydrophilic nature of proteins such as BTX A, delivery of this medicament into 
the skin currently relies on the use of hypodermic needles, which actively perforate 
the stratum corneum barrier.  
The viable epidermis, representing the larger portion of the entire epidermis, resides 
underneath the stratum corneum. It is so termed due to the presence of proliferative 
cells, which are responsible for conservation and regeneration of the epidermal 
structure (Baroni et al. 2012). These cells undergo progressive morphological 
changes while migrating from the viable epidermis, where they are nucleated and 
metabolically active, to the stratum corneum where they became keratinised 
corneocytes that are shed from the body surface in the desquamation process. 
Migration of keratinocytes from the stratum basale to the stratum corneum  usually 
occurs in 21 days (Roberts 1998). Once reached the stratum corneum, the 
corneocytes usually reside for subsequent 13-14 days before shedding in the 
desquamation process (Barry 1983b). 
 
1.2.1.1 Structure of the viable epidermis 
The viable epidermis is composed of four distinct sub layers, which differ in 
thickness, cells morphology and function. The characteristic of each sub layer, from 
the innermost stratum germinativum to the outermost stratum lucidum are described 
in detail overleaf:- 
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The stratum basale  
The stratum basale is constituted by one of two layers of columnar or cuboidal 
keratinocytes approximately 6 µm wide (Kanitakis 2002). Two major classes of 
keratinocytes can be found at this level. The first one is represented by stem cells 
which actively divide to compensate the loss of dead cells from the skin surface 
during the desquamation process (Fuchs 1990). The second cellular population is 
represented by keratinocytes which function to anchor the basal membrane to the 
underlying dermis (Simpson et al. 2011). Secure connection between keratinocytes in 
the basal layer and extracellular components of the underlying basale membrane (at 
the dermo-epidermal junction) is ensured by the presence of protein filaments called 
hemidesmosomes. Human disorders associated with production of these proteins 
and/or loss of specific cytoskeletal keratin filaments, to which the hemidesmosomes 
are attached, results in blistering and epidermal fragility (Simpson et al. 2011). 
The basement membrane plays also an important role in controlling the migration of 
substances from the dermis to the epidermal layer. Water, electrolytes and small 
molecules overcome the membrane to provide supply of nutrients to the overlying 
epidermis from the blood vessels (Barry 1983b).  
 
The stratum spinosum 
The stratum spinosum (5-15 layers) is located between the stratum basale and the 
overlying stratum germinativum (Kanitakis 2002). The prickle appearance of this 
layer is due to the presence of large keratin filaments produced in the cytoplasm of 
the keratinocytes and extending out from the cellular surface. Protein complexes 
called desmosomes interact with these filaments producing intercellular bridges 
between adjacent cells (Fuchs 1990). These intercellular connections provide 
structural and mechanical support to the skin. Presence of granules enriched with 
lipids, termed lamellar bodies, can be detected in the cytoplasm of the outer cells 
layers of the stratum spinosum, especially in proximity of the overlying stratum 
granulosum (Jensen and Proksch 2009). 
 
The stratum granulosum 
The cells of the stratum granulosum (1-3 layers) appear flattened, oriented parallel to 
the skin surface and contain numerous granules of keratohyalin, polygonal granules 
constituted by assembly of profilaggrin and keratin (Kanitakis 2002). The cells of the 
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outer most layers of the stratum granulosum contain also numerous lamellar bodies 
involved in the desquamation process and the formation of the lipid intercellular 
matrix of the stratum corneum (Sondell et al. 1995). 
 
The stratum lucidum 
The stratum lucidum is a thin translucent layer, located at the interface between the 
underlying stratum granulosum and the overlying stratum corneum. This layer is 
found only in specific anatomic sites such as the palm of the hand and the sole of the 
foot (Barry 1983b). 
 
1.2.1.2 The stratum corneum  
The stratum corneum is composed by highly flattened, hexagonal, keratinized 
corneocytes, which represent the last differentiation stage of viable keratinocytes. 
Corneocytes are devoid of nuclei and cytoplasmatic organelles (Roberts 1998). These 
cells are embedded in an extracellular matrix constituted by lipids, produced and 
released by keratinocytes during their differentiation process. Although the stratum 
corneum is generally described as a 15-µm thick layer (Barry 1983b), its thickness 
varies tremendously depending of the anatomic site. For example, the thickness of 
the stratum corneum of palmar or plantar skin is approximately ten times higher than 
the rest of the body (Roberts 1998). 
The corneocytes are mainly composed of a thick matrix of cytoskeletal keratin 
filaments interconnected by disulfide bonds and a cellular envelop consisting of a 
complex of cross-linked proteins such as loricrin, cystatin α and involucrin 
(Kanitakis 2002; Roberts 1998). It is believed the proteins of the cellular envelop 
interact covalently with specific lipids of the extracellular matrix, maintaining the 
structural integrity of the stratum corneum (Jensen and Proksch 2009) and thus its 
barrier function. Nevertheless, cohesiveness of the stratum corneum is also and more 
importantly ensured by the presence of modified desmosomes called 
corneodesmosomes. These are proteinaceous filaments that covalently cross link 
components of the cell envelop, providing strong connections between adjacent 
corneocytes (Ishida-Yamamoto et al. 2011). 
Different lipids such as ceramides, cholesterol, free fatty acids and fatty acids 
esterified with cholesterol constitute the extracellular matrix. Ceramides and 
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cholesterol are the most represented components representing respectively the 40% 
(w/v) and the 27 % (w/v) of the entire lipids population (Baroni et al. 2012). The 
lipidic composition of the extracellular matrix provides an extraordinary barrier to 
chemical penetration.  
Cutaneous permeation of a substance from the outside environment mainly occurs 
through the intercellular lipid matrix. Absorption via skin appendages (sweat glands 
and pilosebaceous glands) can be considered negligible for the majority of materials 
due to their limited distribution in the skin (Rizwan et al. 2009). In anatomic sites 
such as the palms and the soles which are devoid of hair follicles but rich of sweat 
glands, cutaneous penetration may be expected to occur mainly through the sweat 
ducts due to the high thickness of the stratum corneum. However, cutaneous 
absorption of various materials like allergens or histamine is very restricted here, 
thus indicating that the intra-appendageal route is not significant (Barry 1983a).  
Due to the lipophilic composition of the stratum corneum, successful penetration of a 
substance through the intact barrier depends on its capability to partition into the 
lipid matrix and therefore on its lipophilicity. The grade of lipophilicity of a 
substance is associated to the partition coefficient value (log P) (Amorosa 1998a), 
defined as  the ratio of concentrations of the substance in two immiscible solvents 
(usually represented by octanol and water). Therefore higher log P values define 
more lipophilic compounds. 
However, despite the lipophilic nature of the stratum corneum, aqueous regions can 
be found in the underlying viable epidermis. In particular the presence of the so 
called aqueous boundary region, a hydrophilic barrier located between the stratum 
basale and the stratum granulosum, may oppose significant resistance to permeation 
of highly lipophilic compounds (Roberts et al. 1978; Roberts 1998). As a 
consequence of the mixed composition of the skin, substances capable to dissolve in 
both oil and water (log P 1 and 3) would diffuse through the cutaneous layers at 
relatively high rate (Benson 2008). 
 
1.2.2 The dermis 
The dermis is the major component of the skin having a thickness of about 1- 3 mm 
(Jensen and Proksch 2009). Its main functions reside in: i) providing flexibility and 
mechanical resistance to the skin ii) interacting with the overlying epidermis to 
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develop and maintain the integrity of the dermo-epidermal junction, iii) protecting 
epidermal appendages (eccrine and apocrine sweat glands and pilosebaceous units), 
blood vessels, nerves and lymphatic fibres (Haake 2001). 
The dermis is a connective tissue consisting of approximately 80% fibrous proteins i) 
collagen (75%), ii) elastin (4%) and iii) reticulin (0.5%) and for the remaining 20% 
an amorphous matrix of non-fibrous filaments constituted by glycoproteins, 
proteoglycans and glycosaminoglycans (Barry 1983b). These filamentous proteins 
compose the ‘ground substance’ in which all components of the dermis are 
embedded. Cellular components of the dermis include fibroblasts, dendritic cells and 
macrophages. Fibrous and non-fibrous components as well as cell populations in the 
dermis will be described in more details in the following Sections. 
Two main portions can be distinguished in the dermis: an upper papillary region and 
a lower reticular region (Haake 2001) (Figure 1.2). The papillary region, located at 
the interface with the overlying epidermis, contains loose bundles of thin collagen 
and elastic fibres running perpendicularly to the skin surface and immersed in large 
inter-fibrillar spaces (Kanitakis 2002). This layer is characterised by greater 
metabolic and proliferative cellular activities compared to the reticular region. It is at 
this level that the major part of proteoglycans are produced and released into the 
extracellular space. The underlying reticular region is characterised by thicker 
collagen and elastic bundles, which tend to align horizontally to the skin surface 
(Kanitakis 2002; Montagna 1974). 
The papillary region is so termed as it contains finger-like projections (dermal 
papillae), rich in blood vessels, nerves fibres and lymphatic vessels, which alternate 
with epidermal ridges. These inter-digitations increase the surface area and thus the 
rate of exchange of materials between the dermis and epidermis (Sorrell and Caplan 
2004). Blood vessels provide nutrients and oxygen to the epidermis and also regulate 
body temperature and pressure. Nerve fibres modulate cutaneous sensations (i.e 
touch, pain and pressure), whereas lymphatic vessels remove plasma proteins from 
the extravascular space.  
At the interface with the reticular region resides a vascular complex, the rete 
subpapillare, that is sustained by an additional plexus, the rete cutaneum, located in 
the deep dermis (Figure 1.3) (Sorrell and Caplan 2004). This complex vasculature is 
responsible for conveying blood to the dermis itself, the cutaneous appendages and 
the subcutaneous fat. 
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Figure 1.2: Light micrograph of skin. The main components of the Figure are outlined. 
Figure adapted from http://www.microscopy-
uk.org.uk/mag/imgaug02/HistPaper01_Fig2.jpg (undated) 
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Figure 1.3: A schematic representation of the vasculature in human skin. Figure adapted 
from http://cai.md.chula.ac.th/lesson/lesson4410/data/image_s17.jpg (undated). 
1.2.2.1 Fibrous components of the dermis 
 
Collagen 
Collagens are the main fibrous component of skin, bone, ligament and cartilage. 
Although more than 20 genetically distinctive collagens have been reported, 
collagens I, III and V are the most represented in the dermis with the first one 
counting for the 80-90% of the entire collagen weight (Haake 2001). Collagen VI is 
also a fundamental component of the dermal connective tissue and it is mainly 
located within the papillary dermis, the matrix surrounding blood vessels, the nerves, 
the epidermal appendages and the dermo-epidermal junction (Kielty and 
Shuttleworth 1997).  
The protein collagen consists of a 300 nm long triple helical complex constituted by 
three polypeptide α chains, each chain containing approximately 1000 residues 
(Kadler 1996). Collagen is produced by fibroblasts in the form of a soluble precursor 
termed tropocollagen, which undergoes enzymatic hydroxylation and glycosylation 
before being released as an insoluble product into the extracellular space. Outside the 
cells, tropocollagens molecules are enzymatically cleaved by collagen 
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metalloproteinases. Several molecules align and interact covalently with each other 
to aggregate into banded collagen fibrils, which can be detected by light microscopy. 
These are attached to proteoglycan molecules, which are thought to stabilise the 
collagen structure (Montagna 1974). 
 
Elastin 
Elastic fibres extend from the dermo-epidermal junction to the bottom of the dermis 
and are also associated to blood vessels and hair follicles. Their main function 
resides in providing elasticity to the skin due to their capability of stretching and 
deforming under a specific mechanical stress and reverting to the original shape once 
the stress is relieved. 
Two main components can be identified in the elastic fibres: one inner amorphous 
portion composed by the insoluble protein elastin and an outer portion consisting of 
different non elastic protein microfibrils (Barry 1983b). The microfibrilis are 
constituted by a variety of glycoproteins, with fibrillin, a 350 kDa molecule, being 
the most characterised (Sakai et al. 1986). Elastin is produced by the dermal cells in 
the form of the soluble precursor tropoelastin. Similarly to collagen, tropoelastin 
molecules undergo enzymatic modifications before aggregating into insoluble elastin 
complexes (Montagna 1974). 
 
Reticulin  
Reticulin fibres present in minute amount in the dermis are composed by an 
assembly of collagen I and III fibres and fibronectin (Kanitakis 2002). 
 
1.2.2.2 Non-fibrous component of the dermis: the ‘ground 
substance’ 
The ‘ground substance’ is a ‘gel-like’ milieu where the different constituents of the 
dermis (connective fibres, cells, cutaneous vasculature, nerve fibres and skin 
appendages) are embedded. It also contains water, proteins, sugars and electrolytes 
derived from the blood vessels as well as metabolic products of the dermal cells such 
as proteoglycans and glycoproteins (Montagna 1974). The ‘gel-like’ composition of 
this matrix facilitates migration of cells through this cutaneous layer. Proteoglycans 
are large (100-2500 kDa), hydrophilic compounds formerly constituted by 
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glycosaminoglycans attached to a core protein (Kanitakis 2002). The protein is 
specific for each proteoglycan and determines which compound will be incorporated 
in the complex. Glycosaminoglycans consist of 100 up to 5000 monosacharide 
residues organised into repeating disaccharide units. Each unit is usually constituted 
by a molecule of glucuronate or galactose linked to hexosamine. Negative charges 
are distributed along the entire length of the units in the form of either carboxyl or 
ester sulphate groups (Montagna 1974). Various glycosaminoglycan types have been 
identified in the ‘ground substance’, such as hyaluronate, chondroitin 4 or 6 sulfate, 
dermatan sulphate and heparin sulphate, with the first two types being the most 
abundant. Although glycosoaminoglycans exist in the dermis as proteoglycans, the 
hyaluronate is generally not linked to any protein and it is therefore mostly present in 
the form of glycosaminoglycan alone. Different species of proteoglycans (such as 
biglycan, versican, decorin) have been detected in the skin and their distribution 
varies between the two layers of the dermis (papillary and reticular layers) (Haake 
2001). Decorin for example is largely expressed in the papillary layer, whereas 
versican is produced at higher level in the underlying reticular layer (Sorrell and 
Caplan 2004). The extremely large size of the proteoglycans complexes and thus the 
high number of hydrophilic chains control the water content of the dermis and affect 
the compressibility of the skin. Due to the presence of these molecules, the dermis is 
the most hydrophilic compartment of the skin, being composed of 70% water in 
comparison to 10-25% of the epidermis (Amorosa 1998b). Proteoglycans also 
interact with cytokines and growth factors and are therefore implicated in stimulating 
inflammatory responses, tissue repair and cell proliferation (Oh et al. 2011). 
 
1.2.2.3 Cellular populations in the dermis 
Fibroblasts, the most abundant cells in connective tissue, are responsible for the 
synthesis of the main components of the dermis (i.e., collagen, elastin fibres and the 
‘ground substance’). Structurally fibroblasts are characterised by a large nucleus, 
well-developed endoplasmic reticulum and Golgi apparatus and numerous 
cytoplasmic filaments. In particular, the Golgi apparatus is believed to represent the 
site of production of polysaccharides in the dermis and to also mediate collagen 
secretion from the cytosol to the extracellular space (Montagna 1974).  
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Although the majority of fibroblasts are localised within the papillary dermis and 
around the cutaneous vessels, dermal cells can also be found within the reticular 
layer in the spaces between the collagen bundles (Haake 2001). Fibroblasts are also 
known to be involved in tissue repair, wound healing and inflammatory process 
(Haake 2001). Other cells populations are dendritic cells, macrophages and mast 
cells. Dendritic cells and macrophages are immunocompetent cells of the skin and 
constitute, together with the Langherans cells in the epidermis, the cutaneous 
immune system (Roberts 1998). As such, their main function resides in detecting 
allergens in the skin and presenting these agents to T-lymphocytes in the cutaneous 
lymph nodes (German 2005; Merad et al. 2002). Mast cells secrete specific 
mediators that play a key role in stimulating allergic reactions, phagocytosis and 
others functions in the skin (Haake 2001). 
 
1.2.3 The sweat glands  
Human skin contains approximately 3-4 million sweat glands (Saga 2002) located in 
the deep region of the dermis at the border with the subcutaneous fat (Figure 1.1). 
They can be divided into apocrine, so called as they produce a secretion by pinching-
off the apical part of the glandular cells, and eccrine glands, where secretion is 
produced as a liquid with no disintegration of the glandular cells (Sato et al. 1989). 
 
Eccrine sweat glands  
The human body contains 1.6 to 4 million eccrine sweat glands evenly distributed 
over the body surface except for specific anatomic sites such as the genital areas, 
lips, and external ear canal. The density of the glands differ according to individuals 
and anatomic sites with an average density estimated at approximately 200 glands 
per cm
2 
(Wilke et al. 2007). Sites of greatest distribution are the palms, soles, axillae 
and forehead. Sato et al. (1989) reports a surface area density of i) 64 sweat 
glands/cm
2 
on the back, ii) 108 sweat glands/cm
2
 on the forearm, iii) 181 sweat 
glands/cm
2
 on the forehand and iv) 600-700 sweat glands/cm
2
 on palms and soles. 
Moreover, eccrine sweat glands in the palmar and plantar skin have larger 
dimensions than the rest of the body. In all areas however these glands cannot be 
seen with the naked eye as they have a dimension ranging between 0.05 and 0.1 mm 
(Hurley 2001). 
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The eccrine sweat glands consist of a simple tubular epithelium constituted by a 
ductal and a secretory component (Hurley 2001). While the secretory component is a 
tubule located in the deep dermis, the ductal portion consists of a coiled segment, 
which extends into the dermis as a straight dermal duct before crossing the epidermis 
for its entire length (Figure 1.4). The ductal portion, 2-5 mm long, consists of two 
cell layers called basal (outer) and laminal (inner) layers. The secretory component 
has approximately the same length as the ductal portion and it is constituted by 
myoepithelial cells surrounding secretory cells (Saga 2002). Myoepithelial cells 
provide mechanical strength to the tubule wall and induce sweat expulsion from the 
secretory cells through contraction. Myoepithelial cells are restricted to the secretory 
portion of the glands as the coiled duct, the straight dermal duct and the 
intraepidermal duct are devoid of these cells (Ellis 1965). 
 
Figure 1.4: A schematic representation of the distinct portions of the eccrine sweat 
gland. The coiled portion in the deep region of the dermis consists of a secretory tubule and 
a coiled dermal duct. The long straight portion of the duct extends from the dermis into the 
epidermis. The sweat is released on the surface of the skin. 
 
Eccrine sweat glands produce an odourless secretion, which is mainly composed of 
water and electrolytes. This secretion is delivered to the surface of the epidermis by 
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the intradermal duct, which connects the coiled gland with the intraepidermal portion 
and terminates with an open pore on the surface of the skin (Figure 1.4). 
Sweat reduces body temperature by dissipating the heat by evaporation. Therefore, 
eccrine sweat glands play a key role in thermoregulation. Body temperature is 
extremely well controlled in mammals. Thermosensitive neurones, located in specific 
areas of the hypothalamus in the central nervous system (CNS), detect changes in 
core temperature and initiate appropriate responses to maintain the body temperature 
constant (~37 °C) (Wilke et al. 2007). These neurones are also stimulated by 
hormones, physical activity and emotions (e.g. fear or anxiety). Afferent impulses 
originated by peripheral thermo-receptors located in the skin and in the spinal cord 
further stimulate these neurones thus contributing to sweat production (Holzle 2002). 
Acetylcholine (Ach) is the main neurotransmitter involved in sweat gland activation. 
Cholinergic fibres surrounding the secretory tubule of the glands release the 
neurotransmitter into the synaptic space. Once released, Ach activates muscarinic 
receptors located in both secretory and myoephitelyal cells inducing sweat release 
(Kurzen et al. 2004). 
Sweat secretion is believed to be triggered by an electrochemical gradient due to the 
numerous ion channels and ion transporters that have been detected in the secretory 
portion of the glands (Wilke et al. 2007). However, the exact mechanism by which 
this gradient is formed is still not completely understood. Excessive sweat production 
gives rise to hypersecretory disorders such as PFHH. This condition will be 
discussed in more detail in Section 1.3. 
 
Apocrine sweat glands 
The apocrine glands are less numerous than the eccrine sweat glands and are located 
predominantly in the axillae, the groin and in the pubic area (Sato et al. 1989). 
Although similar in structure to the eccrine sweat glands, apocrine glands contain 
coiled portions which are approximately ten times larger than the eccrine sweat 
glands and intradermal ducts which empty into a hair follicle (Hurley 2001). 
Contrarily to the eccrine sweat glands, they produce a viscous sweat that is rich in 
fats, and proteins and is characterised by a specific odour (Saga 2002).  
Although the specific function of these glands is still poorly understood, it is 
believed that they act as scent glands to stimulate sexual attraction in mammals. 
These glands are not thought to be involved in PFHH (Grunfeld et al. 2009). 
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1.3 Primary Focal Hyperhidrosis (PFHH) 
Primary Focal Hyperhidrosis (PFHH) is a chronic disorder characterized by an over-
activity of the eccrine sweat glands, which results in excessive and uncontrollable 
sweating (Farrugia and Nicholls 2005). Although the exact pathogenesis of this 
condition is not clearly understood, evidence of a genetic link has been reported (Ro 
et al. 2002). PFHH has an onset during childhood or adolescence and occurs mainly 
on specific anatomic sites such as the axillae, palms, soles and craniofacial region, 
either alone or in combination (Hamm and Neumann 2009).  
This chronic disorder has been estimated to affect approximately 1% of population in 
UK (Atkins and Butler 2002; http://www.nhs.uk 2011a) and 3-4% of population in 
USA (Grunfeld et al. 2009) and it has a noticeable impact on a patient’s quality of 
life in terms of personal interactions, daily activities and work productivity (Hamm et 
al. 2006; Weber et al. 2005). A study assessing the quality of life of patients affected 
by PFHH revealed a Dermatology Life Quality Index (DLQI) score higher than other 
skin conditions such as acne vulgaris, psoriasis and vitiligo (Swartling et al. 2001). 
Histological studies, comparing the morphology of the eccrine sweat glands in 
patients affected by PFHH with normal individuals, highlighted that neither the 
number, the dimension nor the structure of the glands appear to be modified (Bovell 
et al. 2001). This suggests that PFHH is more likely related to excessive neuronal 
stimulation more than structural abnormalities of the sweat glands. 
 
1.3.1 Therapy options in PFHH 
Different treatment options have been employed for PFHH. These therapies have 
been summarised as follows:- 
 
Topical agents: Over the counter antiperspirants such as aluminium chloride salts 
are commonly used as first line therapy for the treatment of moderate cases of PFHH. 
They are usually used at a concentration of 15% (in aqueous solution thickened with 
methylcellulose) to treat hyperhidrotic armpits or at increased concentrations (i.e., 
25-35%) for hyperhidrotic palms and soles (Hamm and Naumann 2009). These 
compounds are known to block mechanically the duct of eccrine sweat glands thus 
preventing sweat release (Hoorens and Ongenae 2012). This treatment has the 
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disadvantage of requiring daily applications, which often results in skin irritation and 
painful sensation. Moreover it is usually poorly effective for treating anatomic sites, 
other than the axillary region, such as the palms and the soles (Hamm and Naumann 
2009) 
The use of a topical anticholinergic such as 0.5-2% topical glycopyrrolate has also 
been reported (Kim et al. 2008; Sanchez et al. 2010). Although effective and 
generally well tolerated, the treatment relies on repeated applications due to the short 
lasting effect (i.e., euhidrosis was only reported for 2 days) (Kim et al. 2008). 
 
Iontophoresis: Tap water iontophoresis (TWI) is an FDA approved treatment for 
palmo-plantar hyperhidrosis (Glaser et al. 2007c; Hoorens and Ongenae 2012). The 
treatment is generally performed by placing feet or hands into basins filled with tap 
water through which electric current (usually 15-20 mA) is applied for approximately 
15-30 minutes with the aid of electrode devices (Reinauer et al. 1993). Although the 
mechanism by which TWI inhibits sweat production is not entirely known, it is 
believed that the electric current plugs the ducts of the eccrine glands with ions, thus 
obstructing sweating secretion (Karakoc et al. 2002). As a non-invasive technique, it 
is generally the treatment of option for patients for whom the topical agents have not 
produced an acceptable therapeutic effect. Even if effective, it has the disadvantages 
of requiring long and repeated treatments. A range of 6 to 10 treatments are usually 
required to produce a significant sweating reduction, with the need to repeat the 
procedure every 1 to 4 weeks to maintain the therapeutic effect (Hamm and 
Naumann 2009). Additionally, TWI is usually associated with side effects such as 
erythema, pain sensation, skin burning and vesicular formation (Karakoc et al. 2002). 
Moreover, although TWI has been reported to be effective for palmo-plantar PFHH 
(Dahl and Glent-Madsen 1989; Glaser et al. 2007c; Shrivastava and Singh 1977), 
practical considerations limit its use for other forms of PFHH. 
Anticholinergics such as glycopyrrolate or hexopyrronium bromide administered 
through iontophoresis have shown to prolong the anhidrotic effect compared to TWI 
(Abell and Morgan 1974; Dolianitis et al. 2004) However, systemic side effects 
related to the anticholinergic activity of these drugs (i.e. blurred vision, urinary 
retention, constipation, dry mouth and others) have been reported (Abell and Morgan 
1974). 
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Oral drugs: Anticholinergic drugs (i.e.,glycopyrronium and propantheline bromide) 
administered orally have been shown to significantly reduce the secretion of sweat. 
However, the emergence of systemic side effects has limited their use in clinical 
practice (Bajaj and Langtry 2007). These drugs are not licensed in the UK for the 
treatment of PFHH and none has been clinically assessed for this indication (Glaser 
et al. 2007c).  
Other oral agents such as benzodiazepines, anxiolytics and β-blockers have been 
used for patients with PFHH triggered by stress and anxiety (Praharaj and Arora 
2006). However, the first two types of medications can be considered advantageous 
only if administered for short periods, due to their sedative effect and the potential to 
induce dependency (Atkins and Butler 2002).  
 
Botulinum toxin A (BTX A) by intradermal injection: BTX-A (serotype A of 
Botulium toxin) has been officially licensed in the UK since 2004 for the treatment of 
axillary PFHH, becoming a valid alternative treatment for patients for whom topical 
treatments have failed (Price J. 2008a). This alternative treatment is discussed in 
greater details later in this Chapter (Section 1.5). Delivery of BTX A by 
iontophoresis and phonophoresis will also be discussed (Section 1.5.3). 
 
Surgical treatments: 
1. Sweat gland excision. Surgical removal of the eccrine sweat glands from the 
armpit regions of patients affected by axillary PFHH has represented the most 
effective method to achieve a euhidrotic state. However, this treatment has 
largely been abandoned due to the high incidence of complications reported 
(i.e. impairment of arm movement, infections, extensive scars and 
haematomas) (Hoorens and Ongenae 2012).  
2. Endoscopic Transthoracic Sympathectomy (ETS). Although highly 
effective, ETS represents the most invasive surgical treatment for PFHH. 
This procedure involves surgical interruption of the cholinergic message from 
the ganglia to the cholinergic nerve endings, thus resulting in block of 
glandular secretion (Atkinson et al. 2011). ETS has most commonly been 
employed for the treatment of palmar and plantar PFHH as its use for axillary 
and facial hyperhidrosis has been reported as less effective (Hamm and 
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Naumann 2009, Smidfelt and Drott 2011). Common drawbacks associated 
with this procedure are the occurrence of surgical complications as well as 
the appearance of compensatory sweating in areas not previously affected by 
PFHH (usually the back, the abdomen and the legs), some months after the 
treatment (Lin et al. 2001a). Therefore, this treatment it is usually reserved 
for those individuals who have not responded to all the other therapeutic 
options (Hamm and Naumann 2009). 
 
1.4 Botulinum toxin: structure and function 
Botulinum toxin (BTX) was first identified in the 19
th
 century (Van Ermengem 
1897), as the product of the bacterium Clostridium botulinum and the causative agent 
of ‘botulism’ (Erbguth 2009). This is a clinical condition characterized by reduction 
of motor capacity that can progress to respiratory paralysis and death (Pinder 2007). 
Different strains of Clostridium botulinum produce different serotypes of BTX, 
classified with the letter A through G (Dolly and Aoki 2006). All toxin serotypes 
have the same mechanism of action. They prevent the release of acetylcholine (Ach) 
by the cholinergic fibres into the pre-synaptic space, thus inducing muscular 
paralysis and blockade of glandular secretion. The duration of the effect is transitory. 
Recovery of the neurotransmission is eventually re-established through nerve 
regeneration and secretion of new Ach within about 3 months (De Paiva et al. 1999).  
The toxin consists of a single-chain polypeptide of molecular mass 150 kDa which is 
inactive or partially active until cleaved by specific proteases either produced by the 
bacteria or the intoxicated organism (Dressler and Bigalke 2009). Once cleaved, the 
activated BTX consists of two chains: one light chain of 50 kDa and one heavy chain 
of 100 kDa. Both chains are connected by a disulphide bond, and non-covalent 
interactions. The integrity of the disulphide bridge is essential for the activity of the 
toxin making this compound extremely fragile to high temperatures (e.g. 
temperatures higher than 90°C denaturate the toxin in few minutes (Jay 2005)).  
The 100 kDa-heavy chain mediates binding of the toxin to the surface of pre-synaptic 
nerves and subsequent internalisation of the toxin by endocytosis (Arnon 2001) 
(Figure 1.5). The 50 kDa-light chain contains a zinc-dependent protease that 
recognises specific membrane proteins called soluble n-ethylmaleimide-sensitive-
factor attachment receptor (SNARE) proteins (Arnon 2001). These proteins 
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aggregate in a fusion complex, which is responsible for exocytosis of the 
neurotransmitter Ach from the nerve endings to the synaptic space. In particular, 
BTX A cleaves specifically the 25 kDa synaptosome-associated protein (SNAP-25), 
while other BTX serotypes recognise different proteins of the complex (Figure 1.5). 
This results in inhibition of Ach release from the nerve endings with subsequent 
block of muscle contraction and glandular secretion. 
When released by bacteria the toxin is non-covalently associated with accessory 
proteins to form a macromolecular complex, the botulinum complex, with a 
molecular weight of up to 900 kDa. These accessory proteins are non toxic protein 
components consisting of haemagglutinins (HA) and non toxic non haemagglutinin 
(NTNH) proteins (Simpson 2004).  
The presence of these proteins seems to play a key role in the process of oral 
intoxication due to their capability to protect the toxin from the extreme conditions in 
the gut (i.e., low pH and presence of proteolytic enzymes) (Simpson 2004). These 
proteins dissociate at physiological pH. This implies that the toxin should be released 
from the complex once it has entered the systemic circulation. Thus, accessory 
proteins assist migration of the toxin to the ultimate targets of the neuronal cells.  
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Figure 1.5: The mechanism of action of botulinum toxins (BTXs) (A) The fusion 
complex SNAREs (consisting of the proteins Synaptobrevin, SNAP-25 and Syntaxin) 
mediate exocytosis of the neurotrasmitter Ach to the synaptic cleft. Once released, Ach binds 
receptors specifically located on muscle/glandular cells. (B) BTX is internalised into the 
nerves by endocytosis following interaction of the heavy chain of the toxin with specific 
membrane receptors. The light chain of BTX cleaves specific SNARE proteins preventing 
formation of the synaptic fusion complex and thus blocking Ach release. In particular, BTX 
A, C and E cleave SNAP-25, BTX B, D, F and G cleave Synaptobrevin and BTX C cleaves 
Syntaxin. This results in block of muscle contraction and glandular secretion (only muscle 
fibre is illustrated in the Figure). Figure adapted from (Arnon 2001). 
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The discovery that BTX was able to reduce muscle activity by blocking the release 
of Ach was made in 1949 (Price J. 2008a). Since that time, many studies have been 
performed in order to evaluate the structure and mechanism of action of BTX and to 
exploit its properties for therapeutic purposes. Among the different BTX serotypes 
isolated, only types A and B are clinically used. Type A (BTX-A) is the most 
extensively employed, being the serotype with the longer duration of action (ranging 
from 3 to 6 months) (Dolly and Aoki 2006). 
Many different BTX products are currently available in the market for the treatment 
of neurological disorders involving involuntary muscle contraction and excessive 
glandular secretions. The different BTX drugs, as well as their therapeutic 
applications, are discussed in greater detail in the following Section. 
 
1.4.1 Commercially available botulinum toxin formulations  
Five BTX drugs are currently available in the market (Price J. 2008b), four of these 
contain BTX A (Xeomin
®
, Dysport
®
, Botox
®
 and Vistabel
®
), and only one BTX B 
(Neurobloc
®
) (Table 1.1). The latter is commercialised as Myobloc
®
 in USA and 
Canada and it is generally used for those patients who have developed an immune 
response against the serotype A (Truong and Jost 2006).
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Other BTX A drugs include Hengli
®
 (Lanzhou Institute of Biological Products, 
Lanzhou, Gansu Province, China), distributed in some Asian and South American 
countries with the commercial name of CBTX A or Prosigne
®
 and Neuronox
®
 (Medy 
Tox, Ochang, South Korea) sold in Korea and in some other Asian countries 
(Dressler and Bigalke 2009).  
Indications for BTX products currently licensed in Europe, including conditions such 
as cervical dystonia, strabismus and PFHH, are outlined in Table 1.1. PFHH will be 
discussed in greater detail in the following Section (1.5). Off label use is extremely 
extensive and comprises: i) neurological disorders (such as various forms of focal 
dystonias (Truong 2012), tremors and focal spasticity (Das 2009; Truong and Jost 
2006)), ii) urological and gastrointestinal defects (such as overactive bladder (Denys 
et al. 2012) and anal fissure with associated constipation (Keshtgar et al. 2009)), iii) 
skin related conditions (i.e., dyshidrotic hand eczema, inverse psoriasis, 
pachyonichia congenital (for a review see (Feily et al. 2011)), iv) various 
hypersecretory defects (i.e., Frey syndrome (De Bree et al. 2009) and hot flushes in 
menopausal patients (Yagima Odo et al. 2011)) and v) numerous conditions of pain 
(i.e., musculoskeletal pain (Benecke et al. 2011) and headache (Silberstein 2009)).  
Beside the therapeutic use, BTX A represents the most common aesthetic procedure 
employed in the world, with millions of treatments performed every year in the USA 
(www.surgery.org). For cosmetic uses, the toxin is intramuscularly injected to facial 
muscles to reduce the appearance of wrinkles located on the forehand (glabellar 
lines), on the periocular region (‘crow’s feet’) or around the lips (Ghalamkarpour et 
al. 2010; Sposito 2002). 
 
1.4.1.1 Characteristics of different botulinum toxin products 
Clinically approved BTX products contain various protein complexes, consisting of 
the 150 kDa BTX associated to non toxic accessory proteins (as mentioned above). 
This results in different molecular weight BTX dugs. For example, Botox
®
 
(manufactured by Allergan) is produced in the form of a 900-kDa complex, whereas 
Dysport
®
 (manufactured by Ipsen) comprises only a small proportion of the 900-kDa 
complex and it is mainly constituted by various molecular weight BTX A complexes 
(ranging between 500 and 700 kDa). Conversely, Xeomin
®
 (manufactured by Merz) 
contains only BTX A in the form of the naked toxin (150 kDa) (Aoki et al. 2006). 
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Although complexing proteins increase the size of the neurotoxin, studies comparing 
diffusion of different BTX drugs within target tissues have not highlighted any 
significant differences in the extent of toxin diffusion between Xeomin
®
 and Botox
®
 
when delivered either to skin (Dressler 2009) or muscles (Carli et al. 2009; Hexsel et 
al. 2008). This seems to be associated with a rapid dissociation of the BTX complex 
at physiological pH (Eisele and Taylor 2008), so that diffusion would depend 
exclusively on the size of the naked toxin (150 kDa), which is the same for both BTX 
drugs. Nevertheless, a recent study indicated that dissociation of the BTX complex 
occurs within the therapeutic preparation itself (Eisele et al. 2011) and therefore BTX 
would be delivered within the tissue already in its naked form.  
All the BTX drugs differ in terms of excipients and dose of neurotoxin (Price J. 
2008a) as outlined in Table 1.2. Excipients used include sucrose or lactose as a 
means to maintain conformation of the toxin, human serum albumin (HSA) to 
prevent it from aggregating on to the wall of vial or other surfaces and specific buffer 
systems (Carruthers and Carruthers 2008; Panicker and Muthane 2003). The reduced 
pH (5.6) of Myobloc
®
/Neurobloc
®
 in comparison to the other BTX drugs (pH= 7.4) 
has been associated with a more intense pain at the injection site (Dressler et al. 
2002; Yamauchi and Lowe 2004). All BTX preparations, except for 
MyoBloc
®
/NeuroBloc
®
, consist of a powder to be reconstituted with 0.9% w/v 
NaCl/H2O (saline solution) and stored at refrigerated conditions (below 8°C). All 
BTX drugs have a shelf life ranging between 24-36 months when stored at 4-8°C 
(i.e. Dysport
®
 shelf life is equal to 24 months, whereas Botox
®
 and 
Myobloc
®
/Neurobloc
®
 is 36 months), with the exception for Xeomin
®
, which is 
stable for at least 48 months at room temperature (Dressler 2012). 
Significant differences between BTX drugs are related to their biological activity, 
expressed as a mouse unit (MU) (or simply in units (U)), defined as the dose of toxin 
that is able to kill 50% of a mouse population following intraperitoneal injection with 
a BTX drug (Dressler and Bigalke 2009). As the assay methods used to determine 
the activity vary among the different BTX drugs manufactures, the activity labelling 
of the drugs cannot be compared directly. The potency of Botox
® 
has been reported 
to be identical to Xeomin
®
  (i.e, 1 MU of Xeomin
®
 is clinically equivalent to 1 MU 
of Botox
®
) (Dressler et al. 2008), whereas the potency of Dysport
®
 has been 
estimated  to be approximately 1/3 (Ranoux et al. 2002) or 1/4 of Botox
®
 (Moreau 
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2003). As a consequence of the numerous differences between the product 
formulations, the BTX drugs are not interchangeable. 
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1.5 BTX products for the treatment of PFHH 
As previously mentioned (Section 1.3), Botox
®
 represents the sole BTX A 
preparation currently licensed in the UK for the treatment of axillary PFHH. Botox
®
 
approval was based on a large double-bind, placebo-controlled trial that clearly 
indicated the beneficial effect of BTX A, through inhibition of excessive sweat 
secretion and improvement in quality of life, in patients affected by axillary PFHH 
(Naumann and Hamm 2002; Naumann et al. 2001). The treatment was successful in 
82%-94% of the patients treated and lasted for several months. 
Nevertheless, a large variety of published studies have documented the suitability of 
Botox
®
 as a means to reduce sweat secretion in hyperhidrotic sites other than the 
axillary region, such as palms (Gregoriou et al. 2010; Naver et al. 1999, 2000; 
Shelley et al. 1998), soles (Campanati et al. 2003), trunk (Hexsel et al. 2009; Kim et 
al. 2009a) and cranio-facial region (Geddoa et al. 2008; Hexsel et al. 2008; 
Komericki and Ardjomand 2012; Trindade de Almeida et al. 2007). The efficacy of 
BTX A at these sites, assessed both subjectively and quantitatively, has been 
reported to be as high as axillary PFHH (around 80-90%). 
Although Botox
®
 remains the most widely studied preparation for PFHH, reports 
have indicated that this condition can be successfully treated by using other BTX 
drugs i.e. Xeomin
®
 (Dressler 2009), Dysport
®
 (Moreau 2003) and 
Neurobloc
®
/Miobloc
®
 (Dressler et al. 2002; Yamauchi and Lowe 2004). Therapeutic 
effects, comparable to Botox
®
, have been reported by adopting specific dose ratios, 
due to the difference in the potency between different BTX drugs (Section 1.4.1). For 
example, in a study conducted by Moreau et al. (2003) a conversion factor of 1:4 was 
used for Botox
®
 and Dysport
®
 in the treatment of palmar PFHH. Conversely, in the 
studies reported by Dressler et. al. (2002) and Yamauchi and Lowe (2004) a ratio 
1:20 was adopted for Botox
®
 and Neurobloc
®
/Miobloc
®
 for the treatment of axillary 
and cranial PFHH respectively. Conversely, due to the equivalency between Botox
®
 
and Xeomin
®
 a conversion ratio of 1:1 was used to treat cranial, axillary and palmar 
PFHH (Dressler 2009). 
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1.5.1 Dose and injection grid of Botox
®
 for PFHH 
BTX administration for PFHH involves a grid of intradermal injections into the 
affected site(s). The number of injections depends on the size of the area to be 
treated, on the anatomic differences among individuals and on the severity of the 
hypersecretory disorder (Glaser et al. 2007b). These injections require high precision 
and necessitate administration by trained personnel in hospitals and specialist 
centres. 
For the treatment of axillary PFHH, Allergan (http://www.allergan.com/index.htm 
2011) recommends to dissolve the entire vial of Botox
® 
(100 U of toxin = 5 ng) in 4 
ml of 0.9% preservative-free sterile saline solution. Each armpit is subsequently 
treated with 50 U (2.5 ng) of toxin injected intradermally by using a 30 gauge needle, 
in 0.1-0.2 ml aliquots, uniformly distributed in 10-15 sites, spaced 1-2 cm apart. The 
monograph suggests to insert the hypodermic needle to a 2 mm depth and to 
orientate it at a 45° angle to the skin surface with the bevel faced up in order to 
prevent leakage of the formulation and maintain the needle within the dermis 
(http://www.allergan.com/index.htm 2011). However, in clinical practice the range 
of dilutions, the injected volumes and the number of injections are varied according 
to the severity of the sweating and the personal preferences of the physician (Glaser 
et al. 2007b). Dilution volumes ranging between 1.5-5 ml, distributed in aliquots of 
0.05-0.1 ml, have most frequently been reported (Campanati et al. 2003; De Almeida 
et al. 2011; Glaser et al. 2007b; Gulec 2012; Talarico-Filho et al. 2007). Conversely, 
injection volumes larger than 0.1 ml have been less commonly been employed due to 
their higher potential to diffuse to unwanted areas (such as the muscles) or to extrude 
from the injection site (Glaser et al. 2007b). 
Although the Botox
®
 monograph recommends the use of preservative-free saline to 
reconstitute the drug, studies have indicated that preserved saline can be used to 
reduce injection pain (Alam et al. 2002). Moreover, Gulec et al. (2012) reported 
reduction of pain when reconstituting the preparation Botox
®
 with preservative-free 
saline previously mixed to the anaesthetic lidocaine. 
Similar procedures and techniques are usually employed to treat palms and soles, 
although the latter usually requires larger doses. Botox
® 
doses ranging between 25-
220 U (corresponding to a mass of toxin of 1.25-11 ng) have been administered per 
hand (fingers included) by a number of 5-50 injections for palmar PFHH (Figure 1.6 
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B) (Glaser et al. 2007c; Holmes and Mann 1998; Lowe et al. 2002; Naver et al. 
1999). Plantar PFHH has been treated by administering a range of 50-180 U (i.e., 
2.5-9 ng) of toxin per sole distributed in 15-50 sites (Figure 1.6 A) (Campanati et al. 
2003; Vadoud-Seyedi 2004). Studies regarding the treatment of PFHH in the 
craniofacial region have indicated BTX A doses ranging between 20-100 U (0.1-5 
ng) can be administered to a specific area of the face (i.e. the forehead or the nose) 
by a series of 20-30 injection (Geddoa et al. 2008; Glaser et al. 2007a; Tan and 
Solish 2002). Due to the temporary ability of BTX to block sweat production, the 
treatment has to be repeated every 4-6 months (Hamm and Naumann 2009). 
 
 
 
Figure 1.6: Injection grids for plantar (A) and palmar (B) PFHH. The areas to be treated 
are highlighted with a marker pen (blue dots in the images). These markings can be imaged 
as a grid of injection sites. Figures adapted from (Doft et al. 2012). 
 
1.5.2 Side effects related to the administration of BTX A 
using conventional hypodermic needles 
Due to the large number of injections required to effectively treat hyperhidrotic 
areas, administration of BTX is associated with intense pain and discomfort for the 
patient (Gulec 2012; Naumann et al. 1998b; Naver et al. 2000; Sanli et al. 2004). 
Studies have reported that pain is not only perceived during the injection procedure 
(as a consequence of needle penetration and liquid extrusion into the skin) but that it 
also persists up to 1-2 days in the treated areas (Saadia et al. 2001). Therefore, 
adequate anaesthesia is required to eliminate or alleviate pain when administering 
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BTX A, especially to sensitive areas such as the palms and soles. Nerve block is 
generally employed as local anaesthesia for hands and feet (Grunfeld et al. 2009) 
because it enables more precise injections and better comfort for the patients. This is 
usually performed by injecting 2-4 ml of lidocaine or mepivacaine 1-2% to block the 
ulnar and median nerves (wrist block) of the hand and the posterior tibial and sural 
nerves of the feet (Hamm and Naumann 2009). Conversely, topical lidocaine 4% is 
generally sufficient to induce adequate anaesthesia in other anatomic sites (i.e. facial 
and axillary region) characterised by a reduced skin thickness (Glaser et al. 2007a, 
b). 
Potential risks associated with nerve blocking anaesthesia include vascular puncture 
and permanent nerve damage, especially for prolonged and repeated treatments 
(Campanati et al. 2004; Grunfeld et al. 2009; Hayton et al. 2003). Furthermore, the 
discomfort caused to the patient has to be taken into account. The duration of the 
anaesthesia lasts over 1 hour after the treatment and if feet or hands have been treated 
at the same time, the patient will require assistance for several hours after the 
procedure. 
Vibration anaesthesia, administered with handled massagers or other similar devices, 
and cryoanesthesia, employing ice or cold packs of liquid nitrogen to numb the area 
before injections, do not generally provide sufficient analgesia, especially for plantar 
PFHH due to the thicker stratum corneum on the soles (Glaser et al. 2007b; Grunfeld 
et al. 2009; Yamashita et al. 2008). The use of MED-JET
®
 MBX (Medical 
International Technologies, Montreal, QC, Canada), a needle free device that utilises 
air pressure to inject a drug formulation, has also been reported to deliver lidocaine 
2% to hyperhidrotic palms and feet (Benohanian 2007). However, this device has the 
disadvantage of requiring a large number of injections (i.e. an average of 50 
injections in the palm and 30 in the sole) to induce an appropriate analgesic effect. 
The use of a similar device (commercialised as Dermojet
®
) has also been reported for 
intradermal delivery of BTX A (Botox
®
) and will be discussed in greater detail in 
Section 1.5.3. 
 
Muscle weakness 
The most common side effect associated with BTX A treatment is a temporary 
weakness of muscles adjacent to the injection. Muscles weakness usually occurs 
contemporaneously to the reduction of sweat (generally 1 week after the treatment) 
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and lasts for 4-8 weeks. This has most frequently been reported for palmar (Naver et 
al. 2000; Saadia et al. 2001; Sevim et al. 2002) and forehead PFHH (Kinkelin et al. 
2000; Tan and Solish 2002) usually resulting in weakened pinch between the thumb 
and index fingers and partial disability in frowning or wrinkling the muscles of the 
forehead. Conversely, only one study in the published literature has reported the 
emergence of weakness of the muscles in the soles of the feet (Sevim et al. 2002).  
Muscle weakness seems to be correlated to the number of injections, volume and 
dose used and to the difficulty in controlling the injection depth when performing the 
intradermal injection using the Mantoux technique (Glaser et al. 2007b). Published 
studies reporting the use of hypodermic needles with a reduced exposed length (i.e. 
~2-3 mm) have indicated reduction or absence of muscular weakness in treated 
palms (De Almeida et al. 2001; Zaiac et al. 2000). In particular, De Almeida et al. 
(2001) reported the use of a device adapted from a cartridge rubber used in dental 
syringe, to reduce the length of a 30 gauge hypodermic needle from 7 to 3 mm. 
Although a better control of injection depth was achieved, the BTX A treatment still 
required nerve block anaesthesia in the palms to reduce the pain at the injection sites. 
 
Soreness and dry skin 
Another side effect related to BTX administration is soreness at the injection sites. 
This has occurred in BTX treated palms and it has required application of 
moisturizers to reduce the discomfort (Naver et al. 2000).  
 
Systemic effects  
Systemic adverse effects related to the anticholinergic activity of BTX (blurred 
vision, dry mouth, constipation, urinary retention) have not frequently been reported 
and are more likely related to the use of BTX B (Neurobloc
®
/Miobloc
®
) (Dressler et 
al. 2002).  
 
Bleeding and loss of drug formulation  
Other events, typically associated with intradermal administration by conventional 
needles and syringes, are bleeding at the injection site (Hexsel et al. 2008; Trindade 
de Almeida et al. 2007) and extrusion of some formulation (Glaser et al. 2007b). 
Presence of blood during BTX administration represents a professional hazard as it 
exposes personnel to needle stick injuries and thus to potential infections such as 
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HIV and hepatitis. Additionally, loss of drug formulation during administration 
determines waste of expensive material and reduction of dose accuracy. 
 
1.5.3 Use of less invasive methods for intradermal delivery 
of BTX A  
Due to the considerable pain and discomfort associated with BTX treatment and the 
need to repeat the procedure every 4-6 months, efforts have been made to reduce the 
invasiveness of the treatment, but success has been variable (Collins and Nasir 2010; 
Glogau 2007; Vadoud-Seyedi 2004).  
A limited number of published studies have reported intradermal delivery of BTX A 
by iontophoresis for the treatment of palmar PFHH (Andrade et al. 2011; Kavanagh 
2006). Davarian (2008) indicated that palms treated by BTX A administered by 
iontophoresis showed significant sweat reduction 1 week after the treatment and that 
dryness persisted for up to 12 weeks. On the contrary, iontophoresis of hands with 
normal saline showed reduction of therapeutic effect 3 weeks after the treatment. The 
treatment was associated with a good safety profile, as typical BTX A-related side 
effects such as hand muscle weakness were not reported.  
The exact mechanism through which iontophoresis mediates cutaneous delivery of a 
non ionic, large compound such as BTX A, is not completely understood. It has been 
postulated that penetration of BTX A across the skin following application of an 
electric field may be determined by a combination of multiple factors such as: i) 
induction of a flux of liquid solvent containing the uncharged drug through pre-
existing pores in the stratum corneum (electro-osmosis), ii) formation of new pores 
in the skin (electroporation) or iii) increase in size of pre-existing pores (such as hair 
follicles and sweat gland ducts) (Davarian et al. 2008). In particular, iontophoresis is 
believed to force BTX A down the sweat ducts and thus to facilitate direct interaction 
of the medicament with the sweat glands (Kavanagh 2006). 
BTX A has also been delivered to palmar skin by phonophoresis, a technique which 
uses ultrasounds to enhance delivery of topically applied drugs (Byl 1995). There is 
only one study in literature reporting the use of this method for the delivery of BTX 
A for palmar PFHH (Andrade et al. 2011). Within this study, phonophoresis and 
electrophoresis were compared and used as a pre-treatment prior to topical 
application of Botox
®
,
 
mixed with an emollient cream (carbopol cream 1%), on 
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hyperhidrotic palms. Improvements in sweating were reported for both techniques 
but only after 10 days of a 10 daily treatment session. The therapeutic effect was 
maintained over 16 weeks of follow up (after the end of the 10 days-treatment) 
without any occurrence of adverse effects. 
In a study conducted by Chow and Wilder-Smith (2009), simple unassisted (without 
using iontophoresis or phonophoresis) transdermal penetration of BTX A was 
investigated in patients affected by palmar PFHH. For this purpose palms were 
exposed to a thermal lamp before topical application of a BTX A formulation 
(Botox
®
). The lamp was used as a means to increase opening of the pores through the 
heat and thus facilitate internalization of BTX A. The study failed to show significant 
sweat reduction, thereby demonstrating that BTX A cannot penetrate passively into 
the skin.  
Other studies have reported the use of a needle-free, jet injector device (Dermojet
®
) 
to deliver a BTX A formulation for PFHH. The Dermojet
®
 is a medical device 
consisting of an air driven injector which fires a liquid jet into the skin at high speed 
(http://www.robbinsinstruments.com/equipment/dermojet/modelg.html). The liquid 
perforates the stratum corneum barrier and penetrates to the internal layers of the 
skin. The Dermojet
® 
has been commonly used for intradermal injection of local 
anaesthetics (Carpenter C. L. et al. 1965) as well as corticosteroids and bleomycin 
for the treatment of warts and keloids (Saray and Gulec 2005). This device has been 
used to deliver BTX A to hyperhidrotic palms, axillae (Naumann et al. 1998a) and 
soles (Vadoud-Seyedi 2004; Vadoud-Seyedi et al. 2000). However, in the study 
reported by Neumann (1998a) intradermal administration of BTX A by using 
Dermojet
®
 was considerably less effective in reducing sweat production in 
comparison to conventional hypodermic needles. Moreover, the use of Dermojet
®
 is 
not recommended for PFHH due to the high risk of damage to nerves and blood 
vessels in the palms (Vadoud-Seyedi 2004). Better results, in term of patient safety, 
were reported for BTX A administration into the soles of the feet due to the deeper 
location of blood vessels and nerves, in comparison to the hands (Vadoud-Seyedi 
2004). Moreover, the treatment was reported to be effective for 80% of the patients 
and sweating cessation lasted for up to 6 months.  
Topical application of BTX A formulations following combination with transport 
peptides and mixture with emollient creams has also been evaluated for PFHH as 
well as cosmetic applications (Brandt 2011; Collins and Nasir 2010). In a study 
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reported by Glogau (2007) axillary PFHH was treated with the BTX A cream RT001 
(Botulinum Toxin Type A Topical Gel, Revance Therapeutic, Inc.). RT001 contains 
200 U of BTX A (Botox
®
) non-covalently bound to a peptidyl transport system 
which enables cutaneous permeation of the toxin via a pinocytosis process (Collins 
and Nasir 2010). The study indicated a significant sweat reduction in BTX A treated 
axillae (200 U/per site) in comparison to the placebo-control axillae, four weeks after 
BTX A application (significant reduction of ~ 65% compared to the placebo-treated 
reduction of ~25%). In addition, RT001 application was not associated with systemic 
side effects, although local cutaneous reactions such as eczema and erythema were 
reported. Data regarding the duration of the effect were not reported in the study. 
The variety of investigations seeking alternative BTX A delivery methods testifies 
that there is a clear need for a safer and less invasive administration method for this 
medicament. For this reason MDs are proposed as a minimally invasive device to 
facilitate cutaneous administration of BTX A. 
 
1.6 Microneedle array devices (MDs) 
A MD is somewhere between a hypodermic needle and a trans-dermal patch (Figure 
1.7). The device consists of from 1 up to many hundreds of microneedles, generally 
ranging from 100 to 1000 µm in length and projecting from a solid planar support. A 
MD is designed to perforate the stratum corneum barrier to provide direct access for 
medicaments to the underlying epidermis or dermis. 
By bypassing the stratum corneum, microneedles have significantly enhanced the 
cutaneous delivery of molecules, which could not normally be administered across 
the skin. Examples include i) small hydrophilic compounds (Gill and Prausnitz 
2007a; Henry et al. 1998; Park et al. 2006), ii) peptides (Burton et al. 2011; Cormier 
et al. 2004; Wu et al. 2010), iii) proteins (Kim et al. 2009b; Matriano et al. 2002; 
Saurer et al. 2010), iv) oligonucleotides (Lin et al. 2001b), v) plasmid DNA (Birchall 
et al. 2005; Chen et al. 2010), and v) nano and microparticles (Coulman et al. 2009; 
Gill and Prausnitz 2007b; McAllister et al. 2003)  
Microneedles are designed to successfully perforate the stratum corneum barrier 
without reaching the nerves fibres and blood vessels located in the more internal 
layers of the skin (Figure 1.8). MD insertion has been reported as minimally painful, 
effortless and blood free (Birchall 2006; Haq et al. 2009; Kaushik et al. 2001). 
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Therefore, MDs allow a safe and minimally invasive administration of medicaments 
and offer the potential of a self administration. 
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Figure 1.7: Appearance of a microneedle array device. Figure adapted from (Gill and 
Prausnitz 2007b) 
 
 
 
Figure 1.8: Schematic representation of the mechanism of action of a microneedle 
array device. The device perforates the stratum corneum providing direct access of drugs to 
the underlying viable epidermis, without reaching blood vessels and nerve fibres located in 
the dermis.  
 
Although the first MD was proposed in the 1970s (Gerstel 1976), its practical 
application was only demonstrated in the 1990s as a consequence of advances in the 
microelectronic industry. The first MD, realized in 1998 by Dr Mark Prausnitz et al. 
at the Georgia Institute of Technology, consisted of an array of micron sized silicon 
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needles over a solid support (Henry et al. 1998). This study reported the first 
demonstration of drug delivery in human skin by using a microneedle array device. 
Various materials, shapes and designs have been employed in the fabrication of 
microneedles. While initial microneedles were manufactured by using silicon as a 
material, (Arora et al. 2008), metals (steel, titanium and nickel-iron), glass and 
polymers have lately been employed (Birchall 2006).  
 
1.6.1 Mechanism of action of different MD designs 
Different designs of MDs have been produced, each one tailored to the specific 
application required (Figures 1.9 and 1.10). They can be summarised as follows:- 
 
1. Solid microneedles. Usually constituted by silicon or metal, solid 
microneedles can either be pressed or scraped onto the skin and then 
withdrawn. Subsequently, a drug formulation can be topically applied to the 
MD treated skin. The drug will then diffuse through the microchannels to the 
underlying epidermis or dermis (McAllister et al. 2003; Wu et al. 2010). 
 
2. Solid coated microneedles. The drug is encapsulated in a formulation that 
has been dry coated onto solid microneedles (Chen et al. 2009; Gill and 
Prausnitz 2007b; Widera et al. 2006). Following insertion of the array into the 
skin, the coated layer dissolves rapidly (within minutes) in the epidermis or 
dermis and the array is subsequently withdrawn. 
  
3. Dissolving microneedles. Dissolving microneedles have been manufactured 
by using biodegradable or water-soluble polymers. Drug molecules have been 
incorporated within these microneedles for rapid or sustained release within 
the skin following microneedle application. Materials employed in the 
fabrication of this kind of microneedles include poly-L-lactide (PLA), 
polylactic-co-glycolic acid (PLGA) and copolymers of methylvinylether and 
maleic anhydride (PMVE/MA) for controlled drug release (ranging from 
hours to months) (Donnelly et al. 2011; Park et al. 2006) or sugars (i.e., 
carboxymethylcellulose (CMC), trehalose, maltose and sucrose) for rapid 
(within minutes) drug release (Lee et al. 2008; Martin et al. 2012). 
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4. Hollow microneedles. Hollow microneedles contain individual bores 
through which a drug solution can be infused in a manner similar to 
hypodermic injections. Infusion occurs through application of a specific 
pressure that is normally generated by a syringe, to which one single 
microneedle or an array or multiple microneedles can be attached (Alarcon et 
al. 2007; Van Damme et al. 2009). Syringe pumps (Gupta et al. 2009) and 
application springs (Burton et al. 2011) have also been reported to control the 
flow of the liquid through the needle bores. Hollow microneedles have also 
been employed as a microconduits through which a formulation can diffuse 
from a drug reservoir (Hafeli et al. 2009).  
 
5. Pocketed microneedles. Pocketed microneedles are solid microneedles 
containing a central cavity within the needle shaft. They have been generally 
used to facilitate delivery of model drugs in a dry state in a similar manner to 
non pocketed solid microneedles (Gill and Prausnitz 2007b; Gill and 
Prausnitz 2008). The use of this specific microneedle design has not 
extensively been reported within the microneedle research community. As 
such, this represents a relatively novel approach to transdermal drug delivery. 
Characteristics of pocketed microneedles will be discussed in greater detail in 
the following Chapter. 
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Figure 1.9: Schematic representation of mechanism of action of different designs of 
microneedles: a) solid microneedles for increasing the permeability of a drug formulation 
by creating micro-holes across the skin, b) coated microneedles for rapid dissolution on the 
skin of the coated drug c) polymeric microneedles incorporating a drug for rapid or 
controlled release into the skin, d) hollow microneedles to puncture the skin followed by 
active infusion or diffusion of the formulation through the needle bores. Figure adapted from 
(Arora et al. 2008). 
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Figure 1.10: Schematic representation of a pocketed microneedle device. The 
formulation, retained within the needle cavities, is released following insertion of the 
microneedles into the skin.  
 
1.6.2 Microneedle parameters  
The design of a MD is affected by a variety of parameters. First of all, microneedles 
must possess sufficient strength to permit insertion into the skin without breaking. 
Solid microneedles fabricated out of metals are usually robust enough to penetrate 
the skin without failing (Park et al. 2005). Conversely, when polymers are used, 
specific fabrication materials must be selected in order to ensure appropriate 
microneedle strength. 
Other parameters such as sharpness of tip, length, shape and width of the needles all 
affect the force required to apply the microneedles into skin and that required to 
prevent their fracture. In particular, microneedles with sharpened tips require a lower 
force to pierce the skin, whereas microneedles with higher wall thickness, greater 
wall angle and lower length can withstand higher force before failure (Davis et al. 
2004; Park et al. 2005). 
The most commonly reported geometries of a micro-delivery system can be 
summarised as follows (Arora et al. 2008):  
 
 Length: range between 150-1000 µm 
 Base width: range between 50-250 µm 
 Tip diameter: range between 1-25 µm 
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1.6.3 Current microneedle applications 
The capability of a MD to facilitate cutaneous delivery of drugs has been extensively 
studied in vitro, in animals and in humans. Therapeutic compounds have been 
administered for local action in the skin or for systemic effect following adsorption 
of the compounds into the bloodstream. Examples of medicaments administered by 
microneedle devices are discussed in the following Sections.  
 
1.6.3.1 Cutaneous delivery of low molecular weight drugs 
Low molecular weight drugs such as naltrexone, an opioid receptor antagonist used 
for the treatment of alcoholism and opioid addiction, and the anaesthetic lidocaine 
have been delivered across the skin via microneedles. Therapeutic doses of 
naltrexone were delivered from a transdermal patch following permeabilization of 
the skin through insertion of solid microneedles (Wermeling et al. 2008). Lidocaine 
was delivered into pigs following application of a lidocaine coated MD. Lidocaine 
levels assessed in excised skin biopsies were considered appropriate to induce 
sustained local anaesthesia (Zhang et al. 2011). In a more recent study, the 
anaesthetic was delivered into humans by hollow microneedles and compared to 
conventional intradermal administration by hypodermic needles (Gupta et al. 2012). 
The study revealed comparable local anaesthesia between the two delivery systems. 
However, microneedle treatment was perceived as significantly less painful and it 
was strongly preferred by all individuals in the study. Other small hydrophilic 
compounds have been administered by microneedles, as recently been reviewed by 
Kim et al. (2012). 
 
1.6.3.2 Cutaneous delivery of biopharmaceutics 
Microneedles have also been extensively studied as a means to deliver 
biopharmaceutic drugs across the skin. These are peptides, proteins and DNA that 
normally cannot be administered orally (because of poor oral bioavailability) or 
transdermally (because of the high molecular weight) and that are thus almost 
entirely delivered by hypodermic injections. Insulin represents the most widely 
investigated drug among biopharmaceutics. Significant reduction of blood-glucose 
levels has been reported in human subjects and animal models following insertion of 
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solid MDs, as a pre-treatment prior to topical application of an insulin formulation 
(Martanto et al. 2004; Wu et al. 2010) or by hollow microneedle application for 
insulin infusion (McAllister et al. 2003; Nordquist et al. 2007).  
A large variety of other biopharmaceutics have been delivered by microneedles to 
animal models. Drugs such as low molecular weight heparin (Ito et al. 2008), 
desmopressin (Fukushima et al. 2011) and human growth hormone (Burton et al. 
2011; Lee et al. 2011) have been delivered by dissolving or hollow microneedles. 
Desmopressin (Cormier et al. 2004) and parathyroid hormone (Ameri et al. 2009) 
have also been administered by dry coated microneedles, while water soluble 
polymeric microneedles in combination with iontophoresis have been employed to 
facilitate delivery of insulin and BSA (Garland et al. 2012) 
Clinical trials are also underway. Hollow microneedles have been used to administer 
insulin to type 1 diabetes subjects (Gupta et al. 2009, 2011a) and parathyroid coated 
microneedles are now advancing into a phase III clinical trial for the treatment of 
osteoporosis (Daddona 2011). 
 
1.6.3.3 Cutaneous delivery of vaccines  
Microneedles have been extensively investigated as a means to deliver vaccines into 
the skin. The skin offers numerous immunological advantages over conventional 
subcutaneous administration, due to the presence of immunocompetent cells in the 
epidermis (Langherans cells) and dermis (dermal dendritic cells). However, 
cutaneous administration of vaccines has been limited due to the poor reliability of 
the conventional (Mantoux) intradermal injection method. Unlike the Mantoux 
technique, where hypodermic needles have to be inserted at an angle almost parallel 
to the skin surface, microneedles can be applied perpendicularly in the skin due to 
their reduced length, thus enabling more accurate control of the deposition depth 
(Mikszta et al. 2006). Coated microneedles have been largely investigated for 
vaccine administration. In particular in vivo animal studies have indicated that 
influenza vaccines that are delivered from dry coated MDs provide comparable or 
superior immune responses to those administered by intramuscular injections (Chen 
et al. 2009; Koutsonanos 2011; Pearton et al. 2010; Quan et al. 2010; Zhu et al. 
2009). Additional vaccines delivered to animal models from coated MDs include: 
hepatitis C DNA vaccine (Gill et al. 2010), hepatitis B surface antigen (Andrianov et 
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al. 2009), human papilloma (Corbett et al. 2010), herpes simplex virus (Chen et al. 
2010) and others. 
Hollow microneedles have also been used for intradermal delivery of vaccines such 
as anthrax (in the form of a recombinant Bacillus anthracis antigen) in animal models 
(Mikszta et al. 2006) and influenza vaccines in both animals and humans (Alarcon et 
al. 2007; Van Damme et al. 2009). 
Clinical trials have been carried out in healthy adults (Beran et al. 2009) and elderly 
people (Holland et al. 2008) using Soluvia
TM
. This is a microinjection device, 
consisting of a 1.5 mm long, small gauge, hypodermic needle attached to a syringe 
prefilled with influenza vaccine (http://www.bd.com 2012). Although the needle 
contained in Soluvia
TM
 is arguably too long to be defined as a microneedle, its use is 
worth mentioning as it represents the first therapeutic device, based on the 
microneedle concept, which has received marketing authorization. Soluvia
TM
 is 
currently commercialised worldwide as IDflu
®
, Intanza
®
 and Fluzone Intradermal
® 
for intradermal vaccination
 
(http://en.sanofi.com 2009). 
 
1.6.3.4 Microneedle products currently approved in the market 
In addition to the aforementioned Soluvia
TM
, other microneedle products are 
currently available in the market, the majority of which have been used for cosmetic 
purposes. Dermaroller
®
, consisting of metal, 0.2-2.5 mm long-microneedles 
projecting from a cylindrical roller, was firstly sold in Germany in 1999 and it is 
currently commercialised around the world (http://www.dermaroller.com/ 2011). The 
device is designed for home use to improve skin texture (smaller microneedles) or to 
be used in clinics (longer needles) to reduce the appearance of scars. An additional 
commercialised product is represented by LiteClear
®
 used to treat acne in China and 
skin cosmetic imperfections in the rest of the world (http://www.nanomed-
skincare.com 2010; Kim 2012).  
Finally, Micronjet
®
 has received FDA clearance in February 2010 
(http://www.nanopass.com). This device consists of four hollow, less that 500 µm 
long, silicon microneedles protruding from a plastic device, which can be mounted 
onto any conventional syringe (Van Damme et al. 2009). 
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1.6.5 Pain after application of a MD 
The ability of microneedles to pierce the stratum corneum in a painless or minimally 
painful way is determined in part by the length of the needles. Studies have reported 
that the insertion of an array containing 400 microneedles, 150 µm long, was 
perceived as painless in comparison to a 26 gauge hypodermic needle (Kaushik et al. 
2001). In a more recent study the effect of various microneedle parameters (i.e., 
microneedle length, base width, wall thickness, tip radius and number of 
microneedles per array) on the intensity of pain perceived was investigated and 
compared to conventional hypodermic needles (Gill et al. 2008). 
According to this study, pain was determined mainly by the microneedle length i.e., a 
3-time increase in microneedle length (i.e., 500-1500 μm) resulted in a 7-fold 
increase in perceived pain. The number of microneedles per array also influenced 
pain sensation but in a less significant way i.e., a 10 fold increase in the number of 
microneedles (from 5 to 50) produced a 2.5 fold increase in the pain, while other 
geometrical parameters did not affect pain considerably. Overall the studied 
microneedles were significantly less painful than hypodermic needles. Similarly, 
insertion of microneedles shorter than 400 µm has been referred to as painless in 
other studies (Haq et al. 2009; Mikszta et al. 2002). 
Moreover, pain caused by liquid delivery during insertion has been investigated for 
hollow microneedles. A study published by Gupta et al. (2011b) indicated that 
insertion of an hollow microneedle to a skin depth of 1mm and infusion of up to 600 
µl of saline was perceived as minimally painful by human subjects and was overall 
preferred over hypodermic needles. Similar results were confirmed by other studies 
reporting intradermal administration of lidocaine and insulin from a hollow 
microneedle up to 900 µm long (Gupta et al. 2012; Gupta et al. 2011a). 
 
1.6.6 Safety of MD application 
Microneedles have been associated with mild side effects such as localised transient 
erythema and skin irritation in humans and animal models (Gupta et al. 2009, 2011a; 
Martanto et al. 2004; Matriano et al. 2002; Nordquist et al. 2007; Wang et al. 2006). 
These reactions are usually transient and resolve completely within few hours. 
Bleeding has generally not been associated with the use of microneedles up to 1 mm 
long (Alarcon et al. 2007; Dean et al. 2005; Gill et al. 2008; Martanto et al. 2004; 
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McAllister et al. 2003). Conversely, the occurrence of small blood droplets at the 
microneedle insertion sites has been reported for longer needles (i.e., 1000-1500 µm) 
(Gill et al. 2008, Laurent et al. 2007b). Oedema has occurred when using hollow 
microneedles (Burton et al. 2011). However, it is believed that this represents a 
visual indication of the “bleb” of fluid injected, also observed following an 
intradermal injection, rather than an inflammatory reaction. 
 
1.7 Rationale of the project 
This research project has been stimulated by the large number of clinical studies 
reporting intense pain upon treatment of PFHH with intradermal botulinum toxin 
injections. In addition to the discomfort related to the numerous and repeated 
injections required, significant side effects have often been reported. Among these, 
muscle weakness is undoubtedly the most problematic, especially when it occurs at 
anatomic sites such as the hands and the soles of the feet. Delivery of the toxin to 
unwanted sites is mainly determined by the difficulty of performing intradermal 
injections using conventional hypodermic needles. This also results in waste of a 
very expensive therapeutic formulation, as well as reduction of dose accuracy and 
possibly drug efficiency. In addition, the high number of intradermal injections 
required at each treatment site increases the risk of needle-stick injuries and thus the 
potential transmission of blood-borne infections to both patients and healthcare 
providers. Numerous clinical studies report microneedle application as painless or 
associated with minimum discomfort. Driven by these considerations the use of 
microneedles is proposed in this research project as an alternative to hypodermic 
needles. It is hoped that, by using a MD for BTX A intradermal delivery, not only 
will the invasiveness of BTX A administration be mitigated but also the efficacy and 
the safety of the treatment will be enhanced and the occurrence of side effects 
reduced. 
 
1.8 Thesis aim and objectives  
The aim of this project is to investigate the potential of microneedles to deliver 
potent macromolecules such as BTX A to the dermis of human skin. The study has 
been organised to achieve the following objectives:- 
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 To characterise pocketed MDs manufactured for liquid loaded delivery. 
 To evaluate the capability of pocketed MDs to uniformly accommodate a 
formulation mimicking the composition of the commercial preparation 
Botox
®
 and to compare results with established solid MDs. 
 To evaluate the loading capability of pocketed MDs and to compare results 
with established solid MDs. 
 To assess the deposition and distribution of high molecular weight molecules 
delivered to the skin by liquid loaded PMDs and to compare results with 
established solid MDs. 
 To deliver a commercial BTX A preparation (Vistabel®) and a formaldehyde 
inactivated botulinum toxin A (i.e., botulinum toxoid A) into ex vivo human 
skin following application of liquid loaded pocketed MDs. 
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Characterisation and loading of 
solid  
microneedle devices (MDs) with 
BTX A model formulations 
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2.1 Introduction  
The main purpose of the present research project is to assess the feasibility of a 
pocketed MD to deliver commercially available BTX A preparations (Botox
®
) to the 
dermis of human skin. The experiments reported in this Chapter will investigate the 
capability of pocketed MDs to uniformly accommodate a formulation mimicking the 
composition of the commercial preparation Botox
®
. Established dry coated non-
pocketed MDs will be used as a direct comparator for liquid loaded pocketed MDs. 
 
2.1.1 Dry coated MDs 
A number of published studies have described solid MDs that have been coated with 
a dried form of a candidate drug, which rapidly (within minutes) dissolves off the 
microneedles when inserted into the skin. Studies have established that small 
hydrophilic compounds (Gill and Prausnitz 2007b; Xie et al. 2005), but also DNA 
(Chen et al. 2009; Chen et al. 2010), peptides, proteins (Ameri et al. 2009; Ameri et 
al. 2010; Cormier et al. 2004; Widera et al. 2006; Xie et al. 2005), and microparticles 
(Gill and Prausnitz 2007a) can be dry coated onto solid MDs and successfully 
delivered to human and animal skin. Further studies have demonstrated the capability 
of MDs, coated with influenza antigens, to induce an immune response comparable 
or greater than intradermal/intramuscular administration (Chen et al. 2012; Kim et al. 
2010; Kim et al. 2009b; Pearton et al. 2010; Weldon et al. 2011). Human clinical 
trials are also ongoing; parathyroid hormone coated MDs (Macroflux
®
, Zosano 
Pharma) (Daddona 2011) for the treatment of osteoporosis have successfully 
completed phase II clinical trials and are advancing into a Phase III clinical study. 
MDs can be drug coated by immersion into a coating formulation contained within a 
specifically designed dip coating apparatus (Gill and Prausnitz 2007a). Microneedles 
are usually immersed several times with specific time intervals (usually from 10 to 
30 seconds) between each immersion to allow drying of the coating film. Due to the 
reduced dimensions of the MDs, restricting access of the liquid to the shaft of the 
needles without contaminating the base of the array is particularly challenging to 
achieve. Automated dip coating devices have been specifically manufactured for this 
purpose. The use of a coating device employing a roller drum rotating into a drug 
formulation reservoir has been reported (Ameri et al. 2010; Trautman 2008). 
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Following contact of the drum with the formulation, a layer of liquid of controlled 
thickness (~100 µm) is deposited on the drum’s surface. Such coating methodology 
has been employed to succesfully coat hormones (desmopressin and the parathyroid 
hormone) (Cormier et al. 2004; Daddona 2011) and proteins (ovalbumin) (Widera et 
al. 2006) onto microneedles. Furthermore, Weldon et al. (2011) reported the use of 
an automated dip coating device, adapted from Gill and Prausnitz (2007a), consisting 
of a chamber with a coating solution and a microneedle holder attached to a linear 
stage connected to a computer. Microneedles with a length of 700 µm were moved in 
the x and y dimensions with an accuracy of 0.4 µm (2011) and were successfully 
coated with influenza vaccines. Other studies reported reasonable spatial control of 
the coating process on equal microneedle designs (i.e. coatings placed selectively on 
25%, 50%, 75% and 100% of the length of 700 µm long microneedles). The same 
coating apparatus was employed but movement of the microneedle holder was 
performed manually (the details of the coating apparatus employed by Gill and 
Prausnitz will be described in Section 2.3.2.1.1 and discussed in Section 2.4.2). 
Dry coating methodologies that do not involve a dip coating procedure have also 
been investigated as a means to successfully coat proteins and DNA vaccines on 
silicon MDs. Studies have reported the use of a gas jet drying approach to coat a 
densely packed (up to 20,000 microneedles/cm
2
) microneedle patch (called 
NanopatchTM), with a single microneedle length ranging between 30-100 µm (Chen 
et al. 2011; Chen et al. 2009). A gas jet of coating formulation (6-8 m/s) was applied 
to the microneedles at specific incident angles (20°-70°) to allow selective deposition 
of the coating either on the entire length of the microneedles or selectively on their 
apical part. This was achieved by specifically rotating the incident angle, i.e. by 
blowing the coating formulation with an angle of 20°, coatings were placed over the 
entire microneedle length and also on the surface of the patch, whereas increasing the 
angle to 70° allowed selective deposition of the coating on the microneedle tip. 
Microneedles were rotated while coatings were applied to allow uniform coating.  
Mechanically controlled dip coating technologies have been used to achieve coating 
reproducibility and uniformity but composition of the coating formulation plays an 
equally important role. Specific excipients, such as viscosity enhancers and 
surfactants are usually needed to improve coating efficiency (Ameri et al. 2010; 
Chen et al. 2011; Widera et al. 2006; Zhang et al. 2011). A study published by Gill 
and Prausnitz (2007b), assessing coating uniformity by using differently formulated 
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solutions, compared a variety of viscosity enhancers ((i.e., carboxymethylcellulose 
(CMC), sucrose, hyaluronic acid, xanthan gum, sodium alginate, 
polyvinylpyrolidone) and surfactants (Lutrol
®
/Pluronic
®
 F68 and Tween
® 
20). 
According to this study, coating formulations containing a viscosity enhancer 
produced a thicker microneedle coating. This was because more viscous formulations 
allowed retention of increased volumes of liquid on the microneedles upon each 
immersion. While thicker, the coating appeared localised along the centre of the 
microneedle shaft. Uniform coverage of the entire microneedle length was prevented 
by the high surface tension of the viscous solution. Conversely, when a surfactant 
was added to the formulation a more uniform coating was observed over the entire 
microneedle body as a direct result of the reduced surface tension and increased 
wettability of the microneedle surface. Therefore, combining a viscosity enhancer 
with a surfactant enabled a simultaneously thicker and more homogeneous coating. 
The best coating uniformity was observed when the viscosity enhancer CMC and the 
surfactant Lutrol
®
 F68 were used at concentrations of 1% w/v and 0.5% w/v in 
deionised water, using sulforhodamine as the model compound. Similarly, the use of 
other viscosity enhancers such as xanthan gum, sodium alginate and 
poly(vinylpyrrolidone) resulted in enhanced coating efficiency. The combination of a 
viscosity enhancer and a surfactant was shown to be a versatile approach as 
macromolecules (such as BSA and insulin) and 10-20 µm particles could be loaded 
as uniform coatings on the studied microneedles (Gill and Prausnitz 2007a, b).  
Optimization of excipient concentrations in a coating formulation is required in order 
to facilitate spatial control of MD coating. Ameri et al. (2010) reported that a 0.2% 
w/w concentration of the surfactant Tween
®
 20 was optimal as it enabled selective 
deposition of coatings on the tip of the microneedles (~100 µm). On the contrary, 
higher surfactant concentrations determined spreading of the formulation over the 
entire microneedles body and even on the base of the array as a result of the reduced 
surface tension and thus increased wettability of the microneedle surface. 
Conversely, lower concentrations or absence of surfactant resulted in contraction of 
the coating formulation (due the high surface tension of the coating formulation) and 
thus non-uniform coverage of the microneedle tip. 
When dry coated MDs are prepared, lyo/cryoprotectants may also be required to 
maintain the stability of therapeutic proteins such as vaccines (Kim et al. 2010; 
Koutsonanos 2011; Pearton et al. 2010; Weldon et al. 2011). Coating solid 
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microneedles with a drug solution involves a phase change of the solution to a dry 
coated layer. Drying of vaccine formulations has been associated with reduction of 
antigen stability due to denaturation and aggregation of antigen molecules (Amorij et 
al. 2007). Use of stabilizers such as trehalose and inulin for vaccines during the 
formulation of a dry powder has been previously reported (Amorij et al. 2007; Maa 
et al. 2004). A study assessing the capability of different stabilizers (such as 
trehalose, inulin, sucrose, glucose and dextrans) to prevent loss of antigen activity of 
influenza vaccines coated onto microneedles has been published (Kim et al. 2010). 
This study revealed that trehalose was the most effective among the stabilizers tested, 
as its addition to a coating formulation containing CMC 1% w/v and Lutrol
®
 F68 
0.5% w/v was essential to maintain antigen activity. This was due to the capability of 
the sugar to prevent increase in the antigens particle size, which is known to lead to 
particles aggregation and degradation during the drying phase (Amorij et al. 2008). 
Similarly Weldon et al. (2011) reported that the trimeric structure of an influenza 
virus prepared in a coating solution containing CMC 1% w/v and Lutrol
®
 F68 0.5% 
w/v was destroyed during microneedle coating. The addition of trehalose 15% w/v to 
the coating formulation preserved the structure and the immunological property of 
the coated vaccine.  
 
2.1.2 Liquid loaded pocketed MDs 
Pocketed MDs, a variant of solid MDs, contain one or multiple voids in their needle 
shaft that are designed to accommodate a drug in solution following a simplistic one 
step immersion process into a liquid loading formulation. The approach relies on 
capillary action to load a drug in a liquid form. Following application of the MD to 
the skin, the therapeutic can be rapidly released into the tissue (Gill and Prausnitz 
2007b). 
Pocketed MDs have been used for the delivery of small hydrophilic molecules (e.g., 
fluorescein and sulforhodamine) and 10-20 µm microparticles (Gill and Prausnitz 
2007a, b, 2008) to human skin. Studies have indicated that the formulation can be 
loaded in the pockets either as a liquid or dry phase depending on the specific coating 
excipients employed. According to these studies, coating formulations containing 
glycerol 80% v/v as the sole excipient enabled retention of model drugs (such as 
fluorescein and sulforhodamine) in the pockets in a liquid state for approximately 24 
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hours. Conversely, the use of other viscosity enhancers, such as sucrose 25% w/v, 
was associated with the production of solid drug layers in the pockets as a result of 
an increased solid content in the coating formulations. 
The same studies showed that controlled deposition of a drug solution on a pocketed 
microneedle could be achieved by combining specific excipients in the coating 
formulations. Dipping the microneedles into a coating formulation containing a 
viscosity enhancer (e.g., glycerol 80% v/v or sucrose 25% w/v) as the sole excipient 
resulted in selective loading of the liquid in the pockets with no coating the shaft of 
the needle. This was because the high surface tension of the formulation prevented 
the surface (shaft) of the needles being wetted by the liquid formulation. Conversely, 
the addition of a surfactant (e.g. Tween
® 
20 0.2% w/v) resulted in the simultaneous 
filling of the pocket and coating the shaft of the microneedle, as a consequence of the 
reduced surface tension of the formulation. 
The suitability of pocketed microneedles to accommodate multiple drug formulations 
has also been demonstrated (Gill and Prausnitz 2007b). By using a more complex 
multi step immersion process, three different model solutions, containing glycerol as 
viscosity enhancer, were selectively loaded into each of the three pockets contained 
in a pocketed microneedle. This indicated that pocketed microneedles may be 
employed for those therapeutic scenarios, which require delivery of different drug 
formulations from the same microneedle. 
Liquid loaded pocketed MDs represent a valid alternative for drugs unsuited to the 
dry coating process and the associated aspects of formulation. This method of 
delivery may be more suited to the delivery of BTX A. The rationale is that liquid 
loaded pocketed microneedles may offer potential advantages compared to the dry 
coating approach such as: i) greater cutaneous diffusion of the medicament as a 
liquid compared to a dry state, thus facilitating downward and lateral diffusion of 
BTX A to its therapeutic target (the sweat glands) that are located in the deep dermis, 
ii) more uniform and rapid release of the medicament; drug release would in fact not 
rely on dissolution of a dry layer from the needles and it would be expected to occur 
instantaneously following insertion of the needles in the skin, iii) facilitated release 
of formulations containing high molecular weight drugs such as BTX A (formulated 
in Botox
®
 within a complex of up to 900 kDa), which may be difficult to coat on the 
microneedle surface or which would be more likely to wipe off onto the surface of 
the skin upon microneedle insertion (Gill and Prausnitz 2007a, b); iv) possible use of 
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MDs for the delivery of existing BTX A commercial formulations, therefore 
simplification of the eventual use of the MDs in clinical trials.  
A restriction of using MDs is the limited amount of solution that can be loaded into 
the needles due to their micron-sized dimensions. As previously mentioned (Section 
1.4.1), different BTX A pharmaceutical preparations are currently commercially 
available (Botox
®
, Vistabel
®
, Dysport
®
 and Xeomin
®
). A vial of Botox
®
, the only 
BTX A preparation licensed for the treatment of axillary PFHH, contains i) 5 ng of 
BTX A (100 U), ii) 0.5 g of human serum albumin (HSA) and iii) 0.9 mg of sodium 
chloride (NaCl). The vial is currently reconstituted using a volume of 0.9% w/v 
saline solution usually ranging between 1.5 and 5 ml, according to the preference of 
the clinician (Section 1.5.1). The resulting solution is delivered by multiple 
intradermal injections, each one generally with a volume of 0.05-0.1 ml. Therefore, 
in order to enable loading of effective doses of BTX A on pocketed MDs, the 
medicament will have to be reconstituted with smaller volumes, possibly in the 
microlitre range. Therefore, the limit of solubility of HSA and NaCl will be 
investigated in this Chapter in order to establish whether volumes contained in the 
microlitre range can be employed to dissolve a Botox
®
 preparation. 
 
2.1.3 Use of the enzymatic protein β-galactosidase as a 
model representative of BTX A 
Commercially available pharmaceutical formulations of BTX A contain BTX A 
within protein complexes of different molecular weights, ranging between 150 kDa 
(Xeomin
®
) up to 900 kDa (Botox
®
). BTX A is currently difficult to detect, expensive 
and laboratory use of the pure toxin is associated with a number of safety concerns. 
The enzymatic protein β-galactosidase (β-gal) consists of a tetramer with a molecular 
weight of ~465 kDa, with each subunit possessing a molecular weight of 116.3 kDa 
(Fowler 1977). This molecule was therefore selected as a detectable model protein 
with a molecular weight that is comparable to BTX A. 
 
2.1.4 Aim and objectives of the Chapter 
This Chapter will investigate the capability of pocketed MDs to uniformly 
accommodate a formulation mimicking the composition of the commercial 
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preparation Botox
®
. Solid MDs, loaded by using established dry coating 
methodologies, will be used as a comparator for liquid loaded pocketed MDs.  
The experimental objectives of this Chapter are to:- 
1) Characterise pocketed and non-pocketed MDs by bright field and scanning 
electron microscopy (SEM). 
2) Assess the uniformity of coatings on non-pocketed MDs by using an 
established dry coating methodology and fluorescent detectable molecules.  
3) Evaluate the solubility of the excipients present into the commercial 
preparation Botox
®
 when employing volumes in the microlitre range. 
4) Load a representative model formulation of the commercial Botox® 
preparation (‘Botox® like’ formulation) onto pocketed MDs. 
5) Compare the microneedle loading efficiency of liquid loading to the more 
established dry coating methodology. 
6) Evaluate the residency time of a ‘Botox® like’ formulation in the pockets of 
MDs. 
7) Assess the effect of viscosity enhancers on the retention time of a solution in 
the pockets of MDs. 
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2.2 Materials 
2.2.1 Reagents  
All reagents were used as received and were purchased from Sigma-Aldrich Ltd 
(Poole, UK), unless otherwise stated.  
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). Sodium 
chloride was purchased from Fischer Scientific (Loughborough, UK). 
 
2.3 Methods 
2.3.1 MD fabrication and characterisation 
Solid metal MDs, with and without an integrated pocket, were used. They were 
named, respectively, pocketed microneedles devices (PMDs) and non pocketed 
microneedle devices (NPMDs). NPMDs were cut from stainless steel sheets using an 
infrared laser (Trinity Brand Industries, SS 304; McMaster-Carr, Atlanta, GA, USA) 
as described elsewhere (Gill and Prausnitz 2007a). Integrated pockets within the 
microneedle shafts were created as outlined by the methodology described by Gill 
and Prausnitz (2008). Following manufacture, PMDs and NPMDs were 
electropolished, washed and dried as described elsewhere (Gill and Prausnitz 2007a). 
MDs were attached on aluminium stubs and characterised by scanning electron 
microscopy (SEM) (FEI XL30, Eindhoven, The Netherlands). Images of MDs were 
also captured by using a bright field light microscope (Zeiss Stemi 2000-C 
Stereomicroscope, Carl Zeiss, Welwyn Garden City, UK) associated to a digital 
camera (Olympus C 3040-ADL, Watford, UK). An external light source (Schott KL-
1500, Schott AG, Stafford, UK) was also employed to better visualize the samples. 
For light microscopy analysis, the base of each MD was held between the two edges 
of a metallic tweezer. A small strip of adhesive tape was wrapped around those two 
edges in order to maintain the device in position. The mounted MD was then placed 
on the stage of the light microscope.  
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2.3.2 Dry coating NPMDs 
Dry coating was performed for NPMDs as reported elsewhere (Gill and Prausnitz 
2007a) with the aid of a dip coating reservoir device whose details are outlined in the 
following Section. 
 
2.3.2.1 Dry coating NPMDs using a micro scale dip coating reservoir 
device 
The dip coating reservoir device (Figure 2.1) consists of a coating solution reservoir 
produced between two aligned poly(methylmethacrylate) plates, referred to as 
‘bottom plate’ and ‘upper plate’. The first one includes a central feeding channel, 
connected to an inlet port from which the coating solution (around 20-30 µl) can be 
dispensed. The upper plate possesses five microholes positioned at the same interval 
as the microneedles of the MD to be coated. When the coating formulation is injected 
to the central feeding channel, it reaches the microholes, each one acting as a single 
micro reservoir. A MD can be then coated by being dipped and withdrawn, for a 
variable number of times, in the reservoirs. 
 
 
Figure 2.1: Schematic representation of a micro scale dip coating device. Microneedles 
are aligned with the microholes present in the upper plate of the dip coating reservoir device. 
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2.3.2.1.1 Dry coating of NPMDs with fluorescent molecules 
Preliminary experiments were conducted by loading detectable molecules onto 
microneedles in order to assess the coating uniformity. The coating methodology 
reported by Gill and Prausnitz (2007b) and the dip coating reservoir device, 
described previously (Section 2.3.2.1), were employed. Sulforhodamine (λex: 583 
nm, λem: 603 nm, m.w. = 606 Daltons) and latex sulphate modified fluorescent 
nanoparticles (λex: 575 nm, λem: 610 nm, particles diameter size: 100 nm) were 
chosen as representative models of small hydrophilic drugs and high molecular 
weight controlled release/nanoparticulate delivery systems respectively. 
 
Sulforhodamine 
An aqueous coating formulation containing sulforhodamine 0.05% w/v, CMC 1% 
w/v and Lutrol
®
 F68 0.5% w/v was dispensed (approximately 20 µl) into the micro 
scale dip coating reservoir. Ten stainless steel NPMDs, divided into two groups 
(n=5), were used in this experiment. Each group was immersed either 5 or 15 times 
into the coating formulation. Intervals of 15 seconds were employed between each 
microneedle immersion in order to allow drying of the coating. The dip coating 
reservoir was refilled with approximately 10 µl of fluorescent solution after ten 
NPMD immersions. Once coated, NPMDs were allowed to dry for 24 hours at room 
temperature, protected from light. They were subsequently analysed using a 
light/fluorescence microscope (Light/Fluorescent Olympus BX50, Olympus, 
Watford, UK) and representative images were digitally captured (Olympus DP 10, 
digital camera, Watford, UK). 
 
Fluorescent nanoparticles 
A coating suspension containing 100 nm fluorescent red nanoparticles was used in 
this experiment. NPMDs were immersed 5 (n=3) or 15 (n=3) times into the 
suspension, as described for sulforhodamine coating formulation. Once coated, 
NPMDs were allowed to dry over night at room temperature, protected from light. 
Coated NPMDs were subsequently analysed by light and fluorescent microscopy. 
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2.3.3 Evaluation of the solubility of the excipients contained 
in the commercial preparation Botox
®
 
As previously mentioned (Section 2.1.2), loading a PMD with effective doses of 
BTX A would require dissolution of the commercial preparation Botox
®
 by using 
volumes in the microlitre range. As the excipients NaCl and HSA are contained in 
the vial in mg amounts (0.9 mg and 0.5 mg respectively) (Section 1.4.1.1), using 
such constrained volumes may result in incomplete dissolution of the preparation. 
Conversely, the quantity of BTX A contained in the vial is extremely low (5 ng) and 
therefore the toxin is not expected to interfere with dissolution of the preparation. 
For this reason the experiment reported in this Section will investigate the solubility 
of the excipients contained in a vial of Botox
®
 when using a volume less than or 
equal to 100 µl.  
The following solutions were freshly prepared:  
 NaCl 90 mg/10 ml in 0.9% saline solution=0.9 mg/100 µl 
 HSA 5 mg/ml in 0.9% saline solution=0.5 mg/100 µl 
Saline solution (0.9%) was used as it is the diluent recommended by Allergan 
(Botox
®
 manufacture) to reconstitute BTX A commercial preparations (Section 
1.5.1). In addition, solutions containing a decreasing volume of 0.9% saline solution 
were prepared (as outlined by Table 2.1) in order to assess the limit of solubility of 
each of the excipients. The volumes of 0.9% saline solution used to assess the 
solubility of HSA and NaCl ranged, respectively, between 1 and 0.1 ml and 10 to 1 
ml (Table 2.1). 
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Table 2.1: Formulations used to determine the limit of solubility of single excipients 
contained in a vial of Botox
®
.
 
HSA (mg) 0.9% saline solution (ml) NaCl (mg) 0.9% saline solution (ml) 
 
 
 
 
5 
1  
 
 
 
90 
10 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
9 
8 
7 
6 
5 
4 
3 
2 
1 
 
The solubility of the excipients when contemporaneously present was also assessed. 
Five mg of HSA were transferred into a microcentrifuge tube and added to 100 µl of 
NaCl (0.9 mg/100 µl) and 900 µl of saline solution 0.9% w/v. Therefore, the 
resulting solution contained 0.9 mg of NaCl and 0.5 mg of HSA per 100 µl. 
Moreover, 9 solutions containing a decreasing volume of saline solution 0.9% (from 
800 to 100 µl) were prepared (Table 2.2), in order to detect the limits of solubility. 
All of the prepared solutions were inspected with the naked eye against a black and a 
non-glare white panel to assess the presence of undissolved particulate traces. 
Moderate manual agitation was performed to facilitate solubilisation. 
 
Table 2.2: Formulations used to assess the limit of solubility of HSA and NaCl in saline 
solution. Masses are representative of a vial of the commercial Botox
®
 formulation. 
Solution HSA 
(mg) 
NaCl (90 mg/10 ml) 
µl 
0.9% Saline 
solution (µl) 
Approximate total 
volume (µl) 
1 5 100 800 900 
2 5 100 700 800 
3 5 100 600 700 
4 5 100 500 600 
5 5 100 400 500 
6 5 100 300 400 
7 5 100 200 300 
8 5 100 100 200 
9 5 100 / 100 
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2.3.4 Liquid loading PMDs and NPMDs 
PMDs and NPMDs were manually loaded by a single immersion into a reservoir 
containing a small volume (~20 µl) of a β-gal loading formulation. Excess 
formulation that was accidentally collected on the base of the MD during the 
microneedle immersion process was carefully removed using a lintless tissue paper.  
 
2.3.4.1 Liquid loading PMDs with a ‘Botox® like’ formulation 
To predict the residency time of a liquid BTX A formulation, a ‘Botox® like’ 
formulation (final volume of 150 µl) was freshly prepared using 0.9% saline solution 
as a diluent buffer. The formulation contained the following components:- 
1. ~5 ng of β-gal 
2. 0.9 mg of NaCl 
3. 0.5 mg of HSA 
4. 20% v/v of blue colour indicator (a brilliant blue and carmoisine solution) 
The formulation provided a mimic of the commercial BTX A formulation, Botox
®
, 
with the exception of the toxin, which was replaced by the model protein β-gal and 
the inclusion of a dye to enable visualisation. Both PMDs (n=3) and NPMDs (n=3) 
were loaded with the ‘Botox® like’ formulation and visualized under light microscope 
(Zeiss Stemi 2000-C Stereomicroscope). The evaporation process from PMDs was 
monitored using a digital camera (Olympus C3040-ADL). An external light source 
(Schott KL-1500) was also used to enable better visualisation of the microneedles.  
 
2.3.4.2 Liquid loading MDs with a high concentration of the model 
BTX A (β-gal) 
A loading solution of the model BTX A (β-gal 1.3 μg/μl) was freshly prepared in a 
bovine serum albumin (BSA)/bicine buffer (bicine buffer 50 mM pH 7.5 + BSA 100 
μg/ml). Similar to that previously described (Section 2.3.4.1), a blue colour indicator 
was included to permit visualisation of the formulation in the pockets. PMDs (n=3) 
were loaded by a single immersion into a liquid formulation (as described in Section 
2.3.4). PMDs were observed under the light microscope and the evaporation process 
captured with a digital camera. 
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An increased concentration of β-gal, compared to Section 2.3.4.1, was selected for 
this experiment as equal/similar concentrations will be employed to perform 
quantitative analysis of PMD loading capacity and cutaneous delivery studies, 
described respectively in Chapter 3 and 4. A higher concentration of β-gal was 
required to allow detection of the protein using the methodologies described in those 
Chapters. The aim of this experiment is therefore to evaluate the residency time of 
the protein solution in the pockets of the PMD to determine the time that would be 
available, following loading, to insert the loaded PMD into the skin and enable 
delivery of the protein in a liquid state.  
 
2.3.4.3 Enhancing the retention of liquid loaded drug formulations 
in microneedle pockets 
A viscosity enhancer was added to loading solutions in order to reduce the 
evaporation rate and thus increase the residence time of the film within the 
microneedle pockets. 
Aqueous loading solutions were prepared with increasing amounts of glycerine 
 
 Formulation 1: blue (food) colour indicator 100% v/v. 
 Formulation 2: ~20% w/v glycerine plus ~80% v/v of blue food colour 
indicator. 
 Formulation 3: ~50% w/v glycerine plus ~50% v/v of blue food colour 
indicator. 
 Formulation 4: ~80% w/v glycerine plus 20% v/v of blue food colour 
indicator. 
PMDs were loaded with formulation 1 (n=5), 2 (n=3), 3 (n=3) and 4 (n=3) at room 
temperature. The duration of an intact film within the pocket of each microneedle 
was recorded by regular observation under a light microscope (Zeiss Stemi 2000C 
Stereomicroscope) with the aid of an external fibre optic light source (Schott KL-
1500). Observations were conducted consistently for the first 2 minutes and 
subsequently at 30 minutes, 1 hour, 24 hours 48 hours, 120 hours (5 days), 288 hours 
(12 days), 408 hours (17 days), 624 hours (26 days) and 768 hours (32 days). The 
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number of pockets retaining the formulation at each observation time was reported as 
a percentage relative to the total number of pockets examined. 
 
2.4 Results and Discussion 
2.4.1 MD characterization  
PMDs and NPMDs, fabricated by laser etching stainless steel into the desired pattern 
and geometry, were characterised by SEM and light microscopy. Figures 2.2 (A) and 
(B) show a representative NPMD and PMD, imaged by the light microscope. Figures 
2.2 (C) and 2.2 (D) depict two representative adjacent non-pocketed and pocketed 
microneedles, imaged by SEM. PMDs possessed individual needle dimensions of 
~700 x 340 x 65 µm (y, x and z plane respectively). Only 4 out of 5 needles 
contained an internal pocket, each measuring ~365 x 140 x 65 µm (y, x and z plane). 
Each needle of a NPMD measured ~700 x 170 x 70 µm (y, x and z plane) and the tip 
to tip distance between two adjacent microneedles measured ~ 1.5 mm for both 
PMDs and NPMDs. The characterised MDs were manufactured and provided by 
Professor Marc Prausnitz et al. based at the Georgia Institute of Technology, 
Georgia, Atlanta, USA. 
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Figure 2.2 (A-D): Characterisation of NPMDs and PMDs. Brightfield micrographs of an 
in-plane row of five non-pocketed microneedles (NPMD) (A) and pocketed microneedles 
(PMD) (B). Scale bar = 1 mm. Scanning electron micrographs of two adjacent non pocketed 
(C) and pocketed microneedles (D). 
 
As depicted by SEM images (Figure 2.2 D), an irregularity can be observed on the 
edges of both the pockets and the needles of the studied PMDs. These devices 
represented the first PMD generation and PMDs with more regular pockets/needles 
edges have now been produced as a result of manufacturing optimization (Gill and 
Prausnitz 2008). 
The presence of irregularities in the pockets may provide an advantage when loading 
the PMDs. When a liquid interacts with a solid surface, the wettability of this surface 
is described by the contact angle (θ) (Forch R. 2009), proposed by Young and 
defined as the angle at which the liquid/vapour meets the solid. The contact angle is 
influenced by the liquid-solid surface tension and can (in principle) assume any value 
between 180° and 0° depending on the degree of wettability of the solid surface by 
the liquid. Greater wettability, defined by a smaller contact angle and a lower surface 
tension, is normally observed for smooth and regular surfaces. Conversely, rough or 
heterogenous surfaces are generally associated with multiple and increased contact 
angles, a phenomen called contact-angle hysteresis (Blake 1997). This phenomen 
determines a reduction of the mobility of the so-termed wet line, defined as the 
boundary interface between liquid, solid and vapour. The mobility of a liquid is 
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therefore reduced for an irregular surface and thus drug formulations loaded on the 
studied PMDs may be better retained.  
 
2.4.2 Dry coating NPMDs with fluorescent molecules 
Using an established dip coating procedure (Gill and Prausnitz 2007a), fluorescent 
molecules were dry coated onto NPMDs. Increseasing the number of immersions of 
NPMDs into a loading formulation resulted in more uniform and intense coatings. 
Figures 2.3 (A) and 2.3 (B) depict the appearance of NPMDs after 5 and 15 
immersions into a sulforhodamine 0.05% w/v coating formulation containing CMC 
1% w/v and Lutrol
®
 F68 0.5% w/v as excipients. 
 
 
 
Figure 2.3 (A, B): Dry coating of NPMDs with sulforhodamine. Fluorescent micrographs 
of single microneedles dry coated with sulforhodamine after 5 (A) (n=5) and 15 (B) (n=5) 
immersions in sulforhodamine aqueous solution 0.05% w/v containing CMC 1% w/v and 
Lutrol
®
 F 68 0.5% w/v as excipients.  
 
Similarly, an increased number of immersions of NPMDs into a 100 nm nanoparticle 
suspension resulted in a thicker coating and thus increased levels of fluorescence 
(Figure 2.4 A-D). The results indicated that relatively uniform and thick coatings 
could be achieved even when using an excipient free solution. This could be due to 
an inherent high level of viscosity of the nanoparticle suspension and/or a possible 
electrostatic interaction between the nanoparticles and the metallic surface. 
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The use of excipient free coating formulations may be particularly desirable for MD 
loading because some excipients may be incompatible with certain drugs. In 
addition, if excipients are avoided, the drug loading capacity of the coating 
formulation may be optimised and thus greater MD loading may be achieved. 
Moreover, MDs could be used for existing drug formulations such as BTX A 
commercial preparations, without the need to reformulate. This will be discussed 
further in Section 2.4.4. 
 
 
 
Figure 2.4 (A-D): Dry coating of NPMDs with fluorescent nanoparticles. Fluorescent and 
brightfield micrographs of single microneedles dry coated with 100 nm polystyrene 
nanoparticles after 5 (A, B) (n=3) and 15 (C, D) immersions (n=3) in a fluorescent 
nanoparticle coating suspension. Scale bar = 100 µm. 
 
However, coating sulforhodamine/nanoparticles selectively on the shaft of the 
microneedles was almost impossible to achieve. Undesired contact between the 
coating formulation/suspension and the base of the microneedles was reported for all 
the NPMDs used. Additionally, single coated microneedles contained in the same 
NPMD showed different fluorescent intensities. This indicated that the needles were 
not coated in a reproducible manner (Figures 2.5 A and B).  
 
Chapter 2 
 
67 
 
 
 
Figure 2.5 (A, B): The coating variability of fluorescent nanoparticles on MDs. 
Fluorescent and brightfield micrographs of two adjacent microneedles in a row of five 
microneedles (in the same NPMD), dry coated with 100 nm polystyrene nanoparticles after 
15 immersions (n=3) in a fluorescent nanoparticle coating suspension. Scale bar = 100 µm. 
 
Since the coating was performed manually, control of the process was extremely 
difficult to achieve. The insertion of microneedles into the microholes of the dip 
coating reservoir  device (Section 2.3.2.1) resulted in overflow of a proportion of the 
coating solution and therefore contamination of the base of the array. In addition, 
when the solution was injected into the reservoir device, a hetereogenous distribution 
of the solution between the microholes was often observed. As a consequence, some 
needles collected more solution than others, thus resulting in poor uniformity of the 
coating. Moreover, due to the extremely reduced size of the device, maintaining the 
microneedles in a perfectly aligned position while being inserted into the holes was 
difficult to perform using manual methods. Gill and Prausnitz (2007a) reported the 
use of micropositioners, one holding the dip coating reservoir device and one the 
MD, to align the microneedles with microholes of the reservoir device. The MDs 
micropositioner was moved manually to allow immersion of the microneedles into 
the coating formulation. Initial coating attempts were performed using such 
micropositioners. However, due to the difficulty in maintaining the array in a stable 
position on the MDs micropositioner, their use was abandoned. The process was 
subsequently perfomed by placing the coating reservoir on a flat surface and 
inserting the microneedles into the reservoir by hand.  
An automation of the process is certainly nedeed to increase the uniformity of the 
coating. Several published studies indicate efficient spatial control of microneedle 
coatings when using engineered coating procedures. As previosuly mentioned 
(Section 2.1.1), Weldon et al. (2011) adopted the coating apparatus described by Gill 
and Prausnitz (2007a) (and employed in the experiments detailed in this Thesis) to 
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coat stainless steel microneedles (each microneedle having a length of 750 µm and a 
width of 200 µm) with recombinant influenza vaccines. The coating was performed 
using an automated process. The MDs micropositioner was attached to a linear stage 
which enabled insertion of the MDs into the microholes of the dip coating device 
with an accuracy of 0.4 µm. The process was captured by a video camera connected 
to a computer. Furthermore Ameri et al. (2010) described the use of a robust dip 
coating apparatus, engineered to place minute volumes of parathyroid hormone 
(m.w.= ~4 kDa) formulation on the tip (~100 µm) of titanium microneedle arrays 
(Macroflux
®
) (Daddona 2011). The Macroflux
® 
patch system consists of a 2 cm
2
 
array containing 1300 microneedles affixed to an adhesive patch. Each needle has a 
length of 190 µm and a tip featuring a small arrow-head with a length and a width of 
respectively 100 µm and 115 µm. The coating apparatus described by Ameri et al. 
(as mentioned in Section 2.1.1) employed a roller drum which collected a film of 
coating formulation with a controlled thickess (~100 µm). It achieved this by rotating 
(at 50 rpm) into a coating formulation reservoir (containing ~2 ml of formulation). 
Microneedles, moving in the same direction as the rotating drum, were coated by 
multiple immersions (passes) through the film of coating formulation collected on 
the surface of the drum (Trautman 2008). Specific excipients such as viscosity 
enhancers (sucrose ~16% w/w) and surfactants (Tween
®
 20 0.2% w/w) were also 
employed in these studies. The described  technology was shown to be feasibile for 
coating large proteins such ovalbumin (~44 kDa) (Widera et al. 2006) and the 
peptide desmopressin (~1.1 kDa) (Cormier et al. 2004) on similarly designed 
microneedles. 
It may be hypothetised that a coating technology such as this would reduce the 
variability of the results obtained in the study. The coating apparatus employed in 
our experiments relies on the alignment of microholes on the upper plate of the micro 
scale coating device (Section 2.3.2.1) with the microneedles to be coated. This was 
technically challenging and resulted in poor reproducibility of the coatings (as 
discussed above). In the coating technology described by Ameri et al. (2010) the 
needles are immersed into a continous film of coating formulation placed on the 
surface of the rotating drummer. The absence of microreservoirs and the controlled 
immersion process, may permit more uniform collection of the coating formulation 
by the microneedles. Comparable volumes of formulation are placed on each needle 
at each immersion and therefore higher coating reproducibility is obtained. 
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Moreover, due to the automation of the process, the depth at which the microneedles 
are immersed can be controlled and therefore contamination of the base of the array 
is avoided. The microneedles used in our study have a length of 700 µm (Section 
2.4.1). Therefore, if the Macroflux
®
 coating procedure was to be employed to coat 
these microneedles, the drug formulation could be selectively coated onto a small 
portion (e.g.100 µm of the shaft) of the entire microneedle length. The drawback 
would be a significant reduction of the dose loaded per array. However this could be 
overcome by either adapting the coating apparatus to increase the thickness of the 
film of formulation collected on the surface of the drum (and thus on the 
microneedles surface) or by modifying the MD design to increase the number of 
microneedles per array.  
Nevertheless, other approaches could be used to obtain more uniform coatings with 
the micro reservoir approach e.g. using the coating procedure described by Gill and 
Praunitz (2007a). Alternatively, MD design could be tailored in order to reduce 
contamination of the base of the array. For example the length of the needles could 
be increased so that only a portion of the microneedle is immersed in the reservoir. 
This would prevent contact between the coating solution and the surface of the 
needle during the coating procedure. Additionally, a cover layer, such as a removable 
microfilm, could be applied on the base of the array to prevent contact of the base 
plate with the solution during microneedle immersion. The microfilm could 
subsequently be removed after microneedle coating.  
 
2.4.3 Evaluation of the solubility of the excipients contained 
in the commercial Botox
®
 formulation 
As previously mentioned (Section 2.1.2 and 1.5.1), a vial of Botox
®
 is reconstituted 
in the clinical setting usually by using volumes between 1.5 and 5 ml. Such relatively 
large volumes are required as administration of the medicament currently relies on 
the use of conventional needles and syringes. If PMDs were to be used as an 
alternative delivery tool, considerably smaller volumes (e.g. in the microlitre range) 
would have to be used to reconstitute the drug due to the reduced size of the 
microneedles. A greater concentration of the reconstituted Botox
®
 formulation would 
therefore be required to facilitate loading of PMDs with efficient doses of BTX A.  
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Experiments were conducted in order to assess the solubility of the excipients 
contained in a vial of Botox
®
 (HSA 0.5 mg
 
and NaCl 0.9 mg) when using volumes 
contained in the low microlitre range. Saline solution 0.9% was chosen as a diluent 
as it represents the diluent recommended by Allergan to dissolve a vial of BTX A 
and therefore this was also used in these experiments to evaluate solubility. 
The results indicated (Table 2.3) that 5 mg of HSA can be dissolved in a volume of 
diluent ranging between 0.3 and 1 ml, as the solutions obtained appeared perfectly 
clear and free of any visible particulate traces. This indicated that 0.5 mg could be 
dissolved in volumes as low as 30 µl. Conversely, when volumes below 0.3 ml were 
used (0.2 and 0.1 ml), the presence of particulates were detected in the solution, even 
after manual shaking was performed. The result suggested a limit of solubility of 
HSA in saline solution equal to 0.5 mg/30 µl (~16 µg/µl). The data are in agreement 
with the product information sheet provided by HSA manufacturer (Sigma Aldrich) 
indicating a solubility of the protein in water of 50 mg/ml (50 µg/µl) 
(http://www.sigmaaldrich.com 1996).  
Additionally, diluent volumes spanning from 1 to 10 ml successfully dissolved 9 mg 
of NaCl, without requiring manual shaking. This therefore indicated that 0.9 mg of 
NaCl could be dissolved in volumes as low as 10 µl. This is in agreement with the 
solubility specification outlined for NaCl by the British Pharmacopeia (i.e., NaCl is 
freely soluble in water) (http://www.pharmacopoeia.co.uk 2012).
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The solubility of the excipients when contemporaneously present was also assessed 
to better mimic the commercial Botox
®
 formulation (Table 2.4). A solution free of 
any visible particulates was obtained when 5 mg of HSA were dissolved in 0.1 ml of 
NaCl (0.9 mg/0.1ml) plus 0.9 ml of saline solution 0.9%. This indicated that both of 
the excipients were dissolved in 100 µl of diluent. 
Moreover, the data indicated that 5 mg of HSA can be dissolved by using total 
volumes of solutions (consisting of 0.1 ml of NaCl 0.9mg/0.1 ml plus 0.8 ml to 0 ml 
of saline solution 0.9%) ranging between 0.9 and 0.3 ml. Volumes below 0.3 ml were 
not sufficient, as particulates could be visualised in the solution even after vigorous 
manual shaking was applied.  
As a conclusion, the data show that both excipients contained in a vial of Botox
®
 can 
be dissolved with volumes in the microlitre range, as low as 30 µl. The solubility of 
BTX A was not assessed in this experiment due to the extremely low dose of toxin (5 
ng) contained in the vial and the safety concerns related to the handling of larger 
quantities of BTX A. However, nanogram quantities of the protein are not expected 
to interfere with the reconstitution of the pharmaceutical preparation, even when 
dealing with volumes in the microlitre range. Therefore, the results indicate that 
significantly smaller volumes compared to the ones currently used in the clinical 
setting (1.5-5 ml) could be used to reconstitute an entire vial of Botox
®
.  
However, handling volumes in the range of microlitres is technically challenging. 
For example, if a volume of diluent as low as 30 µl was to be used, the solution 
obtained would be difficult to withdraw from the vial. This would lead to waste of 
the costly therapeutic material and inaccuracy of the dose loaded (and thus 
delivered). Therefore, increased volumes may have to be used in order to facilitate 
better handling of the solution. As a consequence, PMD loading of a more diluted 
BTX A formulations may require improvement in the PMD loading capacity. This 
may be achieved by modifying the PMD design (for example increasing the number 
of needles per array). The experiments reported in the following Chapter aim to 
determine the PMDs loading capacity. This will help to estimate the volume of 
Botox
®
 formulation which could be accommodated by a PMD and therefore to 
understand whether optimization of the PMD design is required. 
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Table 2.4: Evaluation of the limit of solubility of HSA and NaCl in saline solution. 
Masses are representative of a vial of the commercial Botox
®
 formulation. 
 
2.4.4 Liquid loading PMDs with a ‘Botox
®
 like’ formulation 
PMDs and NPMDs were liquid loaded by immersing the needles into a ‘Botox® like’ 
formulation. Figure 2.6 (A-C) depicts a representative PMD (A, B) and NPMD (C) 
after one immersion into a ‘Botox® like’ formulation. The pockets of the PMD were 
uniformly filled for a short duration after immersion. Videos captured by a digital 
camera indicated complete evaporation of the liquid component of the formulation 
from the pockets within approximately 90 seconds. Immediately after loading, the 
formulation was visualised on the needles of a NPMD by the naked eye and by light 
microscopy. The same was observed for liquid coated on the shaft of the pocketed 
microneedles and on the central non pocketed microneedle of the PMD (the presence 
of a central non pocketed microneedle in the studied PMDs was shown in Section 
2.4.1). Subsequent analysis of the NPMD under the light microscope revealed a film 
(Figure 2.6 C) on the surface of the needles. Similarly, analysis of the PMD after 
evaporation of the loaded solution resulted in a film coated on the shaft of the 
needles and also the interior surfaces of the pockets (Figure 2.6 B). 
The results indicate that a Botox
® 
formulation can be loaded and retained, in a liquid 
state, by the pockets of a PMD. Importantly, observations suggest that the 
formulation can be maintained in its liquid state for a sufficient time to allow PMD 
application to the skin. Moreover, following evaporation of the solvent, the needles 
of both the PMDs and NPMDs appeared to be uniformly coated after only one 
immersion. This suggests that a Botox
®
 formulation could be loaded onto the MDs as 
either a liquid formulation or a dry coat by a simplistic one step immersion process. 
The inherent viscosity of the protein based formulation, most likely due to the high 
Solution HSA 
(mg) 
NaCl 
(90mg/10ml) ml 
Saline solution 
0.9% (ml) 
Approximate total 
volume (ml) 
Solubility 
1 5 0.1 0.8 0.9   
2 5 0.1 0.7 0.8   
3 5 0.1 0.6 0.7   
4 5 0.1 0.5 0.6   
5 5 0.1 0.4 0.5   
6 5 0.1 0.3 0.4   
7 5 0.1 0.2 0.3   
8 5 0.1 0.1 0.2   x 
9 5 0.1 / 0.1   x 
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concentration of HSA, promoted retention of the formulation in the pockets of 
microneedles without requirement to reformulate. Avoiding reformulation would 
significantly reduce regulatory hurdles and would simplify clinical use of the MD as 
a means to deliver a BTX A formulation. 
 
 
 
Figure 2.6 (A-C): Loading of a ‘Botox® like’ formulation in PMDs and NPMDs. 
Representative brightfield micrographs of a PMD (A, B) and a NPMD (C) after immersion 
into a ‘Botox® like’ formulation. For visualizing purpose, a blue dye was added to the 
loading formulation. The excess of solution accidentally collected on the base of the MDs 
during immersion into the loading formulation was carefully removed by using lintless tissue 
paper. Scale bar = 1 mm. 
 
PMDs offer the advantage of visualisation of the loaded solution. The presence of a 
coloured solution can be detected in the pockets with the naked eye. This would be 
particularly useful in a clinical context, as it would allow the clinician and/or patient 
to i) ensure that successful and uniform loading has occurred before application into 
the skin and ii) visualise whether the drug formulation has been delivered into the 
skin after insertion of the loaded PMD. 
 
2.4.4.1 Liquid loading MDs with a high concentration of the model 
β-galactosidase 
Loading experiments were performed on PMDs using a higher concentration of the 
model BTX A (β-gal 1.3 μg/μl in BSA/bicine buffer) than the concentration 
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employed in a ‘Botox® like’ formulation (β-gal 5 ng/150 µl in saline solution). The 
increased concentration was selected to provide a BTX A model concentration that 
could be employed to perform quantitative analysis of PMD loading capacity 
(Chapter 3) and enable visualisation of cutaneous delivery (Chapter 4). Increased 
concentrations are required to enable loading of PMDs with doses of the BTX A 
model, which can be detected using established experimental methodologies. 
Therefore, the aim of this experiment was to evaluate the residency time of a high 
concentration BTX A model solution in the pockets of a PMD to determine the time 
that would be available to insert a loaded PMD into the skin whilst maintaining the 
model protein in a liquid state.  
The results indicated that loading PMDs with a higher concentration of the model 
BTX A does not affect the uniform loading of the pockets. The formulation was 
retained in the pockets for approximately 90 seconds, after which the solvent 
evaporated. Therefore, the data indicated that loading PMDs with a concentrated 
solution allows retention of the liquid in the pockets for a sufficient time to permit 
application of the loaded PMDs into the skin and delivery the protein in a liquid 
state. 
 
2.4.5 Enhancing the retention of liquid loaded drug 
formulations in microneedle pockets 
The evaporation process of a solution is highly affected by its level of viscosity 
(Chen 1983). Evaporation of a liquid occurs when molecules in a liquid state collide, 
transferring energy to each other and thus becoming gaseous. The rate of the 
evaporation depends on the level of interaction between the molecules in the 
solution. Liquids that do not evaporate at a given temperature are composed of 
molecules that do not tend to rapidly transfer energy to each other and thus do not 
generate enough heat to be converted into vapour. In this case, the evaporation 
process will be less visible as it will occur at a considerably lower rate. 
Increasing concentrations of the viscosity enhancer glycerine were assessed as a 
means to enhance retention of aqueous solutions in MD pockets. Figure 2.7 indicates 
that the longevity of the liquid filled pockets can be dramatically increased by the 
addition of glycerine. Loading formulations containing glycerine 80% w/v were 
retained in the microneedle pockets for up to one month. Conversely, loading 
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solutions without glycerine visibly evaporated from the pockets within seconds. 
Addition of viscosity enhancers may therefore prove useful when volatile liquid 
formulations have to be loaded, in order to increase the residency time prior to 
application to the skin. 
These results confirmed the importance of viscosity for the sustained loading of the 
microneedle pockets (Section 2.4.4). Viscosity enhancers could therefore be added to 
a BTX A drug in order to reduce the evaporation rate of the formulation. This would 
ensure a more stable retaining of the drug into the pockets in a liquid state and may 
turn useful in clinical scenario as it would provide the clinician with an extended 
application time. However, addition of such excipients would determine the need for 
reformulation of existing commercial BTX A formulations and thus a considerable 
increase in the number of regulatory hurdles that would have to be overcome. Studies 
will be required in order to assess the effect of glycerine on the efficacy of BTX A. 
Such viscous formulations may affect the conformation of the toxin and/or reduce its 
migration to therapeutic targets once delivered within the skin. 
 
 
 
Figure 2.7: Effect of viscosity enhancers on PMD loading. The percentage of microneedle 
pockets retaining a glycerine based formulation is shown as a function of time. s = seconds, 
m = minutes, d = day/s. 
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2.5 Conclusion 
Small hydrophilic molecules and nanoparticles can be coated onto NPMDs, in a dry 
state, by using established coating methodologies. Increasing the number of 
immersions in the coating formulation results in better coating efficiency. However, 
automation of the process and/or specific MD design tailoring is needed in order to 
improve coating uniformity.  
Solubility studies indicate that the contents of a Botox
® 
vial (HSA 0.5 mg
 
and NaCl 
0.9 mg) can be dissolved in volumes that are small enough to enable effective MD 
loading of the toxin. PMDs and NPMDs can be uniformly loaded after one single 
immersion into a ‘Botox® like’ formulation. The inherent viscosity of the formulation 
promotes retention of the solution in the pockets of a PMD for a sufficient time that 
would allow subsequent application of the loaded device into the skin. After 
complete evaporation has occurred, a dry layer can be detected on the shaft of 
NPMDs and PMDs. This suggests that a Botox
®
 formulation could be loaded onto 
the MDs and retained either as a liquid formulation or a dry coat. 
The results suggest that the studied MDs are suitable for successfully loading 
existing BTX A formulations. BTX A loaded MDs are therefore a potential means of 
delivering the therapeutic toxin into the skin. 
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Chapter 3 
 
Evaluating the loading capacity of  
pocketed microneedle devices 
(PMDs) 
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3.1 Introduction  
Due to the constrained dimensions of microneedle devices (MDs), the mass of drug 
that can be loaded on each microneedle is limited. For this reason, dry coated MDs 
have been studied as a means to deliver potent biopharmaceutics such as vaccines 
(Kendall 2006; Kim et al. 2011; Quan et al. 2010) and hormones (Ameri et al. 2009; 
Cormier et al. 2004) with effective doses in the range of micrograms (Crommelin et 
al. 2003; Kenney et al. 2004). Due to the high potency of BTX A, therapeutic doses 
of the toxin reside in the low nanogram range (Section 1.4.1.1). Therefore, BTX A is 
a good candidate for MD loading. The experiments reported in Chapter 2 (Section 
2.4.4) indicated that a model of the commercial preparation Botox
® 
(called ‘Botox® 
like’ formulation), can be uniformly coated onto PMDs. The experiments described 
within this Chapter aim to investigate the suitability of PMDs as a means to retain 
therapeutically effective doses of BTX A in a liquid form. The term effective refers 
to the therapeutic doses employed in the treatment of palmar PFHH (Section 1.5.1). 
The loading capacity of liquid loaded PMDs will be compared to the more 
established NPMDs. 
The different strategies that have been employed to coat medicaments onto solid 
MDs (with or without pockets) were previously discussed (Sections 2.1.1 and 2.1.2), 
with a particular focus on the coating strategies for high molecular weight 
therapeutics such as proteins and vaccines. These therapeutics are more closely 
aligned to BTX A than small drug molecules. This introductory Section will provide 
an overview of the doses of medicaments that have been coated on solid MDs (with 
or without pockets) and the different factors that are known to affect the MD coating 
capacity.  
 
3.1.1 The coating capacity of dry coated solid MDs  
Numerous studies have reported MD dry coating with a range of molecules including 
low and high molecular weight model drugs and therapeutics (Daddona 2011; Gill 
and Prausnitz 2007a, b). As previously stated (Section 2.1.1), MDs are generally 
coated by multiple immersions into a coating formulation, with specific time 
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intervals between each immersion to permit drying of the loaded drug. Specific 
excipients such as viscosity enhancers and surfactants are typically added to the 
coating formulations in order increase the coating efficiency.  
Within the published studies, MD coating capacity has been reported to be 
significantly affected by parameters such as i) number of immersions (dips) of the 
microneedles into a coating formulation: increasing the number of immersions into a 
coating formulation results in thicker coatings and thus increased dose of 
medicament per microneedle (Ameri et al. 2010; Gill and Prausnitz 2007b; Zhang et 
al. 2011; Zhu et al. 2009); ii) microneedle design: arrays containing an higher 
number of microneedles can be coated with more material and therefore with greater 
doses of drug (Ameri et al. 2009; Ameri et al. 2010; Cormier et al. 2004; Daddona 
2011; Gill and Prausnitz 2007b; Zhang et al. 2011); iii) concentration of the 
medicament in the coating formulation: more concentrated formulations enable 
greater loading of medicaments per microneedle per immersion (Ameri et al. 2010; 
Cormier et al. 2004; Gill and Prausnitz 2007b; Zhu et al. 2009); iv) viscosity of the 
coating formulation: formulations containing viscosity enhancers (e.g., CMC or 
sucrose) and/or high concentrations of high molecular weight compounds, such as 
peptide and proteins, are usually associated with a higher level of viscosity compared 
to water (Ameri et al. 2010). More viscous formulations allow retention of increased 
volumes of liquid at each microneedle immersion. This promotes thicker coatings 
and thus greater dose loading (e.g., use of CMC within coating formulations has been 
associated with dose coating more than one order of magnitude higher than CMC-
free coating formulations (Kim et al. 2010)). A summary of medicaments that have 
been coated on differently designed MDs, the doses at which they have been coated 
and the different parameters mentioned above, are summarised in Table 3.1. 
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Published studies reporting MD coating with vaccines, and in particular influenza 
vaccines, have indicated vaccine coatings with doses ranging between 0.3 to 10 µg 
per MD (Kim et al. 2010; Koutsonanos DG 2009; Koutsonanos 2011; Quan et al. 
2010; Zhu et al. 2009). MDs employed within these studies contain a reduced 
number (5) of relatively long (700 µm) stainless microneedles per array. MD coating 
with influenza vaccines does not require further optimization of the coating capacity 
as those vaccines are typically of low microgram doses. Conversely, maximization of 
MD coating capacity has been reported for medicaments that require larger doses. 
Typically, this is achieved by using more densely packed MDs. For example up to 40 
µg of parathyroid hormone and 80 µg of desmopressin have been coated on titanium 
MDs (Macroflux
®
) by coating the tip (~100 µm) of the microneedles, which number 
between 280 and 1314 microneedles per array (Ameri et al. 2010; Cormier et al. 
2004; Daddona 2011). An additional published study indicates that up to 225 µg of 
the anaesthetic lidocaine can be coated on MDs containing approximately 316 
microneedles (Zhang et al. 2011). 
As previously mentioned (Section 2.1.1), vaccines have also been coated on short 
densely packed (~20000 microneedles/cm
2
) silicon MDs (Nanopatch
TM
) by using a 
gas jet coating procedure (Chen et al. 2009; Chen et al. 2010). Recent studies 
reported that such MDs were successfully coated with the commercial trivalent 
influenza vaccine Fluvax
® 
2008 (Chen et al. 2012; Fernando et al. 2010). Details 
regarding the mass of vaccines coated on the MDs are not provided. However, 
previous studies performed using ovalbumin as a model antigen indicated that a mass 
of 43.3 +/-1.73 (standard deviation) µg of protein was coated onto the Nanopatch
TM
 
(Crichton et al. 2010). Quantitative analysis of the doses of Fluvax
® 
2008 delivered 
to the skin of animal models revealed that Nanopatch
TM
 technology enables doses 
sparing of up to 30 folds compared to intramuscular injections.  
In summary, the capability of solid MDs to accommodate high molecular weight 
therapeutics such as vaccines, proteins and hormones has been widely assessed. 
Doses in the range of micrograms have been reported for all the medicaments tested. 
This suggests that MDs offer the potential to retain effective doses of BTX A 
(Botox
®
). However, some research groups have reported poor reproducibility of the 
MD coating dose (Cormier et al. 2004; Gill and Prausnitz 2007b; Zhang et al. 2011). 
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This has been generally associated with the use of manual and/or poorly optimised 
coating methodologies, which have resulted in reduced spatial control of the coating 
deposition. Coating uniformity on microneedles has to be guaranteed in order to 
ensure dose reproducibility. This is critical for therapeutic drug delivery and is 
particularly important for potent and potentially toxic therapeutics such as BTX A 
(Botox
®
). For this reason, the experiments reported in this Chapter will investigate 
the reproducibility of BTX A (Botox
®
) doses loaded on the studied PMDs and 
NPMDs.  
 
3.1.2 Liquid loaded capacity of pocketed MDs 
As previously reported (Section 2.1.2), a variant of solid microneedles is a 
microneedle containing single or multiple pockets that may be able to accommodate 
low volume liquid formulations. The concept of this device differs from dry coated 
MDs in that it is hoped that the pockets of this microneedle design can retain the 
drug in a liquid form. Quantitative analysis of the loading capacity of such MDs has 
been studied by Gill and Prausnitz (2007b; 2008) using the model compound 
riboflavin. Within these studies the drug model was loaded on the microneedles as a 
dry coat by using specific excipients. To the best of our knowledge no additional 
studies regarding pocketed MDs have been published. The studies were conducted 
on stainless steel microneedle rows containing 5 microneedles (700 x 200 x 50 µm; 
y, x and z plane), each having a rectangular pocket (400 x 50 x 50 µm; y, x and z 
plane). Similarly designed pocketed MDs, with slightly larger needles and pockets, 
are used in the current research study (as shown in Section 2.4.1). Gill and Prausnitz 
(2007b) compared the dose of riboflavin loaded selectively into the pocket of a 
pocketed microneedle to the amount of riboflavin coated on the surface of a non-
pocketed microneedle (700 x 200 x 50 µm, y, x and z plane). The studies indicate 
that filling drug selectively into the pocket of a pocketed microneedle reduced the 
mass of drug loaded per microneedle compared to the non pocketed microneedle 
(i.e., 0.066 +/- 0.013 µg of riboflavin was loaded into the pocket of a pocketed 
microneedle, which was immersed 6 times into a 3% w/v riboflavin coating 
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formulation, whereas 1.8 µg was coated on the entire surface of a non pocketed 
microneedle). 
Furthermore, the loading capacity of pocketed MDs with both shaft coatings and 
filled pockets was compared to the coating capacity of non pocketed MDs (Gill and 
Praunitz 2008). These results indicate that the dose of riboflavin loaded on the entire 
pocketed microneedle (pocket + shaft of the needle) was slightly greater compared to 
non pocketed microneedles (i.e., 2.8 µg of riboflavin was loaded on a pocketed 
microneedle following only one immersion into a riboflavin 3% w/v coating 
solution, while 1.79 µg was coated on a non pocketed microneedle). However, the 
difference in the loading capacity of the two needle designs was not statistically 
significant. This indicates that the presence of the pockets on microneedles does not 
increase the total dose of drug loaded. Therefore, although pocketed microneedles 
may enable medicaments such as BTX A (Botox
®
) to be delivered in a liquid form, 
they do not increase drug loading capacity of microneedles. 
 
3.1.3 Specific aims and objectives of the Chapter 
Experiments reported within this Chapter will aim to quantify the drug loading 
capacity of PMDs following a single immersion in to a liquid drug reservoir and will 
compare results to established NPMDs.  
 
The experimental objectives of the Chapter are to:- 
1) Determine the dose of a well-characterised low drug (salbutamol sulphate, 
SS, m.w.= 233 Da) that can be loaded on to PMDs. An established high 
performance liquid chromatography (HPLC) assay method will be employed 
in order to enable robust quantitative analysis. 
2) Determine the mass of a model high molecular weight protein (β-gal) that can 
be loaded, as a liquid formulation, on to PMDs. Calibrated spectroscopy 
methods will be established in order to enable robust quantitative analysis. 
3) Determine the reproducibility of PMD liquid loading for low and high 
molecular weight molecules. 
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4) Determine if a therapeutic dose of BTX A (i.e., 0.1-0.25 ng per each 
administration site) can be loaded, as a liquid, on a PMD using a Botox
®
 
mimic formulation. 
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3.2 Materials 
3.2.1 Reagents  
All reagents were used as received and were purchased from Sigma-Aldrich Ltd 
(Poole, UK), unless otherwise stated.  
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). 
Micronised salbutamol sulphate (SS) (mean diameter of 50%; particle population ≤ 
3.07 µm) was purchased from Micron Technologies Ltd (Dartford, UK). Methanol 
99.9%, sodium chloride, Tris Base (Tris(hydroxymethyl)aminomethane), Triton X-
100, trichloroacetic acid 99.8+%, citric acid monohydrate 99.9+%, acetic acid 
glacial, nuclease free water, Tris HCl (Tris(hydroxymethyl)aminomethane 
hydrochloride), glycerol 100% and formaldehyde solution 37% was purchased by 
Fisher Scientific (Loughborough, UK). Sodium dodecyl sulphate (SDS), TEMED (N, 
N, N-tetramethylendiamine) and bromophenol blue were purchased from Bio-Rad 
Laboratories (Hemel Hempstead, UK). Full range rainbow recombinant protein 
molecular weight marker was purchased from GE Healthcare (UK).  
 
3.3. Methods 
3.3.1 Calculation of the theoretical loading volume of a 
PMD 
The theoretical volume of a formulation which can be accommodated by a pocket of 
a single microneedle was calculated by multiplying the three pocket dimensions 
(length (mm), width (mm) and depth (mm)) obtained following visualization of the 
PMD by SEM (Section 2.4.1). The value calculated is the volume expressed as mm
3
. 
Knowing that 1 µl is equivalent to 1 mm
3
,
 
the theoretical
 
volume was converted to µl. 
As each PMD contain 4 pockets, the calculated value was multiplied by four in order 
to obtain the total theoretical volume accommodated by a PMD.  
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3.3.2 Quantitative analysis of MD loading capacity 
Quantitative analysis of MD loading was performed using an established (Ameri et 
al. 2009; Ameri et al. 2010; Cormier et al. 2004; Gill and Prausnitz 2007b; 2008; 
Zhang et al. 2011) two step process consisting of i) collection of the drug loaded on 
the MD by rinsing the array into a determined volume of appropriate buffer and ii) 
quantification of the drug released from the microneedles by calibrated spectroscopy 
or HPLC analysis.  
 
3.3.2.1 Quantifying salbutamol sulphate (SS) loading on MDs using 
HPLC  
SS loading capacity of MDs was assessed by a HPLC methodology, established in 
our laboratories (Bains 2010), as detailed below. 
 
Preparation of the internal standard 
An internal standard solution was freshly prepared by dissolving 8 mg of bamethane 
in 400 ml of methanol before being made up to 1000 ml with deionised water to 
achieve a final bamethane concentration of 8 µg/ml. Six SS standard solutions (n= 3 
for each standard solution) with a concentration ranging from 1 to 80 µg/ml, were 
freshly prepared from a stock solution of 10 mg/ml, by using the internal standard 
solution as a diluent. HPLC data (consisting of the area under the curve (AUC) ratios 
between the known concentration of SS and the bamethane internal standard) were 
used to generate a calibration curve (included in Section 3.4.2.2). 
 
Preparation of the mobile phase  
A buffer solution consisting of 1-heptane sulphonic acid (0.83 mg/ml) was freshly 
prepared in deionised water. One drop of glacial acetic acid was added to the buffer 
solution to adjust the pH to 3.2. Subsequently, methanol was added to the solution to 
achieve a final concentration ratio of methanol 40% v/v-buffer 60% v/v. A 0.2 µm 
Whatman
® 
nylon membrane filter (Whatman International Ltd., Maidstone, UK) was 
then used to filter the mobile phase prepared. 
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Preparation of samples 
The loading formulation was prepared by dissolving 100 mg of SS into 1 ml of 
deionised water. PMDs (n=10) and NPMDs (n=10) were then drug loaded by 
manually immersing the microneedle shafts once into SS solution as previously 
described (Section 2.3.4). Once loaded, each MD (NPMDs and PMDs) was 
immediately transferred into individual polypropylene microcentrifuge tubes, 
containing 500 µl of internal standard. After 1 hour, a 400 µl aliquot (sample 
solution) was withdrawn from each tube. Samples were then analysed by HPLC and 
Chem Quest
®
 4.1 software (Thermo Electron Corporation, Altrincham, UK). The 
characteristics of the HPLC equipment and the chromatographic conditions are 
outlined in Table 3.2. 
The calibration curve (Section 3.4.2.2) was used to determine SS concentration for 
each sample solution. The mass of SS loaded on each MD was then calculated by 
multiplying the measured concentration by the volume used for removal of the SS 
coating from the MDs. This value was used to calculate the volume of formulation 
that was loaded on each MD. A two tailed Mann Whitney U test was performed to 
compare two different groups (PMDs versus NPMDs), with significant differences 
indicated by p values <0.05. 
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Table 3.2: HPLC analysis of SS 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2.2 Quantifying MD loading with a model BTX A formulation 
using spectrophotometric techniques 
The enzyme β-gal, used as a model for BTX A (as previously indicated in Section 
2.1.3), was quantified using an established assay method that involves 
spectrophotometric measurements of the formation of the yellow chromophore o-
nitrophenol (ONP) (λabs max: 420 nm). This compound is the product of the 
hydrolytic reaction between the enzyme and the colourless substrate o-nitrophenyl-β-
D-galactoside (ONPG) (Figure 3.1.) (Griffith and Wolf 2002).The reaction product 
has a peak of absorbance at 420 nm and therefore wavelengths ranging between 410 
and 430 nm are used to obtain the greatest sensitivity (www.promega.com 2006). 
  
HPLC equipment Pump:                                      P200 
Autosampler:                         AS 3000 
Detector:                                UV 2000 
Chromquest software 
Chromatographic Column Genesis C18, 15 cm x 4.6 mm, 120 Å 4 um  
(Grace Vydac, Bannocburn, Illinois, USA). 
Assay conditions Flow rate of mobile phase:       1 ml/min 
UV wavelength:                        278 nm 
Injection volume:                      100 µl 
Retention time SS:                    6 minutes 
Retention time bamethane:      10 minutes 
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Figure 3.1: Schematic representation of the reaction between the enzyme β-gal and the 
substrate ONPG. Adapted from http://2011.igem.org/File:ONPG.png 2011. 
 
The spectrophotometric methodology used was performed according to protocols 
reported by Sigma Aldrich (www.sigmaaldrich.com 1994, 1999) with the 
modifications outlined in details below. The reagents used to perform the analysis are 
outlined in Table 3.3. 
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Table 3.3: Components of the ONPG assay solution 
*
1 
To be prepared in deionised water using sodium phosphate, monobasic, anhydrous 
powder. 
*
2 
To be prepared in deionised water using sodium phosphate, dibasic, anhydrous powder. 
Adjust to pH 7.3 at 37 °C with reagent A. 
*
3
 Solution to be gently warmed until the reagent is completely dissolved 
 
Spectrophotometric assay method for BTX A model determination  
The BTX A model, β-gal (β-gal from Escherichia Coli, Grade VI lyophilized 
powder, 1000 U) was reconstituted in 1 ml of Sodium phosphate buffer (SPB) 100 
mM, pH 7.3 at 37°C, to a concentration of 2.6 µg/µl. The solution was then aliquoted 
and stored at -20°C. An aliquot of the solution was defrosted on the day of the 
experiment and diluted to a concentration of β-gal 1.3 µg/µl in SPB. MDs were 
loaded either with the aid of the micro scale dip coating device (Section 2.3.2.1) or as 
described in Section 2.3.4 (the methodology employed for each experiment will be 
specified in the following Section).  
Once loaded with the BTX A model, the protein was removed for quantification by 
soaking the device in 300 µl of SPB for 1hour. Subsequently, an aliquot (100 µl) was 
withdrawn from each sample solution and added to specific assay reagents to 
produce the test solutions. The assay reagents and the order in which they were 
added are outlined in Table 3.4. After 40 minutes, the reaction was arrested by 
increasing the pH to 11 using sodium carbonate (1 M). This assay was repeated for 
matched blank solutions and also a range of standards (0.4-6.6 ng/µl) with a number 
of standard solutions ≥5. To quantify the colour change, an aliquot (200 µl) was 
ONPG-assay solution 
Reagents Concentration 
A) Sodium phosphate solution*
1
, monobasic, anhydrous, solution 100 mM 
B) Sodium phosphate buffer (SPB) pH 7.3 at 37°C*
2
,  solution 100 mM 
C) ONPG solution (to be prepared in reagent B)*
3
 68 mM 
D) Magnesium chloride (MgCl2) solution  in deionised water 30 mM 
E) 2-Mercaptoethanol solution (2-ME) in deionised water 3.36 M 
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withdrawn from each assay solution and transferred in triplicate into a 96 well 
polypropylene flat-bottomed optically clear plate. Absorbance values were measured 
at λ = 410 nm using a Fluostar fluorometer (BMG Lab technologies, Ortenberg, 
Germany). The results were expressed as a mean of the three readings obtained +/- 
standard deviation. 
Standard solutions were used to generate a calibration curve, which was used to 
determine BTX A model concentration of each sample solution. The mass of the 
BTX A model in the solution was thus calculated by multiplying the measured 
concentration by the volume of SPB used for protein removing from the MDs. The 
mass of protein that was retained by each microneedle was then calculated. Knowing 
the concentration of the BTX A model in the formulation (1.3 µg/µl), the mass value 
obtained was used to predict the volume of formulation loaded on each MD. 
Each test solution was constituted by a sample solution and the corresponding 
matched blank solution. The total volume of each test solution prepared was 5 ml. 
Test solutions of BTX A model standards (standard solutions and matched blank 
solutions) were also prepared according to the sequence outlined by the Table below. 
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Table 3.4: Sequence of addition of the reagents for the preparation of test solutions.  
 Reagent Volume 
added (µl) 
Addition of the 
reagent to the 
test solution? 
Addition of the 
reagent to the 
blank solution 
(negative control)? 
Step 1 Sodium phosphate 
buffer (100 mM) 
pH 7.3 at 37 °C 
(SPB) 
  2600 Yes Yes 
Step 2 
 
Magnesium cloride 
(MgCl2) 30 mM 
100 Yes Yes 
Step 3 β-gal solution  100 Yes No 
Step 4 2-Mercaptoethanol 
(2-ME) 3.36 M 
100 Yes Yes 
Mix and equilibrate to 37 ºC 
Step 5 ONPG (substrate) 
68 mM 
100 Yes Yes 
Mix and incubate for 40 minutes at 37ºC 
Step 6 Sodium Carbonate 
(NaCO3) 1 M 
2000 Yes Yes 
Step 7 β-gal solution  100 No Yes 
 
Assessing the feasibility of the spectrophotometric assay 
Initial experiments were performed in order to assess the suitability of the 
spectrophotometric assay, previously described, to successfully detect the mass of 
the BTX A model liquid that will be loaded on to a MD. 
A standard curve was constructed by using a BTX A model concentration ranging 
between 0.4-6.6 ng/µl (the calibration curve is included in Section 3.4.2.1)  
 
Comparison of PMDs and NPMDs loading capacity  
The spectrophotometric methodology described above was used to compare the mass 
of the BTX A model loaded onto PMDs and NPMDs after a single immersion into 
the BTX A model solution (1.3 µg/µl). In this experiment PMDs (n=8) were 
manually loaded by a single immersion into a reservoir containing a small volume 
(~20 µl) of the BTX A model formulation as previously described (Section 2.3.4). 
NPMDs (n=8) were drug loaded with the aid of a micro scale dip coating reservoir 
device described in Section 2.3.2.1 After the immersion, excess formulation 
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accidentally collected on the base of each PMD and NPMD was carefully removed 
using lintless tissue paper. 
The experiment described above was repeated in order to compare the loading 
capacity of PMDs (n=10) and NPMDs (n=10) when loaded without the aid of a 
microscale dip coating reservoir. Loading was performed as reported above for 
PMDs and described in Section 2.3.4. A two tailed Mann Whitney U test was 
performed to compare two different groups (PMDs versus NPMDs), with significant 
differences indicated by p values < 0.05. 
 
3.3.3 Assessing the feasibility of a PMD to load a 
therapeutic dose of BTX A, as a liquid, using a ‘Botox
®
 
blank’ formulation. 
The commercial formulation Botox
®
 contains a dose of BTX A (5 ng), which is 
considerably difficult to detect by using standard laboratory techniques. As 
previously mentioned (Section 2.1.2), other constituents of Botox
®
 are the excipients 
HSA and NaCl. Within a single vial of Botox
®
 there is 0.5 mg of HSA. HSA was 
chosen as a surrogate measure of BTX A due to its greater mass in the formulation 
and therefore the ability to detect it. MDs were loaded with a dose of HSA that was 
representative of the dose in the clinical formulation and this could be detected by 
standard laboratory methodologies. MDs were liquid loaded with a ‘Botox® blank’ 
formulation containing the same constituents of Botox
® 
(HSA 0.5 mg and NaCl 0.9 
mg) but devoid of BTX A. After loading, MDs were immersed for 1 hour at room 
temperature into an appropriate diluent. The protein released in the diluent was 
subsequently characterised by SDS-PAGE (sodium dodecyl sulphate polyacrylamide 
gel electrophoresis) and visualised by silver staining methodologies.  
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3.3.3.1 Assessing the feasibility of SDS-PAGE and silver staining 
methodology for characterization of the HSA contained in the 
commercial preparation Botox
®
 
Initial experiments were performed in order to assess the feasibility of 
electrophoretic and silver staining techniques to detect the mass of HSA (0.5 mg) 
contained in Botox
®
.  
The commercial BTX A preparation Vistabel
® 
(containing
 
the same excipients as 
Botox
®
) was employed as a substitute of Botox
®
. Standard solutions of the protein 
bovine serum albumin (BSA, 66 kDa) were used as a positive control. 
 
SDS-PAGE methodology 
Preparation of 10% polyacrlyamide resolving gel  
 
A 10% polyacrylamide resolving gel was prepared by mixing the following ragents 
at the volumes indicated:  
i) 2.5 ml of 40% acrylamide/bisacrylamide 
ii) 1.25 ml of 3 M Tris buffer pH 8.8  
iii) 0.1 ml of 10% sodium dodecyl sulphate (SDS)  
iv) 6.1 ml of deionised water  
v) 0.0075 ml of TEMED (N, N, N-Tetramethylendiamine) 
vi) 0.075 ml of ammonium persulfate (APS) 10% w/v in deionised water  
 
Preparation of 4% polyacrlylamide stacking gel  
A 4% polyacrylamide resolving gel was prepared by mixing the following reagents 
at the volumes indicated: 
i) 0.5 ml of 40% acrylamide/bisacrylamide 
ii) 0.65 ml of 1 M Tris HCl buffer pH 6.8  
iii) 0.05 ml of 10% sodium dodecyl sulphate (SDS)  
iv) 3.8 ml of deionised water  
v) 0.005 ml of TEMED (N, N, N-Tetramethylendiamine) 
vi) 0.0375 ml of APS 10% w/v in deionised water  
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Preparation of Vistabel
®
 sample formulation and BSA solution. 
A vial of Vistabel
® 
containing HSA 0.5 mg
 
was reconstitued in 200 µl of 0.9% saline 
solution to a HSA concentration of 2.5 µg/µl. An aliquot (40 µl) of Vistabel
® 
was 
diluted to a HSA concentration of ~1.8 µg/µl in loading buffer ((DTT (DL-
dithiothreitol) ~0.18 M, Tris-HCl pH 6.8 (at 25°C) ~14.2 mM, SDS ~0.53% w/v, 
bromophenol blue ~5.3 x 10
-04 
% w/v, and glycerol ~1.9% v/v)) 
A stock solution of bovine serum albumin (BSA) 1 µg/µl was freshly prepared in 
0.9% saline solution. An aliquot (20 µl) of this stock solution was furthermore 
diluted to a concentration of ~0.3 µg/µl in loading buffer (as above). This was used 
as a positive control (pos. control) 
The sample and control solutions obtained were heated to 96°C for 5 minutes (Tube 
Boiler, Grant, Fisher, UK). Subsequently, aliquots (15 µl) of each solution were 
loaded in triplicate into the polyacrylamide gel previously prepared. Therefore, the 
gel contained ~4.5 µg of BSA (per well) and ~27 µg of HSA (per well). A molecular 
marker (Full-Range Rainbow Molecular Weight Marker, GE Healthcare, UK) was 
also loaded in duplicate (5 µl per well). 
The gel was subsequently dipped in 1X running buffer (per litre distilled water, 3.03g 
Tris base, 14.4 g glycine, 1.0 g SDS) and run for 70 minutes at 110 Volts in a Biorad 
Mini-PROTEAN Tetra Cell (10-well, 1.0 mm thickness, 4-gel system + Mini Trans-
Blot Module) powered by a GE Healthcare EPS-601 power supply. Subsequently, 
the gel was transferred into a weighing boat (Fisher Scientific, UK) containing 
approximately 5 ml of deionised water and washed for 5 minutes at room 
temperature on a rocking platform (Gyro rocker, Stuart, Fisher Scientific, UK). The 
gel was then transferred into a new weighing boat containing approximately 5 ml of 
TCA (trichloroacetic acid 20% w/v in deionised water) and washed overnight at 
room temperature on a rocking platform. Subsequently the gel was processed as 
described below for silver staining methodology. 
 
Silver staining methodology 
Visualisation of the protein bands following SDS-PAGE was performed by a silver 
staining methodology as outlined by Dunn (2002). The following incubation steps 
were performed at room temperature on an orbital platform. 
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Step 1: Sensitization 
The gel was washed twice (2 x 20 minutes) in deionised water before being soaked in 
glutaraldehyde 10% v/v for 30 minutes followed by 3 x 20 minutes washes in 
deionised water.  
 
Step 2: Staining  
The gel was incubated for 30 minutes with a freshly prepared silver diamine staining 
solution consisting of 21 ml of sodium hydroxide 0.36% w/v, 74 ml of deionised 
water, 1.4 ml of ammonium hydroxide and 4 ml of silver nitrate 20% w/v. The latter 
was added dropwise with constant stirring. Subsequently, the gel was washed three 
times in deionised water, 5 minutes each time. 
 
Step 3: Development and Stopping 
Visualisation of protein bands was obtained by soaking the gel in a developing 
solution consisting of citric acid 0.005% w/v and formaldehyde 0.019% v/v in 
deionised water. This treatment was performed for approximately 1 minute before 
being terminated by immersing the gel in stopping solution (ethanol 40% v/v, acetic 
acid 10% v/v in deionised water).  
 
Step 4 Imaging  
The gel was subsequently washed twiced (2 x 15 minutes) in deionised water before 
being imaged by ChemiDoc XRS + System (Bio-Rad Laboratories, Hemel 
Hempstead, UK). 
 
3.3.3.2 Comparison of PMDs and NPMDs loading of BTX A from a 
‘Botox® blank’ formulation 
A ‘Botox® blank’ formulation containing only the excipients of the commercial 
preparation, 0.5 mg of HSA and 0.9 mg of NaCl, was freshly prepared in 150 µl of 
0.9% saline solution. Saline solution is the diluent recommended by Allergan to 
reconsitute a vial of Botox
®
 (Section 1.5.1) and therefore the blank formulation 
provides a close representation of the clinical formulation, the only omission being 5 
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ng of BTX A, This ‘Botox® blank’ formulation differs from the so termed ‘Botox® 
like’ formulation described in Section 2.3.4.1 in that it does not contain β-gal as a 
model for BTX A. 
PMDs (n=6) and NPMDs (n=6) were liquid loaded by a a single immersion into the 
‘Botox® blank’ formulation as previously described (Section 2.3.4). The loaded 
protein was released by soaking each MD in 0.9% saline solution (200 µl) for 1 hour 
at room temperature. An aliquot (40 µl) was withdrawn from each solution where a 
single MD was immersed and diluted to a concentration of approximately 70% v/v in 
loading buffer ((DTT (DL-dithiothreitol) ~0.18 M, Tris-HCl pH 6.8 (at 25°C) ~14.2 
mM, SDS ~0.53% w/v, bromophenol blue ~5.3 x 10
-04  
% w/v, and glycerol ~1.9% 
v/v)). 
Additionally, a stock standard solution (HSA 1 µg/µl) was freshly prepared in 0.9% 
saline solution 0.9% w/v. From this stock solution, six diluted HSA solutions were 
prepared in loading buffer (as above) to a final HSA concentration of approximately 
0.9-180 ng/µl. 
The sample and the standard solutions were subsequently heated at 96 °C for 5 
minutes (Tube Boiler, Grant, Fisher Scientific, UK) as previously described (Section 
3.3.3.1). Aliquots (15 µl) of HSA standard solutions were transferred into each of 2 
polyacrylamide gels (gel 1 and gel 2), prepared according to the methodology earlier 
described (Section 3.3.3.1). Aliquots (15 µl) of the sample solutions obtained either 
from PMDs or NPMDs were loaded respectively into gel 1 (PMDs) and gel 2 
(NPMDs). Each gel contained a decreasing mass of HSA standard, ranging between 
approximately 13 and 2700 ng. SDS-PAGE and silver staining methodology were 
therefore performed as previously described (Section 3.3.3.1). 
The concentration of HSA in the sample solutions was determined by visually 
comparing the intensity of these bands to the intensity of HSA bands generated by 
HSA standards. The mass of HSA loaded on the MDs was subsequently estimated 
(semi-quantitative) by multiplying the sample concentrations by the volume of 
diluent used to remove HSA from the microneedles (200 µl). The volume of 
formulation loaded on each MD was then calculated and the mass of BTX A 
potentially loaded on a MD was subsequently extrapolated. 
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3.4 Results and Discussion 
3.4.1 Calculation of the theoretical loading volume of a 
PMD 
The PMDs dimensions characterised by SEM (Section 2.4.1) and reported in the 
schematic diagram below (Figure 3.2), were used to calculate the volume that could 
theoretically be loaded into each pocket of a PMD. 
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Figure 3.2: Schematic diagram of a pocketed microneedle. The length, the width and the 
depth (µm) of a single microneedle pocket are shown in the Figure. 
 
According to the pocket dimensions, the theoretical volume occupied by each pocket 
was: 
0.360 mm x 0.140 mm x 0.065 mm= ~0.003 mm
3
= ~0.003 µl= ~3nl/pocket. 
Each array contains 4 pocketed microneedles and therefore 12 nl could be 
theoretically loaded into the 4 pockets after immersion of the PMD into a solution. 
The difference between the theoretical volume and the experimental volumes 
obtained by the quantitative analysis of PMD loading capacity, described in the 
subsequent section, will be discussed in Section 3.4.2.3. 
 
3.4.2 Quantitative analysis of MD loading capacity 
Determination of PMD loading capacity for both low molecular weight compounds 
(salbutamol sulphate, SS) and high molecular weight molecule (the BTX A model, β-
gal) was performed respectively by HPLC and calibrated spectroscopy. Established 
NPMDs were used as direct comparison with PMDs. 
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3.4.2.1 Quantifying MD loading with a model BTX A formulation 
using spectrophotometric techniques 
A calibration curve was generated from spectrophotometric data (Figure 3.3). The R
2
 
of the curve was 0.99 and therefore the linear equation was considered valid for 
calculating the concentration of the BTX A model (β-gal) released by loaded MDs. 
The calculated concentration was then used to obtain the mass of BTX A model that 
was loaded on each PMD. 
The data confirmed the feasibility of the assay as a means to quantify the dose of the 
BTX A model loaded onto PMDs. The results indicated (Figure 3.4) that after a 
single immersion into a BTX A model formulation (1.3 μg/μl), an average of 351.53 
+/- 245.80 ng of the BTX A model was loaded on the PMD (n=5). This is equivalent 
to a loaded volume of 270 nl per PMD. The associated standard deviation value 
indicated above (+/- 245.80) revealed high variability of the loading capacity 
between the studied PMDs. 
  
Chapter 3 
104 
 
 
 
Figure 3.3: Calibration curve for the quantification of the BTX A model (β-gal). Data 
are presented as mean (standard-blank) of three absorbance readings (n=3) obtained from 
each standard solution and its matched blank solution +/- SD. 
 
The protein concentration of the model β-gal in the BTX A model formulation 
employed in this experiment (and furthermore adopted in the subsequent 
spectrophotometric analysis) was considerably higher than the concentration of BTX 
A, which would be used in a clinical setting. As previously mentioned (Section 
1.5.1), the entire vial of Botox
®
, containing 5 ng of BTX A, is usually reconstituted 
in volumes ranging between 1.5-5 ml to a concentration of approximately 1-3 pg/µl. 
This concentration is approximately one million times smaller than the one employed 
in our experiments. However, the greater concentration was required to enable 
loading of PMDs with protein quantities that were above the limits of detection of 
the methodologies employed in our experiments.  
y = 0.3407x - 0.075
R² = 0.9971
0
0.5
1
1.5
2
2.5
0 2 4 6 8
A
b
so
rb
a
n
ce
 v
a
lu
es
 (
4
1
0
 n
m
)
BTX A model Standard Concentrations (ng/µl)
Chapter 3 
105 
 
 
 
Figure 3.4: Assessing the feasibility of the spectrophotometric assay to determine the 
mass of the BTX A model (β-gal) liquid loaded on PMDs (n=5). Data are presented as a 
mean +/-SD of three readings obtained from each sample and its matched blank solution. 
 
The experiment was repeated in order to compare the loading capacity of MDs when 
loaded with (NPMDs (n=8)) and without (PMDs (n=7)) the aid of the microscale dip 
coating reservoir device, which was described in Section 2.3.2.1. This was performed 
in order to assess whether the use of the dip coating reservoir device increased the 
reproducibility of MD loading. The data (Figure 3.5) indicates that an average of 
84.74 ng (+/- 44.59) and 134.09 ng (+/- 74.29) of protein could be loaded into a 
PMD (n=7) and a NPMD (n=8), respectively after a single immersion into the BTX 
A model formulation (1.3 μg/μl). This suggested that a volume of approximately 65 
nl and 103 nl could be therefore loaded onto a PMD and a NPMD respectively. 
Similarly to preliminary experiments, the data were associated with high standard 
deviation values, indicating a lack of reproducibility for MD loading capacity. These 
results also demonstrated that the use of the dip coating reservoir device did not 
result in improved loading reproducibility. Statistical analysis indicated that there 
was no significant difference between the loading capacity of the two microneedle 
designs, PMDs and NPMDs (p=0.19). 
0
100
200
300
400
500
600
700
800
900
0 1 2 3 4 5 6
M
a
ss
 (
n
g
) 
o
f 
β
g
a
l 
p
er
 P
M
D
PMDs (1-5)
Chapter 3 
106 
 
 
Figure 3.5: Comparison of the amount (ng) of the BTX A model (β-gal) loaded onto a 
PMD (n=7) and a NPMD (n=8) when using two different drug loading procedures. 
NPMDs were loaded with the aid of a micro scale dip coating device (Section 2.3.2.1), 
PMDs were manually loaded by a single immersion into a reservoir containing a small 
volume (~20 µl) of a BTX A model formulation (Section 2.3.4) *= average. N value for 
PMDs was reduced to 7 as one of the data points was considered to be an outlier (the value 
was almost 10 fold higher than the highest value detected for PMDs). 
 
The loading capacity of PMDs (n=10) and NPMDs (n=10), using the technique 
described in Section 2.3.4, was assessed. The results indicated (Figure 3.6) that a 
mean average of 66.5 ng (+/- 52.27) and 75.8 ng (+/- 89.05) of the BTX A model 
was loaded on the PMD and a NPMD respectively. Therefore, a volume of 
approximately 50-60 nl of the BTX A model was loaded onto both the NPMD and 
PMD. However, standard deviations values were again high and the difference in the 
loading capacity between the two microneedle designs (PMDs and NPMDs) was not 
statistically significant (p=0.79).  
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Figure 3.6: Comparison of the amount (ng) of the BTX A model (β-gal) loaded onto a 
PMD (n=10) and a NPMD (n=10) when using the same drug loading procedure. 
PMDs/NPMDs were manually loaded by a single immersion into a reservoir containing a 
small volume (~20 µl) of a BTX A model formulation (Section 2.3.4) *= average. 
 
3.4.2.2 Quantifying salbutamol sulphate (SS) loading on MDs using 
HPLC  
To determine whether the poor reproducibility of the MD loading was a specific 
problem for the macromolecular analyte β-gal or a limitation of the device/loading 
process, MDs were also loaded with a well characterised small drug molecule, 
salbutamol sulphate (SS). 
A calibration curve was generated from HPLC data (Figure 3.7). The mass of SS 
loaded per each MD was then calculated. The data (Figure 3.8) indicates that an 
average of 13.57 µg (+/- 8.84) and 7.50 µg (+/- 5.20) of SS were loaded on to a PMD 
and NPMD respectively, after a single immersion into a SS loading solution (0.1 
g/ml). This equates to a volume of approximately 136 nl (PMD) and 75 nl (NPMD) 
of SS solution. This data supports the results previously obtained for the BTX A 
model, indicating that the MD loading methodology used is associated with an 
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inherent level of variability. Equally, the difference in the loading capacity of the two 
microneedle designs was not statistically significant (p=0.08).  
 
 
Figure 3.7: Calibration curve for the quantification of SS. Data are presented as mean 
(standard-blank) ± SD; n = 3. 
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Figure 3.8: Quantification of the mass (µg) of SS per PMD (n=10) and NPMD (n=10). 
PMDs/NPMDs were manually loaded by a single immersion into a reservoir containing a 
small volume (~20 µl) of a BTX A model formulation (Section 2.3.4). *= average. 
 
3.4.2.3 Safety, efficacy and reproducibility of the doses of BTX A 
that can potentially be loaded on MDs 
The experiments previously reported (Sections 3.4.2.1 and 3.4.2.2) highlighted the 
high level of variability of the MD loading capacity. This was observed for both high 
and low molecular weight compounds (β-gal and SS) quantified by two different 
robust methodologies, calibrated spectroscopy and HPLC. This indicates that the 
variability of the results obtained is not specifically related to the physicochemical 
characteristics of the analyte to be loaded and/or to the methodology employed to 
quantify it, but most likely to the loading process. The experiments described in 
Chapter 2 also identified the loading process as a potential source of variability. This 
is a manual procedure requiring immersion of the micron-sized microneedle shaft 
into a liquid formulation. The small scale of the microneedle devices and the low 
volumes used to load the MDs implies that during this process microneedles are 
typically immersed to slightly different depths. Therefore, for some needles liquid 
may be loaded on to the base of the array and others only the microneedle shaft. 
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Excess formulation that was collected on the base of the MD during the microneedle 
immersion process was carefully removed using lintless tissue paper. However, 
uniform removal of the formulation from the arrays was considerably difficult to 
achieve.  
Calculation of PMD theoretical loading capacity (Section 3.4.1) indicated that a 
single pocket of a pocketed microneedle could accommodate a volume of 
approximately 3 nl and thus 12 nl could be accomodated by a PMD (containing four 
pocketed microneedles), a volume which is considerably smaller than all the volumes 
calculated in our experiments (50-270 nl per PMD). Such discrepancy between 
theoretical and experimental volumes furthermore suggested that at each PMD 
immersion a considerable volume of liquid was retained on the shaft of the needle (as 
indicated by the experiment described in Section 2.4.4) and potentially on the base of 
the array. Also the central non pocketed microneedle contained in each PMD 
(Section 2.4.1) would also retain a certain volume of formulation (as indicated by the 
experiment reported in Section 2.4.4), thus contributing to the total PMD loading 
capacity.  
Few published studies have reported variability of MD loading. This was mainly 
associated with the use of non automated and or not optimised coating procedures. 
This results in poor spatial control of deposition of the coating formulation over the 
length of the microneedles and deposition of the formulation on the base of the array. 
In a study published by Zhang et al. (2011), assessing the use of lidocaine coated 
MDs as a means to deliver the anaesthetic to animal models, drug loading was 
associated with relative standard deviation (RSD) values higher than 10%. For 
example a mass equal to 90.5+/-14.5 µg of drug was loaded onto one array of 
approximately 360 needles following one immersion into a coating formulation 
containing lidocaine 30% w/w and dextran 30% w/w as a excipient (as indicated in 
Table 3.1). The coating apparatus employed in the study was not specified. However, 
it can be assumed that coating was performed manually as the authors stated that 
automation of the process would have been introduced in future work in order to 
reduce variability. 
Gill and Prausnitz (2008) quantified the dose of the model drug riboflavin coated on 
pocketed and non pocketed stainless steel microneedles by using the dip coating 
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reservoir device previously described (Section 2.3.2.1). The authors reported average 
relative standard deviation values equal to 19% of the results obtained. For example, 
a dose of riboflavin equal to 0.066+/-0.013 µg was loaded into each pocket (400 µm 
long x 50 µm wide) of a pocketed microneedle, following immersions into an 
aqueous formulation containing riboflavin 3% w/v and sucrose 25% w/v as excipient 
(Table 3.1).  
The acceptance criteria for the production of pharmaceutical dosage forms such as 
capsules and tablets is set at RSD ≤ 5% (http://www.fda.gov 2003). Our data has a 
RSD value of > 50%. This clearly indicates that reproducible doses of drug could not 
be loaded on the studied MDs using the loading methodologies currently employed. 
Therefore, an automation of the loading process and/or an optimization of the 
microneedles design are certainly needed in order to reduce the level of variability 
(different strategies to increase MD loading uniformity were discussed in Section 
2.4.2). Dosing uniformity and accuracy is critical for therapeutic drug delivery and is 
particularly important for potent and potentially toxic therapeutics such as BTX A. 
However, therapeutic doses of BTX A are safe due to its large therapeutic window. 
The lethal dose of the toxin is estimated at 1ng/kg of body weight (Gill 1982). An 
entire vial of Botox
®
 contains 5 ng of drug. Therefore, administration of lethal doses 
of toxin is extremely unlikely (impossible) and to date no episodes of fatalities 
related to treatment have been reported. 
When comparing microneedles to other delivery systems such as Transdermal 
Delivery Systems (TDDS) and topical patches, one of the major safety concerns 
related to the use of these devices is the excess of drug which is retained after their 
application into the skin (http://www.fda.gov 2011). TDDS and topical patches 
contain a larger amount of drug than the dose intended to be administered. This is to 
ensure an efficient diffusion gradient of the drug through the skin and thus to 
facilitate delivery of effective doses to the patient. Current TDDS and topical patches 
can retain up to 95% of the dose originally loaded after their application onto the skin 
(http://www.fda.gov 2011). This represents a potential safety issue for patients and 
other individuals in their vicinity. Accidental death of children exposed to the 
discarded TDDS has been reported (http://www.ismp-canada.org 2005). Also there is 
evidence of side effects for patients who fail to remove the TDDS after the required 
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duration of use (http://www.fda.gov 2011; Roberge 2000). Our results suggest that a 
volume of excess loading formulation may also be retained on the base of the PMDs 
and NPMDs. To translate this into a clinical context, if we were to use a Botox
®
 
loaded PMD to treat palmar PFHH, we may expect that this excess of formulation 
may still remain on the PMD after its application to the skin and may therefore be 
present on the discarded PMD. Some formulation may also be deposited on the 
surface of the skin. The presence of this excess formulation is not expected to be a 
safety concern as the dose of toxin in such constrained volumes would be lower than 
the therapeutic doses. Particular care should be taken if PMDs were discarded in 
places accessed by children, due to their reduced total body weight. However, if 
trained personnel in monitored environments such as hospitals or clinics used these 
devices, this risk would be reduced. Residual unused drug formulation on the base of 
a PMD may pose an economic issue though for an expensive drug
 
such as Botox
®
. 
Poor reproducibility of PMD loading would result in variable dose delivery and 
therapeutic effects. However the dose range of BTX A currently used in the clinical 
setting is relatively large, as dose is adjusted based on the response of the patient 
(Naver et al. 1999). As previously mentioned (Section 1.5.1) Botox
®
 manufacturing 
company (Allergan Pharmaceuticals Irvine, CA, USA) recommends to reconstitute 
the drug (BTX A-5ng) in 4 ml of 0.9% saline solution i.e., to a concentration of 1.25 
ng/ml. However in the clinical practice setting different dilutions are used, depending 
on the mass of toxin to be administered and the clinician’s preference. 
For the treatment of palmar PFHH dilutions ranging between 1.5-5 ml have most 
frequently been reported (Glaser et al. 2007b). BTX A doses of 1.25-11 ng per palm 
(corresponding to a number of BTX A (Botox
®
) Units ranging between 25-220 U), 
administered by up to 50 intradermal injections, spaced 1-1.5 cm apart, have resulted 
in satisfactory sweat reduction (Glaser et al. 2007b; Holmes and Mann 1998; Naver 
et al. 1999). Injection volumes ranging between 0.05 and 0.1 ml have generally been 
employed and BTX A is usually delivered at doses of 0.1-0.25 ng at each 
administration site (Glaser et al. 2007a). In particular, a study published by Moreau 
et al. (2003), reported a clinically effective dose of approximately 3.5 ng of BTX A 
for each treated palm. In this study, the entire vial, containing 5 ng of drug was 
reconstituted with 4 ml of 0.9% saline solution to achieve a concentration of 0.125 
Chapter 3 
113 
 
ng per 0.1 ml. Aliquots (0.1 ml) of the Botox
®
 formulation were then injected into 
28+/-1 sites (mean +/- standard deviation) located on each palm. Therefore, if the 
PMD were to directly replace intradermal injections it would need to be applied to 
approximately 28 sites on the palm of the hand and fingers, spaced at approximately 
1-1.5 cm intervals. It would need to deliver approximately 0.1 ml volume of BTX A 
and therefore a dose of 0.125 ng per treatment site. Our studies have demonstrated 
that both the PMD and NPMD have the capacity to deliver this dose of drug.  
However, the limitation of the device is the volume of solution that can be loaded on 
to the needles and therefore, in order to load and thus deliver a therapeutically 
relevant dose using a MD, the medicament would have to be reconstituted using 
lower volumes than in current clinical practice, i.e. the formulation would need to be 
re-constituted with a volume in the microlitre range (e.g. 50-200 µl).  
Experiments were previously conducted in order to determine whether the contents 
of the Botox
®
 vial could be dissolved in volumes that are low enough to enable MD 
mediated delivery of the toxin (Section 2.4.3). These studies confirmed that HSA 
(0.5 mg) and NaCl (0.9 mg) can be dissolved in 0.9% saline solution using volumes 
less than 50 µl. These low volumes would facilitate MD mediated delivery in the 
clinical setting. For example, if we assume that 50 µl of 0.9% saline solution was 
added to a Botox
®
 vial to obtain a 0.1ng/µl solution, it would be needed to deliver 
only approximately 35 µl of this solution to each palm (3.5 ng) to achieve a clinical 
response. If we assume that PMDs were a direct replacement for the intradermal 
injection and a person would be treated with 28 PMD applications, then only 1.25 µl 
of the Botox
®
 formulation (0.125 ng) would have to be loaded onto each PMD. Our 
results (Section 3.3.2.1) indicate that volumes of a BTX A model (β-gal) formulation 
ranging between 50 and 270 nl can be accommodated by a PMD, containing only 5 
microneedles, following one immersion into the formulation. Therefore, although we 
recognise loading is currently variable, a PMD should have the capacity to hold a 
volume of approximately 100 nl, a value 12 times smaller than the required volume 
(1.25 µl). Guided by this analysis, PMDs containing 60 needles, i.e. 10 x 6 out-of-
plane microneedles distributed in an area of ~2 cm
2
, could therefore be used to 
deliver a therapeutically relevant dose of medicament. 
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Even if PMDs were to only deliver a total volume of Botox
®
 equal to 80% (28 µl) of 
the intended volume (35 µl) per palm, a therapeutic effect would still be likely as this 
volume would deliver 0.1 ng of BTX A per administration site, a dose which is 
within the therapeutic range. This indicates that a variability of up to 20% of the dose 
may be accepted by regulators as it would be comparable with current clinical 
administration of Botox
®
, which has a large therapeutic window.  
Loading methodologies currently used in our experiments are therefore currently not 
suitable for BTX A loading in the clinical setting as consistent effective doses of the 
medicament would not be guaranteed. However, variable therapeutic effects have 
been noted in patients treated by intradermal administration of Botox
®
 using the 
traditional syringe and needle (Naver et al. 1999; Saadia et al. 2001). These 
intradermal injections of Botox
® 
are currently performed using the Mantoux 
technique. This is a technique, which relies on the insertion of a needle almost 
parallel to the skin to selectively penetrate the dermal layer without (in theory) 
reaching the underlying tissues. Performing this technique requires training and 
practice and it is frequently poorly reliable and inefficient (Laurent et al. 2007b). 
Accidental delivery of the formulation to unwanted sites such as muscles, usually 
determines appearance of side effects such as muscle weakness (Swartling et al. 
2001) and also reduces the accuracy of the dose. Consistency of the dose delivered 
cannot be guaranteed due to additional factors such as variability of the syringe 
filling volumes, the presence of air bubbles during the purging process, retaining of 
volume of formulation in the syringe after injection (Laurent et al. 2007b) and back 
pressure causing expulsion of some formulation over skin surface while injected. 
In conclusion, therapeutic doses of BTX A could potentially be loaded onto 
specifically tailored MDs (i.e. PMDs containing a greater number of microneedles) 
in a safe manner. However, in agreement with Gill and Prausnitz (2008) (Section 
3.1.2), when comparing dose loading of PMDs and NPMDs, there is not a significant 
difference in the loading capacity of the two microneedle designs. Therefore, 
although pocketed microneedles may enable BTX A to be delivered in a liquid form, 
they would not increase the drug loading capacity of microneedles. However, 
reproducible MD loading of BTX A could not be guaranteed by using the loading 
procedures employed in our experiments. Therefore, reduction of such variation is 
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certainly needed in order to ensure uniform therapeutic effects. According to our 
analysis, to load PMDs with effective doses of BTX A would require reconstitution 
of the Botox
®
 vial in a volume of 50 µl. As previously mentioned (Section 2.4.3), 
this would represent a technical challenge. The reconstituted formulation would be 
difficult to withdraw from the vial and this would lead to a waste of the costly 
medicament. Use of larger volumes (i.e. 500-1000 µl) would certainly facilitate 
easier handling of the formulation but would require PMDs with a greater number of 
microneedles (i.e. 600-1200 microneedles). Alternative microneedle devices with 
increased loading capacity such as hollow microneedles may potentially be more 
suitable for BTX A loading.  
 
3.4.3 Assessing the feasibility of a PMD to load a 
therapeutic dose of BTX A as a liquid using a ‘blank 
Botox
®
’ formulation. 
Previous experiments were performed by using a BTX A model formulation 
containing the enzymatic protein β-gal as representation of BTX A. However the 
composition of this formulation differed from the commercial Botox
®
 preparation. 
Firstly, in order to enable detection, the concentration of the BTX A model was 
greater (1.3 µg/µl) than in Botox
®
 (~1-3.3 pg/µl). Secondly, the solution was not 
formulated with any of the excipients which are present in the Botox
®
 preparation 
(HSA 0.5 mg and NaCl 0.9 mg). It is thus reasonable to assume that the 
physicochemical properties of the two formulations would be different. 
Experiments were therefore performed to obtain an indication of the loading capacity 
of PMDs and NPMDs when loaded with a formulation that contained the same 
excipients (HSA and NaCl) as present in Botox
®
. The commercial preparation was 
therefore employed in these studies. Due to the small mass of BTX A in the 
formulation, HSA was used as an indicator of loading efficiency to enable detection 
by the methodologies employed.  
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3.4.3.1 Assessing the feasibility of SDS-PAGE and silver staining 
methodology for characterization of the protein HSA contained in 
the commercial preparation Vistabel
® 
Preliminary experiments were performed to assess the feasibility of SDS-PAGE and 
silver staining methodology to characterise the HSA contained in the commercial 
BTX A preparation Vistabel
®
. This is a commercial preparation, manufactured by 
Allergan, which is identical to Botox
®
, except that it contains half the mass of BTX 
A, is therefore less expensive, and is licensed for cosmetic application only (Section 
1.4.1). Vistabel
®
 was therefore selected in this experiment as less expensive 
substitute for Botox
®
. 
Figure 3.9 illustrates the appearance of a polyacrylamide gel loaded (in triplicate) 
with Vistabel
®
 and BSA (positive control) solutions and processed by SDS PAGE 
and silver staining methodology. A prominent band with a molecular weight ranging 
between 52 and 76 kDa was resolved for both solutions loaded. As the molecular 
weight of HSA and BSA is 66 kDa, the band detected indicated the presence of 
serum albumin in both samples.  
The dense HSA bands obtained indicate that the amount of protein loaded in the gel 
was too high for the sensitivity of the staining methodology (limit of detection 2-5 ng 
of protein/well) (http://www.qiagen.com 2011).This sensitive technique was selected 
to enable detection of quantities of proteins loaded on MDs, as described in the 
following Section.  
Additional protein bands (Figure 3.9) were detected below 52 kDa for both Vistabel
®
 
and BSA solution. These bands may be related to impurities in the solutions loaded. 
Interestingly, no bands between 66 (HSA) and 225 kDa were detected for Vistabel
®
 
formulation, probably due to the higher purity of the commercial formulation 
compared to the BSA solution. The detection of bands with a molecular weight <66 
kDa (HSA), suggests possible fragmentation of the protein and/or presence of 
impurities with a molecular weight smaller than 66 kDa in both formulations 
(Vistabel
®
 and BSA). The results indicated that the selected methodologies were 
suitable to detect the HSA contained in BTX A commercial preparations (i.e. 
Vistabel
®
) and were therefore adopted for subsequent experiments. 
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Figure 3.9: Assessing the feasibility of silver staining methodology to detect HSA, 
contained in Vistabel
®
. The Figure depicts the appearance of a polyacrylamide gel with 
each well loaded (in triplicate) with ~27 µg of HSA (Vistabel
®
) and ~4.5 µg of BSA 
(positive control). The arrows point to the serum albumin bands (66 kDa). The molecular 
marker (5 µl) was loaded in the first and the fifth lane (by left). The marker bands with their 
relative molecular weights are indicated. 
 
3.4.3.2 Comparison of PMDs and NPMDs loading of BTX A from a 
‘Botox® blank’ formulation 
HSA loaded on MDs was characterised by SDS-PAGE and silver staining 
methodologies (Figure 3.10 A, B). Comparison of samples with the standard profile 
indicated that an approximate dose of HSA ranging between 180 and 2000 ng was 
loaded on a MD following immersion into a Botox
®
 blank formulation (HSA ~3.3 
µg/µl). This suggests that a formulation volume between ~55 and 605 nl could be 
accommodated onto a MD (i.e ~11 to 120 nl per needle). If this experiment had been 
performed with the commercial preparation, the concentration of BTX A would have 
been 5 ng/150 µl (~33 pg/µl). Therefore, a single MD containing 25-300 
microneedles would have accommodated 3 µl of Botox
®
 formulation and thus 
approximately 0.1 ng of BTX A, a dose which is within the therapeutic range (0.1-
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0.25 ng of BTX A per injection site). However, HSA could not be detected in some 
NPMDs samples (Figure 3.10 B): in NPMDs line 3 and 6 the amount HSA was 
below the limit of detection, in NPMD line 5 HSA failed to be detected due to 
improper loading of the sample formulation in the gel). Therefore, the results 
obtained suggest variability of MD loading.  
As suggested by the previous analysis (Section 3.4.2.3), a MD containing 60 
microneedles could load therapeutic doses of BTX A. In that case it was assumed 
that the entire vial of Botox
®
 was dissolved in 50 µl of diluent. However, this 
experiment required greater volume and therefore was performed using an increased 
dilution (150 µl). It is reasonable to assume that if a smaller volume (i.e., 50-100 µl) 
was used to prepare the Botox
®
 blank formulation, detectable doses of HSA may 
have been loaded on all the studied MDs and thus effective dose loading could have 
been achieved for all the MDs. However, due to the high level of variation and the 
semi-quantitative nature of the analysis, accurate predictions cannot be made.  
Previous experiments indicated that a Botox
®
 like formulation was successfully 
loaded on both PMDs and NPMDs (Section 2.4.4). This was confirmed by the 
present study, as the HSA loaded was detected for the majority of the MDs analysed. 
Therefore, physicochemical properties of the Botox
®
 formulation are suitable for 
successful MD loading. The ‘Botox® blank’ formulation employed in the present 
experiment differed from the so termed ‘Botox® like’ formulation described in 
Section 2.3.4.1. The latter contained 5 ng of the BTX A model β-gal to mimic the 
dose of BTX A (5 ng) contained in the commercial preparation Botox
®
. In the 
experiment reported in this Section, the BTX A model was not added to the 
formulation employed as this low mass of protein would not have enabled loading of 
MDs with detectable quantities of protein.  
In conclusion, the result suggested that PMDs and NPMDs with an increased number 
of microneedles have the capacity to accommodate therapeutic doses of BTX A after 
only one immersion in a Botox
®
 formulation. However, as previous quantitative 
loading analysis indicated (Sections 3.4.2.1 and 3.4.2.2), dose reproducibility cannot 
be guaranteed by using the existing drug loading methodologies. 
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Figure 3.10 (A, B): Characterization of HSA loaded on PMDs and NPMDs. The images 
depict the appearance of two polyacrylamide gels processed by SDS-PAGE and silver 
staining methodology. The gels were loaded with HSA standard solutions and samples 
solutions generated by PMDs and NPMDs loaded with a ‘Botox® blank’ formulation (HSA 
~3.3 µg/µl, NaCl 6 µg/µl). Successful characterization of HSA is indicated by the presence 
of a band at 66 kDa. The approximate concentration (ng/µl) of the HSA standards loaded on 
the first 6 lanes (indicated by numbers 1-6) of both of the two gels are the following: 180 (1), 
80 (2), 40 (3), 20 (4), 10 (5), 0.9 (6). The approximate mass of HSA in the sample solutions 
generated from PMDs and NPMDs loading was estimated by multiplying the concentrations 
of HSA standard 5 and 6 by the volume of diluents (200 µl) used to rinse the MDs after HSA 
loading. The molecular marker (5 µl) was loaded on the first and last lane (by left) on each 
gel. The marker bands with their relative molecular weights are indicated. The line in (A) 
and (B) was drawn to facilitate differentiation between the standards (lanes 1-6, by left) and 
the samples (lanes 1-6, by right). 
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3.5 Conclusion 
PMDs employed in the current research project do not have the capacity to load 
effective doses of BTX A due to the reduced number of microneedles contained in 
each device. However, PMDs containing 25-300 microneedles would allow loading 
of therapeutic doses of the existing commercial preparation Botox
®
, re-constituted 
with volumes of 50-150 µl. 
Microneedle loading of low molecular weight (salbutamol sulphate) and 
macromolecular compounds (β-gal and HSA) was associated with a significant level 
of variability. Therefore, PMD loading of reproducible and efficient doses of Botox
®
 
would not be guaranteed by using the existing loading methodologies. However, 
given the large therapeutic window of BTX A, therapeutic dose loading may 
potentially be achieved by employing robustly engineered loading methodologies 
and/or specifically tailored MD designs. 
Due to absence of statistical difference in the loading capacity of the two 
microneedle designs studied, PMDs would not increase the dose of BTX A compared 
to NPMDs. Nevertheless, PMDs may offer the potential to deliver BTX A in a liquid 
form as well as enable dose monitoring.  
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Chapter 4 
 
Characterising cutaneous delivery 
of a BTX A model from liquid 
loaded pocketed microneedle 
devices (PMDs) 
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4.1. Introduction 
The experiments reported in this Chapter will assess the feasibility of liquid loaded 
PMDs to deliver the enzymatic protein, β-gal (~465 kDa), into the dermis of human 
skin. As previously mentioned (Section 2.1.3), this protein was selected as a high 
molecular weight compound that is representative of the BTX A forms that are 
contained in commercially available preparations (molecular weight ranging between 
150 and ~900 kDa). 
For the treatment of skin disorders such as PFHH, targeted delivery to a specific 
depth of the skin is important in order to ensure optimal interaction between the toxin 
and its therapeutic target (the eccrine sweat glands). As previously mentioned 
(Section 1.2.3), the eccrine sweat glands are located in the deep dermis and are 
distributed in the skin with a density which varies tremendously according to the 
anatomic site e.g. 64 sweat glands/cm
2 
on the back versus 600-700 glands/cm
2
 on the 
palm on the hands (Sato et al. 1989). The use of PMDs is proposed in the current 
research study to promote minimally invasive delivery of BTX A formulation to the 
epidermis and the superficial layer of the dermis. Therefore, in order to ensure 
successful interaction with the sweat glands, BTX A would then have to diffuse to 
the deep dermis. For this reason the use of liquid loaded PMDs is proposed as an 
alternative to the dry coated approach, as it is hoped that the delivery of BTX A in a 
liquid state would assist lateral and downwards diffusion of the protein to the lower 
dermal region.  
 
4.1.1 Cutaneous delivery of macromolecules using MDs 
The capability of a MD to facilitate cutaneous delivery of high molecular weight 
molecules such as peptides, proteins and vaccines has been extensively reported. 
Numerous studies have been conducted in in vivo and in vitro systems in both 
humans and animal models for the cutaneous delivery of macromolecules using 
hollow (Alarcon et al. 2007; Burton et al. 2011; Gupta et al. 2009; Hafeli et al. 2009; 
Harvey et al. 2011; Laurent et al. 2007b; McAllister et al. 2003; Mikszta et al. 2006; 
Van Damme et al. 2009; Wang et al. 2006) and solid microneedles fabricated with a 
variety of materials including metal (Cormier et al. 2004; Kim et al. 2009b; Quan et 
al. 2010) glass (McAllister et al. 2003; Wang et al. 2006) silicon  (Chen et al. 2012; 
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McAllister et al. 2003; Wu et al. 2010) and biodegradable polymers (McAllister et al. 
2003; Park et al. 2005, 2006). Water soluble MDs, made out of sugars, have also 
been reported to enhance in vitro transdermal permeation of proteins such as BSA 
(~66 kDa) and recombinant protective antigen (83 kDa) in split-thickness human 
cadaver skin (Wendorf et al. 2011). Soluble microneedles have also been used to 
pierce the skin as a pre-treatment before application of a macromolecule drug 
formulation (“poke with patch approach” (Prausnitz 2004)). Using this approach,  Li 
et al. (2009) showed in vitro delivery of the human IgG (150 kDa) across the 
epidermal and dermal layer of rat skin following application of 500 µm-long maltose 
microneedles.  
  
4.1.2 Intradermal delivery capability of PMDs 
The delivery capability of pocketed microneedles has been assessed in studies 
conducted by Gill and Prausnitz (2007b, 2008) by using the small hydrophilic 
molecule sulforhodamine (~600 Da). This was coated either in a dry (Gill and 
Prausnitz 2008) or a liquid form (Gill and Prausnitz 2007b) on 700 µm long-
pocketed microneedles and delivered up to a depth of ~600 µm in porcine cadaver 
skin. Although this study did not show delivery of high molecular weight molecules 
to the skin, it indicates that a pocketed microneedle can successfully penetrate the 
skin and deliver material to the dermis. No additional studies regarding the use of 
pocketed microneedles have been published to date. 
 
4.1.3 Intradermal delivery of macromolecules using dry 
coated NPMDs 
There are a variety of studies in literature reporting delivery of proteins and vaccines 
to the epidermal/dermal layer of skin (Chen et al. 2012; Pearton et al. 2010; Saurer et 
al. 2010). Widera et al. (2006) investigated the suitability of ovalbumin (~44 kDa) 
coated titanium MDs (Macroflux
®
) to elicit immune response in hairless guinea pigs 
(HGP). Within this study the site of deposition of ovalbumin delivered by MDs 
within the different layers of the skin was assessed in vitro using three different 
microneedle lengths: 225, 400 or 600 µm. The HGP was used as an animal model as 
it has a more comparable skin anatomy (i.e. skin thickness) to humans, compared to 
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other animal models such as mice and rats (Sueki et al. 2000). The authors indicate 
successful delivery of ovalbumin to the epidermal/dermal region of the skin for all 
MD designs employed. Cutaneous delivery of ovalbumin was furthermore confirmed 
by in vivo immunisation studies indicating that a comparable or greater immune 
response was registered in animals treated with MDs and IM administration. A 
previous study (Pearton et al. 2010) has been performed by using solid MDs with the 
same design as the NPMDs employed in the current research project. NPMDs with a 
microneedle length of 700 µm were dry coated with influenza virus like particles and 
manually inserted into ex vivo excised human skin. Histological analysis indicated 
deposition of the particles within the epidermis and superficial layers of the dermis. 
Similarly, Saurer et al. (2010) showed intradermal delivery of the enzymatic protein 
bovine pancreatic ribonuclease A (~13 kDa) to porcine cadaver skin using NPMDs. 
 
4.1.4 Detection of the BTX A model β-gal in the skin  
The organic substrate X gal (also abbreviated BCIG for bromo-chloro-indolyl-
galactopyranoside) is hydrolysed by the enzyme β-gal to form a blue coloured 
insoluble compound. The X-gal staining methodology optimised by Coulman (2006) 
will be adopted in the experiments reported in this Chapter in order to allow visible 
detection of the enzyme β-gal, delivered to the skin by using PMDs.  
 
4.1.5 Specific aims and objectives of the Chapter 
The aim of this Chapter is to assess the deposition and distribution of a high 
molecular weight protein when delivered into the skin using a liquid loaded PMD. 
The cutaneous delivery capabilities of liquid loaded PMDs will be compared to more 
established NPMDs.  
 
The experimental objectives are to:- 
1) Determine the concentration of β-gal that produces a blue pigmentation that 
can be visibly detected in solution. 
2) Evaluate the capability of established dry coated NPMDs to successfully 
deliver β-gal to both the epidermal and dermal layers of human skin. 
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3) Assess the effective release of a β-gal solution from the pockets of a PMD 
following insertion of the microneedles into human skin.  
4) Evaluate the capability of a liquid loaded PMD to successfully deliver β-gal 
to both the epidermal and dermal layer of human skin. 
5) Evaluate the effect of a mechanical vibration on the deposition and 
distribution of a β-gal solution from the pockets of a PMD. 
6) Evaluate the time-dependent diffusion of β-gal in the dermis. 
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4.2 Materials 
4.2.1 Reagents 
All reagents were used as received and purchased from Sigma Aldrich Ltd (Poole 
UK), unless otherwise stated. 
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). Foetal 
Bovine Serum (FBS), penicillin, streptomycin, Dulbecco’s modified Eagle medium 
(DMEM) 25 mM HEPES were purchased from Invitrogen Corporation, (Paisley, 
UK). Optimal Cutting Temperature (OCT) embedding media was purchased from 
RA Lamb Limited, (Eastbourne UK). X-gal powder and Tris buffer (Tris 
(hydroxymethyl) methylamine) were purchased from Fisher Scientific 
(Loughborough, UK). Potassium ferrocyanide trihydrate, A.C.S. reagent grade was 
purchased from ICN Biomedicals Inc. (Aurora, Ohio). Harris’ Haematoxylin and 
Gurrs’ Eosin were purchased from Lab 3 (Bristol, UK). 
 
4.3 Methods 
4.3.1 Evaluating the limit of visible detection of the BTX A 
model β-gal in solution 
As previously mentioned (Section 4.1.4), the enzyme β-gal can be visualised in the 
skin as a result of the reaction with the substrate X-gal. The experiment described in 
this Section will assess the concentration of β-gal, which produces a blue 
pigmentation in solution that can be visibly detected. 
β-gal (from Escherichia coli, Grade VI lyophilized powder, 1000 U equal to 2638 
µg) was reconstituted in 1 ml of BSA/bicine buffer (bicine buffer 50 mM pH 7.5 
containing BSA 100 μg/ml) to a concentration of 2.6 µg/µl. The solution was 
aliquoted and stored at -20°C. On the day of the experiment, one aliquot was 
defrosted and the solution obtained was used to prepare standard solutions (outlined 
in Table 4.1) with a β-gal concentration ranging between 0.0001 µg/µl and 0.6 µg/µl 
in a final volume of 200 µl of BSA/bicine buffer. 
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Table 4.1: β-gal standard concentrations used to assess the limit of visible detection of 
β-gal in solution. 
 
 
 
 
 
 
 
 
 
 
The X-gal staining solution (Coulman 2006) was freshly prepared using the reagents 
listed in Table 4.2. Additionally, two negative control solutions consisting of i) 
BSA/bicine buffer (200 µl) (negative control solution 1) and ii) X-gal staining 
solution (500 µl) (negative control solution 2) were also prepared. 
Five hundred µl of X-gal staining solution were mixed with 200 µl of each β-gal 
standard solution outlined in Table 4.1 and to negative control solution 1. The 
solutions obtained and negative control solution 2 were incubated at 37°C/5% CO2 
and inspected for a colour change after 1 hour and 24 hours.  
Solution β-gal concentration µg/µl 
 
1 
 
0.6 
2 0.1 
3 0.06 
4 0.01 
5  0.006 
6 0.001 
7 0.0006 
8 0.0001 
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Table 4.2 Components of X-gal staining solution. 
X-gal staining solution 
Reagent Concentration % v/v 
X-gal* 40 mg/ml 5 
Potassium ferricyanide 0.6 M 0.84 
Potassium ferrocyanide 0.6 M 0.84 
Magnesium chloride 1 M 0.2 
Tris-HCl, pH 8.5 Tris 200 mM 
HCl 1M 
50 
Deionised water / To 100% 
Incubation conditions / 37 °C 
   *X-gal powder is made up to a 40 mg/ml with N-N-dimethylformamide. 
 
4.3.2 Human skin studies  
The experiments reported in this Chapter were conducted by using skin tissues 
obtained from human subjects in order to generate data that more closely resemble 
the in vivo human conditions. The skin tissues were obtained from patients 
undergoing  breast reduction or mastectomy procedures at the Royal Gwent Hospital, 
Newport, Wales, following informed patient consent and full ethical approval. Once 
excised from the patients, the tissue samples were immediately transferred into a 
suitable nutrient media (usually consisting of DMEM 25 Mm HEPES, 5% foetal 
bovine serum and 1% penicillin-streptomycin) and transported to the laboratory at 
controlled temperature (4°C), as outlined by Pearton at al. (2010). The skin was then 
used on arrival (‘fresh’ skin) or stored at -20°C (‘frozen’ skin). When ‘frozen’ skin 
was used for experiments, it was defrosted on the day of the experiment, at room 
temperature for approximately 90 minutes, in order to allow it to thermally 
equilibrate with the environment. In all cases subcutaneous fat was removed from the 
skin tissue by blunt dissection. The tissue was pinned, epidermis face up, into a 
dissection board in order to ease MD insertion.  
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4.3.3 Cutaneous delivery of the BTX A model β-gal from 
dry coated NPMDs 
The coating formulations employed in the experiment described in this Section were 
prepared in BSA/bicine buffer and consisted of: 
1) Coating formulation A: β-gal 0.65 µg/µl, CMC 1% w/v and Lutrol® F68 0.5% 
w/v. 
2) Coating formulation B (excipient free coating formulation): β-gal 0.65 µg/µl. 
3) Coating formulation C (negative control): CMC 1% w/v and Lutrol F68 0.5% 
w/v. 
These formulations were freshly prepared from an aliquot of β-gal enzyme (2.6 
µg/µl) in BSA/bicine buffer, defrosted on the day of the experiment as described 
previosuly (Section 4.3.1).  
 
NPMD coating  
NPMDs were coated by multiple immersions (i.e. 15) into the appropriate coating 
formulation by using the micro scale dip coating reservoir device as described in 
Section 2.3.2.1 The device was first loaded with coating formulation C and the first 
three NPMDs were coated. Afterwards, coating formulation A and then coating 
formulation B were loaded in order to coat the remaining six NPMDs (n=3 per each 
coating formulation). After each coating, the microholes of the dip coating device 
were rinsed under tap water for ~1 minute and then immersed into a basin filled with 
tap water (~3 litres) for 30 minutes. Afterwards, the coating device was allowed to 
dry at 30°C. Once coated, all the MDs were stored at - 20°C for 24 hours in order to 
allow them to dry. Such storage temperature (i.e. -20°C) was employed as this 
represents the temperature recommended by the manufacture for β-gal storage. 
 
Insertion of NPMDs into human skin  
The experiment was performed on a skin sample aged 56 year old, which was 
defrosted on the day of experiment (‘frozen’ skin sample). Each NPMD, previously 
coated with either formulation A, B or C, was inserted into the skin and left in place 
for 5 minutes before withdrawal. NPMDs were applied to skin sites that were spaced 
approximately 1 cm from each other. To facilitate handling of the NPMDs during 
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application into the skin, a metallic twezeer was used to hold the NPMD (i.e. the 
base of the NPMD was held between the two edges of the metallic tweezers). Once 
inserted into the skin, a moderate pressure was applied to the array for ~5 seconds in 
order to facilitate penetration of the microneedles into the tissue. The base of the 
array was then released from the tweezer and the NPMD was left in situ for 5 
minutes (as mentioned above). The same methodology was employed for the 
experiments described in the following sections unless otherwise specified. 
Following removal of NPMDs from the skin, the treated regions were excised to 
form tissue samples measuring ~1 cm
2
 that were subsequently treated as described 
below. 
In order to assess the β-gal activity in viable human skin tissue, the same experiment 
was repeated on a skin sample obtained from a 60 year old donor and was processed 
within ~2 hours of surgical removal (‘fresh’ skin sample).  
 
4.3.3.1 Culturing and X-gal staining of skin samples 
The samples obtained were cultured as described elsewhere (Birchall et. al 2005) and 
this experimental set-up is illustrated in Figure 4.1. Briefly, the skin samples were 
positioned on lens tissue paper placed on a sterile steel mesh, contained in a six well 
culture plate. Each well containing the skin samples (generally 3 samples per well) 
was filled with 8 ml of freshly prepared nutrient media consisting of 5% v/v foetal 
bovine serum (FBS) and 95% v/v of DMEM 25 mM HEPES. The lens tissue on the 
mesh was soaked with the media by a wicking effect. Skin was incubated at the air-
liquid interface for 1½ hours at 37°C/ 5% CO2.  
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Figure 4.1: Schematic diagram and image of skin samples incubated at the air-liquid 
interface in organ culture. Figure adapted from (Ng et al. 2009) 
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After incubation, each sample was washed with 2 ml of Phosphate buffer solution 
(PBS)/MgCl2 4 mM for 15 minutes and subsequently fixed for 2 hours in 2 ml of 
glutharaldeyde 2% v/v in PBS/MgCl 4mM on ice. Each sample was then rinsed in 2 
ml of PBS/MgCl2 4 mM for 15 minutes before being trasferred into 2 ml of X-gal 
staining solution and incubated at 37°C/5%CO2 for 24 hours to detect the presence of 
the β-gal enzyme. Following incubation, the samples were rinsed twice in PBS (2 x 
15 minutes), and subsequently stored over night in fresh PBS at 4°C before being 
analysed both en face and histologically. 
 
4.3.3.2 En face analysis of skin samples 
The skin samples were positioned between two Superfrost Plus
® 
microscope slides 
and subsequently imaged by using a light microscope (Zeiss Stemi 2000-C 
Stereomicroscope, Carl Zeiss, Welwyn Garden City, UK) attached to a digital 
camera (Olympus C 3040-ADL, Watford, UK). An external electronic light source 
(Schott KL-1500, Schott AG, Stafford, UK) was also used to better visualise the skin 
samples. 
 
4.3.3.3 Histological analysis of skin samples 
The skin samples were embedded in moulds containing OCT, which was frozen 
quickly in a hexane bath on dry ice before being stored at -80 °C. The samples were 
subsequently processed into 10-12 μm cryosections (CM3050S cryostat, Leica 
Microsystems, Milton Keynes, UK), which were collected onto Superfrost Plus
®
 
microscope slides. The skin sections were inspected by light microscopy (Olympus
®
, 
BX50 light/fluorescent microscope, Watford, UK)
 
under various magnifications. 
Representative sections were digitally imaged (Olympus DP-10 digital camera, 
Watford, UK) and a microscope graticule was employed to calculate the image scale. 
Selected slides were stained with Harris’ Haematoxylin and Gurrs’ Eosin (H&E 
staining) according to the methodology described below.  
 
4.3.3.4 H&E staining methodology  
Selected slides were fixed in acetone for 10 minutes and subsequently allowed to dry 
at room temperature. Slides were then rinsed in tap water (5 immersions, 2 seconds 
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each one) before being immersed in Harris’ Haematoxylin for 5 minutes. 
Subsequently, they were rinsed in tap water as above and then immersed in acid 
alcohol (ethanol 70%-chloric acid (HCl) 1M 1%) for 2 seconds. The slides were 
rinsed once more time in tap water before being immersed in Gurrs’ Eosin for 2 
seconds. They were subsequently rinsed under running tap water for ~1 minute and 
then transferred in tap water for 10 minutes. Afterwards, the slides were allowed to 
dry at room temperature. 
 
4.3.4 Cutaneous delivery of the BTX A model β-gal from 
liquid loaded PMDs 
4.3.4.1 Loading and de-loading visualisation of a BTX A model 
formulation from PMDs 
The following experiment was performed to i) assess the capability of a liquid loaded 
PMD to deliver the BTX A model β-gal to human skin; ii) investigate whether 
complete release of the formulation from the pockets occurred following insertion of 
the microneedles in the skin. 
The experiment was carried out on a skin sample obtained from a 60 year old donor. 
The tissue was defrosted on the day of the experiment (‘frozen’ skin sample). 
 
Loading formulations 
The following loading formulations were freshly prepared from a β-gal stock 
solution (2.6 µg/µl in BSA/bicine buffer): 
 Formulation A: β-gal 1.3 µg/µl in BSA/bicine buffer  
 Formulation B: β-gal 1.3 µg/µl, 20% v/v orange food dye (consisting of 
water, quinoline yellow and allura red) + 30% v/v of BSA/bicine buffer. This 
formulation was used for visualisation purposes. 
 
PMD loading and application into human skin  
The PMDs were loaded by manual immersion into the appropriate formulations (A 
or B) as previously described (Section 2.3.4). Following loading of PMDs with 
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formulation B, the pockets were visually inspected (to the naked eye). Loaded PMDs 
were inserted into the skin as follows: 
 Four PMDs loaded with formulation A were manually inserted into the skin 
and maintained in situ for 5 seconds before being withdrawn. 
 Three PMDs loaded with formulation A were manually inserted into the skin 
and maintained in situ for one minute before being withdrawn. 
 Three PMDs loaded with formulation B were manually inserted into the skin 
and maintained in situ one minute before being withdrawn. After removal, the 
PMDs were inspected to the naked eye in order to assess whether successful 
release of the formulation from the pockets had occurred. 
PMDs that were removed after 5 seconds were held in place manually before being 
removed. PMDs that were inserted in the skin for 1 minute were held in place for 5 
seconds. The base of each array was then released from the edges of the metallic 
tweezer (as previously described for dry coated NPMDs in Section 4.3.3) and the 
PMD was left in place for the remaining time. Following PMD removal, the skin was 
dissected in ~1 cm
2
 samples which were subsequently processed as detailed 
previously (Sections 4.3.3.1-3). 
 
4.3.4.2 Application of a mechanical vibration to enhance the 
cutaneous delivery capabilities of liquid loaded PMDs  
The experiment was performed to assess the effect of a mechanical vibration on the 
delivery and distribution of the BTX A model β-gal into human skin from liquid 
loaded PMDs. The brush of a commercially available electric toothbrush (Oral B 
Vitality 3709, Braun, Germany) was removed from the device and a cavity was 
created to accommodate a MD.  
The experiment was carried out on a skin sample aged 75 years old, which was 
defrosted on the day of the experiment (‘frozen’ skin). PMDs (n=3) and NPMDs 
(n=3) were loaded by manually immersion into a β-gal loading solution (0.65 μg/µl 
in BSA/bicine buffer) as previously described (Section 2.3.4).  
Once loaded, each MD was inserted into each skin sample as follows: 
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 Three PMDs attached to an electric toothbrush were inserted into skin sample 
and manually held in situ for 5 seconds. 
 Three NPMDs not attached to the electric toothbrush were inserted into the 
skin sample and manually held in situ for 5 seconds.  
After MD removal, skin samples of ~1 cm
2
 were excised from the tissue and treated 
as previously described (Sections 4.3.3.1-3). 
In order to compare the delivery capabilities of liquid loaded PMDs/NPMDs when 
applied to the skin with and without mechanical vibration, the experiment was 
repeated on skin tissue obtained from a 57 year old donor (‘frozen’ skin) according 
to the following scheme: 
 Three PMDs and three NPMDs attached to an electric toothbrush were 
inserted into the skin sample and manually held in situ for 5 seconds. 
 Three PMDs and three NPMDs not attached to the electric toothbrush were 
inserted into the skin sample and manually held in situ for 5 seconds. 
 
4.3.5 Diffusion of the BTX A model β-gal within the dermal 
layer of human skin  
The experiments described in this section were performed with the aim to assess the 
extent of diffusion of a β-gal formulation topically applied to the dermis of a skin 
tissue as a function of time and concentration. The experiments were performed 
separately (on three different days) on three ‘frozen’ skin tissues obtained from three 
different donors. The size of the skin samples employed in the experiments described 
in the previous Sections (4.3.3 and 4.3.4) was ~1 cm
2
. Conversely, skin samples with 
an increased size (i.e. ranging between ~1.5-3.5 cm
2
,
 
see below for details)
 
were 
required in the following experiments to visualise the total area of β-gal diffusion. 
For this reason, only 2 replications (n=2) could be used for each treatment, due to the 
constrained dimensions of the skin tissue available. Details of the experiments 
described below are also outlined in Table 4.4. 
 
Experiment 1: evaluating the diffusion of β-gal as a function of the time (30 
minutes versus 240 minutes) 
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The experiment was performed on skin sample obtained from a 43 year old donor 
(skin tissue 1). Four skin samples, two measuring ~1.5 cm
2
 and two measuring ~2 
cm
2
 were dissected from the tissue. 
The four skin samples were placed, epidermis side down, in an organ culture set up 
as previously described (Section 4.3.3.1). Each sample was placed within one well of 
a six well culture plate. Subsequently, ten μl of β-gal solution (0.65 μg/μl in 
BSA/bicine buffer) was topically applied to the central portion of the dermis of each 
sample. The first two samples (measuring ~1 cm
2
) were then cultured at 37°C/5% 
CO2 for 30 minutes, whereas the other two (measuring ~2.5 cm
2
) were cultured for 
240 minutes.  
 
Experiment 2: evaluating the diffusion of β-gal as a function of the 
concentration of β-gal 
The experiment was performed on a skin sample excised from an 86 year old donor 
(skin tissue 2). Eight skin samples, four measuring ~1.5 cm
2
 and four ~2.5 cm
2
, were 
dissected from the tissue. The eight skin samples obtained were placed, epidermis 
side down, in an organ culture set up as described above. Subsequently, 10 μl of β-
gal solution (0.65 μg/μl in BSA/bicine buffer) was topically applied to the central 
portion of the dermis of each skin sample. Additionally, 10 μl of a more diluted β-gal 
solution (0.065 μg/μl in BSA/bicine buffer) was applied to the remaining four skin 
samples as reported for the more concentrated β-gal formulation. Skin samples 
measuring ~1.5 cm
2
 (n=4) were cultured at 37°C/5% CO2 for 30 minutes, whereas 
skin samples measuring ~2 cm
2
 (n=4) were cultured for 240 minutes. 
 
Experiment 3: evaluating diffusion of β-gal over an extended time  
The experiment was performed on skin sample excised from a 52 year old donor 
(skin tissue 3). Eight skin samples measuring ~1.5 cm
2 
(n=2), ~2 cm
2
 (n=2) and ~3.5 
cm
2
 (n=4) were dissected from the skin tissue and transferred into an organ culture 
set up as above. Subsequently, 10 μl of β-gal solution (0.65 μg/μl in BSA/bicine 
buffer) was topically applied on the central portion of the dermis of each sample. The 
skin samples were cultured, as described above, at four increasing incubation times 
(as outlined in Table 4.4) according to their size. 
 
Culturing and X-gal staining of skin samples 
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After incubation in organ culture, the samples were treated as described earlier 
(Section 4.3.3.1). Due to the increased size of the samples treated in this study 
(compared to the previous experiments), the volume of the solutions employed to 
perform each step described in Section 4.3.3.1 was at least four times bigger than the 
size of the skin sample treated (e.g. for a skin sample measuring ~3.5 cm
2
 fixation 
was performed in 15 ml of glutaraldehyde 2% v/v/ PBS/MgCl). The samples were 
subsequently analysed en face (Section 4.3.3.2) and imaged by using a digital camera 
(an Olympus DP 10 Digital or a Canon digital Ixus 82 IS). The diffusion area (cm
2
) 
was calculated using ImageJ software (available at http://rsb.info.nih.gov/ij; 
developed by Wayne Rasband, National Institute of Health, MD, USA). Data were 
presented as average +/- standard deviation (SD). 
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Table 4.4 Layout of the diffusion experiments: diffusion of the BTX A model β-gal in 
the dermal region of human skin. The experiments were performed on skin tissues 
obtained from three different skin donors (skin tissues 1-3). Ten µl aliquots of β-gal solution 
(either 0.65 µg/µl or 6.5 µg/µl) were topically applied to the dermis of the skin samples. The 
samples were cultured at 37°C/5% CO2 for an increased time (depending on their size) in 
order to assess the extent of  diffusion as a function of time and β-gal concentration. n.a.= 
not applicable. 
 
4.4 Results and Discussion  
4.4.1 Evaluating the limit of visible detection of the BTXA 
model β-gal in solution 
The experiment was performed with the aim to assess the concentration of the BTX 
A model (β-gal) which produced a blue visible pigmentation to be adopted for 
subsequent skin experiments. Figure 4.2 (A-C) depicts the appearance of a range of 
β-gal standard solutions after 1 (A) and 24 (B) hours of incubation with the substrate 
X-gal at 37°C/ 5% CO2. The results indicated that the reaction is time dependent as a 
more intense blue colouration was observed for equally concentrated solutions after 
24 hours (B) compared to 1 hour (A). In addition, the most suitable concentration 
values ranged between solution 5 (β-gal 0.006 µg/µl) and solution 1 (β-gal 0.6 µg/µl) 
as they provided the most intense colouration. Therefore, in order to enable loading 
of the MDs with a sufficient amount of protein that would allow delivery and 
detection of β-gal in the skin, concentrations equal or higher to standard solution 
number 1 were selected for subsequent experiments. As previously reported (Section 
3.4.2.1), β-gal concentrations comparable to the concentration of BTX A used in a 
Skin 
tissue 
Number of 
samples 
(n) 
Concentration 
of β-gal 
(µg/µl) 
Samples 
cultured 
for 30 
minutes 
Samples 
cultured 
for 240 
minutes 
Samples 
cultured 
for 480 
minutes 
Samples 
cultured 
for 1200 
minutes 
1 4 0.65 2 2 n.a. n.a. 
2 4 0.65 2 2 n.a. n.a. 
4 0.065 2 2 n.a. n.a. 
3 8 0.65 2 2 2 2 
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clinical setting (i.e. ~1-3 pg/µl) could not be employed, as they would not have been 
detected by the methodology employed in our experiments. This implies that the 
dose of β-gal delivered into the skin was considerably higher that the dose of BTX A 
delivered in a clinical setting. This will be discussed later in this Chapter (Section 
4.4.4). 
No blue colouration was observed for negative control solution 1 (diluting buffer) 
and negative control solution 2 (diluting buffer plus X-gal staining solution). This 
confirmed the specificity of the reaction of the enzymatic assay. 
  
Chapter 4 
140 
 
 
 
Figure 4.2 (A-C): Limit of visible detection of the BTX A model (β-gal) in solution. 
Standard concentrations ranging between 0.0001 (standard solution 8) and 0.6 µg/µl 
(standard solutions 1). The solutions were inspected for a colour change after 1 hour (A) and 
24 hours (B) of incubation at 37°C/ 5%CO2 with X-gal staining solution. The presence of 
blue colouration indicates successful interaction between the enxyme β-gal and its substrate 
X-gal; (C) The absence of blue pigmentation of negative control solution 1 (neg. C1) 
(diluting buffer) and negative control solution 2 (neg. C2) (diluting buffer plus X-gal 
staining solution) denotes the specificity of the enzymatic assay. 
 
4.4.2 Cutaneous delivery of the BTX A model β-gal from 
dry coated NPMDs 
Published studies regarding dry coated MDs report the use of specific excipients to 
enhance the uniformity of the coated layer on microneedles (Gill and Prausnitz 
2007b). As previously mentioned (Section 2.1.1), excipients commonly used for this 
purpose are viscosity enhancers and surfactants, used to improve the coating 
outcome by increasing the thickness and the uniformity of the coated microfilm. The 
experiments described in this Section were performed in order to evaluate the 
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delivery capability of the BTX A model (β-gal) from NPMDs that were dry coated 
with an established coating technique (Gill and Prausnitz 2007a). For this purpose, 
NPMDs were coated using a micro scale dip coating reservoir device, previously 
described (Section 2.3.2.1), and a β-gal coating formulation containing CMC 
(viscosity enhancer) and Lutrol
®
 F68 (surfactant) as excipients. An excipient-free β-
gal formulation was also employed in order to assess whether the presence of 
excipients was fundamental to NPMD coating and thus delivery of the protein into 
the skin.  
Successful delivery of β-gal, indicated by the occurrence of blue stained areas at the 
sites of microneedle penetration, was revealed by en face analysis (Figures 4.3 A and 
4.4 A, B). A microneedle array is also shown in Figure 4.3 A for comparison. 
Histological analysis confirmed delivery of β-gal within the epidermal and dermal 
layer of the skin (Figures 4.3 B, C and 4.4 C).  
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Figure 4.3 (A-C): Cutaneous delivery of the BTX A model (β-gal) from a dry coated 
NPMD formulation without specific coating excipients: (A) En face images of β-gal 
stained microchannels and the NPMD, providing a visual reference. Unstained (B) and H&E 
counterstained (C) histological section of β-gal stained microchannels (indicated by the 
arrows). NPMDs were coated by a β-gal (0.65 µg/µl) excipients free-coating formulation.  
The successful delivery of β-gal is shown by the presence of a blue pigmentation 
surrounding the microneedle insertion sites (A). The cryosection (B, C) exhibits delivery of 
β-gal to the epidermis and upper dermis and diffusion of the protein to the more internal 
layers of the dermis. (A) Scale bar = 1 mm, (B, C) Scale bar = 100 µm; Sc = stratum 
corneum, Ep = epidermis, De = dermis. 
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Figure 4.4 (A-C): Cutaneous delivery of a BTX A model (β-gal) from a dry coated 
NPMD. Use of a formulation containing specific coating excipients. En face images (A, 
B) and H&E counterstained histological section (C) of human skin treated with β-gal coated 
NPMDs. NPMDs were dry coated by using a formulation containing β-gal (0.65 µg/µl) and 
CMC and Lutrol
®
 F68 as excipients. (C) The arrow points to the blue stained microchannel 
generated by NPMD application. (C) Scale bar = 100 µm. 
 
Microchannels created in skin following application of dry coated NPMDs appeared 
as approximately 150 µm depth interruptions of the stratum corneum and epidermis. 
The discrepancy between the penetration depth and the length of the microneedles 
(700 µm) was most likely related to the innate elasticity of the skin which resulted in 
a folding of the tissue around the microneedle tip. This has been commonly reported 
in literature for microneedle arrays inserted manually or using hand-held applicators 
(Burton et al. 2011; Coulman et al. 2011; Hansen 2009; Pearton et al. 2010). 
Automated applicators i.e., electrically driven devices (Verbaan et al. 2008) and 
rotator drilling methods (Wang et al. 2006) have been reported as a means to increase 
microneedle penetration efficiency. It is expected that similarly manufactured 
applicators may improve piercing performance of the MDs employed in our study. 
The data indicated that the BTX A model was released into the skin when using an 
excipient-free coating formulation (Figure 4.3 A-C). This was not surprising as 
previous experiments (Section 2.4.2) indicated that high molecular weight molecules 
could be successfully coated on NPMDs without excipients. In control experiments, 
where skin was treated with NPMDs dry coated with β-gal free formulation, blue 
staining was not reported (Figure 4.5), thus confirming the specificity of the β-gal 
assay in the skin tissue. 
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Figure 4.5: En face image of human skin treated with a NPMD dry coated with 
BSA/bicine buffer and CMC and Lutrol
®
 F 68 as excipients (negative control). 
 
In Figures 4.4 A and B, it is apparent that the extent of blue staining was not 
uniform, thus indicating a certain variability in β-gal delivery. This was most likely 
related to the poor reproducibility of the coating procedure. As previously discussed 
(Sections 2.4.2 and 3.4.2.3), uniform microneedle coating could not be guaranteed in 
our experiments by using the established coating methodologies. This implies that at 
each immersion, each microneedle was coated with a slightly different dose of β-gal 
and that a portion of the coating was also placed in the space between adjacent 
microneedles (i.e. the base of the array). This resulted in i) occurrence of blue stained 
areas of variable intensity at the microneedles insertion sites, ii) absence of some 
positively stained microchannels (i.e. only 4 out of 5 blue microchannels were 
detected as depicted by Figure 4.4 B, thus suggesting that only 4 microneedles of a 
NPMD were coated); iii) appearance of blue stained areas between microneedles due 
to the dissolution of the coating retained on the space between adjacent 
microneedles. 
Another possible cause for the variability may reside in the non-uniform insertion of 
the microneedles into the skin and/or incomplete dissolution of the coating from the 
microneedles. As previously described (Section 4.3.3), NPMDs were manually 
inserted into the skin by applying a light pressure for 5 seconds, after which they 
were left in the tissue for 5 minutes. Insertion times ranging between 1 and 15 
minutes have been commonly reported for dry coated MDs with the aim to allow 
dissolution of the coating by the interstitial fluids in the skin (Chen et al. 2011; Gill 
and Prausnitz 2007b; Widera et al. 2006). Even when NPMDs were inserted into the 
skin and held in place, not all microneedles remained in position for the entire 
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duration of the application (i.e. 5 minutes), due to the elasticity of the skin. As a 
consequence, a portion of the coating may have not been released in the tissue from 
some microneedle, thus resulting in variability of the intensity of the stained areas. 
Application of a force (i.e. a downward pressure) on the NPMDs may have 
maintained the microneedles in situ in a more uniform way. However, this could not 
be performed due to the in-plane design of the NPMD (i.e. NPMDs consist of one-
dimensional arrays containing a row of five microneedles orientated parallel to the 
base of the array) and the narrow surface of the base of the array. If out-of-plane 
microneedles arrays (i.e. two-dimensional arrays consisting of microneedles 
orientated at 90° out of the base plate of the device) had been used, application of a 
downward force on the base of the device could have been performed. This may have 
provided a more consistent insertion of the microneedles into the skin and thus a 
more uniform release of the coating. However, the purpose of this study is the use of 
PMDs for delivery of BTX A in a liquid form, which is thus expected to be released 
in the skin quicker (within seconds) than a dry coat. With this in mind, we did not 
pursue the studies related to the dry coated NPMDs further than the experiments 
reported in this Section. 
Delivery of β-gal from dry coated NPMDs was also carried out on freshly excised 
skin (‘fresh’ skin). This was performed to assess the effect of proteases (i.e. 
aminopeptidases and carboxipeptidases), physiologically present in the skin 
(Hotchkiss 1998), on the activity of the delivered protein. 
Given that, in order to assess metabolic activities the viability of the tissue has to be 
ensured (Steinsträsser and Merkle 1995), the skin employed in this experiment was 
processed within a short time (~2 hours) of surgical removal and maintained in a 
defined organ culture media (Birchall et. al 2005). Successful enzymatic activity 
indicated by the emergence of blue stained areas at microneedle insertion sites was 
reported as for ‘frozen’ skin (data not shown). This indicated that β-gal model 
maintained its integrity in viable skin, thus suggesting that therapeutic proteins such 
as BTX A should retain their activity once delivered into the skin by MDs. 
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4.4.3 Cutaneous delivery of the BTX A model β-gal from 
liquid loaded PMDs 
4.4.3.1 Loading and de-loading visualisation of a BTX A model 
formulation from PMDs  
In attempt to assess whether uniform unloading of a BTX A model (β-gal) formulation 
occurred from a PMD following insertion of the microneedles into the skin, PMDs 
were loaded with a formulation containing a dye. Following one immersion of the 
pocketed microneedles in the formulation, the pockets appeared uniformly loaded 
thus confirming the data of previously reported experiments (Section 2.4.4). Visual 
inspection of the pocketed microneedles after insertion and subsequent removal from 
the skin revealed the unexpected persistency of formulation in some pockets. Despite 
this, successful delivery of β-gal was reported for all skin sample treated, as revealed 
by the appearance of positively blue stained microchannels (Figures 4.6 A, B and 4.7 
A, B). Histological analysis demonstrated the capability of the PMDs to deliver β-gal 
to both the epidermal and dermal layer of the skin (Figure 4.7 B). Varying the PMDs 
residence time into the skin i.e., 5 seconds (Figure 4.6 A, B) against 1 minute (Figure 
4.7 A, B), did not result in any significant difference in the extent of delivery of the 
macromolecule. This therefore indicated that the formulation was released almost 
instantaneously to the skin following application of the liquid loaded PMD.  
Contrary to that described for dry coated NPMDs (Section 4.4.2), PMDs were liquid 
loaded by manual immersion into a small volume (~20 µl) of formulation contained 
in a reservoir (Section 2.3.4). Therefore, the micro scale dip coating device 
previously described (Section 2.3.2.1) was not used for PMD loading. The 
subsequent results highlighted a certain variability in the diffusion of the protein, as 
indicated by differences in the blue staining areas surrounding the microneedle 
insertion sites (Figures 4.6 A and B). Variability was also observed previously for 
NPMDs dry coated by using established coating methodologies and therefore the 
results confirmed that both the employed coating methodologies do not facilitate 
uniform and reproducible loading/coating on either PMDs or NPMDs. This may 
represent an issue if PMDs were to be used clinically to deliver BTX A, as 
uniformity of the delivered dose must be guaranteed. The strategies which could 
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potentially increase uniformity and reproducibility of MD loading have been 
discussed previously (Section 2.4.2) 
The extent of diffusion of the blue stained areas at the microneedle insertion sites 
was greater for liquid loaded PMDs (Figures 4.6 A, B and 4.7 A) than for dry coated 
NPMDs (Figures 4.3 A, 4.4 A, B), thus suggesting an increased diffusion of β-gal 
when delivered in a liquid state. This aspect will be discussed further in Section 
4.4.3.2. 
 
 
 
Figure 4.6 (A, B): Delivery of the BTX A model (β-gal) to human skin from liquid 
loaded PMDs. En face images of human skin treated with liquid loaded PMDs. PMDs were 
manually immersed into a β-gal formulation (1.3 µg/µl) before being inserted into the skin 
for 5 seconds. Delivery of β-gal is indicated by the appearance of blue pigmented areas at the 
microneedle insertion sites. Scale bar = 1 mm. 
 
 
 
Figure 4.7: En face image (A) and histological section (B) of human skin treated with 
liquid loaded PMDs. PMDs were loaded following one immersion into a β-gal formulation 
(1.3 µg/µl) before being inserted and left for 1 min in the skin (B). (A) scale bar = 1 mm, (B) 
scale bar = 100 µm.  
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4.4.3.2 Application of a mechanical vibration to enhance the 
cutaneous delivery capabilities of liquid loaded PMDs  
Further experiments were performed with the aim to compare β-gal delivery 
efficiency from liquid loaded PMDs with and without the application of a 
mechanical vibration. Although (as highlighted by the Section above) the application 
of the vibration was not considered essential for a complete release of the loaded 
solution from the pockets, it was hypothesized that it might facilitate distribution of a 
formulation within the skin. A study published by Wang et al. (2006) reported 
insertion of hollow microneedles into ex vivo hairless rat skin by using a vibration. 
According to this study application of the vibration significantly enhanced delivery 
of a tissue-marking dye from the microneedles, however the distribution of the dye 
was assessed only by en face analysis and no histological sectioning was conducted. 
Therefore, deposition of the dye within the different layers of the skin was not 
investigated. Our results indicated successful delivery of the BTX A model for all the 
skin samples treated by PMDs/NPMDs both with and without mechanical vibration 
(Figures 4.8 A-D and 4.9 A-H). Histological analysis suggested a greater diffusion of 
the BTX A model in samples treated with microneedle vibration (Figure 4.8 B and 
4.9 B) compared to samples treated without vibration (Figure 4.8 D and 4.9 D). This 
was more pronounced for samples treated by PMDs than by NPMDs. It is possible 
that the mechanical vibration may have facilitated release of the formulation from the 
pockets. It may also be that mechanical vibration increased diffusion of the 
formulation by reducing the skin dynamic stiffness and/or assisting the disruption 
created by the microneedles within the skin. Although this suggests the feasibility of 
a vibrational approach as a means to increase dermal delivery and diffusion, the 
results cannot be considered conclusive as additional studies are needed in order to 
better evaluate this method. 
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Figure 4.8 (A-D): En face (A, C) images and histological cryosections (B, D) of human 
skin treated with PMDS (A, B) and NPMDs (C, D) loaded with the BTX A model. 
PMDs and NPMDs were loaded by one immersion into a β-gal formulation (β-gal 0.65 
µg/µl) and subsequently inserted into the skin for 5 seconds. PMDs were applied in the skin 
with mechanical vibration, whereas NPMDs were applied without vibration. (A, C): scale 
bar 1mm; (B, D): 100 µm 
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Figure 4.9 (A-H): Comparison of cutaneous delivery capabilities of liquid loaded 
PMDs/NPMDs with and without mechanical vibration. En face images (A, C, E and G) 
and cryosections  (B, D, F, H) of human skin treated with β-gal loaded PMDS (A-D) and 
NPMDs (E-H) either attached (A, B, E, F) or not (C, D, G, H) to an electric toothbrush. 
PMDs and NPMDs were loaded following one immersion into a β-gal formulation and 
subsequently inserted the skin for 5 seconds. Scale bars (A, C, E, G) = 1 mm; (B, D, F, H) = 
100 µm. 
  
When comparing en face images of skin samples treated with dry coated NPMDs 
(Figures 4.3 A and 4.4 A, B) and liquid loaded PMDs (Figure 4.9 C), more diffuse 
staining at the microneedle insertion sites could be detected when β-gal was 
delivered as a liquid. For the purpose of this comparison skin samples treated with 
liquid loaded PMDs with vibration (Figure 4.8 A and 4.9 A) are not taken into 
account as the increased diffusion observed in these samples may have been a feature 
of the vibration (which conversely was not applied for dry coated NPMDs). An 
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increased diffusion of the protein β-gal in a liquid form was also suggested by 
histological analysis (Figure 4.9 D). However diffusion areas surrounding the 
microneedles insertion sites may have not been determined only by diffusion of β-gal 
out from the microneedles within the skin, but also by diffusion of the formulation 
released on skin surface upon contact of the microneedles and the base of the array 
with the tissue. As this formulation was not removed after each PMD application, it 
might have diffused laterally from the microchannels and/or internally within the 
microchannels thus generating the stained areas detected on the surface of the skin 
(as depicted by en face images) and within the skin (as depicted by the cryosection 
images). It is reasonable to assume that if the formulation had been removed from the 
skin surface, i.e., by cleansing the surface of the tissue following PMD removal, 
diffusion may have been reduced. Therefore, although the use of liquid loaded PMDs 
may facilitate greater diffusion of medicaments such as BTX A, in comparison to dry 
coated NPMDs, the degree of diffusion highlighted by our experiments may be 
overestimated. 
For the treatment of a skin disorder such as PFHH, BTX A has to be delivered to a 
specific depth of the dermis to ensure optimal interaction with its therapeutic targets 
(the sweat glands). As previously mentioned (Section 1.2.3), cholinergic fibres 
surround the secretory portion of the sweat glands that are located in the deep dermis. 
It is therefore to this site that BTX A has to migrate to block the cholinergic message 
and thus inhibit sweating. As the thickness of the dermis ranges between 1 and 3 mm 
(Jensen and Proksch 2009), if BTX A was to be delivered by PMDs, it would have to 
diffuse to at least 1 mm from the skin surface to reach its therapeutic target. In our 
experiments, PMDs were able to penetrate the epidermis and reach the superficial 
layer of the dermis to a depth ranging between 100 and 300 µm. Extensive diffusion 
of β-gal was observed within the dermis especially when vibration was applied as the 
protein migrated to a depth of approximately 600 µm (Figure 4.8 B and 4.9 B) 
although, as mentioned above, diffusion of BTX A from liquid loaded PMDs may be 
slightly overestimated. In all cases, not one treated sample showed a degree of 
diffusion of β-gal to a sufficient depth in the dermis, which would guarantee optimal 
contact with its therapeutic target. However, as reported in the Material and Method 
Section (4.3.3.1), following application of the PMDs, skin samples were only 
incubated for 1 ½ hours in organ culture before being fixed in glutaraldehyde. As the 
fixation stopped the diffusion of β-gal, it would be reasonable to assume that the 
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protein may have diffused further if it had been incubated for an increased period of 
time and therefore the PMD delivery technique may be feasible for BTX A.  
In addition, evaluation of the diffusion of β-gal on treated samples relied on the 
visible detection of the blue insoluble pigment generated by the reaction between the 
enzyme and its substrate X-gal. By Fick’s first law (Amorosa 1998a; Wonglertnirant 
et al. 2011), molecules diffuse according to their concentration gradient. Therefore, 
β-gal would diffuse from the point of maximal concentration (the microneedle 
insertion site) to the more internal layers of the skin. As the concentration of β-gal at 
those sites would be considerably lower than that on the surface of the skin, such 
concentrated protein may have resulted in undetectable signal. This implies that the 
protein may have reached deeper layers in the dermis but the signal generated may 
have been below the limit of detection of the methodology employed in our 
experiments. 
BTX A is a highly hydrophilic molecule whose capability to diffuse to anatomical 
sites adjacent to the site of injection has been assessed in both humans and animals 
(Borodic et al. 1994; Carli et al. 2009; Stone et al. 2011; Trindade de Almeida et al. 
2007). Hexsel et al. (2008) assessed the halo of anhidrosis (i.e., the area surrounding 
the injection site where reduction or absence of sweating is observed) following 
injections of the BTX A commercial preparation Botox
® 
(BTX A=5ng) into the 
frontal muscle of 18 volunteers. In this study Botox
®
 was reconstituted in 1 ml of 
0.9% saline and injected in one site (per patient) of the forehand at a volume of 20 µl 
(0.1 ng of BTX A per application site). Injections were performed by using 0.3 ml 
syringes with a 29-gauge needle (0.7 cm in length) whose caps were cut to enable 
control of the needle insertion depth which was performed at ~2-3 mm from the skin 
surface. Patients were evaluated 28 days after the treatment by measuring the 
diameter of the anhydrotic halos with Minor’s test. The mean diameter calculated 
was equivalent to 1.73 cm (+/- 0.37) and thus, given the spherical shape of the halos, 
we could assume a diffusion area of 2.34 cm
2
. PMDs employed in our study possess 
5 in-plane microneedles placed at a distance of ~1.5 mm to each other. Therefore, 
PMDs containing an increased number of microneedles, i.e., 10 x 10 out-of-plane 
microneedles, would permit delivery of BTX A to a surface of the skin equal to 2.25 
cm
2
, which is almost identical to the one highlighted by the experiment mentioned 
above. This therefore suggests that PMDs may represent a realistic alternative to the 
standard intradermal injections.  
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Alternatively designed MDs with an increased loading capacity may also be 
considered for BTX A administration. For example, hollow microneedles have been 
shown to deliver drug formulations with volumes ranging between a few microlitres 
(Hafeli et al. 2009; McAllister et al. 2003; Nordquist et al. 2007; Wang et al. 2006) 
up to millilitres (Burton et al. 2011; Gupta et al. 2009), whereas our experiments 
have suggested that ~100 nl can be loaded on the PMD (Sections 3.4.2.1 and 
3.4.2.3). Similarly designed hollow microneedles would ensure greater diffusion of 
the toxin throughout the dermis as a result of the increased volume injected by the 
microneedles and the pressure applied to eject the formulation (Wonglertnirant et al. 
2011). However, diffusion of BTX A would have to be carefully controlled as 
excessive diffusion of the toxin, resulting from large injected volumes (i.e. higher 
than 100 µl), have a greater potential to cause side effects (i.e. muscle paralysis) due 
to unwanted migration of the toxin to the subcutaneous muscles (Glaser et al. 2007).  
The use of larger microneedles (i.e. with increased length) would also have to be 
considered especially for the treatment of the hyperhydrotic sites characterised by 
high skin thickness. For example, if palmar or plantar hyperhidrosis were to be 
treated, microneedles with a length of 700 µm (such as the ones constituting the 
PMDs employed in our study) would not be able to deliver the drug to the dermis. 
The thickness of the epidermis at these anatomic sites is the highest in the body, 
being ~0.8-1 mm (Barry 1983b) with a stratum corneum measuring ~200-500 µm 
(Alekseev and Ziskin 2007; Egawa et al. 2007). Previous studies assessed the 
penetration efficiency of NPMDs in human volunteers at the palmar site (Coulman et 
al. 2011). NPMDs were applied on the palm and the microneedle insertion was 
imaged in situ by a sophisticated optical imaging method called Optical Coherence 
Tomography. These studies indicated that NPMDs penetrated to a depth in the skin, 
which was primarily limited to the stratum corneum (i.e. ~300 µm). A similar 
behaviour is expected for PMDs as they contain microneedles with the same length 
(700 µm). This strongly suggests that longer microneedles, i.e., 1000 µm in length or 
more, would be needed to facilitate delivery of BTX A to the superficial layer of the 
dermis at the palmar and plantar sites. Delivery of the BTX A exclusively in the 
epidermis would presumably prevent diffusion of the medicament to the underlying 
dermis due to the presence of the dermo-epidermal junction (Section 1.2) and so it is 
important to breach this barrier. Wang et al. (2006) published a study assessing the 
use of hollow microneedles as a means to deliver fluorescently tagged insulin in vitro 
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to the dermis of rat skin. The authors indicated that although the injection was 
performed at a specific depth in the dermis (i.e. 500-800 µm), the large volume of 
fluid injected (i.e. ~5 µl) distributed throughout the dermis and an intense signal was 
detected from this region of the skin. 
Conversely, only small fluorescence was detected from within the epidermis, thus 
suggesting that the peptide had difficulty in crossing the dermal-epidermal junction. 
In contrast, microneedle injections of the small molecule calcein (~900 Da) resulted 
in comparable distribution of the compound between dermis and epidermis. This 
suggests that for high molecular weight medicaments such as BTX A, a microneedle 
capable of perforating the dermo-epidermal junction would have to be employed. 
This would allow direct loading of the medicament to the upper dermis. However, 
the need for longer microneedles may potentially increase the invasiveness of the 
microneedle-aided treatment. As previously discussed (Sections 1.2.1 and 1.2.2), the 
epidermis is devoid of vasculature, whereas the dermis contains a capillary bed 
which is located just below the dermo-epidermal junction (Sorrell and Caplan 2004). 
Therefore, microneedles penetrating deeper than the epidermis could breach these 
capillaries and cause bleeding. Despite this expectation, bleeding has not been 
reported for the majority of the microneedles studies conducted in animals and 
humans (Prausnitz et al. 2009). In humans subjects, bleeding is uncommon when 
using solid microneedles with a length ranging between 500-1000 µm (Gill et al. 
2008) whereas application of 1.5 mm solid or hollow microneedles has lead to the 
occurrence of small droplets of blood at the microneedle insertion sites (Gill et al. 
2008; Laurent et al. 2007b). However, within these studies microneedles were 
applied to anatomical sites (i.e. the forearm) whose epidermis thickness is 
considerably smaller compared to palms and soles (i.e. ~100 µm versus 800 µm). As 
a consequence, it may be expected that insertion of up to 1.5 mm long microneedles 
in thickened anatomical sites such as palms and soles would not cause significant 
damage or bleeding. Moreover, the pain and discomfort associated with insertion of 
relatively long microneedles would be expected to be minimal in these areas of the 
body, especially in comparison to standard hypodermic needles.  
In conclusion, the results indicate that liquid loaded PMDs are suitable tools to 
administer macromolecules such as BTX A to the upper dermis of human skin. The 
macromolecule β-gal diffused to deeper sites of the dermis from the microneedle 
insertion site and this seemed to be more prominent when mechanical vibration was 
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applied. Longer microneedles would be required to administer BTX A to the dermis 
of thickened skin sites such as the palm of the hands and the soles of the feet.  
 
4.4.4 Diffusion of the BTX A model β-gal into the dermis of 
human skin 
In an attempt to predict the diffusion of high molecular weight molecules, such as 
BTX A, in human skin, the BTX A model (β-gal) was topically applied to the dermis 
of excised human skin tissue. The presence of β-gal was confirmed by the emergence 
of a coloured (blue) area after X-gal staining (Figure 4.10 A and B). Table 4.5 
outlines the diffusion area (cm
2
) of the enzyme after application of 10 µl of either β-
gal 0.65 µg/µl or 0.065 µg/µl to the dermis on three different skin samples (1-3). The 
data indicated that thirty minutes after application of 10 µl of β-gal 0.65 µg/µl on 
skin samples, the area measured approximately 0.4 cm
2
 and after 240 minutes lateral 
diffusion of the protein extended to approximately 0.7 cm
2
.
 
The results show 
increased diffusion of the formulation with time, as expected according to Fick’s law 
(Amorosa 1998a). Higher diffusion values were registered for another skin donor 
tissue as an area of 0.73 (+/-0.21) cm
2
 and 1.39 (+/-0.59) cm
2
 was reported after 30 
and 240 minutes respectively of incubation in organ culture. Such variability can be 
expected when comparing samples excised from different donors as the properties of 
the skin (e.g. hydration and skin thickness) vary between different individuals 
(Laurent et al. 2007a). 
Topical application of a less concentrated formulation (i.e., β-gal 0.065 µg/µl) did 
not seem to affect diffusion of the protein within the first 30 minutes as a diffusion 
area similar to that obtained for skin samples treated with a more concentrated 
formulation (i.e., β-gal 0.65 µg/µl) was registered (Table 4.5). However, a slightly 
reduced area was reported when the skin samples were incubated for prolonged time 
(i.e., a diffusion area of 0.54 (+/- 0.03) cm
2
 was recorded after 4 hours of incubation). 
This suggests that dermal diffusion of less concentrated protein formulations may be 
reduced, as expected by Fick’s law (Amorosa 1998a). Within the experiments 
reported in this Section a mass of either 6.5 or 0.65 µg of β-gal was topically applied 
to the surface of the skin (i.e., 10 µl of either β-gal 0.65 µg/µl or 0.065 µg/µl). As 
previously mentioned (Section 3.4.2.3) doses of BTX A ranging between 0.1-0.25 ng 
are generally delivered intradermally at each application site by a standard needle 
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and a syringe. The dose of protein used in our experiments was therefore 6,500 to 
65,000 times higher than the actual dose of BTX A delivered in the clinical setting. 
Doses of β-gal comparable to therapeutic doses of BTX A could not be assessed in 
our experiments as they would have not been detectable by the staining methodology 
employed. Therefore, if BTX A was to be delivered to the epidermis/dermis by 
PMDs, less rapid diffusion, compared to the one estimated in our experiments for the 
model β-gal, may be expected. However, due to the high potency of BTX A and the 
elevated density of sweat glands in hyperhydrotic sites such as the palm of the hand 
and the sole of the foot (600-700 glands/cm
2
) (Sato et al. 1989), BTX A may 
nevertheless reach its therapeutic targets and induce a therapeutic response.  
Skin samples incubated for extended times in organ culture (480 and 1200 minutes) 
did not display any increase in the diffusional area of the enzymatic protein. This 
suggested that diffusion of β-gal occurs readily, reaching the maximum extent within 
the first hour.  
The diffusive capability of proteins within the dermis has been previously reported. 
Widera et al. (2006) assessed the distribution profile of ovalbumin (~44 kDa) within 
the epidermal/dermal layer of skin samples excised from euthanised rats treated with 
ovalbumin coated MDs containing different microneedle lengths (details of this 
study has been described in Section 4.1.3). 
Quantitative analysis of the dose of ovalbumin delivered within the different layers 
of the skin indicated that, independent of the microneedle length employed, almost 
20% of the protein was delivered to the epidermis whereas the remaining 80% was 
found in the dermis at a depth that was located beyond the maximal penetration 
depth of the microneedles. 
According to the authors, this was due to the rapid diffusion of the hydrophilic 
protein within the dermal environment. Similar ovalbumin distribution profiles were 
found in skin samples excised immediately and 1 hour after ovalbumin delivery, thus 
indicating that the protein diffused readily within the skin. These findings are in 
agreement with the data highlighted by our experiments, despite the considerably 
larger size of the studied protein β-gal (~465 kDa) in comparison to ovalbumin (~ 44 
kDa). 
In a more recent study the diffusion of the hydrophilic macromolecules fluorescein 
isothiocyanate dextrans (average m.w. = 4.3 kDa) was assessed in vitro into hairless 
rat skin (Wonglertnirant et al. 2011). The study compared the diffusivity of these 
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compounds in full thickness skin and skin samples devoid of the stratum corneum. 
Diffusivity of the compounds was found to be significantly lower in the stratum 
corneum compared to the underlying viable epidermis/dermis. The authors 
concluded that hydrophilic molecules directly delivered to the epidermis/dermis of 
the skin by using MDs, would be expected to readily diffuse through the deeper 
layers of the skin, as these layers contain more water compared to the stratum 
corneum. 
In conclusion, the results indicated that high molecular weight proteins can readily 
diffuse within the dermal layer of human skin. Therefore if MDs facilitate dermal 
delivery of BTX A, diffusion should ensure that the therapeutic distributes within the 
dermal tissue and interacts with the therapeutic target (the eccrine sweat glands).
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Figure 4.10 (A, B): Diffusion of the BTX A model β-gal within the dermis of human 
skin as a function of time. En face images of human skin samples (dermis side up) 
following topical application of 10 µl of β-gal (0.65 µg/µl) and incubation in organ culture 
for 30 (A) and 240 (B) minutes. The presence of β-gal was confirmed by the emergence of a 
coloured (blue) area after X-gal staining. The skin samples were obtained from an 86 year 
old donor (skin tissue 2). Scale bar = 1cm. 
 
4.5 Conclusion 
The MDs can rapidly (within seconds) facilitate delivery of high molecular weight 
molecules into the dermal layer of human skin. The results suggest that although 
BTX A could be successfully delivered to the dermal layer of human skin by 
established dry coated NPMDs, lateral diffusion in the dermis is enhanced following 
liquid loading via PMDs. Although the application of a mechanical vibration may 
facilitate diffusion of a protein formulation within the cutaneous tissue, the results 
highlighted by the experiments reported in this Chapter cannot be considered 
conclusive. 
The capability of the ~465 kDA macromolecule β-gal to readily diffuse through the 
dermis when topically applied has also been demonstrated. This indicates that BTX 
A should diffuse to the therapeutic targets (the eccrine sweat glands) located in the 
deep dermis, once delivered to the epidermis/dermis by PMDs. Therefore, the results 
suggest that a liquid loaded PMD may provide a suitable tool to deliver BTX A to 
the dermis of human skin for the treatment of skin disorders such as PFHH.  
Administration of BTX A to thick hyperhydrotic areas such as palms and soles 
would require optimization of PMD design, i.e., longer microneedles and possibly 
sharper tips due to the increased thickness of the stratum corneum at these anatomic 
sites. 
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Delivery and detection of BTX A 
therapeutic formulation Vistabel® 
and botulinum toxoid A (BT A) 
within human skin following 
application of liquid loaded 
pocketed microneedle devices 
(PMDs) 
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5.1 Introduction 
The aim of this Chapter was to demonstrate intradermal delivery of BTX A by liquid 
loaded PMDs. The commercial BTX A preparation Vistabel
®
 and the formaldehyde 
inactivated BTX A, i.e. botulinum toxoid A (BT A) was employed for this purpose. 
The use of BTX A in its detoxified form was enforced by safety reasons, due to the 
extremely high toxicity of the active protein (BTX A). Two main methodologies 
were employed for protein detection within the skin: immunohistochemical 
techniques and fluorescence imaging following conjugation of BT A to a tandem 
fluorophore constituted by phycoerythrin and a cyanine (PE/Cy7
®
). 
 
5.1.1 Botulinum toxins (BTXs) detection 
BTXs represent the most toxic substances known, with systemic lethal doses in 
humans estimated at ~1 ng/kg of body weight (Gill 1982). Due to the high risk 
associated with these toxins, extremely sensitive and accurate BTXs detection has to 
be ensured. Due to the tremendously high potency of the toxins, BTXs detection has 
been analytically challenging, especially when toxins are contained in complex 
samples such as food or clinical specimens (i.e. blood and faeces). To date, the only 
accepted method for the detection of BTXs in foodstuff, clinical samples and 
pharmaceutical formulations is the mouse in vivo bioassay. In this method, toxin 
samples are injected intraperitoneally into the mouse. Signs of botulism are 
subsequently observed in the animal over a period of 2-4 days. This method can 
detect BTX to < 10 pg/ml (Grate 2010; Scarlatos et al. 2005). The quantity which 
determines death in a mouse, so termed mouse lethal dose (MLD) is ~ 10 pg. As 
samples are usually injected in 0.5 ml volumes, the limit of detection (LOD) for this 
assay is 2 MLD/ml (Cai et al. 2007; Grate 2010). Although sensitive, this assay is 
time consuming, potentially dangerous to personnel during injection, requires a large 
number of animals and it is associated with inherent variability between assays (due 
to a different response to the toxins between different animals) and laboratories.  
Over the last three decades, numerous investigations have been carried out with the 
aim of developing sensitive and rapid in vitro assays that could replace the mouse 
bioassay. A large variety of sophisticated assays have been developed in the form of 
immune-PCR assays (Chao et al. 2004), enzyme-amplified protein microarray 
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(Varnum et al. 2006), mass spectrophotometric assays (Kalb et al. 2006), real time 
PCR based assays (Mason et al. 2006), assays based upon the peptidase activity of 
the toxins (i.e. the capability to cleave proteins of the SNARE complex) (Rasooly 
and Do 2008) and enzyme-linked immunosorbent assays (ELISA) (Ekong et al. 
1995; Frevert 2010; Grate et al. 2009; Shone et al. 1985). Assays detecting the 
activity of BTXs in tissue samples (e.g. mouse muscles with attached nerves) (Foster 
K. 2006) or neuronal cells (e.g. cells obtained from rat spinal cord) (Pellett et al. 
2007) have also been reported. Advances in BTXs assays have extensively been 
reviewed by Grate et al. (2010). Particular attention will be given in this introduction 
to the ELISA methodology as it is considered more closely aligned to the 
immunodetection methods adopted in the experiments reported within this Chapter.  
 
5.1.2 ELISA principle 
ELISA assays for BTX A rely on the binding of a specific portion of the toxin 
(epitope) to an antibody labelled with an enzyme that can provide amplification of 
the signal detected. The majority of the ELISA methods employ antibodies directed 
against specific features contained in either the entire 150 kDa (i.e., the holotoxin), 
the toxin complex (~500 or ~900 kDa) or defined portions of the holotoxin. As the 
binding affinity of antibody for its specific antigen site is the most important factor 
determining the sensitivity of an immunoassay, many research groups have produced 
their own antibody preparations. These are usually obtained by the sera of animals of 
different species (such as mouse, guinea pig, chicken and others) previously 
immunised with botulinum antigens in the form of either formaldheyde inactivated 
toxin (i.e. botulinum toxoid) or chemically synthesized peptides corresponding to a 
specific portion of the toxin (e.g. a specific region of the 100 kDa heavy chain). 
Monoclonal (reacting with a single antigenic epitope in the toxin) or polyclonal 
antibodies (reacting with multiple epitopes) have been produced either as fragments 
or whole antibodies. ELISAs have been generally used in the form of a sandwich 
ELISA in which a primary capture antibody previously coated to the microwell 
surface of a microtiter plate binds to the botulinum toxin antigen. After antigen 
capture, a primary detection antibody binds to the antigen in a different epitope, thus 
creating the ‘sandwich’ structure. Subsequently, a secondary detection antibody 
conjugated with an enzyme (usually horseradish peroxidase (HRP) or alkaline 
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phosphatase (AP)) binds to the primary detection antibody. The enzyme catalyzes the 
reaction of a specific enzymatic substrate (usually a precipitating chromogen) to a 
coloured product which allows for antigen detection. Between each step, the 
microtiter plate is usually washed in appropriate buffer solution to avoid unspecific 
binding of proteins to antibodies. The optical density of the solution generated in 
each well of the microtiter plate can therefore be measured at the appropriate 
wavelengths (depending on the specific substrate employed) and the quantity of 
antigen determined by calibrated spectroscopy. ELISA assays are usually faster than 
the mouse bioassay as they can generally be performed within 5-6 hours. Although a 
variety of substrates and antibodies have been described for BTXs detection, all the 
ELISA methodologies share the same fundamental immunodetection principle. 
 
5.1.3 Use of amplified ELISA for high sensitivity 
quantification of BTXs   
Many of the ELISA assays developed have reached LODs equal or close to the 
mouse bioassay, i.e. ranging between ~10-60 pg/ml. This has been achieved by using 
high sensitive amplified ELISAs, which allow increases in sensitivity of 100-1,000 
fold, compared to non amplified ELISAs. Use of non amplified ELISAs with LODs 
approaching the mouse bioassay have also been reported (Ekong et al. 1995) (this 
study will be discussed in greater detail in Section 5.1.4).  
Shone et al. (1985) reported an amplified ELISA assay for rapid and sensitive 
detection of BTXs in food and botulinum strain culture. In this study microtiter 
plates were coated with a monoclonal antibody as a capture antibody directed against 
botulinum toxin A. Following addition of the sample solution, an alkaline 
phosphatase conjugated secondary antibody was added as a primary detection 
antibody. A solution of the enzymatic substrate NADP+ was added to the plate and 
converted into to product NAD+ by the enzyme. Amplification was achieved by 
using an amplifier solution containing enzymes catalysing a cycle reaction, which 
allowed the formation of several hundred coloured molecules for each NAD+. By 
using such amplified ELISA the authors achieved a LOD of 66 pg/ml in about 5 
hours and demonstrated the suitability of this assay as a means to detect BTX A in 
both botulinum culture and foodstuff. As a comparison standard (not amplified) 
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ELISA assay for botulinum toxin detections (described within the same study) 
resulted in a LOD 100 fold lower than the amplified method.  Doellgast et al. (1993) 
reported the use of a primary detection antibody labelled with an enzyme obtained 
from the venom of Russel’s viper. This initiated a complex cascade reaction, which 
lead to the formation of thrombin. Subsequent addition of alkaline phosphatase-
fibrinogen determined the formation of alkaline phosphatase-fibrin. The latter, 
following incubation with the appropriate substrate for alkaline phosphatase, gave 
rise to the production of the coloured compound. Previous studies published by the 
same research group reporting the use of such amplified ELISA for the detection of 
other protein antigens revealed that this method allowed increases in sensitivity of 
100-1,000 fold compared to non amplified ELISAs (Doellgast 1987). The high 
sensitivity of the method was confirmed for botulinum toxin antigens as it lead to a 
LOD of < 10pg/ml during a period of > 16 hours. Given the complexity of the 
method reported above, further efforts have been made to develop simpler tests. In a 
more recent report published by Sharma et al. (2006), a sensitive amplified ELISA 
was developed by using a primary detection antibody labelled with the steroid 
digoxigenin. Production of secondary antibodies with a high affinity to this molecule 
resulted in a LOD for the 500-kDa BTX A complex of 60 pg/ml within a period of 4 
hours. 
While sensitive and relatively rapid, not one of the in vitro assays reported in 
literature have currently been used to replace the mouse bioassay. The reason for that 
resides in different factors comprising the complexity of the method (e.g., the need to 
perform multiple amplification steps to increase the sensitivity of the assay), expense 
of the reagents, unwanted interactions of reagents of the assay with some 
components of the samples to be tested (e.g. antibodies produced in chicken cannot 
be used to detect BTXs in foodstuff such as chicken meat and yolk egg) and lack of 
validation for screening a large variety samples. In addition these tests do not assess 
the proteolytic activity of the toxin (capability of the toxins to cleave the proteins of 
the SNARE complex in the neuronal cells) but only the capability of the antibody to 
recognise the toxins. Although some assays determining the proteolytic activity have 
been published (i.e., endopeptidase assays as previously mentioned) their use for 
food testing has generally been limited due to interference by peptidases present in 
food specimens (Rasooly and Do 2008). 
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5.1.4 Quantification of BTX A contained in therapeutic 
preparations 
While the majority of published works report detection of BTXs from foodstuff and 
botulinum strain cultures, only two studies have described detection of BTXs in 
therapeutic preparations (Ekong et al. 1995; Frevert 2010). Both studies selected 
ELISA as a suitable methodology. In particular Frevert (2010) determined the 
quantity of BTX A contained in the commercial preparations Botox
®
, Dysport
®
 and 
Xeomin
®
. In this study primary detection antibodies were specifically raised against 
the 150 kDa BTX A (purified from Clostridium botulinum A culture) detoxified by 
treatment with formaldehyde, i.e. botulinum toxoid. Detection of BTX A contained 
within the three commercial preparations was performed by using a HRP-conjugated 
secondary antibody with a LOD of 0.2 ng/ml. Similarly, Ekong et al (1995) reported 
detection of BTX A in therapeutic preparations by using a primary monoclonal 
antibody specific for BTX A and a high titre HRP-conjugated antibody. The authors 
indicate a sensitivity of the test comparable to the mouse bioassay (LOD ~ 8-25 
pg/ml) 
 
5.1.5 Immunohistochemical techniques for the detection of 
BTX A 
5.1.5.1 IHC principle  
IHC is an immunoassay relying on the specific interaction between an antigen of 
interest and an antibody and subsequent determination of the distribution of the 
antigen in a particular tissue. IHC has been largely used for diagnostic purpose as a 
means to detect tumoral antigens specifically expressed or up-regulated in certain 
cancers (Jordan et al. 2002). It has also been used to evaluate the efficacy of new 
therapeutic molecules during drug development by assessing their capability to 
regulate the expression of disease targets (Dobson et al. 2010). During IHC analysis 
tissue samples are cut into sections, which are subsequently incubated with a specific 
antibody. Biopsies can be processed either as unfixed frozen or formalin fixed 
paraffin embedded tissue sections. While frozen sections guarantee the best antigen 
conservation, paraffin embedded sections are usually associated with a better 
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morphological preservation of the tissue (Beckstead 1994). However, the effect of 
fixation can be detrimental to the antigen-antibody interaction as the protein of 
interest can be masked due to the capability of the fixative to create cross-linkages 
between specific portions of the antigen (i.e. epitopes) and other proteins present in 
the sample. Epitopes on formalin fixed paraffin embedded sections are usually 
unmasked by heating in an appropriate buffer, a procedure known as antigen retrieval 
(Shi et al. 2011).  
As for other immunoassays (such as the aforementioned ELISA) antigen-antibody 
interactions in IHC are identified by an appropriate detection system, which usually 
relies on the formation of an insoluble coloured product. Different detection systems 
are currently available with the two most commonly employed being represented by 
avidin–biotin and polymer-based systems. Avidin-biotin systems rely on the strong 
affinity of the protein avidin for the low molecular weight vitamin biotin. The bond 
between those two molecules is considered irreversible as the affinity between those 
two molecules is over million times stronger than that of most antigen antibody 
interactions (http://www.vectorlabs.com 2011). These systems consist of a three-step 
procedure in which the antigen of interest is recognised by a primary antibody (1
st 
step) to which a biotinylated secondary antibody is attached (2
nd
 step). An avidin-
HRP (or AP) complex will bind the secondary antibody via avidin-biotin bonds to 
produce a coloured reaction (3
rd
 step). The signal can be amplified as avidin 
possesses four binding sites for biotin, thus several biotin-peroxidase complexes can 
be attached to each antigen molecule. 
While sensitive these systems are usually associated with unspecific staining due to 
the presence of endogenous biotin in certain tissues specimens. The more recently 
developed polymer-based systems consist of a two-step procedure and are based on 
dextran technology (EnVision; Dako Corporation). In the first step the antigen of 
interest is recognised by a primary antibody. In the second step the primary antibody 
is attached by a dextran, which is conjugated to numerous secondary antibodies and 
enzyme molecules. These systems have the advantage of allowing an increased 
sensitivity in comparison to the biotin-avidin assays and are less time consuming. For 
this reason they will be employed in the experiments reported within this Chapter. 
In a study conducted by Pacini et al. (2007), delivery of BTX A from the therapeutic 
BTX A preparation Vistabel
®
 (commercialised as a Vistabex
® 
in Italy, the country 
where the study was performed) was demonstrated in vitro by IHC. In this study 
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Vistabel
®
 was delivered by iontophoresis in living rats. Skin specimens excised from 
the treated animals were assessed for BTX A presence by using a commercially 
available monoclonal antibody (against BTX A) and a biotin/avidin system detection 
kit. To the best of our knowledge this represents the only published study showing 
transdermal delivery of BTX A in a tissue and its detection by IHC. Triggered by 
these findings we selected IHC methodology to detect BT A within skin tissue. 
 
5.1.6 Dot blot for the detection of BTX A  
Dot blotting is a simple technique used to identify a protein from solutions without 
the need for protein separation by SDS PAGE. It is an immunoassay in which the 
protein of interest is immobilised on a protein binding membrane usually consisting 
of nitrocellulose or polyvinylidene fluoride. Once the protein is bound to the 
membrane, it can be probed by a primary antibody. As for the aforementioned 
immunoassays, detection of the antigen is obtained by addition of a secondary 
antibody labelled with a specific enzyme (i.e., HRP or AP). Substrates can be used to 
produce either colour (chromogenic detection method) that can be visualised on the 
membrane (to the naked eye) or light (chemiluminescent detection method) that is 
detected with radiography film. Dot blot will be employed in this Chapter as a 
preliminary detection method to assess the capability of the antibodies used in IHC 
techniques to detect BTX A onto a membrane.  
 
5.1.7 Cutaneous delivery of fluorescent conjugated BT A by 
liquid loaded PMDs 
Fluorescence imaging of BT A following its conjugation to a fluorophore, PE/Cy7
®
, 
will be performed in this Chapter in order to support detection of the toxoid in the 
skin by immunohistochemistry techniques. PE/Cy7
®
 is a tandem conjugate with PE 
(the energy donor) having an excitation wavelength of 565 nm and Cy5 (the energy 
acceptor) having an emission wavelength of 778 nm. The compound will be 
employed in the experiments reported in this Chapter as part of a commercial kit 
conceived to label primary antibodies for further applications such as ELISA, 
Western Blot or IHC. However, as specified by the manufacture 
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(http://www.abcam.com 2011), the kit is suitable to tag any protein in solution as the 
the fluorophore binds free amine groups present in lysines and N-terminus of a 
protein. The presence of lysines in BTX A was confirmed by a study evaluating the 
amino acid composition of the neurotoxin (Sathyamoorthy and DasGupta 1985).  
 
5.1.8 Specific aims and objectives of the Chapter 
In this Chapter we aim to demonstrate successful delivery of BTX A (Vistabel
®
) and 
BT A to the dermal layer of human skin using liquid loaded PMDs. 
The experimental objectives are to: 
 Develop an IHC methodology to detect therapeutic BTX A (Vistabel®) 
delivered within the skin from intradermal (ID) injections and PMDs. 
 Detect BTX A (Vistabel®) and BT A by dot blot immunoassay. 
 Develop an IHC methodology to detect BT A delivered within the skin from 
ID injections and liquid loaded PMDs. 
 Use fluorescence microscopy to assess delivery and distribution of PE/Cy7®-
BT A into the skin by using liquid loaded PMDs. 
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5.2 Materials 
5.2.1 Reagents 
All reagents were used as received and were purchased from Sigma Aldrich Ltd 
(Poole UK), unless otherwise stated. 
Deionised water was obtained from an Elga reservoir (High Wycombe, UK). OCT 
embedding media was purchased from RA Lamb Limited (Eastbourne, UK). Tris 
buffer (Tris (hydroxyethyl) methylamine), sodium chloride, Tris base (Tris 
(hydroxymethyl) aminomethane), Triton X-100, Tris HCl (Tris (hydoxymethyl) 
aminomethane hydrochloride), Whatman Protran
®
 nitrocellulose transfer membrane, 
methylene blue, stabilized goat anti-mouse IgG, (H+L), peroxidase conjugated 
antibody (32430), Super Signal
®
 West Pico Kit and formaldeyde solution 37% was 
purchased from Fisher Scientific (Loughborough, UK). Dako EnVision+ System-
HRP (DAB) kit was purchased from Dako Ltd. (Cambridgeshire, UK). Mouse 
monoclonal anti Clostridium botulinum A toxoid primary antibody (ab40786) and 
antibody dilution buffer were purchased from AbCam (Cambridge, UK). Vistabel
®
 
was purchased from University of Wales Hospital (Cardiff, UK). Neurotoxin type A 
Clostridium botulinum toxoid (133A) and chicken anti Clostridium botulinum 
neurotoxin/toxoid type A IgY polyclonal primary antibody (730A) was purchased 
from List Biological Laboratories, Inc. (Campbell, California). 
 
5.3 Methods 
5.3.1 Cutaneous delivery of a BTX A commercial 
formulation (Vistabel
®
)  
A vial of Vistabel
® 
(BTX A, 2.5 ng) was dissolved in 0.9% saline solution to a 
concentration of 2.5 pg/µl. A skin tissue excised from a 34 year old donor on the day 
of the experiment (‘fresh’ skin sample) was prepared as previously described 
(Section 4.3.2). Subsequently, the tissue sample was processed as described for the 
following treatments:- 
Treatment 1: four ID injections of Vistabel
®
, each one of 50 µl (125 pg/ID injection), 
were performed in the skin sample. 
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Treatment 2: 20 µl of the Vistabel
® 
formulation was topically applied to three distinct 
sites (50 pg/site) on the skin surface. A PMD (n=3) was repeatedly inserted (10-20 
times) onto each site where the solution was applied.  
Treatment 3 (negative control): 50 µl of 0.9% saline solution was intradermally 
injected into the skin sample (negative control 1). In addition, a PMD was loaded 
with 0.9% saline solution (PMD loading was performed as described in Section 
2.3.4) and inserted into the skin sample (negative control 2).  
Treated regions of the skin were excised and the samples obtained were cultured for 
1½ hours, as previously described (Section 4.3.3.1). Following incubation in organ 
culture, each tissue sample was washed in PBS for 15 minutes and subsequently 
frozen in OCT before being stored at -80°C (Section 4.3.3.3). Samples were 
subsequently cryosectioned using a cryomicrotome (CM3050S cryostat, Leica 
Microsystems, Milton Keynes, UK). Sections (10-12 μm) were collected on 
microscope slides (Superfrost Plus
®
) and analysed under light microscopy (Olympus 
BX50 light/fluorescent microscope, Watford, UK) to detect areas of microneedle/ID 
injection induced distruption.  
Selected slides were fixed in acetone at – 20°C for 5 minutes and then rinsed thrice 
in PBS, once at 4°C for 5 minutes and then twice, 5 minutes each time, at room 
temperature, in order to allow the tissues to gradually equilibrate to the 
environmental temperature. Subsequently, the tissue sections were processed by IHC 
according to the methodology outlined below.  
 
5.3.1.1 IHC methodology 
IHC was performed by incubating selected tissue sections with a primary monoclonal 
antibody directed against botulinum toxoid A. Reagents, including the secondary 
antibodies which were purchased as parts of a commercial kit (Dako EnVision+ 
System-HRP kit), were used according to the supplier’s recommended protocol and 
by washing the tissue samples between each step with the wash buffer (PBS or PBS 
Tween 0.025% v/v). The tissue samples to be stained were first incubated with Dual 
Endogenous Peroxidase Block (0.03% hydrogen peroxide containing sodium azide) 
for 5 minutes +/- 1 minute to quench endogenous peroxidases. Subsequently, they 
were incubated with anti botulinum toxoid A primary monoclonal antibody, diluted 
either 1/50 or 1/200 (stock concentration not determined by the manufacture) with a 
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commercial antibody dilution buffer. This latter consisted of 1% BSA in PBS pH 7.4 
and 0.005% sodium azide as preservative. Incubation was performed for 60 minutes 
(+/- 1 minute) at room temperature in a humidified chamber in order to prevent 
drying of the tissues. Specimens were subsequently incubated with labelled polymer-
HRP anti mouse reagent consisting of a HRP labelled polymer conjugated to goat 
anti-mouse secondary antibodies in Tris-HCl buffer (containing stabilising proteins 
and antimicrobic agents). Incubation with secondary antibody was performed for 30 
minutes (+/- 1 minute) at room temperature in a humidified chamber. Staining was 
completed by incubation for 5-10 minutes with 3,3'-diaminobenzidine (DAB)+ 
substrate-chromogen. The skin specimens were washed with distilled water in order 
to stop the chromogenic reaction and they were subsequently allowed to dry.  
After IHC staining, processed sections were visualised under light microscopy 
(Olympus BX50 light/fluorescent microscope) with representative images captured 
with a digital camera (Olympus DP 10). Selected representative slides were 
counterstained by quick immersion (approximately ten seconds) in Harris’ 
Haematoxylin. All tissue sections were analysed by light microscopy at various 
magnifications. A microscope graticule was employed to determine the image scale. 
 
5.3.2 Dot blot assay 
5.3.2.1 Detection of α-tubulin by dot blot 
Initial dot blot experiments were performed using the protein α-tubulin as a positive 
control. These experiments had the aim to assess the suitability of the dot blot 
methodology adopted to detect proteins. Dot blot was performed according to the 
protocol outlined by Qiagen (http://www.qiagen.com 2011).  
 
Preparation of the samples solutions 
A solution containing the protein α-tubulin was obtained by cell solubilisation 
techniques. A total protein concentration of 3 µg/µl was previously determined for 
this solution using the bicinchoninic acid (BCA) assay method (Walker 2002). 
Starting from this solution, two more diluted solutions were prepared in PBS, having 
a total protein concentration of 1.5 and 1 µg/µl. An aliquot (10 µl) of each solution 
was added to (5 µl) of denaturation buffer (8 M urea, 100 mM NaH2PO4, 100 mM 
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Tris-HCl, pH 8.0) to obtain a final α-tubulin concentration of respectively 2.4, 1.2 
and 0.8 µg/µl. Denaturation buffer is usually employed in dot blot to increase epitope 
exposure of an antigen to the antibody and thus assist antigen-antibody interaction. In 
this experiment the protein of interest was tested under both native (N) and 
denaturing (D) conditions as the capability of the antibody to detect the antigen in 
either native or denaturing conditions had not been previously tested. Two solutions, 
constituted by only PBS and the denaturation buffer (10 µl of PBS plus 5 µl of 
denaturation buffer), were used as negative controls.  
 
Dot blot procedure  
One µl samples of each prepared solution were spotted in duplicate onto a 
nitrocellulose membrane. A pencil was used to indicate the application site of each 
sample solution on the membrane. The membrane was allowed to dry approximately 
40 minutes and then stored overnight at 4 °C. The following day, dot blot was 
performed according to the protocol outlined by Qiagen. Briefly, the membrane was 
washed twice, ten minutes each time, in TBS buffer (i.e., Tris-buffered saline buffer 
consisting of 10 mM Tris-HCl and 150 mM NaCl, pH 7.5) before being incubated in 
freshly prepared blocking buffer (BSA 3% w/v in TBS buffer) for 1 hour to block 
unspecific binding by the antibodies. Subsequently, the membrane was washed 
twice, 10 minutes each time, in TBS-Tween/Triton buffer ((20 mM Tris-HCl, 500 
mM NaCl, 0.05% (v/v) Tween 20, 0.2% (v/v) Triton X-100, pH 7.5)) before being 
incubated with a 1:1000 dilution of mouse monoclonal anti α-tubulin antibody 
(Sigma Aldrich, T9026, antibody stock concentration not determined by the 
supplier). The antibody was diluted using the same diluent used for IHC (containing 
1% BSA in PBS pH 7.4 and 0.005% sodium azide). Incubation was performed for 1 
hour. Subsequently, the membrane was washed twice in TBS-Tween/Triton buffer 
and then once in TBS buffer, 10 minutes each time, before being incubated for 1 
hour with the same secondary antibody reagent ((supplied as one of the reagents of 
Dako EnVision+ System-HRP (DAB) kit)) used for IHC. The membrane was 
subsequently washed four times, 10 minutes each time, in TBS-Tween/Triton buffer. 
Staining was completed by incubation with DAB+ chromogen solution (as for IHC) 
for approximately 10-15 minutes.  
All the steps described were performed at room temperature with the membrane 
placed onto an orbital shaker to ensure uniform coverage during incubation. When 
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incubation was performed for a longer period (i.e. 1 hour) the vessel (containing the 
membrane) was sealed with plastic film to prevent the membrane from drying out.  
The chromogenic reaction was stopped by washing the membrane with deionised 
water. The membrane was subsequently allowed to dry before being imaged by a 
digital camera (Canon Digital Ixus 82 IS, Canon, Surrey, UK or ChemiDoc XRS + 
System, Bio-Rad Laboratories, Hemel Hempstead, UK) and then stored at 4 °C.  
The same experiment was repeated. In this case α-tubulin standard solutions having a 
protein concentration ranging between 3 µg/µl and 1 pg/µl were employed with the 
aim to evaluate the limit of detection of the dot blot methodology for this protein. 
Eight α-tubulin standard solutions were prepared from a stock solution containing 3 
µg/µl of total protein content. Starting from this solution, a more diluted solution (1 
µg/µl) was prepared in PBS buffer. Six serial dilutions were then prepared (in PBS 
buffer), each solution having a concentration 10 times smaller than the previous. 
Denaturation buffer was not employed for this experiment.  
 
5.3.2.2 Dot blot for BTX A (Vistabel
®
) detection 
Preparation of BTX A samples 
A vial of Vistabel
®
 was dissolved in 200 µl of 0.9% saline solution to a BTX A 
concentration of 12.5 pg/µl. An aliquot (10 µl) of Vistabel
®
 solution was mixed to 
denaturation buffer (5 µl) to a final BTX A concentration of ~8.3 pg/µl. One µl 
samples of Vistabel
®
 formulation and Vistabel
®
 in denaturating condition (i.e. 
Vistabel
®
 added to denaturation buffer) were spotted in duplicate directly onto each 
of four nitrocellulose membranes. As a negative control, one µl samples constituted 
of 0.9% saline solution and denaturation buffer (10 µl of 0.9% saline solution + 5 µl 
of denaturation buffer) were spotted in duplicate, onto each of the four membranes. 
The membranes were allowed to dry for 40 minutes at room temperature. Once dried, 
each membrane was transferred into a plastic vessel and dot blot was performed as 
previously described. In particular the membranes were probed with the same 
primary antibody (directed against botulinum toxoid A) as for IHC with each 
membrane being incubated for 1 hour at room temperature with a different antibody 
titration (i.e. 1/50, 1/200, 1/1000, 1/2000). 
The dot blot experiment for Vistabel
®
 formulation was repeated using higher sample 
volumes (3 µl) of Vistabel
®
 formulation (12.5 pg/µl) that were spotted onto the 
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membrane together with 1 µl samples. This was performed in order to increase the 
dose of BTX A loaded on the membrane. All the samples were spotted in duplicate 
under both denaturing and native conditions. Dot blot was performed as previously 
described except for the following modifications: i) the membrane was probed with 
the same primary antibody as above diluted 1/100; ii) a different secondary antibody 
(goat anti mouse HRP-conjugated antibody purchased from Fisher Scientific, stock 
concentration 10 µg/µl)) was used at a dilution of 1/100 in freshly prepared blocking 
buffer (BSA 3% (w/v) in TBS buffer). 
 
5.3.2.3 Dot blot for detection of formaldehyde inactivated botulinum 
toxoid A (BT A) 
A vial of formaldehyde inactivated botulinum toxoid A (BT A) containing 10 µg of 
BT A was reconstituted in 100 µl of nuclease free water, as recommended by the 
manufacturer. An aliquot of the solution obtained was used to prepare 5 more diluted 
standard solutions in nuclease-free water with a BT A concentration ranging from 
100 ng/µl to 1 pg/µl. Each solution had a concentration ten times smaller than the 
previous one. An aliquot (9 µl) of BT A stock solution (100 ng/µl) was mixed to 
freshly prepared denaturation buffer (4 µl) to a final BT A concentration of ~ 64.3 
ng/µl. From this solution five diluted standard solutions were prepared in nuclease 
free water to a final concentration of BT A equal to 6.43 pg/µl. Each solution was ten 
fold less concentrated than the previous one. One µl samples of each of the standard 
solutions prepared were applied in duplicate onto each one of two nitrocellulose 
membranes. In addition, one µl samples of PBS and PBS plus denaturation buffer 
were spotted in duplicate onto each membrane as negative controls as described 
previously. 
The membranes were then allowed to dry for 40 minutes and stored at 4°C overnight. 
The following day, immunoassay was performed on the membranes as previously 
described with the following modifications: i) all the membranes were incubated 
with the same monoclonal antibody as for IHC, diluted 1/1000; ii) one membrane 
was incubated with the same secondary antibody used for IHC while the other 
membrane was incubated with stabilized goat anti mouse peroxidase conjugated 
secondary antibody (Fisher Scientific) at a dilution of 1/500. 
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Prolonged incubation time of BT A with a primary antibody 
The experiment was repeated in order to assess the effect of a prolonged incubation 
time of BT A with the primary antibody. For this experiment two sample solutions 
one constituted by BT A 100 ng/µl in nuclease free water and one by BT A ~ 66.67 
ng/µl in freshly prepared denaturation buffer were used. One µl samples of each 
solution were spotted in duplicate onto a membrane. Negative controls (consisting of 
nuclease free water and nuclease free water in denaturation buffer) were also applied 
in duplicate. Dot blot was performed as described above with the following 
modifications: i) incubation with the primary antibody was carried out overnight at 
4°C; ii) goat anti mouse peroxidase conjugated secondary antibody (Fisher 
Scientific) was used as secondary antibody at a dilution of 1/500. 
 
Using a different primary antibody against BT A  
Dot blot experiments were furthermore repeated in order to evaluate the capability of 
a different primary antibody to react with BT A. Three µl samples of BT A solution 
(100 ng/µl) were applied onto each one of two membranes in duplicate. One µl 
samples of the same solution were singularly spotted onto each membrane. The 
membranes were allowed to dry for 40 minutes before dot blot was performed as 
described above with the following modifications: i) membranes were incubated 
overnight at 4°C with a chicken anti Clostridium botulinum neurotoxin/toxoid A 
polyclonal antibody (stock concentration: 1 mg/ml) at a dilution 1/1000 in freshly 
prepared blocking buffer (1% (w/v) milk powder/TBS buffer); ii) the membranes 
were subsequently incubated for 1 hour at room temperature with a rabbit anti 
chicken peroxidase antibody (purchased from Sigma Aldrich (A 9046), stock 
concentration: 5.9 mg/ml) at a dilution of 1/500. 
 
5.3.3 Using IHC to detect BT A delivered into human skin 
by ID injections 
Initial experiments were carried out by delivering the toxoid using an ID injection. 
Due to the higher loading capability of standard syringes compared to microneedles, 
delivery of the toxoid by ID injection was used as a positive control.  
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The experiment was performed on a freshly excised skin sample (aged 64 years old), 
which was prepared for the experiment as previously described (Section 4.3.2). The 
skin sample was treated as follows:- 
Treatment 1: ten µl of BT A (100 ng/µl) was delivered into the skin by an ID 
injection. 
Treatment 2: four ID injections of nuclease free water, each one of a volume of 10 
µl, were performed in the same skin tissue (negative control).  
Each treated skin area was excised from the samples and fixed by immersion into 
10% neutral buffered formalin for 48 h. (+/-1 hour) at room temperature. Afterwards, 
each skin sample was rinsed twice in PBS for five minutes each time, before being 
dehydrated using an increasing gradient of ethanol. The dehydrating agents used and 
the different incubation times are outlined by Table 5.1.
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Table 5.1: Composition of dehydrating agents, incubation times and temperatures 
employed to dehydrate skin samples. 
  Volume %  
 Step Dehydrating 
agent 
Deionised 
H20 
Ethanol Time (hour) and incubation 
temperature 
     
1 20% aqueous 
ethanol 
80 20 1hour, room temperature 
2 30% aqueous 
ethanol 
70 30 1hour, room temperature 
3 50% aqueous 
ethanol 
50 50 1hour, room temperature 
4 70% aqueous 
ethanol 
30 70 1hour, room temperature 
5 70% aqueous 
ethanol 
30 70 Overnight, 4 °C 
6 80% aqueous 
ethanol 
20 80 2 changes x 2 hours (each one), 
room temperature 
7 90% aqueous 
ethanol 
10 90 2 changes x 2 hours (each one), 
room temperature 
8 100% aqueous 
ethanol 
- 100 Overnight, 4°C 
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The dehydrated samples were subsequently cleared by two immersions in 
chloroform-ethanol (50%-50% v/v) (for 1 hour each change). The samples were 
subsequently immersed in pure chloroform for 1 hour at room temperature. 
Dehydrated samples were incubated in two changes of molten paraffin (56°C) (2 
hours each change) to allow infiltration of paraffin into the tissue. The tissues were 
then transferred into histological cassettes at -20°C to allow solidification of the 
paraffin. Histological sections of approximately 7 µm generated by using the Leica 
RM2125 RT microtome (Leica Microsystems, Milton Keynes, UK) were floated in 
water at 40°C and collected onto Superfrost
®
 Plus microscope slides (Ng 2010). 
Paraffin was removed from the sections by incubating thrice in fresh xylene (3 rinses 
in xylene, 3 minutes each one). The sections were subsequently rehydrated in an 
(v/v) ethanol gradient (i.e., 100%, 90%, 70%, 50%, 30%, 10% aqueous ethanol, 2 
changes of 2 minutes each one, in the order listed) and kept hydrated in deionised 
water. Selected slides were processed by IHC. IHC protocol was carried out as 
described previously (Section 5.3.1.1). Skin sections were incubated with the same 
antibodies at the same dilutions and incubation times as for dot blot (Section 5.3.2.3). 
After IHC staining, sections were analysed by light microscopy as previously 
described (Section 5.3.1.1). 
 
5.3.3.1 Reagent (antibody) controls 
The following experiment was performed to confirm the specificity of the reagent 
involved in IHC assay and to assess the degree of non-specific background staining 
when the primary antibody was omitted. 
Selected slides, containing tissue sections generated by treatment 1 and 2 were 
incubated with the only chromogenic substrate DAB+. In addition, slides were 
incubated with peroxidase block, primary antibody dilution buffer (blocking buffer), 
secondary antibody and DAB+ substrate. ICH protocol was performed as outlined 
above (Section 5.3.3). 
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5.3.3.2 Investigation of the effect of different primary antibody 
dilutions and primary antibody incubation conditions on the degree 
of nonspecific background staining 
Two different incubation conditions (one hour at room temperature versus overnight 
at 4°C) and dilutions of primary antibody (1/1000 versus 1/5000) were compared in 
order to assess the degree of the effect of those two factors on the IHC background 
staining. 
Selected slides, containing sections generated by treatment 1 and 2, were stained by 
IHC using the same protocol earlier described (Sections 5.3.1.1 and 5.3.3). Slides 
were incubated with anti Clostridium botulinum neurotoxin/toxoid A IgY polyclonal 
primary antibody diluted 1/1000 with commercial antibody dilution buffer either 1 
hour at room temperature or 24 hours at 4°C in a humidified chamber. In addition, 
slides were incubated with the same primary antibody diluted 1/5000 (in the same 
dilution buffer) for 24 hours at 4°C in a humidified chamber. Once processed by 
IHC, the slides were analysed as previously described (Section 5.3.3). 
 
5.3.3.3 Assessing the effect of different blocking buffers on the 
degree of nonspecific background staining  
Different buffers used to dilute the primary antibody were compared in order to 
assess their effect on the presence of non specific background staining. The buffers 
were constituted by: i) milk powder 1% w/v in TBS; ii) commercial (AbCam) 
antibody dilution buffer (containing BSA 1%); iii) TBS buffer.  
Selected slides were processed by the IHC methodology previously outlined (Section 
5.3.3) with few modifications: for each experiment, slides containing skin sections 
generated by treatment 1 and 2 were incubated with the primary antibody overnight 
at 4°C in a humidified chamber. The antibody was diluted 1/000 respectively with 
each one of the three dilution buffer mentioned above. Once processed by IHC, the 
slides were analysed as previously described (Section 5.3.3). 
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5.3.4 Cutaneous delivery of BT A by PMDs 
A PMD was liquid loaded, as previously described (Section 2.3.4), with a 
formaldehyde inactivated BT A solution (100 ng/µl). As a negative control, a PMD 
was likewise loaded with PBS. PMDs were inserted into a skin sample, excised from 
a 41 year old patient, defrosted on the day of the experiment and treated as 
previously described (Section 4.3.2). PMDs were held in situ for approximately 5 
seconds and subsequently withdrawn. The PMD treated areas were then excised, 
mounted in OCT and stored at -80°C prior to cryosection, as indicated previously 
(Section 4.3.3.3). Transverse sections were analysed to detect areas of microneedle 
induced tissue disruption and were subsequently processed by IHC, in order to detect 
BTX A. IHC was performed as previously described (Section 5.3.1.1) except for the 
following modifications: i) sections were incubated for 1 hour at room temperature 
with the same primary polyclonal antibody anti BT A used for dot blot (Section 
5.3.2.3) (anti botulinum toxin/toxoid type A chicken IgY). The primary antibody was 
diluted with freshly prepared blocking buffer containing BSA 1% w/v in PBS/Tween 
20 0.05% v/v; ii) sections were subsequently incubated for 1 hour with the same 
secondary antibody used for dot blot (anti chicken IgY (IgG)-Peroxidase antibody). 
The secondary antibody was used at a dilution of 1/500 in freshly prepared blocking 
buffer containing BSA 3% w/v in PBS/Tween 20 0.05% v/v. After IHC, 
representative slides were counter stained with Harris’ Haematoxylin and imaged 
with a digital camera (Olympus DP 10) as described previously (5.3.1.1). 
 
5.3.4.1 Using a dye to facilitate visualisation of BT A delivered into 
the skin by PMDs 
The experiment was performed with the aim to load a PMD with a BT A formulation 
containing a dye in order to facilitate visualization of BT A delivered into the skin. 
The experiment was performed on a skin sample freshly excised (‘fresh’ skin, 
Section 4.3.2) from a 65 year old donor. A PMD was loaded with a formulation 
consisting of BT A 50 ng/µl in methylene blue 1% w/v in PBS. The formulation (~ 2 
µl) was withdrawn by a Gilson pipette before being loaded directly onto the needles. 
The PMD was inserted into a skin sample and manually held in position for 
approximately 5 seconds. After withdrawal of the PMD, the treated area was 
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removed and treated as described previously (Section 5.3.4). Transverse sections 
collected on microscope slides were analysed under light microscopy (Olympus, 
BX50) to detect sites of microneedles insertions indicated by the appearance of blue 
coloured areas in the skin. Selected slides were processed by IHC and analysed by 
light microscopy as previously described (Section 5.3.4). 
 
5.3.4.2 Assessing the presence of false positive staining generated in 
the skin by PMD disruption 
The experiment was performed in order to assess whether the disruption induced into 
the skin following PMD application caused retention of IHC reagents (i.e., antibodies 
and substrate) and thus false positive staining. The experiment was performed on 
‘frozen’ skin tissue, defrosted on the day of the experiment (Section 4.3.2). The 
sample was excised from a 54 year old patient. 
A PMD was loaded with a formulation consisting of methylene blue 1% w/v in PBS 
(negative control). Loading was performed as previously described (Section 2.3.4). 
The PMD was applied into the skin and the sample obtained was processed for IHC 
as outlined in Section 5.3.4. 
 
5.3.5 Cutaneous delivery of fluorescent conjugated BT A by 
liquid loaded PMDs 
BT A was fluorescently labelled with the compound PE/Cy7 by using the 
commercial conjugation kit EasyLink PE/Cy7
®
 (3 x 10 µg PE/Cy7
®
). The kit 
consisted of the following reagents: i) EL-PE/Cy5 mix 100 µg; ii) EL-Modifier 
reagent; iii) EL-Quencher FD reagent. 
The conjugation process was performed according to the protocol outlined by the 
manufacture (http://www.abcam.com 2011). Briefly, 1 µl of EL-Modifier reagent 
was mixed gently to 10 µl of BT A (100 ng/µl). Next, the screw cap was removed 
from the vial of EL-PE/Cy5 mix and the BT A solution (BT A 100 ng/µl with added 
EL-Modifier) was pipetted directly onto the lyophilised material. The compound was 
re-suspended gently by withdrawing and re-dispensing the liquid twice using a 
pipette. The cap was placed back on the vial and the solution was incubated 
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overnight at 4°C. After incubation, 1 µl of EL-Quencher FD reagent was added to the 
BT A solution and incubated for 30 minutes at room temperature prior to use. 
Subsequently, approximately 2 µl of the prepared solution were withdrawn by a 
pipette and dropped into the pockets of a PMD as described previously (Section 
5.3.4.1). 
The needles of a PMD were observed under light/fluorescent microscope (DM IRB, 
Leica Microsystems, Milton Keynes, UK) immediately and approximately 15 
minutes after loading and imaged by a digital camera attached to the microscope 
(Retiga, Exi digital camera, QImaging, Surrey, Canada). Afterwards, the PMD was 
inserted into excised ‘frozen’ human skin (Section 4.3.2) (age 63 years old) and 
manually held in situ for 1 minute before being withdrawn. After being removed 
from the skin, the PMD was furthermore observed by fluorescent/light microscope in 
order to assess the release of the fluorescent coating from the pockets. An additional 
PMD was loaded with the same formulation and inserted immediately into the skin 
where it was manually held for approximately 5 seconds before being withdrawn. As 
a negative control, a PMD was loaded with PBS and inserted into the skin as 
described above. The PMDs treated areas were then excised, mounted in OCT and 
stored at -80°C prior to cryosection (Section 4.3.3.3). Transverse sections were 
analysed by light/fluorescence microscope to detect delivery of the fluorescent 
compound at the sites of microneedle induced disruptions. Representative images 
were captured by a digital camera. 
 
5.4. Results and Discussion 
5.4.1 Cutaneous delivery of BTX A (Vistabel
®
) 
The Vistabel
®
 formulation was delivered into excised human skin by intradermal 
injections and microneedle applications. Selected cryosections obtained from the 
skin samples were analysed by IHC to detect the protein BTX A. Figure 5.1 (A-G) 
depicts representative cryosections processed by IHC for the detection of BTX A. In 
particular, Figure 5.1 (A) depicts a skin disruption area, which was likely generated 
by microneedle insertion. No positive brown staining could be detected around this 
site, thus suggesting either unsuccessful BTX A detection or a failure to deliver the 
toxin.  
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Figure 5.1 (A-G): Immunohistochemical analysis of the therapeutic BTX A formulation 
(Vistabel
®
) delivered into human skin by PMDs and ID injections. Representative 
haematoxylin counterstained histological cryosections of human skin treated with Vistabel
®
 
formulation (2.5 pg/µl) (A, B, C, E, F) or 0.9% saline solution (negative control) (D, G) and 
processed by IHC for BTX A detection. Vistabel
® 
(50 µl) was injected intradermally (B, C, 
E, F) or applied topically (20 µl) on the top of the epidermis following multiple PMDs 
insertions (A). The pictures (B, C, E, F) depict images of various degree of staining which 
could be detected at different times showing lack of reproducibility. The arrow in (A) points 
to disruption sites in the skin generated by a PMD insertion. The absence of a brown area 
surrounding this site indicates lack of detection of BTX A (Vistabel
®
). Sections (A-D) were 
incubated with primary antibody titration: 1/50, Sections (E-G) with primary antibody 
titration 1/200. Scale bar = 100 µm. Ep = epidermis, De = dermis, neg.= negative control. 
 
As described in the Material and Methods Section (5.3.1), PMDs were used in this 
experiment were repeatedly inserted into the skin surface within an area where a 
small volume (20 µl) of the Vistabel
®
 formulation had been topically applied. This 
implies that even though microneedle application had facilitated transdermal delivery 
of BTX A, the volume of formulation and thus the dose of toxin delivered would 
have been extremely small. Increased volumes of Vistabel
®
 were therefore injected 
by using a conventional needle and syringe in order to increase the mass of BTX A 
delivered into the skin and thus ease detection of the toxin by IHC. When skin 
samples in which Vistabel
®
 was injected intradermally were analysed under the light 
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microscope, signs of penetration of the hypodermic needle could not be detected in 
the skin tissue. However, when the solution was injected into the tissue, a typical 
raised bleb was observed, indicating successful intradermal delivery of the injected 
fluid. 
This therefore suggests that although the needle track could not be detected, the 
formulation was certainly delivered within the tissue. However, IHC stained 
cryosections did not provide conclusive results due to the inconsistency of staining 
between equally treated sections generated by the area of the tissue injected with the 
toxin (Figure 5.1 B, C, E and F). In particular, Figure 5.1 (B) showed lack of positive 
staining on the epidermis and a certain brown discoloration of the dermis. Although 
this discolouration might have been determined by a successful detection of BTX A 
in the dermis (BTX A was intradermally injected and thus most of the toxin would be 
expected to be delivered to the dermal region), this was considered unlikely, as the 
stain was not detected into other sections generated from the same skin sample and 
processed by the same IHC methodology (Figure 5.1 C). As a consequence, the 
brown discolouration observed (Figure 5.1 B) was considered to be most likely 
generated by unspecific background staining. This might have been determined by 
the poor quality of the cryosection, for example the presence of loose dermis, which 
may have resulted in excessive antibody/substrate retention or by an excessive 
antibody concentration (Ramos-Vara et al. 2008). A more diluted primary antibody 
(1/200 instead of 1/50) was thus tested. This resulted in a less intense stain (Figures 
5.1 E and 5.1 F), thus suggesting that the staining depicted by Figure 5.1 B was 
likely due to an inappropriate primary antibody concentration. Primary antibody was 
initially used at a concentration of 1/50 as this was the titration indicated by the 
antibody’s provider (AbCam) for immunofluorescence. As the antibody had never 
been used for IHC, this dilution was chosen as starting concentration for our initial 
experiments. The data strongly suggested that BTX A formulation Vistabel
® 
could 
not successfully be detected into the skin tissues by ICH. 
As previously mentioned (Section 5.1.4), only two studies regarding detection of 
BTX A in therapeutic formulations have been published (Ekong et al. 1995; Frevert 
2010). These studies reported the use of highly sensitive ELISA methods and ‘in 
house’ produced antibodies to reach LODs in the lower nanograms or picograms 
range. Additionally, only one study reporting detection of a commercial BTX A 
preparation (Vistabel
®
) in human skin by IHC has been published (Pacini et al. 
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2007). In this study 40 U/ml of Vistabel
®
 (corresponding to 2 ng/ml) was applied on 
living rat skin, which was subsequently treated by iontophoresis. 
The authors indicated delivery of BTX A within the deep dermis. Detection of the 
toxin was achieved by using commercially available antibodies. In particular, the 
authors reported the use of a monoclonal antibody directed against BTX A, 
purchased from US Biological (Swampscott, Massachusetts) and a biotin/avidin 
system detection kit (Vectastain
®
 ABC) purchased from Vector Laboratories 
(Burlingame, California). In our experiments, the same primary antibody used in the 
cited study could not be employed, as this was not available. In addition, a polymer-
based system (EnVision; Dako Corporation) was used as this has been reported to be 
more sensitive than a biotin/avidin system. 
Failure to detect BTX A in this series of investigations may have been caused by a 
number of different factors. The quantity of protein delivered into the skin may have 
been under the LOD for the IHC methodology employed (i.e. 125 picograms of BTX 
A was delivered for each ID injection). Another possible cause is that the antibody 
could not recognise the antigenic epitope on BTX A. The antibody used in our 
experiments was directed against a synthetic peptide analogue of a specific epitope 
contained in the carboxy-terminal region of BT A. As BTX A (Vistabel
®
) was 
delivered in the skin as a macromolecular complex (i.e., the 150 kDa holotoxin 
complexed with additional non toxic proteins with a resulting molecular weight of ~ 
900 kDa), it may be that the antigenic epitope was masked by the presence of these 
additional proteins and thus not recognised by the antibody. 
In addition, as described in the Material and Methods Section (5.3.1), the skin 
samples were incubated in organ culture for 1½ hours, after being treated with BTX 
A (Vistabel
®
). This was performed in order to assess the distribution of the toxin 
within the skin as it was previously described for the model protein β-gal (Section 
4.3.3.1). When incubated, the protein would have diffused within the skin. This 
could have resulted in a reduced concentration of the toxin at the application site. In 
addition skin samples were not fixed in formalin (the fixative usually employed in 
IHC) due to the known masking effect of the fixation on the antigenic epitopes 
(Section 5.1.5.1). As a consequence, as IHC involved several washing steps, the 
protein could have been diluted in the unfixed tissue or even removed completely. 
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5.4.2 Dot blot immunoassay 
5.4.2.1 Dot blot for α-tubulin immunodetection  
Initial dot blot experiments were performed with an aim to assess the suitability of 
the dot blot methodology for protein detection. Lysate cell samples with an estimated 
total protein concentration ranging between 1 to 3 µg/µl were used for this purpose. 
Figure 5.2 shows the appearance of a nitrocellulose membrane loaded with 1 µl 
samples of the solubilised cell solutions and subsequently incubated with an anti α-
tubulin antibody and a HRP-polymer conjugated secondary antibody. Positive 
immunodetection was indicated by the appearance of brown-coloured spots at the 
sites where the solutions were applied (indicated by a point and a circle in Figure 
5.2). This was observed for samples tested under both native and denaturing 
conditions, thus indicating that the antigenic epitope in the protein α-tubulin was 
exposed to the antibody even when native conditions were employed. The absence of 
brown areas at the sites where the negative control solutions were applied confirmed 
the specificity of the assay.  
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Figure 5.2: Micrograph of a nitrocellulose membrane loaded with α-tubulin and 
processed by dot blot for α-tubulin immunodetection. One µl samples of three standard 
solutions with a total protein concentration of 3, 1.5 and 1 µg/µl were loaded in duplicate 
onto the membrane. The presence of brown-coloured areas on the sites of the membrane 
where the solutions were applied (indicated by the circles and the points), reveals successful 
detection of α-tubulin. The intensity of the signal detected is proportional to the total protein 
concentrations. N=protein under native conditions, D=protein under denaturing conditions. 
neg.= negative control. 
 
Dot blot experiments were repeated on α-tubulin standard solutions with a total 
protein concentration ranging between 3 µg/µl and 1 pg/µl (Figure 5.3). This was 
performed with the aim to investigate the limit of detection of this methodology. The 
results indicated that the lowest quantity of protein detectable was 10 ng.  
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Figure 5.3: Dot blot for α-tubulin detection. Evaluation of the limit of detection. The 
images depict the appearance of a nitrocellulose membrane loaded with α-tubulin standard 
solutions and processed by dot blot. One µl samples of eight standard a-tubulin solutions 
with a total protein concentration ranging between 3 µg/µl (1) and 1 pg/µl (8) were applied 
in duplicate on the membrane. Marker lines indicate the areas where the solutions were 
spotted. Successful detection, revealed by the appearance of spots on the membrane, was 
observed for the first four standard solutions. Intensity of the signal detected appeared to be 
proportional to protein standard solutions, neg.= negative control. 
 
However, as previously mentioned (Section 5.3.2.1), the concentration of the sample 
solutions tested was determined by using a spectrophotometric assay (the BCA 
assay) which measured the total protein content of the sample and not specifically the 
α-tubulin contained in it. This therefore implies that the actual mass of α-tubulin 
detected will have been less than 10 ng. However, the typical limit of detection of the 
dot blot methodology resides in the lower nanograms range when using chromogenic 
detection methods (as the one employed in our experiments) and therefore the 
method was considered appropriate. The sensitivity of the dot blot can also be 
dramatically increased by employing HRP-chemiluminescent substrates. By using 
these substrates LODs approaching the picograms or even the femtograms range can 
be achieved. However, as the aim of the experiments reported in this Chapter was the 
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detection of BTX A within the skin, such substrates were not employed as we did not 
possess suitable facilities to detect chemiluminescent signal within the skin tissue. 
 
5.4.2.2 Dot blot for BTX A commercial formulation (Vistabel
®
) 
immonodetection 
Figure 5.4 (A) depicts the appearance of a representative nitrocellulose membrane 
loaded by 1 µl samples of Vistabel
®
 (12.5 pg/µl) and incubated with primary 
antibody against BT A (AbCam) used at a dilution of 1/2000. The experiment was 
also performed by simultaneously incubating three additional membranes with three 
more dilute concentrations of primary antibody (i.e. 1/50, 1/100 and 1/1000). None 
of the four dilutions used resulted in positive BTX A detection. The experiment was 
furthermore repeated using a different HRP conjugated secondary antibody (Figure 
5.4 B) in order to investigate whether the failure in BTX A detection was due to the 
secondary antibody employed in the first experiment. In addition, increased volumes 
of Vistabel
®
 solution (3 µl together with 1 µl samples) were loaded onto the 
membrane (Figure 5.4 B) in order to increase the amount of BTX A loaded 
(respectively 12.5 and 37.5 pg). No successful detection of the protein was observed. 
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Figure 5.4 (A, B): Dot blot for BTX A (Vistabel
®
) detection. The images depict the 
appearance of two nitrocellulose membranes loaded with 1 (A) or 1 and 3 µl (B) samples of 
BTX A (Vistabel
®
, 12.5 pg/µl). Absence of brown areas at the sites where the solutions were 
applied (indicated by either a line or a point) shows lack of detection of BTX A. The same 
primary antibody (AbCam), directed against BT A, was used for (A) and (B). Two HRP-
conjugated secondary antibodies purchased from two different suppliers (details in the text) 
were employed. N= protein under native conditions, D= protein under denaturing conditions, 
neg.= negative control. 
 
The results confirmed that immunodetection of BTX A contained in the commercial 
preparation Vistabel
®
 is not possible using the primary antibody employed in our 
experiments. This is most likely due to the constrained dose of BTX A protein loaded 
onto the membrane due to the low dose of BTX A in Vistabel
®
 and explains the lack 
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of detection of BTX A (Vistabel
®
) in the skin during the previous IHC experiment 
(Section 5.4.1).  
 
5.4.2.3 Dot blot for immunodetection of botulinum toxoid A (BT A) 
Due to the extremely small dose of BTX A contained in the commercial formulation 
Vistabel
®
 (BTX A 2.5 ng), subsequent experiments were performed using an 
inactivated form of the toxin (i.e. formaldehyde inactivated botulinum toxoid A (BT 
A)), which could be obtained commercially and used at increased doses without 
posing safety concerns. 
Initial dot blot experiments were performed by employing a dose of BT A ranging 
between 100 ng and 1 pg and incubating the membrane with the same primary 
antibody used for the previous experiments. The results (Figure 5.5 A) indicated 
failure in BT A detection as no positive signal could be reported on the membrane 
where the sample solutions were spotted. The same was observed when the 
membrane was incubated for a longer period of time with the primary antibody (i.e., 
overnight at 4°C compared to 1 hour at room temperature) (Figure 5.5 B).  
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Figure 5.5 (A, B): Dot blot for botulinum toxoid A (BT A) detection: use of a primary 
antibody purchased from AbCam. The images depict the appearance of two nitrocellulose 
membranes loaded with 1 µl samples of differently concentrated BT A solutions and 
processed by dot blot for BT A immunodetection. BT A standard solutions ranging between 
100 ng/µl (1) to 1 pg/µl (6) were used for the first membrane (A). BT A stock solution (100 
ng/µl) was loaded in triplicate on the second membrane (B). Both membranes were 
incubated with a primary antibody (AbCam) diluted 1/1000 respectively 1 hour at room 
temperature (A) and overnight at 4°C (B). The absence of stained areas located where the 
samples solutions were applied (indicated by the points) revealed failure in protein detection. 
N = protein under native conditions, D = protein under denaturing conditions, neg.= negative 
control. 
 
As doses equal to 100 ng were tested in these experiments, absence of detection was 
not expected to be caused by a lack of sensitivity of the assay, but most likely by 
absence of interaction between the protein and the antibody. The primary antibody 
used in our experiments was purchased by AbCam. As specified by the 
manufacturer, this antibody was raised against a synthetic peptide analogue of the 
carboxy-terminal region (heavy chain) of BT A. As BT A used in our experiments 
was produced by a different supplier (List Biological Laboratories), the lack of 
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interaction may be explained by the conditions adopted during the detoxification 
process of the toxin. The immunogenicity of the toxin is usually retained after the 
deactivation process. However, some studies have reported a certain variation of 
antigenic structure and thus the immunogenicity of commercially available toxoids 
can differ depending on the severity of formaldehyde reaction conditions (i.e. 
formaldehyde concentration/time of exposure) (Grate 2010; Keller 2008). As a 
consequence, the epitope, which should have specifically been recognised by the 
primary antibody, may have been chemically altered during the detoxification 
process, causing the absence of antigen-antibody interaction. Driven by this 
consideration, dot blot experiments were subsequently performed by using a primary 
antibody produced by List Biological Laboratories. This antibody was specifically 
raised against the binding domain (heavy chain) of BT A used in our experiments. 
By using this antibody a positive BT A detection was achieved (Figure 5.6). 
Detection was observed for membranes loaded with 1 and 3 µl samples of BT A 100 
ng/µl (thus corresponding to a dose of BT A equal to 100 and 300 ng). However, for 
the 3 µl samples, a weaker signal was detected, probably due to greater diffusion of 
the solution applied. This would have resulted in subsequent dilution of BTA 
concentration and thus reduction of the staining intensity. Immunoassay of solutions 
not containing any BT A (negative control) resulted in a complete absence of signal 
confirming the specificity of the assay.  
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Figure 5.6: Dot blot for botulinum toxoid A (BT A) detection: use of a primary 
antibody purchased from List Biological Laboratories.  The images depict the appearance 
of a nitrocellulose membrane loaded with 1 and 3 µl samples of BT A solution (100 ng/µl) 
and processed by dot blot for BT A immunodetection. The presence of stained areas located 
where the samples solutions were applied revealed successful detection of the protein.  
 
5.4.3 Cutaneous delivery of botulinum toxoid A (BT A) by 
intradermal (ID) injections 
Driven by the successful immunodetection of BT A previously achieved, IHC was 
used to detect BT A delivered into the skin by ID injections. As previously reported 
for Vistabel
®
 delivery (Section 5.4.1), the toxoid was injected by using a 
conventional needle and syringe in order to increase the dose of BT A delivered. 
Figure 5.7 (A-H) show representative formalin fixed paraffin embedded sections of a 
human skin sample intradermally injected with BT A (A, B, E and F). The images 
depict brown staining localised in the epidermis. No trace of brown staining could be 
detected at a dermal level. However, it was expected to be stained as BT A 
formulation was injected intradermally. Although the intensity of the staining seemed 
to be higher for skin intradermally injected by BT A (A, B, E, F), a certain 
background level of brown discoloration was also detected for the negative control 
sections (C, D, G, H). The possible causes of the unspecific background staining 
include i) the concentration of primary antibody, ii) the incubation time with the 
primary antibody, iii) the poor specificity of IHC assay reagents and, iv) blocking 
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buffers used. Each of these factors was therefore investigated during the experiments 
described by the following Sections. 
 
 
 
Figure 5.7 (A-H): Immunohistochemical analysis of botulinum toxoid A (BT A) 
delivered into human skin by ID injections Representative formalin fixed paraffin 
embedded sections of human skin intradermally injected with 10 µl of BT A solution (100 
ng/µl) (A, B, E, F) and nuclease free water (negative control) (C, D, G, H) and processed by 
IHC for BT A detection. The sections were imaged before (A, C, E, G) and after (B, D, F, H) 
counterstaining with haematoxylin. Scale bar: 100 µm, neg.= negative control. 
 
5.4.3.1 Investigating the effect of reagents (non-primary antibody) 
on the degree of nonspecific background staining 
The experiment was performed in order to assess the specificity of the reagents of the 
IHC methodology and the presence of non-specific background staining when 
omitting primary antibody. IHC analysis was performed by incubating selected slides 
with either the substrate only, DAB+ (Figure 5.8 A, B, E, F), or with peroxidise 
block, primary antibody dilution buffer, secondary antibody and DAB+ (Figure 5.8 
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C, D). The absence of any significant background staining confirmed the specificity 
of the assay. In addition, the lack of staining reported for samples for which 
peroxidise blocking was not performed (A, B, E, F) indicated that the activity of any 
endogenous peroxidases in the skin tissue was negligible. 
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Figure 5.8 (A-F): Immunohistochemical analysis of botulinum toxoid A (BT A) 
delivered into human skin: reagent (primary antibody) control. Representative formalin 
fixed paraffin embedded sections of human skin intradermally injected with 10 µl of BT A 
solution (100 ng/µl) (A-D) and nuclease free water (negative control) (E, F) and processed 
for reagent (antibody) control. Sections were incubated with either the only chromogenic 
substrate (DAB+) (A, B, E, F) or with peroxidise block, primary antibody dilution buffer, 
secondary antibody and DAB+ (C, D). The sections were imaged before (A, C, E) and after 
(B, D, F) counterstaining with haematoxylin. Scale bar: 100 µm. neg.= negative control. 
 
5.4.3.2 Investigating the effect of primary antibody dilutions and 
primary antibody incubation conditions on the degree of nonspecific 
background staining 
IHC was performed on selected slides by comparing two different primary antibody 
incubation times (1 hour at room temperature versus overnight at 4°C) and two 
different primary antibody dilutions (1/1000 versus 1/5000). Figure 5.9 (A-F) depicts 
haematoxylin counterstained sections generated from a skin sample intradermally 
injected by BT A (Figure 5.9 A, C and E) or nuclease free water (negative control) 
(Figure 5.9 B, D and F). Sections were incubated for 1 hour (Figure 5.9 A, B) or 
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overnight (Figure 5.9 C, D) with primary antibody diluted 1/1000 with a commercial 
antibody dilution buffer. A slightly more intense staining was detected for longer 
incubation times of the primary antibody (Figure 5.9 C, D) as would be expected. In 
particular, skin specimens generated from the negative control (Figure 5.9 D) 
appeared more intensely stained than samples injected by BT A solution (Figure 5.9 
C). Figure 5.9 (E, F) depicts the appearance of cryosections incubated overnight with 
a more diluted primary antibody (1/5000). No excessive background staining was 
detected for these sections (Figure 5.9 E, F) probably due to the higher dilution of the 
primary antibody used. The results obtained by this experiment showed that different 
antibody concentrations and incubation times did not result in significant variation in 
background staining. However, they indicated that the data previously reported 
related to the delivery of BT A by ID injections (Section 5.4.3) were not reproducible 
as no positive BT A detection was obtained for any of the processed sections. 
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Figure 5.9 (A-F): Immunohistochemical analysis of botulinum toxoid A (BT A) 
delivered into human skin: evaluation of different primary antibody dilutions and 
incubation times. Representative formalin fixed paraffin embedded sections generated from 
human skin intradermally injected with 10 µl of BT A solution (100 ng/µl) (A, C, E) and 
nuclease free water (negative control) (B, D, F) and processed by IHC for BT A detection. 
Sections were counterstained with haematoxylin. Primary antibody was diluted 1/1000 (A-
D) and 1/5000 (E, F). Sections were incubated 1 hour at room temperature (A, B) or 
overnight at 4°C (C-F). Scale bar: 100 µm, neg.= negative control. 
 
5.4.3.3 Assessing the effect of different blocking buffers on the 
degree of nonspecific background staining 
The presence of background staining in IHC can often be caused by non-specific 
interaction between the antibodies and sites on non-specific proteins (‘active sites’) 
that are similar to the epitopes on the target antigens. For these reasons, samples are 
incubated with specific blocking buffers. By definition, blocking buffers, so called as 
they block unspecific sites to which antibodies could otherwise bind, are used to 
improve the sensitivity of the assay by reducing background interference 
(http://www.piercenet.com). Blocking buffers commonly used are normal serum, 
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non-fat dry milk and BSA. The efficiency of a specific blocking buffer cannot be 
predicted for all IHC experiments. Experimental testing is essential to achieve the 
best results for specific antigen and antibodies. For this reason IHC analysis was 
repeated in order to compare the effectiveness of two different blocking buffers (the 
commercial antibody dilution buffer (AbCam) and non fat dry milk 1% w/v/TBS 
buffer) with a non-blocking buffer (TBS). The results show (Figure 5.10 A-N) that 
reduced background staining, indicated by complete absence of brown discolouration 
on the negative control sections, was obtained when dry milk 1% w/v/TBS was used 
(A-D). This blocking buffer was used in the previous IHC assays, and therefore the 
presence of certain background interference in the negative control sections (Section 
5.4.3) remained unexplained.  
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Figure 5.10 (A-N): Immunohistochemical analysis of botulinum toxid A (BT A) 
delivered into human skin: evaluation of different antibodies dilution buffers. 
Representative formalin fixed paraffin embedded sections of human skin intradermally 
injected with 10 µl of BT A solution (100 ng/µl) (A, B, E, F, I, L) and nuclease free water 
(negative control) (C, D, G, H, M, N) and processed by IHC for BT A detection. Sections 
were imaged before (A, C, E, G, I, M) and after haematoxylin counterstaining (B, D, F, H, L, 
N). The following buffers were used to dilute 1/1000 the primary antibody: i) non fat milk 
1% (w/v) /TBS (A-D), ii) a commercial buffer (AbCam) containing BSA 1% (w/v) in TBS 
(E-H), iii) TBS (I-N). 
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5.4.4 Cutaneous delivery of botulinum toxoid A (BT A) by 
liquid loaded PMDs 
IHC analysis of skin samples treated with BT A loaded PMDs suggested successful 
delivery of the protein by the microneedle. This was indicated by the appearance of 
brown staining areas specifically located at the penetration sites (Figure 5.11 A, B). 
No background staining was reported in non BT A treated skin (negative control) 
(Figure 5.11 C). This suggested that IHC methodology used was suited to selectively 
detect the target antigen. As previously mentioned, initial experiments were 
conducted by delivering BT A by conventional ID injection (Section 5.4.3). 
Conventional needle and syringe enable delivery of higher volumes compared to 
PMDs. Therefore, it was hypothesised that delivery of BT A by ID injections would 
have resulted in a larger area of staining and a means to ensure intradermal delivery 
of a dose. However, this was not indicated by the experiments previously reported. 
Conversely, a more intense and localised staining was reported here for PMD-
mediated delivery. It may be hypothesised that due to the greater volume injected by 
ID injections, a more diluted BT A formulation was delivered in the tissue thus 
resulting in a weaker staining. In addition due to the pressure applied during ID 
injections, BT A would have diffused extensively within the tissue, this contributing 
to the reduced intensity of the staining. Moreover, as described in the Material and 
Methods Section (5.3.4), the skin tissue processed by IHC in this experiment was 
snap frozen immediately after application of the BT A loaded-PMD and 
subsequently cryosectioned. Conversely, for the experiment reported in Section 
5.4.3, the tissue was fixed in formalin and then processed in paraffin-embedded 
sections (Section 5.3.3). This process involves a large number of washing steps and 
exposure of the skin sample to different solvents (i.e., ethanol and chloroform) and 
relatively high temperatures (i.e., equal or higher than 60°C). As a consequence, it 
may be that the brown staining observed in the epidermis of the skin sections was 
caused by alteration of the skin structure, which resulted in retention of one or more 
IHC reagents during the incubation steps. 
As mentioned above, in the experiment reported within the present Section the skin 
samples was not fixed in formalin, while the ones reported in the previous Section 
(5.4.3) were. Due to the known masking effect of this fixative on the antigens, it may 
be hypothesised that the lack of fixation of the tissue facilitated detection of BT A.  
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Figure 5.11 (A-C): Delivery of BT A within human skin by liquid loaded PMDs. 
Haematoxylin counterstained histological cryosections of human skin inserted with BT A 
(A, B) and PBS (C) (negative control) liquid loaded PMDs and processed by IHC for BT A 
detection. The arrows point to disruption sites in the skin. The presence of a brown area 
surrounding those sites suggests a successful delivery of BT A into the epidermal and dermal 
layers of the skin. Scale bar = 100 µm. Sc = stratum corneum, Ep = epidermis, De = dermis  
 
5.4.4.1 Using a dye to facilitate visualisation of botulinum toxoid A 
(BT A) delivered into the skin by PMDs 
In order to support detection of BT A in the skin by IHC, PMDs were loaded with a 
BT A formulation containing a dye (methylene blue) to enable visualisation of 
microneedle penetration within the tissue. PMD delivery of the formulation into skin 
was confirmed by the presence of blue stained areas at the microneedle disruption 
sites (Figure 5.12 A, C). IHC analysis failed to detect BT A (Figure 5.12 B), as 
brown stained areas could not be observed, as expected, at those specific sites. The 
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blue areas detected disappeared after IHC staining, thus indicating that the dye was 
washed away when the tissue sections were processed. The results highlighted by 
this experiment did not confirm what previously indicated (Section 5.4.4) (i.e., 
successful detection of BT A, delivered by a PMD, by IHC).  
 
 
 
Figure 5.12 (A-C): Using a dye to facilitate visualisation of BT A delivered into the skin 
by PMDs. Representative hystological cryosections of human skin inserted with BT 
A/methylene blue liquid loaded PMDs. The sections were imaged before (A, C) and after (B) 
being processed by IHC for BT A detection. The appearance of diffused blue stained areas at 
the microneedles insertion points indicates successfully delivery of the BT A solution. The 
absence of brown stained areas after IHC (B) indicates lack of detection of BT A. Scale bar: 
100 µm. 
 
However, in this experiment, a 50% less concentrated BT A loading formulation was 
used for PMD loading, as BT A formulation was mixed at a 50-50% v/v ratio with 
methylene blue solution. As a consequence, the dose of BT A loaded on the PMD 
and thus delivered into the skin may have been too small to be detected. Moreover, 
the presence of the dye may have affected the immunogenic detection of BT A by the 
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primary antibody. Chemical or electrostatic interactions between the protein and the 
dye could be hypothesised due to the hydrophilic nature of both compounds. 
 
5.4.4.2 Assessing the presence of false positive staining generated in 
the skin by PMD disruption 
In order to confirm that skin disruption generated by PMDs insertion did not result in 
excessive antibody/substrate retention and thus false positive staining, sections 
generated by skin samples treated with methylene blue liquid loaded PMDs (negative 
control) were processed by IHC methodology. Figure 5.13 (A, B) depicts the 
appearance of a microneedle channel before (A) and after IHC staining (B). The 
absence of brown colouration around the microneedles insertion site, confirmed that 
disruption of the skin did not result in reagents retaining and thus false positive 
brown staining. This suggests that the presence of darkened area surrounding the 
microchannels depicted previously (Section 5.4.4) was generated by the delivery of 
BT A more that an artefact of the IHC staining. 
 
 
 
Figure 5.13 (A, B): Assessing the presence of false positive staining generated in the 
skin by PMD disruption. Representative hystological cryosections of human skin inserted 
with PMDs liquid loaded with methylene blue (negative control). Sections were imaged 
before (A) and after (B) IHC staining for BT A detection. The sections were subsequently 
counterstained with haematoxylin. Distinct microneedles channels could be detected (as 
indicated by the arrow). The absence of brown staining (B) at the microneedles insertion site 
indicates that skin disruption does not result in reagents retention and false positive staining. 
Scale bar: 100 µm. 
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5.4.5 Cutaneous delivery of fluorescent tagged botulinum 
toxoid A (BT A) by liquid loaded PMDs 
BT A detection in the skin by IHC techniques was not as robust as hoped and 
therefore it was supported by fluorescence imaging of BT A following its 
conjugation to a fluorophore, PE/Cy7
®
. 
Figure 5.14 (A-I) depicts brightfield (A, C) and fluorescent (B, D) micrographs of a 
single pocketed microneedle loaded with fluorescent BT A before (A, B) and after 
(C, D) being inserted into human skin. The absence of any fluorescence in the pocket 
after application of the PMD into the skin, suggests successful BT A release from the 
PMD. The fluorescent loading depicted by the micrographs (B) was likely to be a 
dried film as the image was captured approximately 10 minutes after PMD loading. 
When the PMD was observed straight away after being immersed into the 
formulation, the fluorescence signal detected was considerably less intense than the 
depicted image. In particular the pocket appeared devoid of formulation. Following 
approximately 10 minutes, a pink film visible to the naked eye, could be detected on 
the pockets of the microneedles. When analysed under the fluorescence microscope 
the entire microneedles (pocket plus shaft) appeared completely fluorescent (B). This 
indicates that the aqueous component of the formulation may have evaporated, thus 
concentrating the fluorescent toxoid and generating a stronger signal. Cutaneous 
delivery of BT A was confirmed by histological analysis. Figure 5.14 (E-G) depicts 
successful deposition of fluorescent BT A into the skin surrounding microneedle 
disruption sites at both epidermal and dermal level. The images illustrated were 
generated from a skin sample that was treated by a PMD loaded just before being 
inserted into the tissue and BT A was therefore assumed to be delivered into this 
sample as a liquid. Figure 5.14 (H, I) depicts the appearance of cryosections 
generated by a skin sample treated with the (presumably) dry coted PMD. The 
intensity of the signal detected appeared weaker compared to the other sections, thus 
suggesting that a higher dose of BT A was delivered in a liquid form. This may have 
been a result of incomplete release of the dry coating from the microneedles during 
their insertion into the skin. As depicted by Figure 5.14 (D), the microneedle pocket 
appeared devoid of fluorescent coating following application into the skin. However, 
fluorescence was detected on the microneedle shaft. This suggests that some BT A 
may be retained at this level and thus not delivered to the skin. However, direct 
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comparisons cannot be made as the liquid loaded PMD was not imaged after 
application into the skin. This would have provided an indication of the efficiency of 
delivery of the liquid formulation from the PMDs. 
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Figure 5.14 (A-I): Delivery of PE/Cy7
®
 conjugated BT A within human skin by liquid 
loaded PMDs. Fluorescent and brightfield micrographs of a single pocketed microneedle 
(A-D) loaded with PE/Cy7
®
 conjugated BT A before (A, B) and after insertion (C, D) into 
human skin. Representative histological cryosections of human skin inserted with a PE/Cy7
®
 
conjugated BT A liquid loaded (E-G) and (possibly) dry coated PMD (H, I) observed under 
light and fluorescence microscopy. (G) was obtained by overlying figures (E) and (F). The 
fluorescent area detected at the microneedles disruption sites indicates a successful delivery 
of BT A to the epidermal and dermal layer of the skin. Scale bar= 100µm. 
 
Differences in the degree of diffusion of the BT A within the two skin samples were 
not observed. This was presumably because both tissues were snap frozen 
immediately after being treated. Therefore, diffusion of the protein within the skin 
tissue was prevented. The data indicated that PMDs can successfully load and 
subsequently deliver BT A into the dermal layer of human skin as a liquid 
formulation. Experiments previously performed using the model protein β-gal 
(Section 4.4.3.2) highlighted the capability of high molecular weight molecules to 
diffuse readily within the skin. Similar behaviour may be expected for BTX A. 
Further studies are therefore now required to characterise delivery and distribution of 
Chapter 5 
209 
 
the BTX A and establish the clinical efficacy of the toxin delivered by liquid loaded 
PMDs. 
 
5.5 Conclusion 
BTX A contained in the commercial preparation Vistabel
®
 cannot be detected by 
standard IHC techniques. IHC analysis of human skin treated with PMDs liquid 
loaded with BT A tentatively suggests successful delivery of the toxoid into the 
epidermal and dermal layer of the tissue. IHC data were supported by fluorescence 
microscopy analysis of skin samples treated with BT A following its conjugation to 
an appropriate fluorophore. The results have demonstrated that BTX-A loaded 
microneedle devices are a feasible minimally invasive intradermal delivery system 
for this macromolecular therapeutic. 
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General Discussion 
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6.1 Significance, limitations and future work 
The aim of this Thesis was to investigate the suitability of liquid loaded PMDs to 
deliver BTX A to the dermis of human skin for the treatment of PFHH. Pocketed 
microneedles, metallic 700 µm-long needles containing a cavity within the needle 
shaft, were selected as an appropriate delivery device for the task. Initial experiments 
were performed with the aim of investigating the suitability of a PMD to uniformly 
accommodate a liquid formulation within the microneedle pockets (Chapter 2). 
Microneedle pockets were loaded following a single immersion into a formulation 
that mimicked the composition of the commercial Botox
®
 formulation, with the 
exception of BTX A, which was replaced by the model protein β-galactosidase (β-
gal, ~465 kDa) and a water-soluble dye, which was included to enable visualization. 
The inherent viscosity of the formulation enabled retention of the solution in the 
pockets for a sufficient time that would enable application of the device into the skin 
and delivery of the drug as a liquid formulation. This suggests that Botox
®
 could be 
loaded onto a PMD and retained as a liquid without requirement to reformulate. 
Avoiding reformulation would significantly reduce regulatory hurdles and would 
simplify clinical use of the PMD as a means to deliver BTX A. Moreover, addition of 
a dye to the formulation has enabled visualisation of the loaded solution in the 
pockets. This may prove particularly useful in the clinical context, as it would allow 
the clinician and/or patient to ensure that the formulation has been successfully 
loaded on the microneedle device and the drug released into the skin following 
microneedle application. 
Loading uniformity of a microneedle device will be important in order to ensure dose 
reproducibility. This is critical for therapeutic drug delivery and is particularly 
important for potent and potentially toxic therapeutics such as BTX A. 
Determination of microneedle loading capacity and reproducibility of dose loading 
was assessed in Chapter 3 by using an established spectrophotometric assay for the 
model β-gal. The data indicated that the loading capacity of microneedle devices is 
appropriate for therapeutic BTX A formulations, as nanograms doses of protein can 
be accommodated on individual microneedles (for comparison the entire vial of 
Botox
® 
contain only 5 ng of BTX A). However, dose reproducibility cannot be 
guaranteed using the loading methodology employed in our experiments. Spatial 
control of the deposition of the formulation on the microneedle array is challenging 
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when the loading process is performed manually. This would certainly not be 
acceptable from a clinical prospective, as it would result in delivery of variable doses 
and thus unpredictable therapeutic effects. In the future, automation of the process 
and/or optimization of the microneedle design would help to reduce such variability. 
Although the Botox
® 
manufacturing company (Allergan Pharmaceuticals, Irvine, 
CA, USA) recommends to reconstitute the drug in 4 ml of saline solution 
(http://www.allergan.com/index.htm 2011), dilution volumes ranging between 1.5 
and 5 ml are most commonly employed in the practice setting, dictated mainly by the 
clinician’s preference. Due to the constrained dimensions of the pocket within the 
microneedle, loading a PMD with effective doses of BTX A would require further 
concentration of the Botox
® 
preparation (i.e. reconstitution of the entire vial by using 
volumes as small as 50 µl) and use of a larger PMD containing a higher number of 
microneedles (i.e., at least 25 pocketed microneedles would be needed instead of the 
current 5 microneedles contained on a PMD). The use of MDs containing 50 
microneedles with a similar design as the ones used in our study has already been 
reported and thus this is not expected to represent a technical issue (Gill and 
Prausnitz 2007a). Conversely, the need to reconstitute the entire vial of medicament 
with extremely low volumes (i.e., 50 µl) may represent a practical challenge in the 
clinical setting. If the entire vial of Botox
® 
was to be reconstituted in a volume of 
diluent as low as 50 µl, the solution obtained would be difficult to withdraw from the 
vial. As a consequence, this would result in waste of a costly medicament. 
Using larger volumes, comparable to those currently used in the clinical setting 
would certainly ease handling of the formulation and would eliminate concerns 
related to complete dissolution of the therapeutic preparation. However, this would 
require PMDs with a considerable greater number of microneedles (i.e., microneedle 
arrays containing more than 1000 pocketed needles would be required to load 
effective doses of medicament). Alternative microneedle devices with increased 
loading capacity, such as hollow microneedles, may therefore be more suitable for 
BTX A delivery as they would not require concentration of the Botox
®
 formulation. 
Studies indicate that hollow microneedles can load volumes spanning from a few 
microliters up to 1.5 ml (Burton et al. 2011; McAllister et al. 2003). In particular 
Micronjet
®
 received FDA approval in February 2010 (http://www.nanopass.com). 
This device consists of four 450 µm-long hollow microneedles attached to a plastic 
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device that can be mounted on any conventional syringe. As such, this device could 
theoretically deliver any volume that has been previously loaded in the syringe. 
The Micronjet
®
 has been used for intradermal delivery of commercially available 
drug formulations including influenza vaccines, lidocaine and insulin, to human 
subjects and its application has been reported as effective, accurate and almost 
painless (http://www.nanopass.com ; Van Damme et al. 2009). Therefore, the use of 
a similarly designed microneedle device would enable administration of the existing 
formulation Botox
®
 using the same dilutions and injection volumes that are currently 
used in the clinical setting. By using such devices, loading of Botox
®
 could be 
performed by using a conventional syringe. This would avoid the need for the 
manual load process used for the MD, as discussed in this Thesis, and thus would 
reduce the variability associated with the loading process. 
Liquid loaded PMDs facilitated rapid delivery (within seconds) of high molecular 
weight molecules to the epidermal/dermal layer of human skin. Experiments reported 
in Chapter 4 indicated that the high molecular weight molecule β-gal, used as a 
model for BTX A, diffused readily through the more internal layers of the dermis 
following incubation of the skin samples in organ culture. This therefore suggests 
that BTX A should diffuse to the therapeutic target (the eccrine sweat glands), once 
delivered intradermally by PMDs. 
However, the results did not indicate diffusion of the model protein to a skin depth, 
which would enable successful interaction of BTX A with the eccrine sweat glands. 
While those glands are located in the deep dermis, diffusion of the model protein 
following PMD application appeared to be restricted within the central portion of the 
dermis. Skin samples were incubated for a defined period (1 and ½ hours) in organ 
culture before being fixed in glutaraldehyde. The fixative prevents further migration 
of the protein within the tissue and therefore it is reasonable to assume that greater 
diffusion could have been observed if the samples had been incubated for longer 
periods (i.e., 12 hours or even days). Unfortunately, due to time constraints, it has not 
been possible to investigate the effect of the time on β-gal diffusion following 
delivery by PMDs. In the future, additional experiments are warranted in order to 
further investigate this parameter.  
In addition, evaluation of the diffusion of β-gal on treated samples relied on the 
visible detection of a blue insoluble product, i.e., the product of the reaction between 
the enzyme and its substrate, X-gal. As a consequence, the intensity of the staining 
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detected in the skin decreased from the microneedle application site (where the 
concentration of β-gal was maximal) to the more internal layer of the skin (where the 
enzymatic concentration was reduced). Protein may have reached deeper layers in 
the dermis, but the staining generated in these areas may not have been detectable. In 
the future, experiments could be performed by using more sensitive detection 
systems (e.g., fluorescently tagged proteins) in order to detect lower levels of protein 
and therefore greater diffusion. 
Moreover, studies assessing distribution of the eccrine sweat glands in the skin 
would also be useful. They would provide information of whether a protein, 
delivered to the skin by a PMD, would diffuse to a depth of the tissue that would 
allow interaction with the eccrine sweat glands. Several studies in the literature 
report the use of histological and immunohistological methodologies to visualize the 
sweat glands in cutaneous tissues (Saga 2001; Saga and Morimoto 1995). Such 
techniques rely on the detection of specific markers (usually enzymes or other 
proteins), which are abundantly expressed in the eccrine sweat glands. In the future, 
similar techniques could be employed in order to assess distribution of proteins 
delivered by PMDs in relation to the eccrine sweat glands in the skin.  
The design of the MDs employed would have to be tailored to the anatomical 
characteristics of the specific hyperhidrotic body site. Treatment of palmar/plantar 
PFHH would require the use of longer microneedles compared to facial or axillary 
PFHH, due to the increased thickness of the stratum corneum. Optical imaging 
methods such as optical coherence tomography (OCT) have been recently employed 
to characterise microneedle penetration in vivo in human subjects (Coulman et al. 
2011; Donnelly et al. 2011). In vivo data produced by the OCT system revealed real 
time imagining of morphological changes induced in the skin following microneedle 
insertion and provided a more accurate evaluation of microneedle penetration in 
comparison to conventional histological methods. In addition, it provided real time 
information of structural features of the skin, such as thickness of stratum corneum, 
epidermis and dermis and enabled visualisation of skin appendages such as sweat 
glands and pilosebaceous units. Therefore, this technique could be employed in the 
future to design MDs to target delivery of BTX A to specific regions of the skin at 
different anatomical sites, where skin thickness differs.  
In particular, optimal delivery of BTX A may have to be targeted within the central 
portion of the dermis, i.e., the region underlying the papillary dermis (located at the 
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interface between epidermis and dermis) to reduce systemic absorption of the 
medicament from the capillary network of the papillary layer and thus reduce 
depletion of the medicament in the underlying dermis. Moreover, it would prevent 
microneedles reaching larger blood vessels and nerve fibres located in the reticular 
layer (at the bottom of the dermis), thus reducing the invasiveness of the treatment, 
while enabling delivery of BTX A to a region of the skin which would be relatively 
close to the deep dermis where the sweat glands are located. On the contrary, if the 
toxin was to be delivered to the upper layer of the dermis it would have to migrate 
further from the application site in order to reach its therapeutic target and this may 
result in a delayed therapeutic effect or even reduced or absent effect (e.g., if the 
toxin failed to reach the glands or if the concentration of the toxin in proximity of the 
glands was too low to be effective). 
The two most common side effects associated with the administration of BTX A are 
pain and temporary weakness of the muscles adjacent to the injection site. While the 
former is caused by the penetration of the hypodermic needle into the skin, as well as 
by the extrusion of the liquid formulation by the needle, the latter is mainly 
determined by difficulty in selective delivery of the drug to the dermis using the 
traditional Mantoux technique. Due to the reduced dimensions of the microneedles, 
insertion of a MD into the skin should result in minimum pain and discomfort. This 
may possibly eliminate the need for local anaesthesia upon administration of BTX A, 
especially in highly innervated anatomic sites such as the palms of the hands and 
soles of the feet. BTX A administration by microneedles may also reduce the 
occurrence of muscle weakness. The Mantoux technique is technically challenging to 
perform, as the hypodermic needle has to be oriented almost parallel to the skin 
surface due to its relative high length. Conversely microneedles can be applied 
perpendicularly into the skin. This would likely reduce the risk for accidental 
delivery of the toxin to non-targeted sites (i.e. the muscles) as it would ease placing 
and maintaining the microneedles within the dermis. However, a certain variability 
of the delivery depth could be expected due to the difference in skin thickness 
between different areas of the body in the same individual (intra-variability) as well 
as the difference in skin thickness existing between different individuals (inter-
variability). In addition the diffusion pattern of the delivered toxin would be difficult 
to predict and therefore muscle weakness may still be an adverse effect with 
microneedles. However, the capability of microneedles to facilitate targeted 
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intradermal delivery of vaccines has extensively been reported and thus similar 
results may be expected for BTX A administration (Koutsonanos DG 2009; Van 
Damme et al. 2009; Widera et al. 2006). 
With the aim of confirming the findings highlighted for the model protein β-gal, 
experiments reported in Chapter 5 were conducted using the protein BTX A. 
Working with BTX A was associated with number of technical issues. First of all, 
BTX A is one of the most toxic substances known (Gill 1982). As such, laboratory 
use of the toxin in high doses requires specific containment facilities and poses risk 
to the researcher. Experiments could be performed using therapeutic doses of BTX A 
(in the form of the commercial preparation Vistabel
®
-BTX A 2.5 ng), without safety 
concerns. However, in studies detailed in this Thesis, BTX A could not be detected 
using standard laboratory methodologies due to the extremely low dose of 
medicament contained in the commercial preparation. Further studies were 
performed using higher (non-therapeutic) doses of the detoxified form of BTX A 
(formaldehyde inactivated BTX A, i.e botulinum toxoid A (BT A)). BT A loaded 
PMDs were applied into the skin and the deposition pattern of the protein was 
investigated by IHC. Although the data suggested the presence of BT A in the treated 
skin, BT A detection by IHC was not particularly robust. Therefore, delivery and 
deposition of BT A via PMDs were further investigated following conjugation of the 
protein to an appropriate fluorophore. PMDs were shown to uniformly accommodate 
the fluorescent formulation and to successfully deliver BT A to the dermis of human 
skin.  
Despite this, eccrine sweat glands were not localised within the tissue in our 
experiments. As a consequence it was not possible to establish with certainty whether 
the protein delivered by a PMD migrated to its therapeutic target and, most 
importantly, whether this would have resulted in a therapeutic effect. Delivery of the 
toxin in proximity of its therapeutic target may not necessarily represent an 
indication of its efficacy. Induction of a therapeutic effect would be the result of a 
complex series of events including: migration of the toxin to the secretory portion of 
the glands (located at the bottom of the dermis), internalization of the toxin within 
the cholinergic fibres, cleavage of specific SNARE complex proteins within the 
cytosol of the nerve cells and finally inhibition of the release of Ach into the synaptic 
space. 
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Evaluation of the occurrence of all these events can only be determined by 
performing in vivo studies. Due to the lack of animal models for PFHH, efficacy of 
BTX A is usually assessed in vivo in human subjects by measuring the level of 
anhidrosis by qualitative (i.e. quality of life questionnaires assessing how the 
treatment has been perceived by the patient and whether or not it has improved 
his/her quality of life) and quantitative methods (including the gravimetry and the 
Minor starch-iodine tests) (Trindade de Almeida et al. 2007). 
Given these considerations, clinical studies would certainly be required in the future 
in order to evaluate the effectiveness of a microneedle-mediated BTX A 
administration for the treatment of PFHH. Clinical trials could be carried out as a 
means to compare efficacy of Botox
®
 when administered by standard hypodermic 
needles and MDs. If patients with palmar PFHH were to be treated, microneedles 
could be applied to one palm and standard injections to the other. Efficacy of the 
treatment could be assessed by evaluating the difference in sweat production before 
and after the treatment on each palm. As sweating reduction is usually observed 1-2 
weeks following Botox
®
 administration, evaluation of the therapeutic effect could be 
assessed 7 and 14 days after the treatment and then every month for a follow up 
period of at least 4 months, which is usually the time at which the therapeutic effect 
starts to decrease. Microneedles could be applied by using the injection grid currently 
used for ID injections in such a way as to mimic Botox
®
 administration by 
conventional hypodermic needles. As the PMDs used within this research project 
would not guarantee loading of effective and reproducible doses of BTX A, it may be 
more appropriate, at this stage, to use hollow microneedles. The use of hollow 
microneedles may not require reformulation of the botulinum product and would 
enable delivery of the same volumes as standard ID injections (i.e., 100 µl per 
injection site). In this way Botox
®
 could be administered at both sites (i.e., one vial 
per each palm) at the same dilution (i.e., by using a volume of 4 ml of saline solution 
to reconstitute each Botox
®
 vial) and this would allow accurate comparison of the 
two delivery methods. Clinical studies would also provide crucial information 
regarding invasiveness and safety of the microneedle application in comparison to 
conventional hypodermic needles and would enable a more comprehensive 
understanding of the advantages of the delivery tool. 
Beside clinical trials, in vitro studies could be used in the future to assess the activity 
of BTX A in the skin once delivered by MDs and could possibly be used in 
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conjunction with in vivo studies. As reported in Chapter 5, numerous efforts have 
been made to develop sensitive in vitro assays for the detection of BTX A, as a 
means to replace the gold standard mouse bioassay. In particular, Pellett et al. (2007) 
described the use of a neuronal-cell based immunoassay which is able to detect doses 
of BTX A as small as 1.5 pg (for comparison, the mouse bioassay can detect ~10 pg 
of BTX A). Within this assay, neuronal cells obtained through homogenization of rat 
spinal cords were incubated with different dilutions of BTX A. Detection of the toxin 
was subsequently achieved by assessing the presence of cleaved SNAP 25 proteins in 
the cell lysate by Western blot analysis. SNAP 25 is the substrate of BTX A in the 
cholinergic fibres and therefore detection of cleaved proteins provided a clear 
indication of the functionality of the toxin. As a consequence, one may assume that a 
similar assay could be employed to assess the activity of BTX A once delivered to 
the skin from a MD. Moreover, as the presence of cleaved proteins is directly 
proportional to the dose of BTX A present in a given sample, this method might 
provide information of the quantity of toxin delivered in the skin (i.e., by comparing 
the intensity of the signal of the protein bands against standard concentration of the 
toxin).  
However, future application of this methodology would require the use of active 
toxin. As mentioned above, the use of BTX A in doses higher than the therapeutic 
ones is associated with a series of safety concerns. For this reason, this method could 
only be performed if therapeutic preparations of BTX A, i.e. containing only 5 ng of 
medicament, were to be used. 
As this assay is able to detect BTX A doses of 1.5 pg, one would have to ensure that 
microneedles would load and thus deliver doses of toxin which would be above this 
LOD. As previously mentioned, therapeutic doses of BTX A range between 0.1-0.25 
ng per each administration site. Therefore, if microneedles able to deliver effective 
doses of BTX A were to be used (i.e. PMDs containing an increased number of 
pocketed microneedles or hollow microneedles), this methodology could be 
employed to detect the presence of active BTX A within the skin. Although 
potentially useful in the future, this methodology may be technically challenging as it 
would rely on detection of extremely low doses of proteins (generated by the 
proteolytic activity of BTX A) released form nervous cells in such complex matrix as 
the human skin. 
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Alternatively, Ellies et al. (2000) investigated the activity of Botox
®
 in ex vivo 
excised parotid glands by assessing variation in production of the enzyme 
acetylcholinesterase (AchE). The role of this enzyme resides in the depletion of 
excess of Ach from the synaptic space. As a consequence, application of BTX A 
results in reduction of the synthesis and activity of this enzyme through inhibition of 
the release of Ach from the cholinergic nerves. Within this study the parotid glands 
of living rats were locally injected with BTX A (Botox
®
) and subsequently excised 
(at specific time intervals) and processed into sections. Detection of the AchE 
enzyme was performed by IHC and the intensity of staining was assessed against 
untreated samples in order to determine the effect of BTX A on the glands. It may be 
assumed that a similar methodology could be used in the future to investigate the 
activity of BTX A therapeutic formulations in the eccrine sweat glands in human 
skin. This method would provide indication of the functionality of the toxin but it 
may be practically easier to perform as it would not require cell extraction from the 
skin tissue. 
As a final note it is worth considering the effect that microneedle-mediated 
administration would have of the cost of BTX A treatment. Patients who have not 
responded to over the counter antiperspirants (the first-line therapy for PFHH) are 
usually referred by their general practitioners (GP) to a dermatologist for BTX A 
treatment in hospitals or clinics within secondary care (http://www.nhs.uk 2011b). 
However, due to the high cost of the procedure, the availability of BTX A on the 
NHS is extremely variable and it generally depends on the policy of the local 
primary care trust. As a consequence, many patients are forced to approach private 
clinics to access the treatment. Cost for private treatment varies considerably 
depending on the area of the body to be treated. Larger sites require more injections 
and are therefore associated with higher costs (e.g., treating the forehand usually 
costs around £150 while injecting both axillae costs between £350-600 
(http://www.healthcentre.org.uk)). In addition, due to the large number of injections 
required to treat each hyperhidrotic area and the need to administer local anaesthesia 
to certain anatomic sites, BTX A administration is also time consuming for 
consultants, with a consequent additional effect on the total cost of the procedure. 
Cost of the treatment is furthermore increased by the need to repeat the procedure 
several times a year due to the temporary effect of BTX A on the sweat glands.  
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BTX A administration by microneedles is expected to be technically easier compared 
to the Mantoux technique, due to the reduced length of the needles. Furthermore, 
microneedle application may also be safer as it is less likely to be associated with 
unwanted delivery of the toxin to non-targeted sites (i.e. the muscles) and will 
hopefully be blood free. As a consequence, a microneedle-mediated BTX A 
administration might be delivered by less trained personnel such general practitioners 
or nurses within primary care. This would reduce secondary care cost for BTX A 
treatment and would also be advantageous for the patients due to the improved 
accessibility to primary care. However, in order for microneedles to replace current 
intradermal injections, we would have to ensure that microneedle mediated BTX A 
administration would be at least as safe and effective as standard hypodermic 
needles. Those two aspects can only be determined in clinical studies. 
 
6.2 Concluding remarks 
PMDs can be loaded after one single immersion into a Botox
® 
like formulation. This 
suggested that PMDs could be suitable as a means to successfully load existing 
Botox
®
 formulations without the need to add excipients and reformulate.  
PMDs containing a large numbers of microneedles (i.e., at least 25  pocketed 
microneedles) would have the capacity to accommodate therapeutic doses of the 
Botox
® 
preparation when re-constituted with volumes in the microlitre range. 
However, due to the inherent level of variability associated with the loading process, 
reproducible and efficient dose loading is not guaranteed. Robustly engineered 
loading methodologies and/or specifically tailored PMD designs would have to be 
employed in future to reduce this variability. Different microneedle designs, i.e. 
hollow microneedles, could also be employed in the future to increase microneedle 
loading capacity and potentially reduce the variability associated with the loading 
process.  
Liquid loaded PMDs enabled rapid delivery of high molecular weight molecules to 
the dermis of human skin. The capability of proteins to readily diffuse within the 
dermis was also demonstrated. This suggests that following delivery of BTX A from 
a liquid loaded PMD, the medicament should migrate through the tissue to its 
therapeutic target (the sweat glands) located in the deep dermis. 
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Therapeutic doses of BTX A could not be detected by standard laboratory 
techniques. IHC analysis of human skin treated with PMDs liquid loaded with 
botulinum toxoid A (BT A) suggested successfully delivery of the toxoid into the 
epidermal and dermal layer of the tissue. IHC data were supported by fluorescence 
microscopy analysis of skin samples treated with BT A following its conjugation 
with an appropriate fluorophore. 
This study has demonstrated that PMDs are able to accommodate and deliver liquid 
formulations into human skin and that BTX A (Botox
®
)-loaded microneedle devices 
are a feasible minimally invasive delivery system for this macromolecular 
therapeutic. Future studies are now required in order to optimise a microneedle 
device that is most suited to clinical practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
222 
 
Publications, abstracts and conference proceedings 
 
Torrisi B.M., Anstey A., Zarnitsyn V., Prausnitz, M., Birchall, J.C., Coulman S.A.  
Pocketed microneedles for rapid delivery of a liquid state botulinum toxin A formulation into 
human skin (submitted to The Journal of Controlled Release). 
 
Torrisi B.M., Anstey A., Pearton M., Zarnitsyn V., Prausnitz, M. Birchall, J.C, Coulman S.A. 
Determining the feasibility of a microneedle delivery system for intradermal botulinum toxin 
administration (2012), 2
nd
 International Microneedle Conference, Cork, Ireland (UK) (5 minute 
oral and poster presentation). 
 
Torrisi B.M., Anstey A., Pearton M., Zarnitsyn V., Prausnitz, M. Birchall, J.C, Coulman S.A. 
Evaluating the capability of a pocketed microneedle device to facilitate delivery of potent 
therapeutic proteins into human skin (2011), Welsh School of Pharmacy Post-Graduate Research 
Day, University of Cardiff, UK (oral presentation). 
 
Torrisi B.M., Anstey A., Pearton M., Zarnitsyn V., Prausnitz, M. Birchall, J.C, Coulman S.A. 
Evaluating the capability of a pocketed microneedle device to facilitate delivery of potent 
therapeutic proteins into human skin (2010), Cardiff Institute of Tissue Engineering and Repair 
(CITER) 9th Annual Meeting and Arthritis Research UK Biomechanic and Bioengineering 
Centre 1st Annual Meeting, Eastwood Park, Falfield, Gloucestershire, UK (oral presentation). 
 
Torrisi B.M., Anstey A., Pearton M., Zarnitsyn V., Prausnitz, M. Birchall, J.C, Coulman S.A. 
Solid and pocketed microneedle devices for the delivery of therapeutic proteins into human skin 
(2010), United Kingdom and Ireland Controlled Release Society (UKICRS) Symposium, 
University of Hertfordshire, UK (poster presentation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
223 
 
Bibliography 
 
Abell, E. and Morgan, K. 1974. Treatement of idiophatic hyperhidrosis by 
glycopyrronium bromide and tap water iontophoresis. British Journal of 
Dermatology 91(1), pp. 87-91. 
 
Alam, M. et al. 2002. Pain associated with injection of botulinum A exotoxin 
reconstituted using isotonic sodium chloride with and without preservative: a double-
blind, randomized controlled trial. Archives of Dermatology 138(4), pp. 510-514. 
 
Alarcon, J. B. et al. 2007. Preclinical evaluation of microneedle technology for 
intradermal delivery of influenza vaccines. Clinical and Vaccine Immunology 14(4), 
pp. 375-381. 
 
Alekseev, S. I. and Ziskin, M. C. 2007. Human skin permittivity determined by 
millimeter wave reflection measurements. Bioelectromagnetics 28(5), pp. 331-339. 
 
Ameri, M. et al. 2009. Demonstrated solid-state stability of parathyroid hormone 
PTH(1-34) coated on a novel transdermal microprojection delivery system. 
Pharmaceutical Research 26(11), pp. 2454-2463. 
 
Ameri, M. et al. 2010. Parathyroid hormone PTH(1-34) formulation that enables 
uniform coating on a novel transdermal microprojection delivery system. 
Pharmaceutical Research 27(2), pp. 303-313. 
 
Amorij, J. P. et al. 2008. Development of stable influenza vaccine powder 
formulations: challenges and possibilities. Pharmaceutical Research 25(6), pp. 1256-
1273. 
 
Amorij, J. P. et al. 2007. Rational design of an influenza subunit vaccine powder 
with sugar glass technology: preventing conformational changes of haemagglutinin 
during freezing and freeze-drying. Vaccine 25(35), pp. 6447-6457. 
 
Amorosa, M. 1998a. Forme farmaceutiche a rilascio modificato. In: Amorosa, M. ed. 
Principi di tecnica farmaceutica. Bologna: Librearia Universitaria L. Tinarelli. pp. 
510-538. 
 
Amorosa, M. 1998b. Preparati per uso dermatologico In: Amorosa M. ed. Principi di 
tecnica farmaceutica. Bologna: Libreria Universitaria L. Tinarelli. pp. 367-402. 
 
Andrade, P. C. et al. 2011. Use of iontophoresis or phonophoresis for delivering 
onabotulinumtoxinA in the treatment of palmar hyperidrosis: a report on four cases. 
Anais Brasileiros De Dermatologia 86(6), pp. 1243-1246. 
 
Andrianov, A. K. et al. 2009. Poly[di(carboxylatophenoxy)phosphazene] is a potent 
adjuvant for intradermal immunization. Proceedings of the National Academy of 
Sciences of the United States of America 106(45), pp. 18936-18941. 
 
224 
 
Aoki, K. R. et al. 2006. Using translational medicine to understand clinical 
differences between botulinum toxin formulations. European Journal of Neurology 
13 Suppl 4, pp. 10-19. 
 
Arnon, S. S. et al. 2001. Botulinum toxin as a biological weapon: medical and public 
health management. The Journal of the American Medical Association 285(8), pp. 
1059-1070. 
 
Arora, A. et al. 2008. Micro-scale devices for transdermal drug delivery. 
International Journal of Pharmaceutics 364(2), pp. 227-236. 
 
Atkins, J. L. and Butler, P. E. M. 2002. Hyperhidrosis: A review of current 
management. Plastic and Reconstructive Surgery 110(1), pp. 222-228. 
 
Atkinson, J. L. D. et al. 2011. Endoscopic transthoracic limited sympathotomy for 
palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. 
Mayo Clinic Proceedings 86(8), pp. 721-729. 
 
Bains, B. K. 2010. Novel pDNA particles for pulmonary administration. Ph.D. 
Thesis, Cardiff University.  
 
Bajaj, V. and Langtry, J. A. A. 2007. Use of oral glycopyrronium bromide in 
hyperhidrosis. British Journal of Dermatology 157(1), pp. 118-121. 
 
Baroni, A. et al. 2012. Structure and function of the epidermis related to barrier 
properties. Clinics in Dermatology 30(3), pp. 257-262. 
 
Barry, B. W. 1983a. Skin trasport. In: Barry, B. W. ed. Dermatological formulations. 
Percutaneous absorption. New York: Marcel Dekker, Inc., pp. 95-126. 
 
Barry, B. W. 1983b. Structure, function, diseases, and topical treatment of human 
skin. In: Barry, B. W. ed. Dermatological formulations. Percutaneous absorption. 
New York: Marcel Dekker. Inc., pp. 1-48. 
 
Beckstead, J. H. 1994. A Simple technique for preservation of fixation-sensitive 
antigens in paraffine-embedded tissues. Journal of Histochemistry & Cytochemistry 
42(8), pp. 1127-1134. 
 
Benecke, R. et al. 2011. Botulinum type A toxin complex for the relief of upper back 
myofascial pain syndrome: how do fixed-location injections compare with trigger 
point-focused injections? Pain Medicine 12(11), pp. 1607-1614. 
 
Benohanian, A. 2007. Needle-free anaesthesia prior to botulinum toxin type A 
injection treatment of palmar and plantar hyperhidrosis. British Journal of 
Dermatology 156(3), pp. 593-596. 
 
Benson, H. A. E. and Namjoshi, S. 2008. Poteins and peptides: strategies for delivery 
to and across the skin. Journal of Pharmaceutical Sciences 97(9), pp. 3591-3610. 
 
225 
 
Beran, J. et al. 2009. Intradermal influenza vaccination of healthy adults using a new 
microinjection system: a 3-year randomised controlled safety and immunogenicity 
trial. Biomed Central Medicine 7(13), pp. 1-15. 
 
Birchall, J. C. et al. 2005. Cutaneous DNA delivery and gene expression in ex vivo 
human skin explants via wet-etch micro-fabricated micro-needles. Journal of Drug 
Targeting 13(7), pp. 415-421. 
 
Birchall, J. C. 2006. Microneedle array technology: the time is right but is the 
science ready? Expert Review of Medical Devices 3(1), pp. 1-4. 
 
Blake, T. D. and Rushak, K. J. 1997. Wetting: static and dynamic contact lines. In: 
Kistler, S.F., Schweizer, P. M. eds. Liquid film coating. Scientific principles and 
their technological implications. London: Chapman and Hall, pp. 63-66. 
 
Borodic, G. E. et al. 1994. Histologic assessment of dose-related diffusion and 
muscle fiber response after therapeutic botulinum A toxin injections. Movement 
disorders: official journal of the Movement Disorder Society 9(1), pp. 31-39. 
 
Bovell, D. L. et al. 2001. Ultrastructure of the hyperhidrotic eccrine sweat gland. 
British Journal of Dermatology 145(2), pp. 298-301. 
 
Brandt, F. 2011. Efficacy and safety evaluation of a novel botulinum toxin topical 
gel for the treatment of moderate to severe lateral canthal lines. Dermatologic 
Surgery 37(7), pp. 2111-2118. 
 
Burton, S. A. et al. 2011. Rapid intradermal delivery of liquid formulations using a 
hollow microstructured array. Pharmaceutical Research 28(1), pp. 31-40. 
 
Byl, N. N. 1995. The use of ultrasound as an enhancer for transcutaneous drug-
delivery – phonophoresis. Physical Therapy 75(6), pp. 539-553. 
 
Cai, S. et al. 2007. Botulism diagnostics: from clinical symptoms to in vitro assays. 
Critical Reviews in Microbiology 33(2), pp. 109-125. 
 
Campanati, A. et al. 2004. Local neural block at the wrist for treatment of palmar 
hyperhidrosis with botulinum toxin: technical improvements. Journal of the 
American Academy of Dermatology 51(3), pp. 345-348. 
 
Campanati, A. et al. 2003. Quality-of-life assessment in patients with hyperhidrosis 
before and after treatment with botulinum toxin: results of an open-label study. 
Clinical Therapeutics 25(1), pp. 298-308. 
 
Carli, L. et al. 2009. Assay of diffusion of different botulinum neurotoxin type a 
formulations injected in the mouse leg. Muscle & Nerve 40(3), pp. 374-380. 
 
Carpenter, C. L. et al. 1965. Dermojet histopathological artifacts, Archives of 
Dermatology 92(3), pp. 304. 
 
226 
 
Carruthers, A. and Carruthers, J. 2008. Botulinum toxin products overview. Skin 
therapy letter 13(6), pp. 1-4. 
 
Chao, H.-Y. et al. 2004. A highly sensitive immuno-polymerase chain reaction assay 
for Clostridium botulinum neurotoxin type A. Toxicon 43(1), pp. 27-34. 
 
Chen, B. T. 1983. Investigation of the solvent-evaporation effect on spin coating of 
thin films. Polymer Engineering & Science (23), pp. 399-403. 
 
Chen, X. et al. 2012.Rapid kinetics to peak serum antibodies is achieved following 
influenza vaccination by dry-coated densely packed microprojections to skin. 
Journal of Controlled Release 158(1), pp 78-84. 
 
Chen, X. et al. 2011. Improving the reach of vaccines to low-resource regions, with a 
needle-free vaccine delivery device and long-term thermostabilization. Journal of 
Controlled Release 152(3), pp. 349-355. 
 
Chen, X. et al. 2009. Dry-coated microprojection array patches for targeted delivery 
of immunotherapeutics to the skin. Journal of Controlled Release 139(3), pp. 212-
220. 
 
Chen, X. F. et al. 2010. Improved DNA vaccination by skin-targeted delivery using 
dry-coated densely-packed microprojection arrays. Journal of Controlled Release 
148(3), pp. 327-333. 
 
Chow, A. and Wilder-Smith, E. P. 2009. Effect of transdermal botulinum toxin on 
sweat secretion in subjects with idiopathic palmar hyperhidrosis. British Journal of 
Dermatology (160)3, pp 721-722. 
 
Collins, A. and Nasir, A. 2010. Topical botulinum toxin. The Journal of Clinical and 
Aesthetic Dermatology 3(3), pp. 35-39. 
 
Corbett, H. J. et al. 2010. Skin vaccination against cervical cancer associated human 
papillomavirus with a novel micro-projection array in a mouse Model. PloS One 
5(10), pp 1-9. 
 
Cormier, M. et al. 2004. Transdermal delivery of desmopressin using a coated 
microneedle array patch system. Journal of Controlled Release 97(3), pp. 503-511. 
 
Coulman, S. A. 2006. Gene delivery to human skin using microneedle arrays. Ph.D. 
Thesis, Cardiff University.  
 
Coulman, S. A. et al. 2009. Microneedle mediated delivery of nanoparticles into 
human skin. International Journal of Pharmacy Practice 366(1-2), pp. 190-200. 
 
Coulman, S. A. et al. 2011. In vivo, in situ imaging of microneedle insertion into the 
skin of human volunteers using optical coherence tomography. Pharmaceutical 
Research 28(1), pp. 66-81. 
 
227 
 
Crichton, M. L. et al. 2010. The effect of strain rate on the precision of penetration of 
short densely-packed microprojection array patches coated with vaccine. 
Biomaterials 31(16), pp. 4562-4572. 
 
Crommelin, D. J. et al. 2003. Shifting paradigms: biopharmaceuticals versus low 
molecular weight drugs. International Journal of Pharmaceutics 266(1-2), pp. 3-16. 
 
Daddona, P. et al. 2011. Parathyroid Hormone (1-34) coated microneedle patch 
system: clinical pharmacokinetics and pharmacodynamics for treatment of 
osteoporosis. Pharmaceutical Research 28(1), pp. 159-165. 
 
Dahl, J. C. and Glent-Madsen, L. 1989. Treatment of hyperhidrosis manuum by tap 
water iontophoresis. Acta Dermato-Venereologica 69(4), pp. 346-348. 
 
Das, C. P. et.al. 2009. Treatment of focal hand dystonia. In: Truong, D. D., et al. eds. 
Manual of botulinum toxin therapy.  New York: Cambridge University Press, pp. 61-
75. 
 
Davarian, S. et al. 2008. Effect and persistency of botulinum toxin iontophoresis in 
the treatment of palmar hyperhidrosis. Australasian Journal of Dermatology 49(2), 
pp. 75-79. 
 
Davis, S. P. et al. 2004. Insertion of microneedles into skin: measurement and 
prediction of insertion force and needle fracture force. Journal of Biomechanics 
37(8), pp. 1155-1163. 
 
De Almeida, A. R. T. et al. 2001. Improving botulinum toxin therapy for palmar 
hyperhidrosis: wrist block and technical considerations. Dermatologic Surgery 27(1), 
pp. 34-36. 
 
De Almeida, A. R. T. et al. 2011. Handling Botulinum toxins: an updated literature 
review. Dermatologic Surgery 37(11), pp. 1553-1565. 
 
De Bree, R. et al. 2009. Repeated Botulinum toxin type A injections to treat patients 
with Frey Syndrome. Archives of Otolaryngology-Head & Neck Surgery 135(3), pp. 
287-290. 
 
De Paiva, A. et al. 1999. Functional repair of motor endplates after botulinum 
neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve 
sprouts and their parent terminals. Proceedings of the National Academy of Sciences 
of the United States of America 96(6), pp. 3200-3205. 
 
Dean, C. H. et al. 2005. Cutaneous delivery of a live, attenuated chimeric flavivirus 
vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. 
Human Vaccines 1(3), pp. 106-111. 
 
Denys, P. et al. 2012. Efficacy and safety of low doses of onabotulinumtoxinA for 
the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, 
randomised, placebo-controlled dose-ranging study. European Urology 61(3), pp. 
520-529. 
228 
 
 
Dobson, L. et al. 2010. Image analysis as an adjunct to manual HER-2 
immunohistochemical review: a diagnostic tool to standardize interpretation. 
Histopathology 57(1), pp. 27-38. 
 
Doellgast, G. J. 1987. Enzyme-linked coagulation assay. IV. Sensitive sandwich 
enzyme-linked immunosorbent assays using Russell's viper venom factor X 
activator-antibody conjugates. Analytical Biochemistry 167(1), pp. 97-105. 
 
Doellgast, G. J. et al. 1993. Sensitive enzyme-linked immunosorbent assay for 
detection of Clostridium botulinum neurotoxins A, B, and E using signal 
amplification via enzyme-linked coagulation assay. Journal of Clinical Microbiology 
31(9), pp. 2402-2409. 
 
Doft, M. A. et al. 2012. Treatment of hyperhidrosis with Botulinum toxin. Aesthetic 
Surgery Journal 32(2), pp. 238-244. 
 
Dolianitis, C. et al. 2004. Iontophoresis with glycopyrrolate for the treatment of 
palmoplantar hyperhidrosis. The Australasian Journal of Dermatology 45(4), pp. 
208-212. 
 
Dolly, J. O. and Aoki, K. R. 2006. The structure and mode of action of different 
botulinum toxins. European Journal of Neurology 13(4), pp. 1-9. 
 
Donnelly, R. F. et al. 2011. Design, optimization and characterisation of polymeric 
microneedle arrays prepared by a novel laser-based micromoulding technique. 
Pharmaceutical Research 28(1), pp. 41-57. 
 
Dressler, D. 2009a. Routine use of Xeomin in patients previously treated with Botox: 
long term results. European Journal of Neurology 16(2), pp. 2-5. 
 
Dressler, D. 2012. Five-year experience with incobotulinumtoxinA (Xeomin (R)): 
the first botulinum toxin drug free of complexing proteins. European Journal of 
Neurology 19(3), pp. 385-389. 
 
Dressler, D. et al. 2002. Botulinum toxin type B for treatment of axillar 
hyperhidrosis. Journal of Neurology 249(12), pp. 1729-1732. 
 
Dressler, D. and Bigalke, H. 2009. Pharmacology of botulinum toxin drugs. In: 
Truong, D. D., et al. eds. Manual of Botulinum toxin therapy. New York Cambridge 
University Press, pp. 13-22. 
 
Dressler, D. et al. 2008. Equivalent potency of Xeomin
®
 and BOTOX
®
. Toxicon 51, 
pp. 10-10. 
 
Dunn, M. 2002. Detection of proteins in polyacrylamide gels by silver staining. In: 
Walker, J., M. ed. The protein protocols handbook. New Jersey: Human Press. pp. 
265-271. 
 
229 
 
Egawa, M. et al. 2007. In vivo estimation of stratum corneum thickness from water 
concentration profiles obtained with raman spectroscopy. Acta Dermato-
Venereologica 87(1), pp. 4-8. 
 
Eisele, K. H. et al. 2011. Studies on the dissociation of botulinum neurotoxin type A 
complexes. Toxicon 57(4), pp. 555-565. 
 
Eisele, K. H. and Taylor, H. V. 2008. Dissociation of the 900 kDa neurotoxin 
complex from C. botulinum under physiological conditions. Toxicon 51(1), pp. 10-
10. 
 
Ekong, T. A. et al. 1995. Immunological detection of Clostridium botulinum toxin 
type A in therapeutic preparations. Journal of Immunological Methods 180(2), pp. 
181-191. 
 
Elias, P. M. 2005. Stratum corneum defensive functions: An integrated view. Journal 
of Investigative Dermatology 125(2), pp. 183-200. 
 
Ellies, M. et al. 2000. The effect of local injection of botulinum toxin A on the 
parotid gland of the rat: An immunohistochemical and morphometric study. Journal 
of Oral and Maxillofacial Surgery 58(11), pp. 1251-1256. 
 
Ellis, R. A. 1965. Fine structure of the myoepithelium of the eccrine sweat glands of 
man. The Journal of Cell Biology 27(3), pp. 551-563. 
 
Erbguth, F. J. 2009. The pretherapeutic history of botulinum toxin. In: Truong D. D. 
et al. eds. Manual of Botulium toxin therapy. Cambridge: Cambridge University 
Press, pp 1-7. 
 
Farrugia, M. K. and Nicholls, E. A. 2005. Intradermal botulinum A toxin injection 
for axillary hyperhydrosis. Journal of Pediatric Surgery 40(10), pp. 1668-1669. 
 
Feily, A. et al. 2011. A succinct review of botulinum toxin in dermatology; update of 
cosmetic and noncosmetic use. Journal of Cosmetic Dermatology 10(1), pp. 58-67. 
 
Fernando, G. J. et al. 2010. Potent immunity to low doses of influenza vaccine by 
probabilistic guided micro-targeted skin delivery in a mouse model. PloS One 5(4), 
pp 1-11. 
 
Forch  R., S. H. and Jenkins A. T. A. 2009. Appendix C. Contact angle goniometry. 
In: Forch R., S. H. and Jenkins A. T. A. eds. Surface design: applications in 
bioscience and nanotechnology. Weinheim: Wiley-VCH, pp. 471-475. 
 
Foster K., B. H., Aoki R. 2006. Botulinum neurotoxin - From laboratory to bed side. 
Neurotoxicity Research 9(2, 3), pp. 133-140. 
 
Fowler, A. V. and Zabin, I. 1977. Amino Acid Sequence of β-Galactosidase of 
Escherichia Coli. Proceedings of the National Academy of Science of the United 
States of America 74(4), pp. 1507-1510. 
 
230 
 
Frevert, J. 2010. Content of botulinum neurotoxin in Botox
®
/Vistabel
®
, 
Dysport
®
/Azzalure
®
 and Xeomin
®
/Bocouture
®
. Drugs in R&D 10(2), pp. 67-73. 
 
Fuchs, E. 1990. Epidermal differentiation – the bare essentials. Journal of Cell 
Biology 111(6), pp. 2807-2814. 
 
Fukushima, K. et al. 2011. Two-layered dissolving microneedles for percutaneous 
delivery of peptide/protein drugs in rats. Pharmaceutical Research 28(1), pp. 7-21. 
 
Garland, M. J. et al. 2012. Dissolving polymeric microneedle arrays for electrically 
assisted transdermal drug delivery. Journal of Controlled Release 159(1), pp. 52-59. 
 
Geddoa, E. et al. 2008. The successful use of botulinum toxin for the treatment of 
nasal hyperhidrosis. International Journal of Dermatology 47(10), pp. 1079-1080. 
 
German, W. J., Stanfield, C. L. 2005. The immune system. In: German, W. J., 
Stanfield, C. L. eds Principles of human physiology. 1st ed. San Francisco: Benjamin 
Cummings, pp. 726-736. 
 
Gerstel, M., S. and Place, V., A. 1976. United States Patent 3964482: Drug delivery 
device. Available at: http://www.freepatentsonline.com/3964482.html [Accessed: 
2nd June 2010]  
 
Ghalamkarpour, F. et al. 2010. Supraciliary wrinkles and botulinum toxin A. Clinical 
and Experimental Dermatology 35(4), pp. 388-391. 
 
Gill, D. M. 1982. Bacterial toxins: a table of lethal amounts. Microbiological 
Reviews 46(1), pp. 86-94. 
 
Gill, H. S. et al. 2008. Effect of microneedle design on pain in human volunteers. The 
Clinical Journal of Pain 24(7), pp. 585-594. 
 
Gill, H. S. and Prausnitz, M. R. 2007a. Coated microneedles for transdermal 
delivery. Journal of Controlled Release 117(2), pp. 227-237. 
 
Gill, H. S. and Prausnitz, M. R. 2007b. Coating formulations for microneedles. 
Pharmaceutical Research 24(7), pp. 1369-1380. 
 
Gill, H. S. and Prausnitz, M. R. 2008. Pocketed microneedles for drug delivery to the 
skin. The Journal of Physics and Chemistry of Solids 69(5-6), pp. 1537-1541. 
 
Gill, H. S. et al. 2010. Cutaneous vaccination using microneedles coated with 
hepatitis C DNA vaccine. Gene Therapy 17(6), pp. 811-814. 
 
Glaser, D. A. et al. 2007a. Facial hyperhidrosis: best practice recommendations and 
special considerations. Cutis 79(5), pp. 29-32. 
 
Glaser, D. A. et al. 2007b. Palmar and plantar hyperhidrosis: best practice 
recommendations and special considerations. Cutis 79(5), pp. 18-28. 
 
231 
 
Glaser, D. A. et al. 2007c. Primary focal hyperhidrosis: scope of the problem. Cutis 
79(5), pp. 5-17. 
 
Glogau, R. G. 2007. Topically applied botulinum toxin type A for the treatment of 
primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled 
study. Dermatologic Surgery 33(1), pp. 76-80. 
 
Grate, J. W. et al. 2009. Renewable surface fluorescence sandwich immunoassay 
biosensor for rapid sensitive botulinum toxin detection in an automated fluidic 
format. The Analyst 134(5), pp. 987-996. 
 
Grate, J. W. e. a. 2010. Advances in assays and analytical approaches for botulinum-
toxin detection. Trends in Analytical Chemistry 29(10), pp. 1137-1156. 
 
Gregoriou, S. et al. 2010. Effects of Botulinum toxin-A therapy for palmar 
hyperhidrosis in plantar sweat production. Dermatologic Surgery 36(4), pp. 496-498. 
 
Griffith, K. L. and Wolf, R. E., Jr. 2002. Measuring beta-galactosidase activity in 
bacteria: cell growth, permeabilization, and enzyme assays in 96-well arrays. 
Biochemical and Biophysical Research Communications 290(1), pp. 397-402. 
 
Grunfeld, A. et al. 2009. Botulinum toxin for hyperhidrosis a review. American 
Journal of Clinical Dermatology 10(2), pp. 87-102. 
 
Gulec, A. T. 2012. Dilution of botulinum toxin A in lidocaine vs. in normal saline for 
the treatment of primary axillary hyperhidrosis: a double-blind, randomized, 
comparative preliminary study. Journal of the European Academy of Dermatology 
and Venereology 26(3), pp. 314-318. 
 
Gupta, J. et al. 2012. Rapid local anesthesia in humans using minimally invasive 
microneedles. The Clinical Journal of Pain 28(2), pp. 129-135. 
 
Gupta, J. et al. 2009. Minimally invasive insulin delivery in subjects with type 1 
diabetes using hollow microneedles. Diabetes Technology & Therapeutics 11(6), pp. 
329-337. 
 
Gupta, J. et al. 2011a. Rapid pharmacokinetics of intradermal insulin administered 
using microneedles in type 1 diabetes subjects. Diabetes Technology & Therapeutics 
13(4), pp. 451-456. 
 
Gupta, J. et al. 2011b. Infusion pressure and pain during microneedle injection into 
skin of human subjects. Biomaterials 32(28), pp. 6823-6831. 
 
Haake, A. et al. 2001. Structure and function of the skin: overview of the epidermis 
and the dermis. In: Freinkel, R.K. and Woodley, D. T. eds. The biology of the skin. 
New York: The Parthenon Publishing Group. pp. 19-45. 
 
Hafeli, U. O. et al. 2009. In vivo evaluation of a microneedle-based miniature 
syringe for intradermal drug delivery. Biomedical Microdevices (11)5, pp. 943-950. 
 
232 
 
Hamm, H. et al. 2006. Primary focal hyperhidrosis: disease characteristics and 
functional impairment. Dermatology 212(4), pp. 343-353. 
 
Hamm, H. and Naumann, M. K. 2009. Hyperhidrosis. In: Truong D. D., et al. eds. 
Manual of botulinum toxin therapy. New York: Cambridge University Press., pp. 
123-131. 
 
Hansen, K. et al. 2009. Trasdermal delivery. A hollow microstrucured trasdermal 
system (hMTS) for needle-free delivery of biopharmaceuticals. [online]. Available 
at: 
http://www.drugdeliverytechonline.com/drugdelivery/200909?pg=39&search_term=
hMTS&doc_id=-1&search_term=hMTS#pg39 [Accessed 28th December 2011]. 
 
Haq, M. I. et al. 2009. Clinical administration of microneedles: skin puncture, pain 
and sensation. Biomed Microdevices 11(1), pp. 35-47. 
 
Harvey, A. J. et al. 2011. Microneedle-based intradermal delivery enables rapid 
lymphatic uptake and distribution of protein drugs. Pharmaceutical Research 28(1), 
pp. 107-116. 
 
Hayton, M. J. et al. 2003. A review of peripheral nerve blockade as local anaesthesia 
in the treatment of palmar hyperhidrosis. British Journal of Dermatology 149(3), pp. 
447-451. 
 
Henry, S. et al. 1998. Microfabricated microneedles: a novel approach to transdermal 
drug delivery. Journal of Pharmaceutical Sciences 87(8), pp. 922-925. 
 
Hexsel, D. et al. 2008. A randomized pilot study comparing the action halos of two 
commercial preparations of botulinum toxin type A. Dermatologic Surgery 34(1), pp. 
52-59. 
 
Hexsel, D. M. et al. 2009. Increasing the field effects of similar doses of clostridium 
botulinum type A toxin-hemagglutinin complex in the treatment of compensatory 
hyperhidrosis. Archives of Dermatology 145(7), pp. 837-840. 
 
Holland, D. et al. 2008. Intradermal influenza vaccine administered using a new 
microinjection system produces superior immunogenicity in elderly adults: A 
randomized controlled trial. Journal of Infectious Diseases 198(5), pp. 650-658. 
 
Holmes, S. and Mann, C. 1998. Botulinum toxin in the treatment of palmar 
hyperhidrosis. Journal of the American Academy of Dermatology 39(6), pp. 1040-
1041. 
 
Holzle, E. 2002. Pathophysiology of sweating. Current Problems in Dermatology 30, 
pp. 10-22. 
 
Hoorens, I. and Ongenae, K. 2012. Primary focal hyperhidrosis: current treatment 
options and a step-by-step approach. Journal of the European Academy of 
Dermatology and Venereology 26(1), pp. 1-8. 
 
233 
 
Hotchkiss S. A. M. 1998. Dermal Metabolism. In: Roberts, M.S. and Walters, K. A. 
eds. Dermal absorption and toxicity assessment. New York: Marcel Dekker, p 58 
 
http://2011.igem.org/Team:NTNU_Trondheim/rrnB. 2011. Available at: 
http://2011.igem.org/wiki/images/6/6e/ONPG.png [Accessed: 23th June 2012]. 
 
http://en.sanofi.com. 2009. FDA licences new influenza vaccine designed 
specifically for people 65 years of age and older. Available at: 
http://en.sanofi.com/Images/14032_20091223_FLU_HIGH_DOSE_en.pdf 
[Accessed: 3rd June 2012]. 
 
http://www.abcam.com. 2011. EasyLink PE/Cy7
®
 Conjugation Kit (3 x 10µg 
PE/Cy7
®
) (ab102904). Available at: http://www.abcam.com/EasyLink-PECy7-
Conjugation-Kit-3-x-10g-PECy7-ab102904.pdf [Accessed: 10th August 2011]. 
 
http://www.allergan.com/index.htm. 2011. Botox (botulinum toxin type A) purified 
neurotoxin complex prescribing information. Available at: 
http://www.allergan.com/assets/pdf/botox_pi.pdf [Accessed: 15th June 2012]. 
 
http://www.bd.com. 2012. BD Soluvia™ Prefillable Microinjection System. 
Available at: URL: http://www.bd.com/pharmaceuticals/products/microinjection.asp 
[Accessed: 3rd June 2012]. 
 
http://cai.md.chula.ac.th. Available at: 
http://cai.md.chula.ac.th/lesson/lesson4410/data/image_s17.jpg [Accessed: 7th June 
2012]. 
 
http://www.dermaroller.com. 2011. Available at: 
http://dermaroller.com/index.php?option=com_content&view=frontpage&Itemid=1
&lang=en [Accessed: 3rd June 2012]. 
 
http://www.dkimages.com. Human skin, cross section. Available at: 
http://www.dkimages.com/discover/home/Health-and-Beauty/Human-Body/Skin-
Hair-and-Nails/Skin-Hair-and-Nails-43.html [Accessed: 7th June 2012]  
 
http://www.fda.gov. 2003. Draft guidance for industry on powder blends and 
finished dosage units-stratified in process dosage unit sampling and assesment. 
Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0493-gdl0001.pdf 
[Accessed: 7th March 2012]. 
 
http://www.fda.gov. 2011. Guidance for industry residual drug in transdermal and 
related drug delivery systems. Available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM220796.pdf [Accessed 7th March 2012]. 
 
http://www.healthcentre.org.uk. Cost of Botox for Hyperhidrosis. Available at: 
http://www.healthcentre.org.uk/cosmetic-treatments/botox-hyperhidrosis-cost.html 
[Accessed: 21st June 2012]. 
 
234 
 
http://www.ismp-canada.org. 2005. Overdose a risk of transdermal patch in diverse 
settings. Problems occur even with discarded patch. Available at: http://www.ismp-
canada.org/download/CPJ2005SepOct.pdf [Accessed: 8th March 2012]. 
 
http://www.microscopy-uk.org.uk/mag/indexmag.html?http://www.microscopy-
uk.org.uk/mag/artaug02/gohisto.html. Human histology for amateur microscopists. 
Available at http://www.microscopy-uk.org.uk/mag/imgaug02/HistPaper01_Fig2.jpg 
[Accessed: 18th July 2012]. 
 
http://www.nanomed-skincare.com. 2010. LitClear. Available at: 
http://www.nanomed-skincare.com/ [Accessed: 3rd June 2012]. 
 
http://www.nanopass.com. Microneedle technology at your fingertips. Available at: 
http://www.nanopass.com/content-d.asp?tcid=19&cid=24 [Accessed: 15th June 
2012]. 
 
http://www.nanopass.com. Microneedle technology at your fingertips (Available at: 
http://www.nanopass.com/content-c.asp?cid=22) [Accessed: 15th June 2012]. 
 
http://www.nhs.uk. 2011a. Hyperhidrosis. Available at: 
http://www.nhs.uk/conditions/Hyperhidrosis/Pages/Introduction.aspx [Accessed: 
15th June 2012]. 
 
http://www.nhs.uk. 2011b. Hyperhidrosis. Treatment Available at: 
http://www.nhs.uk/Conditions/Hyperhidrosis/Pages/Treatment.aspx [Accessed: 15th 
June 2012]. 
 
http://www.pharmacopoeia.co.uk. 2012. Sodium Chloride. Available at: 
http://www.pharmacopoeia.co.uk/bp2012/ixbin/bp.cgi?a=display&r=OCy_ifw7GFI
&n=85&id=6729&tab=search [Accessed: 2nd July 2012]. 
 
http://www.piercenet.com. Overview of immunohistochemistry. Available at:  
http://www.piercenet.com/browse.cfm?fldID=F95B91A9-3DC1-4B56-8E8D-
59CA044A8BA7#blocking [Accessed: 21st February 2011]. 
 
http://www.promega.com. 2006. β-Galactosidase Enzyme Assay System with 
Reporter Lysis Buffer. Technical bullettin. Available at: 
http://www.promega.com/tbs/tb097/tb097.html [Accessed: 5th June 2009]. 
 
http://www.qiagen.com. 2011. Protein. Available at: 
http://www.qiagen.com/literature/benchguide/pdf/1017778_benchguide_chap_4.pdf. 
[Accessed: 3th March 2011]. 
 
http://www.robbinsinstruments.com/equipment/dermojet/modelg.html. The Original 
Dermo-jet "Model G". Available at: 
http://www.robbinsinstruments.com/downloads/dj_instructions.pdf [Accessed: 9th 
June 2012] 
 
http://www.sciencedaily.com/releases/2012/03/120306073011.htm. 2012. 
Microneedle vaccine patch boosts flu protection through robust skin cell immune 
235 
 
response. Available at: http://images.sciencedaily.com/2012/03/120306073011.jpg. 
[Accessed: 9th June 2012]. 
 
http://www.sigmaaldrich.com. 1994. Enzymatic assay of beta galactosidase. 
Available at: 
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Enzyme_Assay/bgalactosida
seonp.Par.0001.File.tmp/bgalactosidaseonp.pdf [Accessed: 7th July 2009]. 
 
http://www.sigmaaldrich.com. 1996. Albumin Human. Product information. 
Available at: 
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/a
4327pis.Par.0001.File.tmp/a4327pis.pdf [Accessed: 22nd June 2012]. 
 
http://www.sigmaaldrich.com. 1999. Enzymatic assay of beta galactosidase. 
Available at: 
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Enzyme_Assay/g5635enz.Pa
r.0001.File.tmp/g5635enz.pdf [Accessed: 5th July 2009]. 
 
Hurley, H. J. 2001. The eccrine sweat glands: structure and function. In: Freinkel, 
R.K. and Woodley, D. T. eds. The biology of the skin. New York: Parthenon 
Publishing. pp. 47-76. 
 
Ishida-Yamamoto, A. et al. 2011. Order and disorder in corneocyte adhesion. The 
Journal of Dermatology 38(7), pp. 645-654. 
 
Ito, Y. et al. 2008. Evaluation of self-dissolving needles containing low molecular 
weight heparin (LMWH) in rats. International Journal of Pharmaceutics 349(1-2), 
pp. 124-129. 
 
Jay, J. M., Loessner, M. J, Golden, D. A. 2005. Food poisoning caused by Gram-
positive sporeforming bacteria In: Jay, J.M. et al eds Modern food microbiology. 
New York: Springer Science p. 582. 
 
Jensen, J. M. and Proksch, E. 2009. The skin's barrier. Giornale Italiano di 
Dermatologia e Venereologia 144(6), pp. 689-700. 
 
Jordan, R. C. K. et al. 2002. Advanced diagnostic methods in oral and maxillofacial 
pathology. Part II: Immunohistochemical and immunofluorescent methods. Oral 
Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 93(1), pp. 
56-74. 
 
Kadler, K. E. et al. 1996. Collagen fibril formation. Biochemical Journal 316, pp. 1-
11. 
 
Kalb, S. R. et al. 2006. The use of Endopep-MS for the detection of botulinum toxins 
A, B, E, and F in serum and stool samples. Analytical Biochemistry 351(1), pp. 84-
92. 
 
Kanitakis, J. 2002. Anatomy, histology and immunohistochemistry of normal human 
skin. European Journal of Dermatology 12(4), pp. 390-400. 
236 
 
 
Karakoc, Y. et al. 2002. Safe control of palmoplantar hyperhidrosis with direct 
electrical current. International Journal of Dermatology 41(9), pp. 602-605. 
 
Kaushik, S. et al. 2001. Lack of pain associated with microfabricated microneedles. 
Anesthesia and Analgesia 92(2), pp. 502-504. 
 
Kavanagh, G. M. 2006. Botulinum toxin type A by iontophoresis for primary palmar 
hyperhidrosis. Journal of the American Academy of Dermatology 55(5), pp. S115-
S117. 
 
Keller, J. E. 2008. Characterization of new formalin-detoxified botulinum neurotoxin 
toxoids. Clinical and Vaccine Immunology 15(9), pp. 1374-1379. 
 
Kendall, M. 2006. Engineering of needle-free physical methods to target epidermal 
cells for DNA vaccination. Vaccine 24(21), pp. 4651-4656. 
 
Kenney, R. T. et al. 2004. Dose sparing with intradermal injection of influenza 
vaccine. The New England Journal of Medicine 351(22), pp. 2295-2301. 
 
Keshtgar, A. S. et al. 2009. Transcutaneous needle-free injection of botulinum toxin: 
a novel treatment of childhood constipation and anal fissure. Journal of Pediatric 
Surgery 44(9), pp. 1791-1798. 
 
Kielty, C. M. and Shuttleworth, C. A. 1997. Microfibrillar elements of the dermal 
matrix. Microscopy Research and Technique 38(4), pp. 413-427. 
 
Kim, W. O. et al. 2009a. Botulinum Toxin: A Treatment for Compensatory 
Hyperhidrosis in the Trunk. Dermatologic Surgery 35(5), pp. 833-838. 
 
Kim, W.O. et al. 2008. Topical glycopyrrolate for patients with facial hyperhidrosis. 
British Journal of Dermatology 158(5), pp. 1094-1097. 
 
Kim, Y. C., Park, J.H., Prausnitz, M. P. 2012. Microneedles for drug and vaccine 
delivery. Advanced Drug Delivery Reviews, in press.  
 
Kim, Y. C. et al. 2010. Formulation and coating of microneedles with inactivated 
influenza virus to improve vaccine stability and immunogenicity. Journal of 
Controlled Release 142(2), pp. 187-195. 
 
Kim, Y. C. et al. 2011. Stability kinetics of influenza vaccine coated onto 
microneedles during drying and storage. Pharmaceutical Research 28(1), pp. 135-
144. 
 
Kim, Y. C. et al. 2009b. Improved influenza vaccination in the skin using vaccine 
coated microneedles. Vaccine 27(49), pp. 6932-6938. 
 
Kinkelin, I. et al. 2000. Effective treatment of frontal hyperhidrosis with botulinum 
toxin A. British Journal of Dermatology 143(4), pp. 824-827. 
 
237 
 
Komericki, P. and Ardjomand, N. 2012. Hyperhidrosis of face and scalp: repeated 
successful treatment with botulinum toxin type A. Indian Journal of Dermatology 
Venereology & Leprology 78(2), pp. 201-U177. 
 
Koutsonanos D. G. et al. 2009. Transdermal influenza immunization with vaccine-
coated microneedle arrays. PloS One 4(3), pp. 1-10. 
 
Koutsonanos, D. G. et al. 2011. Serological Memory and Long-term Protection to 
Novel H1N1 Inﬂuenza Virus After Skin Vaccination. Journal of Infectious Diseases 
204(4), pp. 582-591. 
 
Kurzen, H. et al. 2004. Phenotypical and molecular profiling of the extraneuronal 
cholinergic system of the skin. The Journal of Investigative Dermatology 123(5), pp. 
937-949. 
 
Laurent, A. et al. 2007a. Echographic measurement of skin thickness in adults by 
high frequency ultrasound to assess the appropriate microneedle length for 
intradermal delivery of vaccines. Vaccine 25(34), pp. 6423-6430. 
 
Laurent, P. E. et al. 2007b. Evaluation of the clinical performance of a new 
intradermal vaccine administration technique and associated delivery system. 
Vaccine 25(52), pp. 8833-8842. 
 
Lee, J. W. et al. 2011. Dissolving microneedle patch for transdermal delivery of 
human growth hormone. Small 7(4), pp. 531-539. 
 
Lee, J. W. et al. 2008. Dissolving microneedles for transdermal drug delivery. 
Biomaterials 29(13), pp. 2113-2124. 
 
Li, G. et al. 2009. In vitro transdermal delivery of therapeutic antibodies using 
maltose microneedles. International Journal of Pharmaceutics 368(1-2), pp. 109-
115. 
 
Lin, T. S. et al. 2001a. Pitfalls and complication avoidance associated with 
transthoracic endoscopic sympathectomy for primary hyperhidrosis (analysis of 2200 
cases). International Journal of Surgical Investigation 2(5), pp. 377-385. 
 
Lin, W. et al. 2001b. Transdermal delivery of antisense oligonucleotides with 
microprojection patch (Macroflux) technology. Pharmaceutical Research 18(12), pp. 
1789-1793. 
 
Lowe, N. J. et al. 2002. Efficacy and safety of botulinum toxin type A in the 
treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled 
study. Dermatologic Surgery 28(9), pp. 822-827. 
 
Maa, Y. F. et al. 2004. Influenza vaccine powder formulation development: spray-
freeze-drying and stability evaluation. Journal of Pharmaceutical Sciences 93(7), pp. 
1912-1923. 
 
238 
 
Martanto, W. et al. 2004. Transdermal delivery of insulin using microneedles in vivo. 
Pharmaceutical  Research 21(6), pp. 947-952. 
 
Martin, C. J. et al. 2012. Low temperature fabrication of biodegradable sugar glass 
microneedles for transdermal drug delivery applications. Journal of Controlled 
Release 158(1), pp. 93-101. 
 
Mason, J. T. et al. 2006. Liposome polymerase chain reaction assay for the sub-
attomolar detection of cholera toxin and botulinum neurotoxin type A. Nature 
Protocols 1(4), pp. 2003-2011. 
 
Matriano, J. A. et al. 2002. Macroflux microprojection array patch technology: a new 
and efficient approach for intracutaneous immunization. Pharmaceutical Research 
19(1), pp. 63-70. 
 
McAllister, D. V. et al. 2003. Microfabricated needles for transdermal delivery of 
macromolecules and nanoparticles: fabrication methods and transport studies. 
Proceedings of the National Academy of Sciences of the United States of America 
100(24), pp. 13755-13760. 
 
Merad, M. et al. 2002. Langerhans cells renew in the skin throughout life under 
steady-state conditions. Nature Immunology 3(12), pp. 1135-1141. 
 
Mikszta, J. A. et al. 2002. Improved genetic immunization via micromechanical 
disruption of skin-barrier function and targeted epidermal delivery. Nature Medicine 
8(4), pp. 415-419. 
 
Mikszta, J. A. et al. 2006. Microneedle-based intradermal delivery of the anthrax 
recombinant protective antigen vaccine. Infection and Immunity 74(12), pp. 6806-
6810. 
 
Montagna, W., Parakkal, P. F. 1974. The dermis. In: Montagna, W. and Parakkal, P. 
F. eds. The structure and function of the skin. New York: Academic Press pp. 96-
141. 
 
Moreau, M. S. et al 2003. A double-blind, randomized, comparative study of Dysport 
vs. Botox in primary palmar hyperhidrosis. British Journal of Dermatology 149(5), 
pp. 1041-1045. 
 
Naumann, M. et al. 1998a. Botulinum toxin for focal hyperhidrosis: technical 
considerations and improvements in application. British Journal of Dermatology 
139(6), pp. 1123-1124. 
 
Naumann, M. and Hamm, H. 2002. Treatment of axillary hyperhidrosis. British 
Journal of Surgery 89(3), pp. 259-261. 
 
Naumann, M. et al. 1998b. Focal hyperhidrosis: effective treatment with 
intracutaneous botulinum toxin. Archives of Dermatology 134(3), pp. 301-304. 
 
239 
 
Naumann, M. et al. 2001. Botulinum toxin type A in, treatment of bilateral primary 
axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled 
trial. British Medical Journal 323(7313), pp. 596-599. 
 
Naver, H. et al. 1999. Treatment of focal hyperhidrosis with botulinum toxin type A. 
Brief overview of methodology and 2 years' experience. European Journal of 
Neurology 6, pp. S117-S120. 
 
Naver, H. et al. 2000. Palmar and axillary hyperhidrosis treated with botulinum 
toxin: one-year clinical follow-up. European Journal of Neurology 7(1), pp. 55-62. 
 
Ng, K. W. 2010. Microneedles for intraepidermal hepatitis B vaccination. Ph.D. 
Thesis, Cardiff University.  
 
Ng, K. W. et al. 2009. Development of an ex vivo human skin model for intradermal 
vaccination: tissue viability and Langerhans cell behaviour. Vaccine 27(43), pp. 
5948-5955. 
 
Nordquist, L. et al. 2007. Novel microneedle patches for active insulin delivery are 
efficient in maintaining glycaemic control: an initial comparison with subcutaneous 
administration. Pharmaceutical Research 24(7), pp. 1381-1388. 
 
Oh, J. H. et al. 2011. Changes in glycosaminoglycans and related proteoglycans in 
intrinsically aged human skin in vivo. Experimental Dermatology 20(5), pp. 454-
456. 
 
Pacini, S. et al. 2007. Transdermal delivery of Clostridium botulinum toxin type A 
by pulsed current iontophoresis. Journal of the American Academy of Dermatology 
57(6), pp. 1097-1099. 
 
Panicker, J. N. and Muthane, U. B. 2003. Botulinum toxins: pharmacology and its 
current therapeutic evidence for use. Neurology India 51(4), pp. 455-460. 
 
Park, J. H. et al. 2005. Biodegradable polymer microneedles: fabrication, mechanics 
and transdermal drug delivery. Journal of Controlled Release 104(1), pp. 51-66. 
 
Park, J. H. et al. 2006. Polymer microneedles for controlled-release drug delivery. 
Pharmaceutical Research 23(5), pp. 1008-1019. 
 
Pearton, M. et al. 2010. Influenza virus-like particles coated onto microneedles can 
elicit stimulatory effects on Langerhans cells in human skin. Vaccine 28(37), pp. 
6104-6113. 
 
Pellett, S. et al. 2007. A neuronal cell-based botulinum neurotoxin assay for highly 
sensitive and specific detection of neutralizing serum antibodies. FEBS Letters 
581(25), pp. 4803-4808. 
 
Pinder, R. M. 2007. Botulinum toxin - From WMD to therapeutic agent and cosmetic 
aid. Neuropsychiatric Disease and Treatment 3(6), pp. 703-704. 
 
240 
 
Praharaj, S. K. and Arora, M. 2006. Paroxetine useful for palmar-plantar 
hyperhidrosis. Annals of Pharmacotherapy 40(10), pp. 1884-1886. 
 
Prausnitz, M. R. 2004. Microneedles for transdermal drug delivery. Advanced Drug 
Delivery Reviews 56(5), pp. 581-587. 
 
Prausnitz, M. R. et al. 2009. Microneedle-based vaccines. Current Topics in 
Microbiology and Immunology 333, pp. 369-393. 
 
Price J. et.al 2008a. Botulinum toxin: its form, formulation and pharmacology. 
Hospital Pharmacist 15, pp. 319-321. 
 
Price J. et al. 2008b. Botulinum toxin, its place in therapy. Hospital Pharmacist 15, 
pp. 323-328. 
 
Quan, F. S. et al. 2010. Intradermal vaccination with influenza virus-like particles by 
Using microneedles induces protection superior to that with intramuscular 
immunization. Journal of Virology 84(15), pp. 7760-7769. 
 
Ramos-Vara, J. A. et al. 2008. Suggested guidelines for immunohistochemical 
techniques in veterinary diagnostic laboratories. Journal of Veterinary Diagnostic 
Investigation 20(4), pp. 393-413. 
 
Ranoux, D. et al. 2002. Respective potencies of Botox and Dysport: a double blind, 
randomised, crossover study in cervical dystonia. Journal of Neurology 
Neurosurgery and Psychiatry 72(4), pp. 459-462. 
 
Rasooly, R. and Do, P. M. 2008. Development of an in vitro activity assay as an 
alternative to the mouse bioassay for Clostridium botulinum neurotoxin type A. 
Applied and Environmental Microbiology 74(14), pp. 4309-4313. 
 
Reinauer, S. et al. 1993. Iontophoresis with alternating current and direct current 
offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. 
British Journal of Dermatology 129(2), pp. 166-169. 
 
Rizwan, M. et al. 2009. Enhanced transdermal drug delivery techniques: an extensive 
review of patents. Recent Patents on Drug Delivery & Formulation 3(2), pp. 105-
124. 
 
Ro, K. M. et al. 2002. Palmar hyperhidrosis: Evidence of genetic transmission. 
Journal of Vascular Surgery 35(2), pp. 382-386. 
 
Roberge, R. J. et al. 2000. Transdermal drug delivery system exposure outcomes. 
The Journal of Emergency Medicine 18(2), pp. 147-151. 
 
Roberts, M. S. et al. 1978. The percutaneous absorption of phenolic compounds: the 
mechanism of diffusion across the stratum corneum. Journal of Pharmacy and 
Pharmacology 30(1), pp. 486-490. 
 
241 
 
Roberts, M. S., Walters, K. A. 1998. The relationship between structure and barrier 
function of the skin. In: Roberts, M.S. and Walters, K. A. eds. Dermal absorption 
and toxicity assessment. New York: Marcel Dekker, pp. 1-42. 
 
Saadia, D. et al. 2001. Botulinum toxin type A in primary palmar hyperhidrosis: 
randomized, single-blind, two-dose study. Neurology 57(11), pp. 2095-2099. 
 
Saga, K. 2001. Histochemical and immunohistochemical markers for human eccrine 
and apocrine sweat glands: an aid for histopathologic differentiation of sweat gland 
tumors. The Journal of Investigative Dermatology 6(1), pp. 49-53. 
 
Saga, K. 2002. Structure and function of human sweat glands studied with 
histochemistry and cytochemistry. Progress in Histochemistry and Cytochemistry 
37(4), pp. 323-386. 
 
Saga, K. and Morimoto, Y. 1995. Ultrastructural localization of alkaline phosphatase 
activity in human eccrine and apocrine sweat glands. The Journal of Histochemistry 
and Cytochemistry 43(9), pp. 927-932. 
 
Sakai, L. Y. et al. 1986. Fibrillin, a new 350-KD glycoprotein, is a component of 
extracellular microfibrils. Journal of Cell Biology 103(6), pp. 2499-2509. 
 
Sanchez, A. I. G. et al. 2010. Effectiveness and safety of glycopyrrolate for 
hyperhidrosis. European Journal of Hospital Pharmacy Practice 16(1), pp. 38-41 
 
 
Sanli, H. et al. 2004. Idiopathic localized crossed (left side of the upper part of the 
body, right side of the lower part of the body) hyperhidrosis: successful treatment of 
facial area with botulinum a toxin injection. Dermatologic Surgery 30(4), pp. 552-
554. 
 
Saray, Y. and Gulec, A. T. 2005. Treatment of keloids and hypertrophic scars with 
dermojet injections of bleomycin: a preliminary study. International Journal of 
Dermatology 44(9), pp. 777-784. 
 
Sathyamoorthy, V. and DasGupta, B. R. 1985. Separation, purification, partial 
characterization and comparison of the heavy and light chains of botulinum 
neurotoxin types A, B, and E. The Journal of Biological Chemistry 260(19), pp. 
10461-10466. 
 
Sato, K. et al. 1989. Biology of sweat glands and their disorders. I. Normal sweat 
gland function. Journal of the American Academy of Dermatology 20(4), pp. 537-
563. 
 
Saurer, E. M. et al. 2010. Layer-by-Layer Assembly of DNA- and Protein-
Containing Films on Microneedles for Drug Delivery to the Skin. 
Biomacromolecules 11(11),  pp. 3136-3146. 
 
242 
 
Scarlatos, A. et al. 2005. Methods for detecting botulinum toxin with applicability to 
screening foods against biological terrorist attacks. Journal of Food Science 70(8), 
pp. 121-130. 
 
Sevim, S. et al. 2002. Botulinum toxin-A therapy for palmar and plantar 
hyperhidrosis. Acta Neurologica Belgica 102(4), pp. 167-170. 
 
Sharma, S. K. et al. 2006. Detection of type A, B, E, and F Clostridium botulinum 
neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay 
with digoxigenin-labeled antibodies. Applied and Environmental Microbiology 
72(2), pp. 1231-1238. 
 
Shelley, W. B. et al. 1998. Botulinum toxin therapy for palmar hyperhidrosis. 
Journal of the American Academy of Dermatology 38(2), pp. 227-229. 
 
Shi, S. R. et al. 2011. Antigen retrieval immunohistochemistry: review and future 
prospects in research and diagnosis over two decades. Journal of Histochemistry & 
Cytochemistry 59(1), pp. 13-32. 
 
Shone, C. et al. 1985. Monoclonal antibody-based immunoassay for type A 
Clostridium botulinum toxin is comparable to the mouse bioassay. Applied and 
Environmental Microbiology 50(1), pp. 63-67. 
 
Shrivastava, S. N. and Singh, G. 1977. Tap water iontophoresis in  palmoplantar 
hyperhidrosis. British Journal of Dermatology 96(2), pp. 189-195. 
 
Silberstein, S. D. 2009. The use of botulinum toxin in the management of headache 
disorders. In: Truong, D. D., et al. eds. Manual of Botulinum toxin therapy. New 
York: Cambridge University Press pp. 175-183. 
 
Simpson, C. L. et al. 2011. Deconstructing the skin: cytoarchitectural determinants of 
epidermal morphogenesis. Nature Reviews Molecular Cell Biology 12(9), pp. 565-
580. 
 
Simpson, L. L. 2004. Identification of the major steps in botulinum toxin action. 
Annual Review of Pharmacology and Toxicology 44, pp. 167-193. 
 
Smidfelt, K. and Drott, C. 2011. Late results of endoscopic thoracic sympathectomy 
for hyperhidrosis and facial blushing. British Journal of Surgery 98(12), pp. 1719-
1723. 
 
Sondell, B. et al. 1995. Evidence that stratum-corneum chymotryptic enzyme is 
transported to the stratum-corneum extracellular-space via lamellar bodies. Journal 
of Investigative Dermatology 104(5), pp. 819-823. 
 
Sorrell, J. M. and Caplan, A. I. 2004. Fibroblast heterogeneity: more than skin deep. 
Journal of Cell Science 117(5), pp. 667-675. 
 
Sposito, M. M. M. 2002. New indications for botulinum toxin type A in cosmetics: 
Mouth and neck. Plastic and Reconstructive Surgery 110(2), pp. 601-611. 
243 
 
 
Steinsträsser, I. and Merkle, H. P. 1995. Dermal metabolism of topically applied 
drugs: pathways and models reconsidered. Pharmaceutica Acta Helvetiae 70(1), pp. 
3-24. 
 
Stone, H. F. et al. 2011. Characterization of diffusion and duration of action of a new 
botulinum toxin type A formulation. Toxicon 58(2), pp. 159-167. 
 
Sueki, H. et al. 2000. Hairless guinea pig skin: anatomical basis for studies of 
cutaneous biology. European Journal of Dermatology 10(5), pp. 357-364. 
 
Swartling, C. et al. 2001a. Side-effects of intradermal injections of botulinum A 
toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. European 
Journal of Neurology 8(5), pp. 451-456. 
 
Swartling, C. et al. 2001b. Botulinum A toxin improves life quality in severe primary 
focal hyperhidrosis. European Journal of Neurology 8(3), pp. 247-252. 
 
Talarico-Filho, S. et al. 2007. A double-blind, randomized, comparative study of two 
type A botulinum toxins in the treatment of primary axillary hyperhidrosis. 
Dermatologic surgery 33(1 Spec No.), pp. S44-50. 
 
Tan, S. R. and Solish, N. 2002a. Long-term efficacy and quality of life in the 
treatment of focal hyperhidrosis with botulinum toxin A. Dermatologic Surgery 
28(6), pp. 495-499. 
 
Trautman, J. C. et al. 2008. United States Patent 7435299: Method and apparatus for 
coating skin piercing microneedles. Available at: 
http://www.freepatentsonline.com/7435299.html [Accessed 17th February 2012]. 
 
Trindade de Almeida, A. R. et al. 2007. Pilot study comparing the diffusion of two 
formulations of botulinum toxin type A in patients with forehead hyperhidrosis. 
Dermatologic Surgery 33(1), pp. 37-43. 
 
Truong, D. D. 2012. Botulinum toxins in the treatment of primary focal dystonias. 
Journal of the Neurological Sciences 316(1-2), pp. 9-14. 
 
Truong, D. D. and Jost, W. H. 2006. Botulinum toxin: clinical use. Parkinsonism & 
Related Disorders 12(6), pp. 331-355. 
 
Vadoud-Seyedi, J. 2004. Treatment of plantar hyperhidrosis with botulinum toxin 
type A. International Journal of Dermatology 43(12), pp. 969-971. 
 
Vadoud-Seyedi, J. et al. 2000. Treatment of plantar hyperhidrosis with dermojet 
injections of botulinum toxin. Dermatology 201(2), pp. 179-179. 
 
Van Damme, P. et al. 2009. Safety and efficacy of a novel microneedle device for 
dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), pp. 
454-459. 
 
244 
 
Van Ermengem, E. P. 1897. U¨ ber einen neuen anaeroben Bacillus und seine 
Beziehung zum Botulismus. Z Hyg Infektionskrankh 26(1) 56 (English version: Van 
Ermengem, E. P. 1979. A new anaerobic bacillus and its relation to botulism. 
Reviews of Infectious Diseases 1(4), pp. 701-719. 
 
Varnum, S. M. et al. 2006. Enzyme-amplified protein microarray and a fluidic 
renewable surface fluorescence immunoassay for botulinum neurotoxin detection 
using high-affinity recombinant antibodies. Analytica Chimica Acta 570(2), pp. 137-
143. 
 
Verbaan, F. J. et al. 2008. Improved piercing of microneedle arrays in dermatomed 
human skin by an impact insertion method. Journal of Controlled Release 128(1), 
pp. 80-88. 
 
Walker, J. M. 2002. The bicinchoninic acid (BCA) assay for protein quantitation In: 
Walker, J. M. The protein protocols handbook  2
nd
 ed. New Jersey: Human Press. pp. 
11-14. 
 
Wang, P. M. et al. 2006. Precise microinjection into skin using hollow microneedles. 
Journal of Investigative Dermatology 126(5), pp. 1080-1087. 
 
Weber, A. et al. 2005. Psychosocial aspects of patients with focal hyperhidrosis. 
Marked reduction of social phobia, anxiety and depression and increased quality of 
life after treatment with botulinum toxin A. British Journal of Dermatology 152(2), 
pp. 342-345. 
 
Weldon, W. C. et al. 2011. Microneedle vaccination with stabilized recombinant 
influenza virus hemagglutinin induces improved protective immunity. Clinical and 
Vaccine Immunology : CVI 18(4), pp. 647-654. 
 
Wendorf, J. R. et al. 2011. Transdermal delivery of macromolecules using solid-state 
biodegradable microstructures. Pharmaceutical Research 28(1), pp. 22-30. 
 
Wermeling, D. P. et al. 2008. Microneedles permit transdermal delivery of a skin-
impermeant medication to humans. Proceedings of the National Academy of Sciences 
of the United States of America 105(6), pp. 2058-2063. 
 
Widera, G. et al. 2006. Effect of delivery parameters on immunization to ovalbumin 
following intracutaneous administration by a coated microneedle array patch system. 
Vaccine 24(10), pp. 1653-1664. 
 
Wilke, K. et al. 2007. A short history of sweat gland biology. International Journal 
of Cosmetic Science 29(3), pp. 169-179. 
 
Wonglertnirant, N. et al. 2011. A Hollow Microneedle Carrier for Enhancing Skin 
Penetration of Large Molecular Compounds. Biological and Pharmaceutical 
Bullettin 33(12), pp. 1988-1993. 
 
Wu, Y. et al. 2010. Sustained release of insulin through skin by intradermal 
microdelivery system. Biomedical Microdevices 12(4), pp. 665-671. 
245 
 
 
Xie, Y. et al. 2005. Controlled transdermal delivery of model drug compounds by 
MEMS microneedle array. Nanomedicine: Nanotechnology, Biology, and Medicine 
1(2), pp. 184-190. 
 
Yagima Odo, M. E. et al. 2011. Botulinum toxin for the treatment of menopausal hot 
flushes: a pilot study. Dermatologic Surgery 37(11), pp. 1579-1583. 
 
Yamashita, N. et al. 2008. Local injection of botulinum toxin A for palmar 
hyperhidrosis: usefulness and efficacy in relation to severity. Journal of Dermatology 
35(6), pp. 325-329. 
 
Yamauchi, P. S. and Lowe, N. J. 2004. Botulinum toxin types A and B: Comparison 
of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and 
hyperhidrosis. Clinics in Dermatology 22(1), pp. 34-39. 
 
Zaiac, M. et al. 2000. Botulinum toxin therapy for palmar hyperhidrosis with ADG 
needle. Dermatologic Surgery 26(3), pp. 230-230. 
 
Zhang, Y. et al. 2011. Development of lidocaine-coated microneedle product for 
rapid, safe, and prolonged local analgesic action. Pharmaceutical Research, pp. 1-8. 
 
Zhu, Q. et al. 2009. Immunization by vaccine-coated microneedle arrays protects 
against lethal influenza virus challenge. Proceedings of the National Academy of 
Sciences of the United States of America 106(19), pp. 7968-7973. 
 
